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Abstract 
Chlamydiae are gram-negative bacteria which cause diverse diseases of humans and 
animals. Chlamydia trachomatis, the focus of this work, causes the blinding eye disease 
trachoma, and reproductive tract infections. Trachoma affects 500 million individuals of 
whom seven million are blind. Chlamydia is the most common reproductive tract 
infection and can cause pelvic inflammatory disease and tubal infertility. In both cases 
treatment with antibiotics is effective but they may not be available, recurrent infection 
is common and the long-terrn complications irreversible. A vaccine is needed but 
attempts at developing one have met with limited success. The recent discovery of a 
family of antigenic surface proteins, the polymorphic membrane proteins, has 
revitalised the search for potential vaccine candidates. 
One member of this family, pmpG, was cloned in two fragments and the recombinant 
products expressed and purified. Humoral and cellular responses to these and other 
chlamydial antigens, and to common recall antigens, were examined in human subjects 
in The Gambia using immunoblotting, whole blood assay and cytokine ELISA 
techniques. Children with active trachoma, adults with trachomatous scarring and 
women with tubal infertility were examined, together with matched controls. 
PmPG was shown to be a target of both humoral and cellular responses. These responses 
were more commonly directed towards the amino- (PmpGa), rather than carboxyl- 
terminal (PmpGc) fragment. Antibodies to PmPGa were associated with a reduced risk of 
active trachoma but antibodies to PmpGc were associated with conjunctival scarring. 
PmPGa stimulated the production of TNF(x, IFNy and TGFP. Children with active 
trachoma produced higher levels of TNF(x and IL-10 than controls in response to 
PmPGa. High levels of IL-10 in response to both chlamydial and common recall 
antigens were noted in children with active trachoma and this may be a mechanism by 
which Chlamydia survives intracellularly. Responses to other chlarnydial proteins were 
characterised and an association between intestinal helminth infection and conjunctival 
scarring was noted. 
2 
Table of Contents 
I BACKGROUND .................................................................................................... 25 
1.1 CHLAMYDIA, THE ORGANISM ........................................................................... 
25 
1.2 EPIDEMIOLOGY AND DISEASE ........................................................................... 
25 
1.2.1 Trachoma 
................................................................................................. 
25 
1.2.2 Chlamydia trachomatis urogenital tract infection ................................... 
26 
1.2.3 Other chlarnydial infections .................................................................... 
27 
1.3 IMMUNE RESPONSES ......................................................................................... 
28 
1.3.1 Innate responses ...................................................................................... 
28 
1.3.2 Humoral responses .................................................................................. 
29 
1.3.3 T-cell responses ....................................................................................... 
30 
1.3.4 Cytokine responses and the relative importance of THI- and TH2-type 
responses ................................................................................................. 
31 
1.4 CHLAMYDIAL ANTIGENS ................................................................................... 
34 
1.4.1 Major Outer Membrane Protein (MOMP) .............................................. 
34 
1.4.2 Outer Membrane Protein 2 (omp2) .......................................................... 
35 
1.4.3 Heat-shock protein 60 (HsP60) ................................................................ 
36 
1.4.4 The polymorphic membrane proteins (PMPs) ........................................ 37 
1.4.5 Other antigens .......................................................................................... 
45 
1.5 PATHOGENESIS 
................................................................................................. 
46 
1.6 PREVIOUS VACCINE WORK ................................................................................ 
49 
1.7 LoCATIONS 
....................................................................................................... 
50 
1.7.1 London School of Hygiene & Tropical Medicine ................................... 50 
1.7.2 Medical Research Council Laboratories, Fajara and Farafenni, The 
Gambia .................................................................................................... 50 
1.7.3 Study villages, The Gambia .................................................................... 50 
1.8 Aims OF THE PROJECT ....................................................................................... 52 
2 MATERIALS AND METHODS .......................................................................... 54 
2.1 CLONING 
.......................................................................................................... 
54 
2.1.1 Preparation of Chlamydia trachomatis serovar A DNA ......................... 54 
2.1.1.1 Purification ofChlamydia trachomatisserovarA DNA ..................... 54 
2.1.1.2 Spectrophotometric estimation of concentration, yield andpurity of 
DNA ..................................................................................................... 55 
3 
2.1.1.3 Digestion of chlamydial DNA with restriction enzymes ...................... 
55 
2.1.2 PCR Amplification ................................................................................. . 
56 
2.1.2.1 Clontech Advantage' PCR ................................................................. . 56 
2.1.2.2 Hi-fidelity Pfu amplification ............................................................... . 
57 
2.1.3 Purification of PCR products ................................................................. . 57 
2.1.3.1 Ethidium bromide gel electrophoresis ................................................ 
57 
2.1.3.2 Crystal violet gel electrophoresis ........................................................ 
58 
2.1.3.3 Qiaex H DNA extraction kit ................................................................. 58 
2.1.3.4 Invitrogen Snap Columns* 
................................................................... 58 
2.1.4 Preparation of vectors and inserts for ligation ......................................... 59 
2.1.4.1 pGEM-7` ............................................................................................. 59 
2.1.4.2 pTrcHis . .............................................................................................. 59 
2.1.4.3 pBluescript' Hphagemid (SKII) .......................................................... 60 
2.1.4.4 pBAD-TOPO TA ................................................................................ 60 
2.1.4.5 pCR-II-TOPO ...................................................................................... 60 
2.1.4.6 PE T- 3 0' ............................................................................................... 60 
2.1.4.7 Isolation of restriction fragments for use as inserts ............................ 61 
2.1.4.8 De-phosphorylation of vector or insert termini prior to cloning ........ 61 
2.1.4.9 Filling in 5'single stranded extensions with Klenowfi-agment ofDNA 
polymerase ........................................................................................... 62 
2.1.5 Ligation ................................................................................................... 62 
2.1.5.1 Calculation of vectorlinsert ratio ........................................................ 62 
2.1.5.2 pGEM-7 . ............................................................................................. 63 
2.1.5.3 pTrcHis . .............................................................................................. 63 
2.1.5.4 pBluescript R...................................................................................... 63 
2.1.5.5 pBAD-TOPO ....................................................................................... 63 
2.1.5.6 pCR-H-TOPO ...................................................................................... 63 
2.1.5.7 pPE7 . .................................................................................................. 
63 
2.1.5.8 Preparation of competent cells ............................................................ 64 
2.1.6 Transformation into competent cells ....................................................... 64 
2.1.6.1 Competent cells used ........................................................................... 64 
2.1.6.2 Transformation intoUl-Blue ............................................................ 65 
2.1.6.3 Transformation into Top] 0 One-Shot' competent cells ...................... 65 
2.1.6.4 Transformation into BL21 ................................................................... 66 
2.1.7 Screening of transformants ...................................................................... 66 
4 
2.1.7.1 Screening by antibiotic selection ......................................................... 66 
2.1.7.2 Bluelwhite screeningfor lacZ ....................... ...................................... 
66 
2.1.7.3 Quick plasm id preparation ............................ ...................................... 
67 
2.1.7.4 Restriction enzyme analysis ofplasmid DNA ...................................... 67 
2.1.8 Purification and archiving of plasmid constructs and plasmid-bearing 
bacterial strains ........................................................................................ 68 
2.1.8.1 Plasm idpurification - QIA well 8' kit ................................................. 68 
2.1.8.2 Plasm idpurification -Plasm id Midi Kit'ý ............................................ 69 
2.1.8.3 Freezing ofplasm id- bearing bacterial strains .................................... 69 
2.1.9 Individual cloning strategies ................................................................... 70 
2.1.9.1 Cloning ofpTrcHislpmpG-1410 .......................................................... 70 
2.1.9.2 Cloning ofpBluescriptlpmpD-1218 .................................................... 70 
2.1.9.3 Cloning ofpBADIpmpG ...................................................................... 71 
2.1.9.4 Cloning ofpPETIpmpGc ..................................................................... 71 
2.1.9.5 Cloning ofpCR-IIlpmpG ..................................................................... 72 
2.1.9.6 Cloning ofpPETIpmpGa ..................................................................... 72 
2.2 
2.2.1 
EXPRESSION 
..................................................................................................... 
73 
Basic techniques ...................................................................................... 73 
2.2.1.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) ...................... 
73 
2.2.1.2 Western blotting & immuno-detection 
................................................ 
74 
2.2.2 pTrcHis constructs ................................................................................... 75 
2.2.3 pBAD constructs ..................................................................................... 76 
2.2.4 pPET constructs ....................................................................................... 77 
2.2.5 rMOMP construct .................................................................................... 77 
2.3 
2.3.1 
RECOMBINANT PROTEIN PURIFICATION 
........................................................... 
78 
General methods ...................................................................................... 78 
2.3.1.1 Determination of the solubility of recombinant proteins in PBS ........ 78 
2.3.1.2 Purification of inclusion bodies .......................................................... 78 
2.3.2 Purification of rMOMP ........................................................................... 79 
2.3.3 Ni-NTA Protein Affinity Purification ..................................................... 80 
2.3.4 ProBondo Column Resin Affinity Purification ....................................... 80 
2.3.5 TALOW'Metal Affinity Resin Column ................................................. 82 
2.4 WHOLE BLOOD AsSAY ..................................................................................... 
84 
2.4.1 Preparation of antigens ............................................................................ 84 
2.4.1.1 Phytohaemagglutinin ........................................................................... 84 
5 
2.4.1.2 Purifiedprotein derivative .................................................................. 
84 
2.4.1.3 Candida albicans ................................................................................. 
84 
2.4.1.4 InducedpPET without insert ............................................................... 84 
2.4.1.5 Chlamydia trachomatis elementary bodies ......................................... 
85 
2.4.1.6 MOMP ................................................................................................. 85 
2.4.1.7 omP2 .................................................................................................... 85 
2.4.1.8 HsP60 ................................................................................................... 85 
2.4.1.9 PmpGc .................................................................................................. 86 
2.4.1.10 PmpGa .................................................................................................. 86 
2.4.2 Preparation of antigen plates ................................................................... 86 
2.4.3 Setting up whole blood assays ................................................................. 87 
2.5 CYTOKINE ELISA 
............................................................................................ 
88 
2.5.1 Standard ELISA protocol ........................................................................ 88 
2.5.2 Variations on the standard method for individual cytokine ELISA ........ 89 
2.5.2.1 TNFa ................................................................................................... 89 
2.5.2.2 IFNy ..................................................................................................... 89 
2.5.2.3 TGFP ................................................................................................... go 
2.5.2.4 IL-2 ...................................................................................................... 90 
2.5.2.5 IL-5 ...................................................................................................... 90 
2.5.2.6 IL-10 .................................................................................................... 90 
2.5.3 Preparation of whole blood assay control supernatants .......................... 
90 
2.6 IMMUNOBLOTTING 
........................................................................................... 
91 
2.7 FULL BLOOD COUNT ......................................................................................... 
92 
2.8 EXTRACTION OF DNA FROM WHOLE BLOOD .................................................... 
92 
2.9 CHLAMYDIA PCR 
............................................................................................. 
92 
2.9.1 Extraction of DNA from eye swabs ........................................................ 
92 
2.9.2 Amplicor CT8 PCR for Chlamydia ......................................................... 
93 
2.9.3 Stool microscopy ..................................................................................... 
93 
2.10 RECRUITMENT 
.................................................................................................. 
93 
2.10.1 Sample size calculation ........................................................................... 
94 
2.10.2 WHO classification of trachoma ............................................................. 
94 
2.10.3 Active trachoma ...................................................................................... 
95 
2.10.4 Trachomatous scarring ............................................................................ 96 
2.10.5 Infertile women ....................................................................................... 96 
II SUMMARY OF RECRUITMENT, INVESTIGATIONS AND DATA SETS GENERATED ... 
97 
6 
2.12 STATISTICAL ANALYSIS .................................................................................... 
98 
2.12.1 General data management ....................................................................... 
98 
2.12.2 Statistical analysis ................................................................................... 98 
3 RESULTS 1- GENERATION OF PLASMID CONSTRUCTS AND 
EXPRESSION OF RECOMBINANT PROTEIN ................................................ 101 
3.1 CLONING 
........................................................................................................ 
101 
3.1.1 Purification of Chlamydia trachomatis serovar A DNA ....................... 101 
3.1.2 PCR Amplification 
................................................................................ 101 
3.1.3 Restriction enzyme analysis of PCR products ....................................... 102 
3.1.3.1 pmpG ................................................................................................. 102 
3.1.3.2 pmpD ................................................................................................. 103 
3.1.4 Preparation of competent cells .............................................................. 105 
3.1.5 Individual cloning strategies ................................................................. 105 
3.1.5.1 Cloning ofpTrcHis1pmpG-1410 ........................................................ 105 
3.1.5.2 Cloning ofpBluescriptIpmpD-1218 .................................................. 108 
3.1.5.3 Cloning ofpBAD1pmpG .................................................................... 109 
3.1.5.4 Cloning ofpPET1pmpGc ................................................................... III 
3.1.5.5 Cloning ofpCR-H1pmpG ................................................................... 112 
3.1.5.6 Cloning ofpPET1pmpGa ................................................................... 113 
3.2 EXPRESSION AND PURIFICATION OF RECOMBINANT PROTEINS ........................ 
114 
3.2.1 pTrcHis/pmpG ....................................................................................... 114 
3.2.1.1 Expression ofpTrcHis1pmpG ..................................................... ....... 114 
3.2.1.2 Determination of solubility of recombinant proteins from 
pTrcHislpmpG ................................................................................... 
115 
3.2.1.3 Purification of recombinant proteins ftom p TrcHisIpmp G ........ ....... 
115 
3.2.2 pBAD/pmpG ................................................................................. ........ 
117 
3.2.2.1 Expression ofpBADIpmpG ....................................................... ........ 
117 
3.2.2.2 Purification of recom b inant proteins from pBADIpmp G .......... ........ 
118 
3.2.3 pPET/pmpGc ................................................................................. ........ 
119 
3.2.3.1 Expression ofpPET1pmpGc ...................................................... ........ 
119 
3.2.3.2 Purification of recombinant proteins from pPETIpmpGc ......... ........ 
120 
3.2.4 pPET/pmpGa ................................................................................. ........ 
122 
3.2.4.1 Expression ofpPETIpmpGa ...................................................... ........ 
122 
3.2.4.2 Purification of recombinant proteins from pPETIpmp Ga ......... ........ 
123 
7 
3.2.5 pPET without insert ............................................................................... 
125 
3.2.5.1 Expression ofpPET without insert and purification of induced 
products ............................................................................................. 
125 
3.2.6 MOMP ................................................................................................... 
126 
3.2.6.1 Expression andpurification of rMOMP ............................................ 126 
4 RESULTS 2- RESULTS OF FIELD WORK IN THE GAMBIA ................. 128 
4.1 QUALITY CONTROL ISSUES ............................................................................. 
128 
4.1.1 Quality control issues for immunoblots ................................................ 
128 
4.1.2 Quality control issues for cytokine ELISAs .......................................... 
128 
4.2 DEMOGRAPHY 
................................................................................................ 
132 
4.3 RESULTS OF STUDIES ON INDIVIDUALS WITH TRACHOMA ............................... 
135 
4.3.1 Immunoblot results ................................................................................ 
135 
4.3.1.1 Active trachoma ................................................................................. 
135 
4.3.1.2 Scarred trachoma .............................................................................. 139 
4.3.2 Cytokine ELISAs from whole blood assays .......................................... 
142 
4.3.2.1 Active trachoma ................................................................................. 
142 
4.3.2.1.1 TNF-a .......................................................................................... 
142 
4.3.2.1.2 IFNy ............................................................................................ 
147 
4.3.2.1.3 IL-2 .............................................................................................. 
151 
4.3.2.1.4 IL-5 .............................................................................................. 
154 
4.3.2.1.5 IL-10 ............................................................................................ 
157 
4.3.2.1.6 TGF-P .......................................................................................... 
162 
4.3.2.2 Scarred trachoma .............................................................................. 
165 
4.3.2.2.1 TNF-a .......................................................................................... 
165 
4.3.2.2.2 IFNy ............................................................................................ 
168 
4.3.2.2.3 IL-2 .............................................................................................. 
171 
4.3.2.2.4 IL-5 .............................................................................................. 
174 
4.3.2.2.5 IL-10 ............................................................................................ 
177 
4.3.2.2.6 TGFP ........................................................................................... 
181 
4.4 RESULTS OF STUDIES IN INFERTILE WOMEN .................................................... 
184 
4.4.1 Immunoblot results ................................................................................ 
184 
4.4.2 Cytokine ELISAs from whole blood assays .......................................... 
187 
4.4.2.1 TNF- a ................................................................................................ 
187 
4.4.2.2 IFNy ................................................................................................... 
190 
8 
4.4.2.3 IL-2 .................................................................................................... 
193 
4.5 
4.5.1 
4.5.2 
4.5.3 
4.5.4 
4.5.5 
4.6 
4.4.2.4 IL-5 .................................................................................................... 
196 
4.4.2.5 IL-10 .................................................................................................. 
199 
4.4.2.6 TGF-P ................................................................................................ 202 
MISCELLANEOUS RESULTS ............................................................................. 
205 
Effect of gender ..................................................................................... 205 
Effect of ethnicity .................................................................................. 206 
Chlarnydial PCR results ........................................................................ 209 
Effect of BCG vaccination .................................................................... 
210 
Effects of helminth and parasitic infestation ......................................... 
212 
SUMMARY OF RESULTS ................................................................................... 214 
5 DISCUSSION ....................................................................................................... 220 
5.1 PRINCIPAL FINDINGS ....................................................................................... 
220 
5.2 LIMITATIONS OF THIS STUDY .......................................................................... 
233 
5.3 CONCLUSIONS AND IMPLICATIONS .................................................................. 
240 
5.4 UNANSWERED QUESTIONS AND FUTURE RESEARCH ........................................ 
243 
BIBLIOGRAPHY ....................................................................................................... 248 
APPENDIX - IMMUNOBLOT SCORES BY OBSERVER ................................... 280 
9 
Table of Figures 
Figure 1-1: Clinical progression of trachoma .................................................................. 26 
Figure 1-2: Putative model of the envelope of chlarnydial elementary bodies. Adapted 
12 129 from Everett et al 8 and Hatch . ........................................................................... 35 
Figure 1-3: pmp gene arrangement within Chlamydia trachomatis genome .................. 40 
Figure 1-4: Map of The Gambia showing study villages ................................................ 51 
Figure 2-1: PET-30a expression vector ........................................................................... 61 
Figure 2-2: Whole blood assay plate layout .................................................................... 87 
Figure 2-3: WHO classification of trachoma (from Dawson et al)6 ................................ 95 
Figure 2-4: Summary of recruitment, investigations and data sets generated ................. 97 
Figure 3-1: Restriction enzyme analysis of Chlamydia trachomatis genomic DNA .... 101 
Figure 3-2: pmpC, pmpD and pmpG PCR products amplified using the Clontech 
Advantage'ý'PCR kit and visualised on an ethidium bromide-stained agarose gel 
under 254nm UV illumination .............................................................................. 102 
Figure 3-3: pmpC and pmpG PCR products amplified using Pfu DNA polymerase and 
visualised on an ethidium bromide-stained agarose gel under 254nm UV 
illumination 
........................................................................................................... 102 
Figure 3-4: PredictedpmpG PCR product restriction map ........................................... 102 
Figure 3-5: Fragments obtained on restriction enzyme analysis ofpmpG PCR product 
and visualised under 254nm UV illumination after agarose gel electrophoresis.. 102 
Figure 3-6: pmpD PCR product. Predicted restriction map .......................................... 104 
Figure 3 -7: pmpD PCR product. Results of restriction enzyme analysis (BamH I+ BgIll 
digestion not shown) ............................................................................................. 104 
Figure 3-8: Predicted restriction map of pGEM-T/pmpG ............................................. 105 
Figure 3-9: Restriction enzyme analysis of pGEM-T/pmpG ........................................ 106 
Figure 3- 10: Predicted restriction map of pTrcHis/pmpG- 1410 ................................... 107 
Figure 3-11: Restriction enzyme analysis of pTrcHis/pmpG-1410 .............................. 107 
Figure 3-12: Predicted restriction map of pBluescript/pmpD-Bam-1218 ..................... 108 
Figure 3 -13: Restriction enzyme analysis of pBluecript/ pmpD-Bam- 1218 (Kpnl + Eagl 
digestion not shown) ............................................................................................. 
108 
Figure 3-14: Potential point mutations leading to a novel Sacl site in pmpD .............. 109 
Figure 3-15: Predicted restriction map of pBAD/pmpG ............................................... 110 
Figure 3-16: Restriction enzyme analysis of pBAD/pmpG ......................................... 110 
Figure 3-17: XholSac fragment of pmpG used for cloning pPET/pmpGc ................... III 
10 
Figure 3-18: Predicted restriction map of pPET/pmpGc ............................................... III 
Figure 3-19: Restriction enzyme analysis of pPET/pmpGc ......................................... III 
Figure 3-20: Predicted restriction maps of pCRIVpmpG showing both forward and 
reverse orientations of insert ................................................................................. 112 
Figure 3-21: Restriction enzyme analysis of pCRIPpmpG ........................................... 112 
Figure 3-22: Predicted restriction map of pPET/pmpGa ............................................... 113 
Figure 3-23: Restriction enzyme analysis of pPET/pmpGa ......................................... 113 
Figure 3-24: Expression of recombinant protein from pTrcHis/pmpG - SDS-PAGE.. 114 
Figure 3-25: Expression of recombinant protein from pTrcHis/pmpG - Western blot. 115 
Figure 3-26: Solubility of recombinant protein from pTrcHis/pmpG - Western blot ... 115 
Figure 3-27: Ni-NTP column purification of recombinant protein from pTrcHis/pmpG - 
SDS-PAGE 
............................................................................................................ 116 
Figure 3-28: Ni-NTP column purification of recombinant protein from pTrcHis/pmpG - 
Western blot .......................................................................................................... 116 
Figure 3-29: ProBond resin column purification of recombinant protein from 
pTrcHis/pmpG - SDS-PAGE ............................................................................... 117 
Figure 3-30: ProBond resin column purification of recombinant proteins from 
pTrcHis/pmpG - Western blot .............................................................................. 117 
Figure 3-3 1: Expression of recombinant protein from pBAD/pmpG- SDS-PAGE ...... 118 
Figure 3-32: Expression of recombinant protein from pBAD/pmpG- Western blot .... 118 
Figure 3-33: Purification of recombinant protein from pBAD/pmpG using Clontech 
TALON and Qlagen Ni-NTA methods - SDS-PAGE ........................................... 119 
Figure 3-34: Purification of recombinant protein from pBAD/pmpG using Clontech 
TALON and Qiagen Ni-NTA methods - Western blot ......................................... 119 
Figure 3-35: Expression of recombinant protein from pPET/pmpGc - SDS-PAGE .... 120 
Figure 3-36: Expression of recombinant protein from pPET/pmpGc - Western blot ... 120 
Figure 3-37: TALON spin-column purification of recombinant protein from 
pPET/pmpGc - SDS-PAGE .................................................................................. 
121 
Figure 3-38: TALON spin-column punfication of recombinant protein from 
pPET/pmpGc - Western blot ................................................................................. 
121 
Figure 3-39: Pro-Bond purification of recombinant protein from pPET/pmpGc - SDS- 
PAGE ..................................................................................................................... 
121 
Figure 3-40: Pro-Bond purification of recombinant protein from pPET/pmpGc - 
Western blot .......................................................................................................... 
122 
Figure 3-4 1: Expression of recombinant protein from pPET/pmpGa - SDS-PAGE .... 122 
11 
Figure 3-42: Expression of recombinant protein from pPET/pmpGa - Western blot ... 123 
Figure 3-43: TALON spin-column purification of recombinant protein from 
pPET/pmpGa - SDS-PAGE ................................................................................... 
123 
Figure 3-44: TALON spin-column purification of recombinant protein from 
pPET/pmpGa - Western blot ................................................................................. 123 
Figure 3-45: Pro-Bond purification of recombinant protein from pPET/pmpGa - SDS- 
PAGE 
..................................................................................................................... 124 
Figure 3-46: Pro-Bond purification of recombinant protein from pPET/pmpGa - 
Western blot .......................................................................................................... 124 
Figure 3-47: Pro-Bond purification of products of induction of pPET vector without an 
insert - SDS-PAGE ................................................................................................ 125 
Figure 3-48: Pro-Bond purification of products of induction of pPET vector without an 
insert - Western blot .............................................................................................. 125 
Figure 3-49: Purification of recombinant MOMP - SDS-PAGE .................................. 126 
Figure 4- 1: Two typical immunoblots ........................................................................... 128 
Figure 4-2: Distribution of values for cytokine positive control wells ......................... 129 
Figure 4-3: Spread of values for TGFP by ELISA, for each antigen or control .......... 131 
Figure 4-4: Age distribution graph of all cases and controls ......................................... 132 
Figure 4-5: Distribution of study participants by ethnicity ........................................... 133 
Figure 4-6: Frequency-distribution graphs of immunoblot density scores for children 
with active trachoma and their controls ................................................................. 
135 
Figure 4-7: Mean immunoblot density scores and 95% confidence intervals for children 
with active trachoma and their controls ................................................................. 
137 
Figure 4-8: Frequency distribution of immunoblot scores for individuals with scarring 
and their controls ................................................................................................... 
139 
Figure 4-9: Mean immunoblot density scores for scarred individuals and their controls 
............................................................................................................................... 
140 
Figure 4- 10: Frequency distribution of TNF(x responses in children with active 
trachoma and their controls ................................................................................... 
142 
Figure 4-11: Mean TNF(x concentrations in children with active trachoma and their 
controls .................................................................................................................. 
144 
Figure 4-12: Frequency- distribution graphs of IFNy responses in children with active 
trachoma and their controls ................................................................................... 
147 
12 
Figure 4-13: Mean IFNy concentrations in children with active trachoma and their 
controls .................................................................................................................. 
149 
Figure 4-14: Frequency- distribution graphs of IL-2 responses in children with active 
trachoma and their controls ................................................................................... 
151 
Figure 4-15: Mean IL-2 concentrations in children with active trachoma and their 
controls .................................................................................................................. 
153 
Figure 4-16: Frequency- distribution graphs of IL-5 responses in children with active 
trachoma and their controls ................................................................................... 
154 
Figure 4-17: Mean IL-5 concentrations in children with active trachoma and their 
controls .................................................................................................................. 
155 
Figure 4-18: Frequency-distribution graphs of IL-10 responses in children with active 
trachoma and their controls ................................................................................... 
157 
Figure 4-19: Mean IL-10 concentrations in children with active trachoma and their 
controls .................................................................................................................. 
158 
Figure 4-20: Frequency-distribution graphs of TGFP responses in children with active 
trachoma and their controls ................................................................................... 
162 
Figure 4-2 1: Mean TGFP concentrations in children with active trachoma and their 
controls .................................................................................................................. 
163 
Figure 4-22: Frequency- di stribution graphs of TNF(x responses in individuals with 
trachomatous scarring and their controls ............................................................... 
165 
Figure 4-23: Mean TNF(x concentrations in individuals with trachornatous scarring and 
their controls .......................................................................................................... 
167 
Figure 4-24: Frequency- distribution graphs of IFNy responses in individuals with 
trachornatous scarring and their controls ............................................................... 
168 
Figure 4-25: Mean IFNy concentrations in individuals with trachornatous scarring and 
their controls .......................................................................................................... 
169 
Figure 4-26: Frequency- distribution graphs of IL-2 responses in individuals with 
trachomatous scarring and their controls ............................................................... 
171 
Figure 4-27: Mean IL-2 concentrations in individuals with trachornatous scarring and 
their controls .......................................................................................................... 
172 
Figure 4-28: Frequency-distribution graphs of IL-5 responses in individuals with 
trachomatous scarring and their controls ............................................................... 
174 
Figure 4-29: Mean IL-5 concentrations in individuals with trachornatous scarring and 
their controls .......................................................................................................... 
176 
13 
Figure 4-30: Frequency- di stributi on graphs of IL- 10 responses in individuals with 
trachomatous scarring and their controls ............................................................... 177 
Figure 4-3 1: Mean IL- 10 concentrations in individuals with trachomatous scarring and 
their controls .......................................................................................................... 178 
Figure 4-32: Frequency- distribution graphs of TGFP responses in individuals with 
trachomatous scarring and their controls ............................................................... 181 
Figure 4-33: Mean TGFP concentrations in individuals with trachornatous scarring and 
their controls .......................................................................................................... 182 
Figure 4-34: Frequency- di stributi on graphs of immunoblot density scores from infertile 
women and their controls ...................................................................................... 184 
Figure 4-35: Mean immunoblot density scores from infertile women and their controls 
.............................................................................................................................. 185 
Figure 4-36: Frequency- distribution graphs of TNF(x responses in infertile women and 
their controls .......................................................................................................... 187 
Figure 4-37: Mean TNF(x concentrations in infertile women and their controls .......... 188 
Figure 4-38: Frequency- distribution graphs of IFNy responses in infertile women and 
their controls .......................................................................................................... 190 
Figure 4-39: Mean IFN7 concentrations in infertile women and their controls ............ 191 
Figure 4-40: Frequency- distribution graphs of IL-2 responses in infertile women and 
their controls .......................................................................................................... 
193 
Figure 4-41: Mean IL-2 concentrations in infertile women and their controls ............. 194 
Figure 4-42: Frequency- distribution graphs of IL-5 responses in infertile women and 
their controls .......................................................................................................... 
196 
Figure 4-43: Mean IL-5 concentrations in infertile women and their controls ............. 197 
Figure 4-44: Frequency- distribution graphs of IL-10 responses in infertile women and 
their controls .......................................................................................................... 
199 
Figure 4-45: Mean IL- 10 concentrations in infertile women and their controls ........... 200 
Figure 4-46: Frequency- distribution graphs of TGFP responses in infertile women and 
their controls .......................................................................................................... 
202 
Figure 4-47: Mean TGFP concentrations in infertile women and their controls .......... 203 
Figure 4-48: Likelihood of having received BCG vaccination by age group ............... 
210 
Figure 4-49: Summary of results - cases vs. controls for all groups ............................. 214 
14 
Table of Tables 
Table I-1: Characteristics of the Chlamydia trachomatis pmps ..................................... 
38 
Table 2-1: Primer sequences used for PCR ..................................................................... 56 
Table 2-2: Plasmid antibiotic resistance .......................................................................... 66 
Table 2-3: SDS-PAGE gel composition .......................................................................... 73 
Table 2-4: IPTG concentrations used to induce expression in pTrcHis constructs ......... 75 
Table 2-5: Arabinose concentrations used to induce expression in pBAD constructs .... 76 
Table 2-6: IPTG concentrations used to induce expression in pPET constructs ............. 77 
Table 3- 1: Predicted and observed fragments of the pmpG PCR product after restriction 
enzyme analysis ..................................................................................................... 103 
Table 3-2: Predicted and observed fragments of the pmpD PCR product after restriction 
enzyme analysis ..................................................................................................... 104 
Table 3-3: Transfon-nation efficiencies of competent cells ........................................... 105 
Table 3-4: Predicted and observed fragments of pGEM-T/pmpG after restriction 
enzyme analysis ..................................................................................................... 
106 
Table 3 -5: Predicted and observed restriction fragments of pTrcHis/pmpG- 1410 ....... 107 
Table 3-6: Predicted and observed fragments of pBluescript/pmpD-Bam- 1218 after 
restriction enzyme analysis ................................................................................... 
108 
Table 3-7: Predicted and observed fragments of pBAD/pmpG after restriction enzyme 
analysis .................................................................................................................. 
110 
Table 3-8: Predicted and observed fragments of pPET/pmpGc after restriction enzyme 
analysis .................................................................................................................. 
III 
Table 3-9: Predicted and observed fragments of pCRII/pmpG after restriction enzyme 
analysis .................................................................................................................. 
112 
Table 3- 10: Predicted and observed fragments of pPET/pmpGa after restriction enzyme 
analysis .................................................................................................................. 
113 
Table 4-1: Correlation coefficients between observers for immunoblot scores ........... 128 
Table 4-2: Quality control statistics for cytokine ELISAs ............................................ 
129 
Table 4-3: Correlation coefficients between values for the positive control wells and 
those for patient samples on the same plate .......................................................... 
130 
Table 4-4: Distribution of study participants by ethnicity ............................................ 
132 
Table 4-5: Distribution of study participants by village of residence ........................... 
133 
Table 4-6: Clinical classification of trachoma in study participants ............................. 
134 
15 
Table 4-7: Individuals with negative immunoblot responses to chlamyclial antigens 
(numbers are unique identifiers for individual study participants) ....................... 
136 
Table 4-8: Mean immunoblot density scores for children with active trachoma and their 
controls .................................................................................................................. 136 
Table 4-9: Conditional logistic regression of immunoblot scores from children with 
active trachoma and their controls ......................................................................... 137 
Table 4-10: X2 analysis for trend for immunoblot scores to MOMP in children with 
active trachoma and their controls ......................................................................... 
138 
Table 4-11: X2 analysis for trend for immunoblot scores to PmpGa in children with 
active trachoma and their controls ......................................................................... 
138 
Table 4-12: Mean immunoblot density scores for scarred individuals and their controls 
............................................................................................................................... 140 
Table 4-13: Conditional logistic regression of immunoblot scores for scarred individuals 
and their controls ................................................................................................... 
141 
Table 4-14: X2 analysis for trend for immunoblot scores to PmpGc in scarred individuals 
and their controls ................................................................................................... 
141 
Table 4-15: Mean TNF concentrations in children with active trachoma and their 
controls .................................................................................................................. 
143 
Table 4-16: Conditional logistic regression of TNF(x concentrations in children with 
active trachoma and their controls ......................................................................... 
144 
Table 4-17: X2 test for trend for TNF(x responses to Candida in children with active 
trachoma and their controls ................................................................................... 
145 
Table 4-18: X2 test for trend for TNF(x responses to chlarnydial EBs in children with 
active trachoma and their controls ......................................................................... 
145 
Table 4-19: test for trend for TNFu responses to omP2 in children with active trachoma 
and their controls ................................................................................................... 
145 
Table 4-20: X2 test for trend for TNFu responses to HsP60 in children with active 
trachoma and their controls ................................................................................... 
146 
Table 4-2 1: X2 test for trend for TNF(x responses to PmPGa in children with active 
trachoma and their controls ................................................................................... 
146 
Table 4-22: Mean IFNy concentrations in children with active trachoma and their 
controls .................................................................................................................. 
148 
Table 4-23: Conditional logistic regression of IFNy concentrations for children with 
active trachoma and their controls ......................................................................... 
149 
16 
X2 in children with active trachoma Table 4-24: " test 
for trend for IFNy responses to PHA II 
and their controls ................................................................................................... 
150 
Table 4-25: X2 test for trend for IFN7 responses to chlamyd, al EBs in children with 
active trachoma and their controls ......................................................................... 
150 
Table 4-26: Mean IL-2 concentrations in children with active trachoma and their 
controls .................................................................................................................. 
15" 
Table 4-27: Conditional logistic regression of IL-2 concentrations for children with 
active trachoma and their controls ......................................................................... 
153 
Table 4-28: Mean IL-5 concentrations in children with active trachoma and their 
controls .................................................................................................................. 
155 
Table 4-29: Conditional logistic regression of IL-5 concentrations for children with 
active trachoma and their controls ......................................................................... 
156 
Table 4-30: Mean IL-10 concentrations in children with active trachoma and their 
controls .................................................................................................................. 
158 
Table 4-31: Conditional logistic regression of IL-10 concentrations for children with 
active trachoma and their controls ......................................................................... 
159 
Table 4-32: X2 test for trend for IL- 10 responses to Candida in children with active 
trachoma and their controls ................................................................................... 
159 
72 test for trend for IL- 10 responses to PPD in children with active Table 4-33: , 
trachoma and their controls ................................................................................... 
159 
Table 4-34: X2 test for trend for IL-10 responses to chlarnydial EBs in children with 
active trachoma and their controls ......................................................................... 
160 
Table 4-35: X2 test for trend for IL- 10 responses to omP2 in children with active 
trachoma and their controls ................................................................................... 
160 
Table 4-36: X2 test for trend for IL- 10 responses to HSP60 in children with active 
trachoma and their controls ................................................................................... 
160 
Table 4-37: X2 test for trend for IL- 10 responses to PmPGa in children with active 
trachoma and their controls ................................................................................... 
161 
Table 4-38: X2 test for trend for IL- 10 responses to PmPGc in children with active 
trachoma and their controls ................................................................................... 
161 
Table 4-39: Mean TGFP concentrations in children with active trachoma and their 
controls .................................................................................................................. 
163 
Table 4-40: Conditional logistic regression of TGFP concentrations for children with 
active trachoma and their controls ......................................................................... 
164 
17 
Table 4-41: Mean TNF(x concentrations in individuals with trachornatous scarring and 
their controls .......................................................................................................... 166 
Table 4-42: Conditional logistic regression of TNFoc concentrations for individuals with 
trachornatous scarring and their controls ............................................................... 167 
Table 4-43: Mean IFN7 concentrations in individuals with trachomatous scarring and 
their controls .......................................................................................................... 169 
Table 4-44: Conditional logistic regression of IFNy concentrations for individuals with 
trachornatous scarring and their controls ............................................................... 170 
Table 4-45: Mean IL-2 concentrations in individuals with trachornatous scarring and 
their controls .......................................................................................................... 172 
Table 4-46: Conditional logistic regression of IL-2 concentrations for individuals with 
trachomatous scarring and their controls ............................................................... 173 
Table 4-47: Mean IL-5 concentrations in individuals with trachomatous scarring and 
their controls .......................................................................................................... 175 
Table 4-48: Conditional logistic regression of IL-5 concentrations for individuals with 
trachornatous scarring and their controls ............................................................... 176 
Table 4-49: Mean IL- 10 concentrations in individuals with trachornatous scarring and 
their controls .......................................................................................................... 
178 
Table 4-50: Conditional logistic regression of IL- 10 concentrations for individuals with 
trachomatous, scarring and their controls ............................................................... 
179 
Table 4-5 1: X2 test for trend for IL- 10 responses to chlamydial EBs in individuals with 
trachornatous scarring and their controls ............................................................... 
179 
Table 4-52: X2 test for trend for IL- 10 responses to pmpGc in individuals with 
trachomatous scarring and their controls ............................................................... 
180 
Table 4-53: Mean TGFP concentrations in individuals with trachornatous scarring and 
their controls .......................................................................................................... 
182 
Table 4-54: Conditional logistic regression of TGFP concentrations for individuals with 
trachomatous scarring and their controls ............................................................... 
183 
Table 4-55: Mean immunoblot density scores from infertile women and their controls 
185 
Table 4-56: Conditional logistic regression of immunoblot density scores for infertile 
women and their controls ...................................................................................... 
186 
Table 4-57: X2 test for trend for immunoblot density scores in response to MOMP in 
infertile women and their controls ......................................................................... 
186 
18 
Table 4-58: Mean TNF(x concentrations in infertile women and their controls ........... 188 
Table 4-59: Conditional logistic regression of TNF(x concentrations for Infertile women 
and their controls ................................................................................................... 189 
Table 4-60: Mean IFN7 concentrations in infertile women and their controls ............. 191 
Table 4-6 1: Conditional logistic regression of IFN7 concentrations for infertile women 
and their controls ................................................................................................... 19-1 
Table 4-62: X2 test for trend for IFN7 responses to PHA in infertile women and their 
controls .................................................................................................................. 192 
Table 4-63: Mean IL-2 concentrations in infertile women and their controls .............. 194 
Table 4-64: Conditional logistic regression of IL-2 concentrations for infertile women 
and their controls ................................................................................................... 195 
Table 4-65: X2 test for trend for IL-2 responses to PHA in infertile women and their 
controls .................................................................................................................. 195 
Table 4-66: Mean 11-5 concentrations in infertile women and their controls ................ 197 
Table 4-67: Conditional logistic regression of IL-5 concentrations for infertile women 
and their controls ................................................................................................... 198 
Table 4-68: Mean IL-10 concentrations in infertile women and their controls ............ 200 
Table 4-69: Conditional logistic regression of IL- 10 concentrations for infertile women 
and their controls ................................................................................................... 201 
Table 4-70: Mean TGFP concentrations in infertile women and their controls ............ 203 
Table 4-7 1: Conditional logistic regression of TGFP concentrations for infertile women 
and their controls ................................................................................................... 204 
Table 4-72: Effects of gender ........................................................................................ 205 
Table 4-73: Effects of ethnicity - Mandinka ................................................................. 206 
Table 4-74: Effects of ethnicity - Fula .......................................................................... 
207 
Table 4-75: Effects of ethnicity - Wolof ....................................................................... 
207 
Table 4-76: Effects of ethnicity - Jola ........................................................................... 
208 
Table 4-77: Chlamydial PCR results ............................................................................. 
209 
Table 4-78: Effects of positive chlarnydial PCR ........................................................... 
209 
Table 4-79: Likelihood of having received BCG vaccination by age group ................. 210 
Table 4-80: Effects of prior BCG vaccination .............................................................. 
211 
Table 4-8 1: Prevalence of helminth and protozoan infection, and comparison with 
previous studies in The Gambia ............................................................................ 
212 
Table 4-82: Effects of intestinal helminth infection ...................................................... 
213 
19 
Table 4-83: Effects of intestinal protozoan infection .................................................... 213 
Table 5- 1: Stimulation of TNF(x, IL- I O! P IFN7 and 
TGFP by PMPG recombinant proteins 
............................................................................................................................... 
222 
Table 5-2: Number of cases required to give adequate power to determine significant 
differences between cases and controls ................................................................. 239 
20 
Abbreviations 
ýtg 
ýtl 
ýtm 
lox 
BCG 
BCIP 
bp 
BSA 
C. I. 
C02 
COW 
CTL 
dH20 
DNA 
dNTP 
EB 
EDTA 
ELISA 
FHAB 
9 
HIV 
HLA 
hsp 
ICAM- I 
IFN, y 
IgA 
IgE 
IgG 
IL- 
Inc 
IPTG 
kb 
kDa 
kHz 
LB 
LPS 
m 
MAdCAM-1 
mg 
MIF 
MIP 
ml 
mm 
MOMP 
A4D f" 
microgram 
microlitre 
micromolar 
ten-times strength 
bacillus Calmette-Gu6rin 
5-bromo-4-chloro-3-indolyl phosphate 
base pair 
bovine serum albumin 
confidence interval 
carbon dioxide 
chlarnydial outer-membrane complex 
cytotoxic T lymphocyte 
distilled/deionised water 
deoxyribonucleic acid 
deoxynucleotide triphosphate 
elementary body 
ethyl en edi amin etetrac eti c acid 
enzyme-linked immunosorbent assay 
filamentous haernagglutinin 
unit of gravity 
human immuno-deficiency virus 
human leukocyte antigen 
heat-shock protein 
intercellular adhesion molecule I 
interferon-, y 
immunoglobulin A 
immunoglobulin E 
immunoglobulin G 
interleukin - 
inclusion membrane protein 
isopropyl P-D-thiogalactopyranoside 
kilobase 
kilodalton 
kilohertz 
Luria-Bertani 
lipopolysaccharide 
molar 
mucosal addressin cell adhesion molecule I 
milligram 
microirnmunofluorescence assay 
macrophage infectivity potentiators 
millilitre 
millimolar 
major outer membrane protein 
XA -A. - -1 DL c'--l 
21 
mRNA messenger ribonucleic acid 
NBT nitro-blue tetrazoliurn 
OD optical density 
OEA ovine enzootic abortion strain (of Chlamydia psittaci) 
omP2 outer membrane protein 2 
omP4 outer membrane protein 4 
ORF open reading frame 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PCR polyrnerase chain reaction 
pgp3 polypeptide encoded by ORI`3 of the Chlamydia 
PHA phytohaernagglutinin 
PID pelvic inflammatory disease 
PIPES piperazine-N, N'-bis(2-ethanesulfonic acid) 
PMP polymorphic membrane protein 
PMP gene encoding polymorphic membrane protein 
POMP polymorphic (outer) membrane protein (-= PMP) 
PorB porin B 
PPD purified protein derivative 
RNAse ribonuclease 
RompA rickettsial outer-membrane protein A 
RPMI Roswell Park Memorial Institute 
RT-PCR reverse transcriptase polymerase chain reaction 
SDS sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SFS simple frozen storage 
STD sexually transmitted disease 
STI sexually transmitted infection 
TBS tris-buffered saline 
TEMED N, N, N', N'-tetramethylethylenediamine 
TF follicular trachoma 
TGFP transforming growth factor 
TI intense trachoma 
TLR2 Toll-like receptor 2 
TNFa tumour necrosis factor oc 
Tris tris(hydroxymethyl)aminomethane 
TS scarred trachoma 
TT trichiasis 
UK United Kingdom 
USA United States of America 
UV ultraviolet 
V volts 
v/V volume/volume 
VCAM-1 vascular cell adhesion molecule I 
W/v weight/volume 
W/W weight/weight 
x-gal 5-bromo-4-chloro-3-indolyl P-D-galactopyTanoside 
22 
Acknowledgments 
As a result of undertaking this piece of work I have learnt many things, some academic 
and some not. I have had the privilege of working with many fellow scientists and 
clinicians in London, Uganda and The Gambia and now count many of them as friends. 
I would especially like to thank David Mabey for helping to develop the original 
project proposal, for supervising my PhD studies, for his critical reading of the 
manuscript and for being my academic mentor for many years. Patrik Bavoil, and 
Ru-ching Hsia were also instrumental in developing the project proposal and in the 
molecular biology aspects of this work. I am also grateful to Robin Bailey for his input 
into the project development and for facilitating and coordinating the field work. 
I am grateftil to Alison Elliott for familiansing me with the whole blood assay, for 
introducing me to field-work in Africa and for her great hospitality in Entebbe; and to 
Angela Hunt-Cooke for coming to The Gambia to diagnose helminth and protozoal 
carriage. I am indebted to many colleagues in The Gambia, especially to Hassan Joof 
for his untiring and good-natured help with the field-work and for much sound advice; 
to Roland Roberts for his enthusiastic and conscientious processing of the immunoblots; 
to Gijs Walraven and Ros Coleman for their hospitality in Farafenni and to them and to 
Gloria Ekpo for help in recruiting the infertile women and controls; to Esther Aryee for 
carrying out the Amplicor PCRs on the conjunctival swabs; to Beryl West for carrying 
out the original PCRs, for always being happy to help with logistical problems, and for 
her friendship; to Nkoyo Faal for preliminary data analysis and to all the staff of the 
MRC laboratories in The Gambia for all their assistance and kindness. 
This study would not have been possible without the generous gifts of Chlamydia 
trachomatis elementary bodies from Rosanna Peeling, Mike Ward and Sylvia Everson, 
and of omP2 and HsP60 from Professor Hill Gaston. 
My wholehearted thanks goes to a few people whose help has gone far beyond the call 
of duty. Jim Todd stepped in to provide expert and very practical statistical advice; 
Sowsan Atabani demonstrated perfect African hospitality whilst at the same time having 
a solution to every problem both in the laboratory and outside it; Mike Kidd provided 
scientific help and advice, friendship and a roof over my head in The Gambia and 
indispensable critical advice on the manuscript; and Tamara Hurst who was involved in 
developing the original project proposal, provided scientific input into the whole blood 
assay and cytokine ELISAs, provided logistical support throughout the project, 
critically read the manuscript and whose scientific and pastoral support to all Fellows of 
the Wellcome Bloomsbury Centre for Tropical Medicine cannot be underestimated. 
Finally I would like to thank The Wellcome Trust Tropical Interest Panel for supporting 
this project through a Training Fellowship in Clinical Tropical Medicine, all the 
villagers in The Gambia who took part in the study, and my parents whose support for 
my endeavours has never wavered, and to whom this work is dedicated. 
23 
Cha ter One lp 
Background 
24 
Background 
1 
Background 
1 
.1 Chlamydia, the organism 
Chlamydiae are a phylogenetically unique group of gram-negative bacteria responsible 
for a large variety of diseases in humans, animals and birds. Four species are currently 
recognised: Chlamydia trachomatis, Chlamydia pneumoniae, Chlamydia psittaci and 
Chlamydia pecorum. Chlamydia trachomatiS and Chlamydia pneumoniae are 
principally pathogens of humans however Chlamydia trachomatis can also infect 
rodents and pigs' and Chlamydia pneumoniae can infect horses, koalas and frogS2. 
Chlamydia psittaci is primarily a pathogen of lower vertebrate mammals, koalas and 
birds with humans being accidental hosts. Chlamydia trachomatis is the focus of this 
work. There has recently been some discussion regarding radical changes to the 
taxonomy of Chlamydiacae 3, however this remains contentioUS4 and for the purposes of 
this thesis the current classification will be used. 
Within the host, Chlamydia exist in a non-acidified vacuole (inclusion) which does not 
fuse with the cell's lysosomes. Here the bacteria sustain a unique intracellular 
developmental cycle. Shortly after entry, the infectious but metabolically inert 
elementary bodies (EBs) differentiate to the metabolically active reticulate bodies (RBs) 
which undergo several rounds of multiplication before differentiating back to EBs. The 
host cell is then lysed to release the infectious EBs. 
1.2 Epidemiology and disease 
1.2.1 Trachoma 
Chlamydia trachomatis is the causative agent of trachoma, the commonest infectious 
cause of blindness and, some consider, the most common preventable cause of 
blindness. It is thought to account for an average of 15.5 per cent of blindness in 
developing countries, with figures ranging from 6.8% in Latin America and the 
Caribbean, to 19.4% in sub-Saharan Africa and 25.7% in the Middle East and central 
Asia. 5 Some 500 million individuals are affected by trachoma of whom 7 million are 
blind 6. Although not restricted to the tropics, trachoma is most prevalent in these 
regions through which it is widely distributed. Active disease is usually seen in children 
Background 
with transmission occurring either through close contact or by flies, and thus it is 
associated with overcrowding, poor sanitation, substandard levels of hygiene and 
medical care and poor standards of living. 
Infection begins in early childhood with conjunctivitis. Repeated cycles of trachomatous 
conjunctivitis and secondary bacterial infections follow. Over a number of years this 
leads to scarring of the conjunctiva and the eyelids (Figure 1-1). Scarring of the 
underside of the eyelids causes them to turn inwards so that the eyelashes abrade the 
cornea causing pain, inflammation, further bacterial infections and ultimately blindness. 
Antibiotic treatment is effective, though often not available, but the infection recurs 
rapidly leading to progressive eye damage. 
711M 
Trichiasis & corneal 
opacity 
Figure 1-1: Clinical progression of trachoma 
The field-work for this study took place in The Gambia. Here the second National 
Survey of Low Vision and Blindness in 1996 showed that 5.9% of children under 10 
years of age had active trachoma whilst 3.3% of adults had trichiasis. The situation is 
improving due to an excellent national eye care program and these are significant 
improvements from the initial study some 10 years earlier, for example the prevalence 
of active trachoma has decreased by 54%. 7 However recent reports of the emergence of 
drug-resistant mutants are cause for concern. 8 
1.2.2 Chlamydia trachomatis urogenital tract infection 
Chlamydia trachomatis infections are the most common bacterial sexually-transmitted 
infections (STIs) causing mostly urethritis and cervicitis. In United States there are an 
estimated 4 million cases occurring each year. 9"O The cost of treating these infections 
and their sequelae approached $1.4 billion a year in 1987 and must be considerably 
more now. Estimates of the prevalence of chlarnydial infection vary widely and most 
studies tend to collect data from individuals attending STD or ante-natal clinics where 
the prevalence is clearly very different forrn that in the general population. One recent 
study investigated the prevalence of infection in a variety of venues including Chinese 
26 
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food markets, Peruvian barrios, Zimbabwean villages and student dormitories in Russia. 
Overall the prevalence was 7.4%. The prevalence in women ranged from 13.9% in 
Russia to 3.7% in Zimbabwean villages. In men the prevalence ranged from 6.9% in 
Peruvian barrios to 1.6% in Zimbabwean villages. '' In the United Kingdom, as part of a 
national survey of sexual attitudes and lifestyles (Natsal 2000), 11,161 randomly 
selected, sexually active men and women aged 18-44 were screened for Chlamydia 
trachomatis by a ligase chain reaction (LCR) test on urine. Overall 2.2% of men and 
1.5% of women tested positive for Chlamydia trachomatis with the highest prevalence 
being in the 25-34 year olds where 3% of men and 3.1% of women had a positive 
antigen test for Chlamydia trachomatis. 12 
Approximately 10% of women who acquire Chlamydia trachomatis urogenital tract 
infections develop upper genital tract complications, such as salpingitis and pelvic 
inflammatory disease (PID), chronic inflammation and subsequent fallopian tube 
scarring which greatly increases the risk of ectopic pregnancy and tubal infertility. 13 
Epididymitis and prostatitis may complicate urogenital infection in men and Chlamydia 
trachomatis has been implicated in male infertility. ' 4,15 Chlamydial urogenital infection 
may also be associated with a reactive arthritis. 
The LI L2 and L3 strains of Chlamydia trachomatis cause another sexually transmitted 
disease, lymphogranuloma venereum, characterised by inguinal and sometimes 
generalised lymphadenopathy, and systemic symptoms such as fever, headache and 
myalgia. 
1.2.3 Other chlarnydial infections 
In addition to trachoma and urogenital tract infections which are the focus of this work, 
Chlamydia trachomatis also causes inclusion conjunctivitis in both adults and neonates, 
and pneumonia in infants. 
Chlamydia psittaci is primarily a pathogen of lower vertebrate mammals and birds but 
humans are sometimes infected and suffer a pneumonic illness, psittacosis, which may 
be severe. 
Chlamydia pneumoniae is an important cause of community-acquired pneumonia' 
6 and 
is currently the source of much interest due to its association with atherosclerosis. 
17 
Saikku first demonstrated higher titres of anti-Chlamydia pneumoniae antibodies in 
patients with atherosclerosis, 18 and subsequently the organism has been detected in 
27 
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atherosclerotic lesions by a immunohistochemistry, electron microscopy, polymerase 
19,20 
chain reaction (PCR) and culture. Animal models have shown that Chlamydia 
pneumoniae infection initiates vascular atheromatous changes in rabbits, 21 promotes 
atheroma development in mice, 22 and that antibiotic treatment of infected rabbits 
23 inhibits these atheromatous changes . Large studies are now underway in humans to 
see if antibiotic treatment of patients with coronary heart disease may be of benefit. 24 
1.3 Immune responses 
There is clear evidence of a degree of immunity developing in individuals with 
chlarnydial infection. Pathology is often due to repeated or recurrent infections, with 
epidemiological evidence suggesting that solid immunity is acquired slowly and may be 
strain specifiC25 . For example, active trachoma and the isolation of live organisms from 
the conjunctiva is seen principally in childhood 26 , and isolation rates in genital disease 
fall with age 27 or increasing duration of exposure 25 . This immunity appears to operate 
through both humoral (antibody mediated) and cellular mechanisms (in which antigen 
specific T-cells play the principal role), and there appear to be differences in the 
response to a primary and secondary infection. 
1.3.1 Innate responses 
The first line of defence against most bacterial infections are the phagocytes of the 
innate immune system, the neutrophils and the macrophages. 
Neutrophils appear to be important in controlling primary infection with Chlamydia 
where depletion of neutrophils results in a much higher bacterial load and more severe 
disease 28,29 but are of lesser importance in secondary infection where mice depleted of 
neutrophils are as able as a wild type mice to eradicate infection. 
30 
Chlamydia are effectively phagocytosed by macrophages and monocytes 
31 and induce 
the differentiation of monocytes into macrophages, 
32 which then act as antigen 
presenting cells and release interleukin-12 (IL-12) thus activating T-cells and triggering 
the adaptive immune response. However Chlamydia may persist within 
macrophages, 31,33 and macrophages activated by Chlamydia produce interferon -Y 
34 35 36 (IFN, y), nitric oxide and matrix metal loproteinases. Chlamydia may also replicate 
inside monocytes or macrophages triggering the production of pro-inflammatory 
28 
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cytokines such as turnour necrosis factor cc (TNFec), interleukin-I (IL-1) and 
interleukin-6 (IL-6). 37 
1.3.2 Humoral responses 
The importance of humoral responses to chlamydial infection has been the subject of 
much contention. Initially it was felt that humoral responses were of primary 
importance in defence against chlamydial infection. Certainly immature plasmablasts, 
or antibody secreting cells, responsive to chlamydial major outer membrane protein 
(MOMP), heat-shock protein-60 (HSP60) and whole EBs have been detected in the 
blood of patients with chlarnydial urogenital disease and individuals with both active 
and scarred trachoma, 38 and Chlamydia-specific immunoglobulin-G (IgG) and 
immunoglobulin-A (IgA) are detected in urethral swabs from men with Chlamydia 
trachomatis urethritis. 39 Women with cervical infection and high anti-chlamydial IgG 
levels are protected against subsequent salpingitiS40 and mice immunised intra-nasally 
with Chlamydia organisms developed antibody responses and were protected against 
subsequent genital infection and infertilit 1,42 . 
In the guinea pig model of genital tract 
infection also, Chlamydia-specific antibody seems to play a significant role in immunity 
as guinea-pigs given pooled immunoglobulins from immune animals had a lower 
43 organism load on subsequent genital infection with Chlamydia 
However, humoral responses are not essential in combating chlamydial infection. The 
presence of anti-chlarnydial antibodies in mice correlates poorly with protection from 
re-infection, 
44 
indeed mice deficient in B-cells and antibody develop strong immunity to 
45 
re-infection with Chlamydia trachomatis both in short and long-term . 
The evidence seems to suggest that humoral factors may be more important in 
resistance to re-infection than in combating primary infection. A study in B-cell 
knockout mice showed that cell-mediated immunity alone was sufficient to clear 
primary infection but that the B-cell deficient mice were then more susceptible to re- 
infection 46 , whilst 
Fc-receptor knockout mice were able to clear primary infection as 
well as wild-type mice but tended to have a more severe secondary infection. -'7 A 
similar study showed that B-cell deficient mice demonstrate no difference in immunity 
to re-infection to wild type mice to Chlamydia trachomatis 45 days after primary 
infection '48 
but after 70 days B-cell deficient mice are more susceptible to colonisation 
and re-infection . 
46 In another study, following resolution of primary infection, mice 
were depleted of both CD4 and CD8 T-cells and then re-challenged with Chlai? iYdia. 
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Depletion of both CD4 and CD8T-cells had only a very limited effect on the course of 
secondary infection suggesting that B-cell and/or antibody play an important role in 
immunity to secondary infection . 
49 Thus the evidence appears to suggest that B-cells 
and humoral responses may be more important for long-term memory. 
1.3.3 T-cell responses 
A rapidly expanding body of evidence points to the importance of T-cell responses in 
immunity to chlarnydial infection. Strong lymphoproliferative responses, to a number of 
50 
chlamydial antigens, are associated with resolution of chronic infection in trachoma . 
The fact that Chlamydiae reside within a vacuole inside the host cell makes it unclear 
how chlarnydial antigens could gain access to either the major histocompatibility 
complex (MHC) class I or class 11 processing systems. Despite this around 30 human 
leukocyte antigen (HLA) class 11-restricted T-cell epitopes 51,52 and eight HLA class I- 
53,54 
restricted cytotoxic T-lymphocyte (CTL) epitopes in MOMP have been described . 
Evidence regarding the relative contributions of CD4 and CD8 T-cells is not clearly 
defined and at times conflicting. Approximately equal numbers of CD4 and CD8 T-cells 
are seen in acute chlarnydial infection of the human cervix 
55, 
the guinea-pig genital tract 
56 57,58 
and eye and the genital tract and eyes of non-human primates . Increased MHC 
class I and class II expression has been seen in infected epithelial cells in trachoma, 59 
though MHC class 11 restricted T-cell responses, but not MHC class 1, were shown to be 
important in resolving genital Chlamydia trachomatis in mice 60 . 
Depletion of both CD4 and CD8 T cells in mice leads to increased pulmonary organism 
load in Chlamydia trachomatis pneumonia, but only CD4 T cell deletion leads to 
increased mortality 61 . 
In further studies, both CD4T cells (producing both THI and TH2 
cytokines on stimulation)62 and CD8 cells 
63,64 were able to transfer adoptive immunity. 
Depletion of CD4but not CD8 T-cells leads to a much prolonged course of secondary 
infection in B-cell deficient mice but has no effect on the ability of animals to resolve 
65 that infection and in humans the risk of pelvic inflammatory disease (PID) is 
independently associated with falling CD4 T cell levels in human immunodeficiency 
66 
virus (HIV) infection 
The role of MHC Class I-restricted CD8 T-cells in protective immunity remains 
controversial. CD8 cells from the synovial fluid of patients with Reiter's syndrome 
proliferate in response to chlamydial antigens, 67 and Chlamli,, (Iia-specific cytotoxic T 
cells have been found in the blood of patients with trachoma, 
68 but the significance of 
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these remains uncertain. In vitro studies suggest that CD8 T-cells are cytotoxic for 
Chlamydia-infected cells, 69-7 1 but in vivo studies suggest only a minor role. Chlamydia- 
specific CD8 cells, isolated from mice following infection with Chlamydia trachomati . S11 
were able to lyse Chlamydia-infected cells and adoptively transfer protection to naive 
mice in some experiments 63 , 
but not in others, 62 and in the murine model, depletion of 
CD8 cells had no effect on clearance of infection. 65 CD8 T-cells may also have a role to 
play through the production of IFN'y, 72 which appears to mediate cytotoxicity 73 , and also 
inhibits chlamydial activity. 74,75 Chlamydia suppresses IFNy-inducible MHC class I and 
11 expression. 76,77 The suppression of MHC class I synthesis would prevent the 
processing and presentation of chlamydial epitopes on the infected cell surface and 
therefore preclude recognition and subsequent lysis by CTLs. 76 Human peripheral 
blood mononuclear cells (PBMCs), infected with Chlatnydiapneutnonlae, secrete IL-10 
which down-regulates expression of MHC class I molecules. One consequence of this 
may be a reduction in the presentation of bacterial epitopes by MHC. This would 
77 decrease the ability of CD8 T-cells to eliminate infected cells . 
1.3.4 Cytokine responses and the relative importance of TH1- 
and TH2-type responses 
Much of the field work in this study concentrates on the cytokine responses to a number 
of chlarnydial antigens. The inter-relationships between the various cytokines produced 
in response to infection is hugely complex. One useful way to look at cytokine 
responses is in terms of the THI/TH2 dichotomy. 
Mosmann et al first identified two sub-populations of CD4T-cells in mice in 1986 on 
the basis of their cytokine secretion patterns. He described THI-type T-cells which 
produce interleukin-2 (IL-2) and IFN7 and a TH2-type population which produce 
interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin- 10 (IL-10). Subsequently it 
was felt that these two subsets were derived from 
THO cells that secrete both 
THI and 
TH2 cytokines. 78,79 There was some controversy as to whether a similar dichotomy 
existed in humans until the first evidence was presented in 1991. " A THI -type response 
is now defined as a strong cellular response with nonnal or increased 
levels of IL-2, 
IFN7, TNF(x and/or IL- 12, while a TH2-type response is characterised by a 
predominantly humoral response with an increase in the levels of ILA IL-5, 
IL-6, IL- 10 
and interleukin-13 (IL-13) together with an increase in one or more B-cell activities 
(hypergammaglobul ina emi a, autoantibody production or hyper-immunoglobulin E). 
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The classification is based on the relative predominance of either a cell-mediated or 
humoral-type response and not on an absolute dichotomy of either type of cytokine 
response. The definition of THI and TH2-type responses is now generally expanded to 
include not only responses by T-cells, but also those by monocytes/macrophages, 
natural killer cells, B cells, mast cells and eosinophils, all of which are now known to 
produce cytokines originally attributed only to CD4+ T-cells. 
Differing cytokine profiles have been described for T-cell responses to various 
microbial pathogens. THI responses have characteristically been associated with the 
resistance to, and elimination of, intracellular pathogens such as Mycobacterium 
tuberculosis 81,82 , 
Mycobacterium leprae 83 and Leishmania major 84 . 
TH2 responses, on 
the other hand, are elicited by helminth infection and correlate with protective immunity 
85,86 for several species of parasitic nematode 
A study of the progress of chlarnydial genital infection in mice showed that cells 
producing the THI pro-inflammatory cytokines IL-12 or TNF(x were the first to be 
detected, with cells producing the TH2 anti -inflammatory cytokines IL-4 and IL -10 
being present in greatest numbers at three weeks post infection, a time when the 
infection was nearing resolution. They were unable to convincingly demo nstrate the 
presence of either IL-5 or IFNy using immunohistochernical staining. 
87 THI -type 
responses however appear to be essential for the resolution of chlarnydial infection. 
THI-deficient mice fail to clear primary genital infection with Chlamydia despite 
generating high levels of a specific antibody, whilst TH2-knockout mice clear infection 
as well as wild type mice . 
44 THI-type responses are associated with resolution of 
Chlamydia trachomatis infection in mice 314 and TH2-type responses with scarring in 
trachoma 315. Interestingly, mice mounted a predominantly THI-type response to primary 
genital chlarnydial infection but a more mixed picture on subsequent infection 
89 
. 
Lymphocytes isolated from Chlamydia-infected genital tracts demonstrate a 
predominance of THI-type cytokine and messenger ribonucleic acid 
(mRNA) 
responses9o, 9'. Additionally anti-cytokine antibodies that diminished TH2-type responses 
are beneficial and those that inhibit THI-type responses are 
detrimental to the host 
92 
response to infection 
Much recent work has focused on Chlamydia pneumoniae due to its association with 
atherosclerosis. Due to the differences in the structure, biology and pathogenesis of 
Chlam, výha pneumoniae and Chlam. vdia trachomat's extrapolating the results of 
experiments with Chlamy, dia pneumoniae to other chlamydial species should be 
done 
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with caution. However, infection with Chlamydia pneumoniae appears to be a potent 
inducer of pro-inflammatory cytokine production. The growth of Chlamydia 
pneumoniae inside monocytes or macrophages triggers the production of pro- 
inflammatory cytokines such as TNF(x, IL-1 and IL-6 37 and PBMCs stimulated with 
sonicated Chlamydia pneumoniae produce TNFoc, IL-1, IL-6, interleukin-8 (IL-8), 
monocyte chemoattractant protein-I and macrophage inflammatory protein-1.93 . This 
appears to be mediated through the Toll-like receptor-2 (TLR2), an innate immune 
receptor involved in the pattern recognition of bacterial pathogens. 94 IL-12 is an 
important pro-inflammatory cytokine which augments natural killer cell and T-cell 
cytotoxic activity, promotes THI differentiation and induces the production of IFN'Y and 
other cytokines. 95 IL- 12 is critical for the development of TH I -type responses, and IFN'y 
production induced by chlamydial infection is mediated largely in an IL-12 dependent 
fashion. Mice with pulmonary Chlamydia pneumoniae infection produced IL- 12, IFN'Y, 
TNF(x and IL-10. Depletion of IL-12 resulted in markedly reduced levels of IFN'Y 
production and a much higher organism load. Clearance of the organism was delayed 
but it did occur. 96 
IFN, y appears to play a very important role in clearing chlarnydial infection. IFNy has 
been shown to directly inhibit the growth of Chlamydia trachomatis, Chlamydia psittaci 
and Chlamydia pneumoniae. 75 Neutralisation of IFNy resulted in an increase in both in 
the number of organisms seen in the lung and also in the severity of pneumonia in the 
murine Chlamydia pneumoniae model'97 whilst mice deficient in IFN'y are unable to 
completely resolve genital tract infection, and chlarnydial infection in those mice 
disseminates to systemic sites 98. In other experiments IFNy-receptor knockout mice 
were able to clear primary genital infection but were not able to resist re-infection 
suggesting that they failed to develop protection, whilst IFN'y knockout mice were 
unable to clear even primary infection. 44 
TNF(x is another cytokine which has been extensively studied in the context of 
chlamydial infection. TNF(x is a pro-inflammatory cytokIne released primarily from 
monocytes and macrophages upon invasion of the host by a wide variety of pathogens. 
Mouse spleen cells infected with Chlamydia trachomatiS generate TNFOC99 and high 
levels of TNFoc are found in genital tract secretions during the first week of primary 
chlarnydial infection. 100 In humans TNF(x is found in the genital tract of women with 
chlarnydial salpingitislol and levels of TNF(x in the tears 
102 and conjunctivae' 03 are 
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higher in individuals with trachoma than in controls. In a murine model of chlarnydial 
pneumonia, exogenous administration of anti-TNF(x increased the bacterial load in the 
lungs and significantly accelerated mortality. ' 04 TNF(x also appears to directly inhibit 
the growth of Chlamydia, at least in vitro. 105 However TNF(x is not essential for 
clearance of Chlamydia: mice deficient in the TNF(x receptor show only a marginal 
delay in the rate of clearance of Chlamydia from the genital tract, 106 whilst local 
blockade of TNFcc in the genital tract had no effect on the course of the ascending 
infection or on the resultant chronic tissue pathology. 107 
1.4 Chlarnydial antigens 
1.4.1 Major Outer Membrane Protein (MOMP) 
The major outer membrane protein of Chlamydia trachomatis (MOMP) is the dominant 
surface protein (-60% of outer membrane content) which functions as a structural 
protein. 108 but also as a porin'09,110 and possibly an adhesin"'. It is the serologically 
variant antigen that defines the serovars. 1 12,113 MOMP is encoded by the ompA gene 
which consists of five conserved sequence regions alternating with four variable 
regions. 1 14 Serovar-specific antibodies are directed towards amino-acids sequences 
encoded in these variable segments. ' 15 Over 15 serovariants, or serovars, of Chlamydia 
trachomatis have been described. The tendency for successive infections to be with 
different serovars of Chlamydia trachomatis suggests that protective immunity is in part 
associated with sequences that vary among scrovars 25 and this, together with the relative 
abundance of MOMP has meant that it has been extensively studied. 
61% of individuals with chlarnydial urethritis or cervicitis were found to be positive for 
anti-Chlamydia trachomatis MOMP IgG compared to 16% of 'healthy' blood donors. 116 
A number of B-cell epitopes have been determined, and neutralising antibodies have 
been produced to a number of these' 17-11 9. T-cell responses to epitopes in both the 
constant and variable regions of MOMP have been described in Chlamydia trachomatis 
infected subjects. 52 
There have been some successes using MOMP as a potential vaccine candidate. Rabbit 
anti-MOMP IgG has been shown to neutralise infectivity despite not affecting 
internalisation' 20, and passive immunisation of pregnant mice with anti-MOMP 
ics prevented infection and foetal loss 121. One anti-MOMP monoclonal antibody antibod* I 
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was able to protect mice from intravenous challenge with EBs and prevent infection of 
monkey's conjunctivae 122 The T-cell epitope, TINKP, elicited recall responses and 
protected against salpingitis, 123 and MOMP, enclosed within 'liPophilic immune 
response stimulating complexes' and injected intramuscularly, has been shown to 
induce a local genital mucosal THI response which protected against subsequent 
Chlamydia trachomatis infection and which could be adoptively transferred to naive 
syngeneic animals. 124 
In general, however, attempts at generating protection using peptide and denatured 
Chlamydia trachomatis MOMP protein have failed (review 125). Intramuscular 
immunization of mice with chlamydial deoxyribonucleic acid (DNA) encoding the 
chlamydial MOMP induced both cellular and humoral immune responses suggestive of 
a THI-biased immunity, and the immunized mice suffered less weight loss and had a 
100-fold reduction in pulmonary organism load. 126 In another experiment however, 
MOMP DNA vaccination failed to protect mice against subsequent genital challenge. 127 
Though initially the most promising sub-unit vaccine candidate, MOMP has so far 
failed to deliver on that promise. 
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Figure 1-2: Putative model of the envelope of chlarnydial elementary bodies. Adapted 
from Everett et a 1128 and Hatch . 
129 
1.4.2 Outer Membrane Protein 2 (omp2) 
OMP2 is the second most abundant protein in chlarnydial elementary bodies and is 
expressed when reticulate bodies differentiate into elementary bodies. ' 30 Antibodies to 
omP2 have been reported to be present in the majority of patients infected with 
Chlamydia. 1 31,132 17/17 patients with Chlamydia trachomatis urethritis had antibodies to 
omP2 133 in one study whilst in another 89% of individuals with chlamydial urethritis or 
cervicitis were found to be positive for anti-OMP2 IgG compared to 43% of 'healthy' 
blood donors. 116 The authors suggested that the high level of false positives might be 
35 
Background 
due to cross reaction with Chlamydia pneumoniae omP2. Another group tested seven 
different fragments of the omP2 protein for immunoreactivity in the sera of patients with 
Chlamydia infection and all were found to be reactive. 134 The importance of these 
antibodies is uncertain however as OmP2 appears to be confined to the inner surface of 
the EB's outer membrane. 130,135 
T-cells responsive to omP2 have been detected in both mice' 36 and humans. Chlamydia 
trachomatis-specific CD4 T-cells from patients with Chlamydia trachomatis-induced 
reactive arthritis and with chlamydial urethritis, have been shown to respond to both 
whole omP2 and epitopes of OMP2, though the levels of response were lower than those 
to whole EBs, suggesting that, although omP2 represents a major component of the 
protein composition of EBs, other less abundant proteins may be more important as 
targets of the immune response. ' 37 
1.4.3 Heat-shock protein 60 (HsP60) 
Heat shock proteins are highly conserved across species, chaperoning newly synthesised 
or damaged proteins during their intracellular folding or unfolding, assembly and 
translocation and also function to stabilise cellular proteins during a variety of 
conditions such as heat shock, infection and inflammation. 138 Antibodies to chlamydial 
HsP60 are common in chlamydial infections, 61% of individuals with chlamydial 
urethritis or cervicitis were found to be positive for anti-chlarnydial HsP60 IgG 
compared to 23% of 'healthy' blood donors, 116 and seem to be more common with 
prolonged or recurrent infection - the prevalence of antibodies to HsP60 is low amongst 
healthy controls but increases as chlamydial genital tract disease becomes more 
severe. 139 HsP60 antibody responses were found in 32% of Gambians with trachomatous 
scarring compared to 16% of controls (P < . 001)140 and anti-HSP60 antibodies were 
found in tears of Nepalese subjects with trachoma. 
14 1 T-cell proliferative responses are 
seen in trachoma patients who resolve their infection 
50 
. 
HsP60 has been shown to be a potent stimulant of immune and inflammatory responses. 
Both human and chlamydial HsP60 activate human PBMCs, monocyte-derived 
macrophages and endothelial cells through CD14 signalling and p38 mitogen-activated 
protein kinase via NF-KB through the Toll-like receptor 4,142 in the same way as 
bacterial lipopolysaccharide (LPS). 143 Chlamydial HsP60 has been shown to induce the 
expression of TNFCC, IL-6, matrix metal loprotease s, E-selectin, intercellular adhesion 
molecule- I (ICAM- 1), and vascular cell adhesion molecule- I (VCAM- 1). 
144-147 
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Mice immunised intra-nasally with a DNA vaccine encoding Chlamydia pneumoniae 
HSP60 demonstrated a reduced bacterial load and decreased seventy of disease after 
challenge though no specific antibodies were detected. In contrast mice immunised 
intradermally developed Ch lamydia- specific IgG but were not protected against 
challenge with Chlamydiapneumoniae. 148 
Because of the highly conserved nature Of HsP60, responses directed against microbial 
lisp may also be deployed against autolOgOUS HSP. These cross-reactive responses could 
convert the protective immune responses into pathological ones. This is discussed 
further in section 1.5. 
1.4.4 The polymorphic membrane proteins (PMPs) 
The family of polymorphic membrane proteins, known as PMPs or POMPs , were 
first 
identified, by Longbottorn. et al, in 1996 on screening of a Chlamydia psittaci /'ýgt II 
genomic expression library with post-abortion sera from sheep infected with C psittaci 
ovine enzootic abortion strain (OEA). They identified four members of a multigene 
family encoding proteins of approximately 90 kilodaltons (kDa) which appeared to be 
localized to the chlamydial surface membrane 149 .A number of other groups also began 
looking at this gene family and the Chlamydia Genome Project (http: //chlamydia- 
www. berkeley. edu: 4231) later reported 9 members of the pmp family in Chlamydia 
trachomatis and 21 in C. pneumoniae. There are at least 6 pmp genes in Chlamydia 
psittaci. 150 
Comparison of the pmp genes encoded within isolates of Chlamydia pneumoniae from 
the United States and from Japan demonstrated truncation of two of the pmp genes in 
the Japanese strain. This appeared to be due to frameshift mutation. The remainingpmp 
genes were very highly conserved between the two strains. 151 Similarly, comparison of 
the pmp genes encoded within isolates of Chlamydia pneumonlae from the United 
States and from Denmark demonstrated only one nucleotide difference between the two 
strains and this also resulted in a truncated PMP protein due to the deletion of a single 
residue which gave rise to a premature stop codon. 1 52 In a restriction fragment length 
polymorphism analysis (RFLP) all the pmps (except pmpB) were compared from 
isolates of Chlamydia trachomatis serovars B and K and the previously sequenced 
serovar D. Between these serovars, pmpH vaned by almost 4% and pmpE by 2%. 
Serovar K had a6 base pair (bp) deletion at the 5' end and serovar B had a3 bp 
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insertion at the 5' end. No 'marked' variation was noted in the pmpA, pmpC, pmpF, 
pmpG, pmpH or pmpI genes. 153 
The PMPs appear to be surface-localised proteins. The predicted secondary structure of 
these proteins is predominantly of P-pleated sheets, typical of bacterial surface proteins 
whose membrane spanning regions are formed by P-strands. Also typical of bacterial 
outer membranes is the consistently present carboxyl-terminal phenylalanine' 54 . These 
proteins are relatively cysteine-rich, having between 9 and 26 cysteine residues in the 
case of Chlamydia trachomatis PMPs, representing between 0.9 and 2.1% of the 
proteins' amino acid composition; this is similar to the figure of 1.9% for MOMP. 
These cysteine residues may be important for disulphide cross-linkage of the surface 
proteins as has been shown for MOMP - which does not migrate on sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) unless a reducing agent is 
added to break these disulphide bonds. The 98 kDa proteins do migrate on SDS-PAGE 
in the absence of a reducing agent which is more suggestive of intra-molecular rather 
than inter-molecular bonding 155 . More recent computer modelling has predicted parallel 
P-helices in the amino-terminal regions of most pmp genes in Chlamydia 
pneumoni . ae. 156 imi ar structures are found in a number of pathogenic organisms and 
are often associated with virulence, such as the filamentous haemagglutinin adhesin of 
Bordetellapertussis. 157 
Amino Mol wt. i 
Cysteine 
acids kDa P No % 
pmpA 975 106 8.58 9 0.9 
pmpB 1751 183 5.52 19 1.1 
PMPC 1770 187 4.52 14 0.8 
pmpD 1531 161 4.75 26 1.7 
pmpE 964 105 6.80 15 1.6 
pmpF 1034 112 8.88 13 1.3 
pmpG 1002 106 5.26 15 1.5 
pmpH 1016 108 6.08 14 1.4 
pmpl 1 878 96 6.09 18 2.1 
Table 1 -1: Characteristics of the Chlamydia trachomatis pmps 
Apart from these predictions based on the amino acid sequence, a considerable body of 
evidence pointing towards a surface localisation comes from studies of the chlamydial 
outer membrane complex (CONIC) which can be isolated and purified'08. Chlamydia 
psitfaci COMCs contain an immunogenic 89 kDa protein which is synthesised early in 
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the life cycle and is not particularly strongly cross-linked by disulphide bonds, 58 . 
Further immunoblotting studies of Chlamydia psittaci COMCs with post-abortion sera 
from infected ewes demonstrated a triplet of bands at 90-95 kDa which, on Coomassie 
staining of SDS-PAGE gels, were shown to correspond to proteins present only in very 
small amounts, suggesting that these proteins are highly immunogenic 159 . Immune sera 
from convalescent animals recognises the 98 kDa antigen on SDS-PAGE separated 
COMC's of Chlamydia pneumoniae 155 . Evidence that these proteins are indeed the 
PMPs has been facilitated by the cloning of a number of pmp genes as this has allowed 
the production of recombinant proteins for immunoblotting, and specific monoclonal 
antibodies which can then be used for immuno-staining of whole Chlamydia and 
COMCs. In one study a recombinant 98.9 kDa PMP protein from Chlamydia 
pneumoniae was recognised by polyclonal antibody to Chlamydia pneumoniae COMCs 
whilst conversely monoclonal antibody against this PMP recognised a double band of 
proteins from Chlamydia pneumoniae EB's at 96-97 kDal 60 . Interestingly this group 
found that recognition of their recombinant proteins was greater when samples were not 
boiled before SDS-PAGE (when the 97/99 kDa proteins migrate as if 65 kDa) 
suggesting that conformational, non-linear epitopes may be important 161 . One of their 
PMPs, outer membrane protein 4 (omM), was shown to be exposed on Chlamydia 
pneumoniae organisms in the lungs of infected mice by immuno-staining with 
polyclonal anti-omP4 antibody whilst another, outer membrane protein 5 (OmP5) was 
shown to be exposed on Chlamydia pneumoniae in tissue culture but was not seen in 
vivo, suggesting that perhaps not all the PMPs are expressed in vivo'61. Immuno- 
electron microscopy of Chlamydia psittaci demonstrated surface localisation of the 
162 
PMP proteins on RBs but not on EBs where it appeared to be located periplasmicaly . 
This was in contradiction to other findings, a similar study, using different antibodies 
does appear to convincingly demonstrate surface localisation of the Chlamydia psittaci 
PMPs on both EBs and RBs'63. A recent study, using a combination of electrophoresis 
and mass spectroscopy has clearly demonstrated that at least PmPG and PmPH are 
located on the outer membrane of Chlamydia trachomatis, 
164 whilst another study, using 
both immuno-staining and detergent solubility, showed that PmPD of Chlamydia 
trachomatis L2 is also located on the surface. 165 
It has been suggested that the Chlamydia psittaci PMPs might have two domains 
separated by the short central polyglycine region, and that the carboxyl-terminal domain 
might be hidden. Supporting evidence comes from the fact that in natural infection in 
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sheep, antibodies are not produced to the carboxyl-terminal, even though it has been 
shown to be immunogenic, whilst antibodies are generated to the amino-tenninal 
'domain' 159 
. Further evidence 
is provided by the paucity of immuno-staining of whole 
EBs with antibodies to the carboxyl-terminal compared to marked staining by amino- 
terminal antibodies' 63 . Further studies are required to confirm or refute this hypothesis. 
In Chlamydia trachomatis only one of the PMPs, PMPH, has a polyglycine region. 
pff4vD nrM 
cordig 10 5 
912B, MOB rWA PrIVE 
corgig 11 2 
contig 11 3 
cordig 11 ýý 
EF 
entire genome ABC D GHI 
Figure 1-3: pmp gene arrangement within Chlamydia trachomatis genome 
In Chlamydia trachomatis the nine PMPs have predicted molecular weights ranging 
from 96 to 187 kDa, with a mean molecular weight of 129 kDa. Despite the small 
genome of Chlamydia these genes comprise 3.2% of the Chlamydia trachomatis 
genome. In an organism with such a small genome and so little redundant DNA it seems 
unlikely that a multigene family such as this would be present if it did not fulfil an 
essential role. The amino acid identity within the family varies from 2- 26% 166 . This 
figure hides the fact that within the genes are regions of high homology separated by 
much more variable regions. Structurally the pmp genes are encoded within three 
clusters, one containing pmpA, pmpB and pmpC, one containing only pmpD and finally 
one containing pmps E to I (Figure 1-3). Phylogenetically they also fall into three major 
groups but these do not appear to have any relationship to their localisation within the 
genome. These groups can be further subdivided into 6 smaller groups which, if 
analysed together with the Chlamydia pneumoniae pmps, each contain at least one 
Chlamydia trachomatis and one Chlamydia pneumoniae pmp, suggesting that perhaps 
each of these sub-groups has a specific function' 67 . The exception to this 
is Chlamydia 
trachomatis pmpG which clusters with II Chlamydia pneumoniae pmps which appear 
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to have arisen through gene duplication. The presence of the repetitive GGAI element 
has been noted to be a feature of the pmp family of genes 167 in Chlamydia pneumoniae 
and are seen here in all the Chlamydia trachomati .s pmp genes with the exception of 
pmpH which co-incidentally is the only Chlamydia trachomatis pmp which does 
possess the polyglycine central region which is a feature of the Chlamydia psittaci pmPs 
identified to date. As noted for Chlamydia pneumoniae this GGAI motif is confined to 
the amino-terminal of the proteins. 
There is some evidence that the PMP proteins may undergo some post-translational 
modification. Certainly there are glycosylation and phosphorylation sites present in the 
pmp genes which may be involved in post-translational modification. ' 68 
Work on the functional biology of the PMPs is still at an early stage. Reverse- 
transcriptase polymerase chain reaction (RT-PCR) studies suggests that all the pMPs are 
transcribed and at least four are transcribed as early as 10 hours, 66 although 
immunofluorescent staining did not detect PMPs until 30-36 hours, 59,169. This 
discrepancy may be explained by the low abundancy of the proteins and the lesser 
sensitivity of the method. If they are all transcribed throughout the life cycle this implies 
that they are functionally important in both RBs and EBs. The function of these proteins 
remains unknown although it is tempting to speculate that such a family of homologous 
genes might be involved in antigenic variation, in adaptation to various host 
environments, or in tissue tropism, though the number of genes in Chlamydia 
trachomatis is low compared to those involved in antigenic variation in trypanosomes 
and plasmodia for example. A search of genome databases for proteins with homology 
to the Chlamydia PMP proteins, looking for the GGAI or the GGA[I/L/Vj and FxxN 
motifs, revealed homology to membrane proteins of four other bacterial species: the 
rickettsial outer membrane protein A (RompA) of several Rickettsia species which 
appear to be involved in adhesion, Bordetella pertussiS adhesin FHAB, Helicobacter 
pylori HP1288 and Eschericia Coli YFAL proteins, the functions of which are 
unknown. 1 52 
Homology searches also showed that the Chlamydia pmp genes were frequently 
identified with members of the autotransporter family, leading one group of researchers 
to suggest that the chlarnydial PMP proteins may indeed be members of this family. ' 70 
The autotransporter family, sometimes known as the Type V secretion system, is a 
highly efficient mechanism of protein export found amongst gram-negative bacteria. 
Proteins secreted through this pathway all have a similar configuration consisting of a 
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signal sequence, a passenger domain and a carboxyl-terminal translocating unit. The 
secreted protein crosses the inner membrane by a sec-dependent mechanism but then the 
carboxyl terminus assembles into a P-barrel pore in the outer-membrane and the 
passenger domain is transported through this to the bacterial surface. At the surface the 
passenger domain and the P-domain either remain intact or are cleaved into separate 
subunits. Autotransporters may be the primary mechanism of protein transport in many 
gram negative pathogens with autotransporter proteins being discovered in Neisseria, 
Haemophilus, Bordetella and Helicobacter as well as several members of the 
Enterobacteriacae including Shigella and Eschericia Coll -. 171 It is suggested that the size 
of the proteins (90 - 187 kDa) greatly exceeds that expected for membrane proteins 
which are typically 30 to 90 kDa but would be typical sizes for autotransporter proteins 
which range from 50 to 300 kDa. 171 One 144 kDa PMP protein has been shown to 
migrate on SDS-PAGE as a 100 kDa protein which would be consistent with a 
processed protein having had the -40 kDa carboxyl-P barrel cleaved from the passenger 
domain. They also argue that the arrangement of motifs within the gene would be 
typical of autotransporters with a signal sequence being followed by functional motifs 
and then the carboxyl terminal unit. Certainly there are interesting functional motifs 
encoded within the pmp genes including serine proteases, leucine zippers and RGD 
adhesion motifs. Additionally the PMP proteins all have a predicted carboxyl-terminal 
amphipathic P-sheet which might be capable of forming a P-barrel translocation unit. 
The GG[A/LN/1][I/LN/Y] motif followed at a variable distance by the FxxN motif, 
found throughout the PMP proteins, is a common feature of many autotransporter 
17 1 proteins. 0 The authors find themselves drawn to the conclusion that the chlamyd'al 
PMP proteins really are autotransporters. Clearly this is speculative but the evidence is 
fascinating and certainly plausible. 
Evidence of the immunogenicity and importance of these proteins has been building 
over the last decade, even though the identity of the 90-98 kDa proteins was not known. 
In 1989 it was noted on SDS-PAGE analysis of Chlamydia psittaci that invasive strains 
172 
had a protein band present at 98 kDa which were not seen with non-invasive strains 
Later these virulent, abortion- inducing, strains were noted to be mostly of serotype I 
whilst the non-invasive intestinal forms belonged to two other serotypes 
173 
. This raised 
the possibility that the 98 kDa strains might somehow be involved in virulence an/or be 
scrotype specific. Antibodies to this virulent strain, raised in rabbits and mice, were 
shown to recognise Chlamydia psittaci proteins of 96,90 and 88 kDa on 
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immunoblotting 174 
. 
Later the same group noted the presence of highly reactive 
antibodies to 80-90 kDa proteins on immunoblots of Chlamydia psittaci EB's when 
screened with sera from post-abortion ewes infected with Chlamydia psittaci OEA. 
These antibodies appeared to be serotype-specific suggesting variability in the relcý'ant 
antigens between serovars 175 
Although antibodies to a number of chlamydial proteins, such as MOMP demonstrate 
considerable cross -reactivity between the species, antibody responses to the 90-98 kDa 
proteins show considerable species and even serovar specificity. This has been noted 
both in rabbits, using Chlamydia pneumoniae 98 kDa protein 155 , and in humans. 
Immunoblotting convalescent sera from patients with Chlamydia pneumoniae infection 
against Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci EB 
proteins, the 98 kDa proteins of Chlamydia pneumoniae but not those of Chlamydia 
trachomatis or Chlamydia psittaci were recognized by the sera whereas there was 
considerable cross -reactivity of other proteins (68,60,30 kDa proteins and MOMP). 
Reaction to the 98 kDa proteins appeared to correlate with high titres of circulating anti- 
Chlamydia pneumoniae antibody when followed over time in individual patients. No 
sera from patients negative for anti-chlarnydial antibodies recognized the 98 kDa 
proteins but all patients from whom Chlamydia pneumoniae was isolated, did 176 . In 
another series, protein from the EBs of Chlamydia trachomatis, Chlamydia pneumoniae 
and Chlamydia psittaci was immunoblotted with sera from patients infected with 
Chlamydia trachomatis, Chlamydia pneumoniae or both. They found that antigens of 
1705 155,145,120,115,100,57 and 38 kDa were specific for Chlamydia trachomatis, 
antigens of 175,130,110,98 and 30 kDa were specific for Chlamydia pneumoniae and 
antigens of 90,80,75,62,60 and 55 kDa were recognized by sera from patients 
infected with either of the species. Only 39% of their Chlamydia pneumoniae patients' 
sera recognised Chlamydia pneurnoniae 98 kDa protein 177 . In one other similar study 
sera from the majority of patients with Chlamydia pneumoniae infection recognised the 
98 kDa Chlamydia pneumoniae protein but it was not recognized by sera from patients 
with Chlamydia frachomatis infection, who recognised only Chlamydia pneumoniae 
proteins of 73,68,65 and 62 kDa 178 . 
Since the formal identification of the PMP family, 
work has been ongoing to demonstrate specific responses to these proteins. PMP10 (of 
the PmPG family) from Chlamydia pneumoniae has been shown to be an 
immunodominant antigen, with antibodies against it being generated during natural 
disease. 179 In further, recently reported work, an indirect enzyme-linked immunosorbent 
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assay (ELISA) test was used to determine antibody responses to both MOMP and to a 
recombinant POMP-9 IB from Chlamydia psittaci OEA, in sheep with experimentally 
induced abortion. The POMP-based ELISA successfully detected all cases of 
Chlamydia psittaci OEA infection and antibodies became detectable early in the 
infection. In contrast antibodies to MOMP developed later with a small number of 
animals never having detectable anti-MOMP antibodies. They concluded that a POMP- 
based ELISA could be a highly sensitive and specific test of Chlamydia psittacl OEA 
infection in sheep flocks. 180 
It seems clear then that antibodies to the 90-98 kDa antigens appear to be produced in 
response to chlamydial infection, they have even been implicated in the association 
between Chlamydia pneumoniae and coronary heart disease. Patients with circulating 
antibodies to the Chlamydia pneumoniae 98 kDa antigens appear to have an increased 
incidence of coronary heart disease with an odds ratio of 2.3 (95% confidence interval 
1.3-3 . 9)181, whilst investigation of the antibodies bound to circulating immune 
complexes in coronary heart disease showed them to be specific for 98 and 42 kDa 
Chlamydia pneumoniae proteins' 82 . Even more controversially 55% of patients with 
sarcoidosis were noted to have antibodies to Chlamydia pneumoniae 98 kDa antigen 
compared to 30% of patients with acute respiratory infection. Unfortunately there was 
no control group and the differences here are not significant 183 . One 
difficulty of these 
immunoblotting studies is that there is no standardisation of the antigen quantities used 
or the dilution of sera, the latter ranging from I in 20 to I in 200 in the studies quoted 
here. The results, therefore, must be interpreted with some caution. 
Evidence of the importance of the pmp gene products in cell-mediated immunity is 
scarce. pmpD was identified as the target of Chlamydia-reactive human T-cell clones 
from an expression library and the recombinant protein was later shown to stimulate the 
proliferation of synovial fluid mononuclear cells from individuals with Chlamydia- 
associated reactive arthritis. ' 84 
COMCs, of which PMPs are a constituent, have already been shown capable of 
inducing protective immunity. Inoculation of pregnant ewes with a COMC preparation 
of Chlamydia psittaci provided good protection against subsequent abortion due to C. 
psittaci OEA 185 and mice were similarly protected against infection and foetal loss by a 
similar Chlamydia trachomatiS COMC preparation, though not by recombinant 
186 MOMP 
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In summary then the pmps compose a multigene family encoding highly immunogenic, 
surface-localised proteins. These demonstrate species and serovar specific epitopes, 
making them useful diagnostically, and may generate protective antibodies and hence 
have potential as vaccine candidates. 
1.4.5 Other antigens 
The antigens described above are those which have been subjected to the most scrutiny, 
however a number of others appear to stimulate immune responses and may be potential 
vaccine candidates though much further work is required. 
Two other chlamydial heat shock proteins are recognised by the immune system. 
Chlamydial HSPIO appears to be associated with chronic chlamydial genital tract 
infection' 87 and is also recognised by antibodies from women with tubal infertility, 
where serological response correlates with the severity of genital tract disease. 1 88 
Chlamydial HSP70 is thought not to be surface-exposed on chlamydial EBs but is 
thought to be important in the early stages of infection. 189,190 Despite not being surface- 
localised, antibodies to HSP70 were found in 65% of 17 patients with chlamydial genital 
tract disease, ' 33 and HsP70 has been shown in vitro to be a target of neutralising 
antibodies 119,191. At least one T-cell epitope capable of stimulating T-cell proliferative 
92 responses has been determined' . 
Rockey et al have been working on a group of chlamydial proteins for some time. They 
have now identified over 40 inclusion membrane proteins (INCS) from each chlamydial 
species. Five out of six of these from Chlamydia trachomatis were shown to reside in 
the inclusion membrane. Some members of this family of proteins have been shown to 
be immunogenic in patients recovering from chlamydial genital infection and 
Chlamydia pneumoniae infection' 93 . Although several 
INC proteins are localized to the 
inclusion membrane, virtually nothing is known of their function. INCA from 
Chlamydiapsittaci is a serine-threonine phospho-protein that contacts the cytosol of the 
host cell. It is possible that the INC proteins may be effector molecules transported out of 
the chlarnydial RB through the Type-III secretion pathway. 
194 
Like MOMP, the 38 kDa outer membrane protein PORB appears to function as a porin 
but is more highly conserved' 95 . Antibodies to 
PORB are capable of neutralising 
chlarnydial infectivity. ' 96 PorB is predicted to consist of 16 trans-membrane anti- 
parallel P-sheets with the antigenic regions protruding into the extracellular matrix. 
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Unlike MOMP, PORB is highly conserved between species and serovars and thus 
warrants ftirtber investigation as a possible vaccine candidate. 
CAPI, an inclusion membrane-localised chlarnydial protein of unknown function, 
stimulates the generation of the Chlamydia-specific CD8 T-cells during natural infection 
of mice with Chlamydia trachomatis. A Vaccinia construct including a portion of the 
CAPI molecule was able to generate a level of protection from subsequent chlamydial 
genital infection. 197 
PGP3 is a protein constituent of the elementary body which is encoded on the chlarnydial 
plasmid. 81% of patients with urogenital chlamydial infection had antibodies to PGP3, 
compared to none in healthy controls with a negative Chlamydia trachomatis 
microimmunofluorescence test NIF). ' 98 
A further antigen, macrophage infectivity potentiator (MIP), has recently been identified 
with similarity to the MIPs of Legionella pneumophila and Coxiella burnetii. It appears 
to be localised to the outer membrane, and polyclonal anti-MIP antibodies were able to 
reduce infectivity of cell cultures in the presence of complement. 199,200 
Chlamydial protease-like activity factor (CPAF) is currently the subject of much 
interest. CPAF is secreted into the host cytosol by both Chlamydia trachomatis and 
Chlamydia pneumoniae, 318,317 where it selectively degrades host transcription factors 
including RFX5 (a critical component of the RFX transcription complexes required for 
MHC antigen expression). CPAF seems to be exclusively secreted into the host cytosol 
with none detectable in either RBs or EBs. 316,317 suggesting that its prime function is to 
manipulate host cells. Although this poses the risk of CPAF being processed and 
presented to T-cells, CPAF appears highly stable in the cytosol suggesting poor 
degradation by host proteosomes. 316 The usefulness of CPAF as a diagnostic or 
therapeutic target remains to be determined. 
1.5 Pathogenesis 
A common feature of many chlarnydial infections is that they are often asymptornatic 
and may persist for long periods of time if left untreated. It may be that this inability of 
the host to clear the chlarnydial infection enables the organism to establish a chronic 
state which eventually leads to the resultant adverse immuno-pathology. It seems that 
the host responses to that infection may be the primary cause of the long-term sequelae. 
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Cell-mediated immunity appears to be essential in resolving infection and developing 
protective immunity to Chlamydia, however, it is also thought to be involved in the 
immunopathogenesis of chlarnydial diseases. This view was first mooted after animal 
experiments which showed that sensitisation of guinea pigs with an extract of 
chlamydial EBs accelerated ocular inflammation. 'O' In a ftirther study with a non-human 
primate model, follicular conjunctival responses to chlamydial antigens were seen only 
in previously infected monkeys and not in naive animals, demonstrating the importance 
202 of hypersensitivity responses in repeated chlamydial infection . Chlamydial HsP60 has 
been strongly implicated as being at least one of the antigens responsible for this 
203 
effect . 
Because of the highly conserved nature of HSP60, responses directed against microbial 
hsp may also be deployed against autologous hsp. The expression of chlamydial hSP60 
is enhanced during persistent infection33 and this is marked by the appearance of 
chlamydial HsP60-specific antibodies in the patient serum. Later the development 
antibodies to human HSP60 may be seen. 204 These cross-reactive responses could 
convert the protective immune responses into pathological ones. '38 Responses to 
chlamydial HsP60 have been associated with the sequelae of upper genital tract disease 
including ectopic pregnancY205, pelvic inflammatory disease and chronic pelvic 
pain 204,206,207, perihepatitIS208 and tubal infertility. 209-211 Some, however, argue that the 
enhanced humoral response to chlamydial HsP60 is simply a consequence of the intense 
stimulation of the immune system by continuous or recurrent infections. Certainly 
chlarnydial HSP60 has been shown to elicit a severe inflammatory response, almost 
identical to that seen in trachoma, when inoculated into the conjunctivae of previously 
immunised guinea pigs and monkeys. 203,212,213 
Chlamydia appear to be potent inducers of inflammatory responses. The infection of 
both murine and human reproductive tract epithelial cells with Chlamydia trachomatis 
results in the expression of the adhesion molecules Mucosal Addressin Cell Adhesion 
Molecule-I (MAdCAM-1) and VCAM-I/CD106 which then recruit effector T-cells to 
the site of inflammation 214,215 and PBMCs infected with Chlamydia trachomatis have 
been shown to produce reactive oxygen species which oxidise cellular membrane 
216 lipids . 
Whole EBs, MOMP, OMP2 and HsP60 from Chlamydia pneumoniae, and probably other 
Chlain, vdia, stimulate the expression of matrix metalloproteinases and these may also be 
important In the aetlology of trachomatous scarring. These enzymes are important both 
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for normal extracellular matrix turnover and for the exaggerated extracellular matrix 
breakdown associated with pathological conditions including turnour invasion and 
metastasis, angiogenesis, inflammatory reactions, wound healing and scar formation. 
The major members of this family include collagenases, gelatinases A and B, and 
stromolysinS 217. Many chronic inflammatory conditions which result in a restructuring 
of connective tissue are characterised by a local accumulation of macrophages. These 
bring about connective tissue destruction either directly, by the secretion of matrix 
metal loprote i nase s 218 , or indirectly, by the production of pro- inflammatory cytokines, 
including IL-1 or and TNFoc which themselves induce matrix metal loprote inas e gene 
expression. Increased numbers of macrophages have been demonstrated in the 
conjunctiva of patients with active trachoma and these macrophages were shown to be 
expressing IL-1, TNF(x and platelet-derived growth factor 1 03 . The production of 
gelatinase B is also stimulated by bacterial LPS 218 . Gelatinase B, produced 
by 
macrophages, monocytes and neutrophils, has been found to be present at increased 
levels at in the conjunctiva of patients with trachoma 2 19. Gelatinase B degrades 
denatured collagen, collagen types IV, V, VII and XI, elastin and fibronectin so this 
may be one of the contributing factors towards conjunctival damage and scarring in 
trachoma. 
The nature of the cytokine response to chlarnydial infection appears to be important in 
the development of long terin sequelae. Studies using mice that display different levels 
of TNF(x production and correspondingly different pathological outcomes of chlarnydial 
genital infection suggest that whilst TNF(x and other inflammatory cytokines may aid in 
the eradication of Chlamydia infection, they may also promote long-term tissue 
damage. 220 Polymorphisms in the TNFcc promoter also appear to be important. These 
polymorphisms have previously been associated with severe malaria . 
22 1 The TNF(x- 
308A allele (associated with greater TNF(x production)222 is also associated with 
trachomatous scarring in the Gambia and there is a trend towards association with the 
TNF(x-238A allelel 02 but no association with the TNF(x-376A allele. 
223 The importance 
of a THI vs. TH2 response is discussed in section 1.3.4. 
The importance of CD8 T-cells in immunopathology remains controversial. 
Associations between HLA-A31 and PID 66 and between HLA-A*6802 and scarring 
trachoma suggest that CD8 T-cells may be involved in immunopathology. HLA-A28, 
subtype HLA-A*6802, is significantly more common in those with trachomatous 
scarring than in controls, suggesting that HLA-A*6802-restricted responses may play a 
48 
Background 
role in the pathogenesis of trachomatous scarrin g. 224 Follow-up studies to investigate 
CTL responses to a number of peptides with the predicted binding motifs for HLA- 
A*6802, however, failed to demonstrate CTL activity or IFNY release, suggesting that 
either HLA-A*6802 CD8+ T cells may not be important in ocular infections or that the 
peptides chosen did not represent epitopes. 225 
In summary, it appears that the long-term sequelae associated with chlamydial infection 
are a combination of direct effects of chronic infection, and 'collateral damage' 
sustained during the immune response to that infection. The mechanisms of damage are 
multiple and host genetic factors probably play a significant role. 
1.6 Previous vaccine work 
Although antibiotics are effective at treating individual episodes, regular treatment is 
often not available in endemic areas, early infection is often asymptornatic and re- 
infection occurs rapidly after treatment. Regular face washing has proved moderately 
effective in reducing the incidence of blinding trachoma 226 but is poorly sustainable. 
Clearly an effective vaccine would be of enormous benefit in the control of trachoma 
and would have the potential to prevent millions of cases of blindness in the future from 
this painful, disabling disease. A number of trachoma vaccine studies took place in the 
'60s and '70s with mixed results. Preliminary experiments in a variety of primate 
models demonstrated some short lived protection which was often, though not always, 
11 ic. In certain cases, however, vaccination appeared to induce stra n specifi 
hypersensitivity which was not strain specific, and which outlived the protective 
immumt Y227-229 . 
Results of vaccination trials in children, using whole killed organisms, 
mirrored these results. Protection lasted less than two years, was partial, and again 
associated with hypersensitivity responses to infection in some case 
230,231 
- 
Laboratory 
testing of a variety of antigens as potential vaccines has continued and is discussed 
under the various antigens, however no human trials have taken place since the 1970s 
due to the risk of hypersensitivity. This combination of protective and damaging 
immune responses has so far continued to confuse and confound developments towards 
an effective human vaccine. In contrast a highly successful live vaccine against the C. 
psittaci OEA abortion strain is available in the form of a temperature sensitive 
mutant232. 
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1.7 Locations 
1.7.1 London School of Hygiene & Tropical Medicine 
Molecular biology work was undertaken at The London School of Hygiene and 
Tropical Medicine. 
1.7.2 Medical Research Council Laboratories, Fajara and 
Farafenni, The Gambia 
Field work was undertaken at the Medical Research Council's main laboratories at 
Fajara and at the field station at Farafenni. 
Since 1981 the MRC has operated a continuous demographic surveillance system in 40 
villages and hamlets in the Farafenni area, on the north bank of the river Gambia and a 
number of studies are being undertaken in the field of reproductive health. Women for 
the infertility arm of the study and their controls were recruited from this population. 
1.7.3 Study villages, The Gambia 
Individuals were recruited from a number of villages. These are listed in detail in 
section 4.2. Long-term studies of trachoma have been ongoing in the villages of 
Berending (in south-western Gambia) and in Jah (close to the Kiang West National Park 
in central Gambia). Ninety-three individuals were recruited from these two villages. The 
remainder were recruited from other villages in the central region. These villages are 
underlined on the map overleaf. 
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1.8 Aims of the project 
* To clone and express PMP protein antigens from Chlamydia trachomatIS scrovar A. 
* To assess the immunogenicity of these proteins and develop a whole blood cytokine 
assay for field use. 
e To assess the immune responses of selected groups of trachoma patients and controls 
in an endemic area to determine those responses associated with protection from 
blinding trachoma. 
* To assess the immune responses of women with secondary tubal infertility and 
controls in order to determine if responses are similar to those with scarring trachoma 
9 To compare responses in those with and without current helminth infection. 
The following hypotheses will be addressed: 
9 That individuals with chlarnydial salpingitis and with ocular trachoma will 
demonstrate humoral or cell mediated responses, or both, to the PMP proteins. 
9 That trachoma patients with a predominantly THI-type response will suffer less 
severe pathology than those with either a reduced THI or a predominantly TH2-type 
response. 
e That individuals with concurrent helminth infection will demonstrate either a 
reduced 
THI or a predominantly TH2-type response. 
The long term benefits of this project are: 
That the characterisation of immune responses to these proteins may give some 
insight into their cell biology and may identify those antigens which may be useful 
diagnostically or as new vaccine candidates. 
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2 Materials and Methods 
2.1 Cloning 
2.1.1 Preparation of Chlamydia trachomatis serovar A DNA 
2.1.1.1 Purification of Chlamydia trachomatis serovar A DNA 
Chlamydia trachomatis serovar A EBs were kindly provided by Dr Rosanna Peeling 
(Laboratory Centre for Disease Control, Winnipeg, Manitoba, Canada). This strain had 
been isolated from the eye of a patient in The Gambia with trachoma, and propagated in 
tissue culture in Dr Peeling's laboratory. The EB's were provided in a suspension of 
700 micrograms per millilitre (ýtg/ml) EB protein and stored at -700C. 
One millilitre EB suspension was transferred to a 14ml round-bottom polyethylene tube 
and centrifuged at 7840g for 30 minutes at 40C. The supernatant was removed and the 
pellet re-suspended in 200 microlitres (ýtl) TES (20% w/v sucrose, 50 millimolar (mM) 
Tris-HCI pH 7.6,50mM ethylenediarninetetracetic acid (EDTA) - Sigma, Poole, UK) 
and transferred to a 2ml microfuge tube. 20ýtl 10% sodium dodecyl sulphate (SDS) and 
4ýtl protemase K (20 milligrams per millilitres (mg/ml) - Promega, Southampton, UK) 
was added to the suspension and incubated for one hour at 650C. 200ýLl 
distilled/deionised water (dH20) was added followed by 400ýtl of cold 100% 
isopropanol (Sigma). The solutions were mixed by gentle inversion and the precipitated 
DNA threads spooled onto a glass rod, transferred to 100ýLl TE buffer (I OmM Tris. Cl, 
ImM EDTA, pH 7.5) and solubilized by incubation at 650C for 15 minutes. The 
supernatant was then spun at 16,000g for 30 minutes at 40C after which a very small 
pellet was visible. This pellet was solubilized in 2%fl TE buffer and the two DNA 
solutions combined. 
Ribonucleic acid (RNA) was removed by the addition of 2ýtl ribonuclease A (RNAse A 
- Promega) and incubation for 45 minutes at 
370C. 120ýd phenol/chloroform (50: 50 v/v) 
was then added and mixed by gentle inversion. The solution was centrifuged at 16,000g 
for 10 minutes at 40C and the aqueous phase transferred to a fresh microfuge tube. 
120p I dH-)O was added to the organic phase and mixed by gentle inversion. The mixture 
was centrifuged at 16,000g for 10 minutes at 40C and the aqueous phase added to that tD 
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obtained with the first extraction. Finally, 260ýtl isopropanol was added and mixed by 
gentle inversion. The precipitated DNA strands were spooled onto a glass rod, 
transferred into 100ýtl TE buffer pH 8.5 and solubilized by incubation at 650C for 15 
minutes. 
The concentration and purity of the DNA was estimated as detailed below. Remaining 
organic solvents were then removed by ether extraction; 100ýtl water-saturated ether 
was added to the DNA solution and mixed by gentle inversion. The two phases were 
allowed to separate by standing for 5 minutes and the ether phase removed. This process 
was repeated three times. Spectrophotometry was repeated to estimate concentration 
and quality. 
2.1.1.2 Spectrophotometric estimation of concentration, yield 
and purity of DNA 
The concentration and purity of the DNA was estimated by spectrophotometry 
measuring the absorbance of a 100-fold dilution at 260 nanometre (nm) and 280nm 
wavelengths. The DNA concentration was calculated on the basis that an optical density 
(OD) of 1.0 at 260nm corresponds to approximately 50ýLg/ml of double-stranded DNA. 
The purity was estimated from the ratio of the OD at 260nm and at 280nm with pure 
DNA preparations being assumed to have an OD26o/OD280 ratio of 1.8 - 2.0. 
2.1.1.3 Digestion of chlarnydial DNA with restriction enzymes 
In order to confirm that genomic DNA was present, digestion was performed with the 
restriction enzymes BamHl, EcoRl and Pstl. For each reaction, 2ýd of the DNA 
solution prior to ether extraction (900 nanograms (ng)) was added to 15ýtl dH20,2ýtl 
enzyme buffer and 20 units restriction enzyme (Promega) in a 500ýtl microfuge tube. 
The mixture was incubated overnight. 2ýd ten-times strength (IOX) agarose gel loading 
buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 25% Ficoll 400) was added 
to each tube and mixed thoroughly. The mixture was then electrophoresed in a 0.8% 
agarose (Promega) gel containing 0.5ýtg/ml ethidiurn bromide (Sigma) using TAE 
buffer (0.04M Tris. acetate, 0.001M EDTA) at 96 volts for 90 minutes with a ýjPstl 
marker, and the products visualised under 254nin ultraviolet light irradiation. 
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2.1.2 PCR Amplification 
The gene sequences of pmpC, pmpD and pmpG as described on the Chlam-vdia 
trachomatis serovar D Sequencing Project at http: //chlamydia-www. berkeley. edu: 42)'I/ 
were examined (Genbank accession numbers: pmpD - 15605546, pmpG - 15605607) 
Signal P, available online at http: //www. cbs. dtu. dk/services/SignalP and SMART, from 
the European Molecular Biology Laboratories at http: //smart. emb1-heidleberg. de, were 
used to identify signal sequences in the translated amino acid sequence. Corresponding 
DNA sequences were then input to the Primer 3 program, available online through the 
Whitehead Institute for Biomedical Research/MIT Centre for Genome Research at 
http: //www-genome. wi. mit. edu/cgi-bin/primer/primer3. cgi, to suggest potential primers. 
Primer sequences were selected to exclude the signal sequences and examined to 
exclude any potential secondary structures, which might lead to amplification artefacts 
or errors. The final choice of primers is detailed in the table. 
Primer Oligonucleotide Sequence (5'-3') Target 
I 
Position Description 
DpmpD-3' TCG CAA TCC AGT ATT CGC CTC A 
D 
4596-4617 
- 
4450bp product used 
t d 
DpmpD-5' TGG TAT ATC3 TAG GCC CTC AAG CGG 
pmp 
167-190 
o pro uce 
pTrcHis/pmpD-1218 
DpmpG-3' TTC CTG CAC TCA AAC CAT AAC CTC G 3028-3052 2925bp product used 
DpmpG-5' TCA AGG AAT TTA CGA TGG GGA GAC G 
pmpG - 
6-150 
to produce 
pTrcHis/pmpG-1 410 
DpmpG2-5' CAA GGA ATT TAC GAT GGG GAG A 127-148 2924 bp product 
DpmpG2-3' TCC TGC ACT CAA ACC ATA ACC 
pmpG - 
3031-3051 
used to produce 
pBAD/pmpG 
Table 2-1: Primer sequences used for PCR 
2.1.2.1 Clontech AdvantageO PCR 
PCR amplification was undertaken using the Advantage PCR Kit (Clontech, 
Basingstoke, UK) according to the manufacturers instructions. The amplification mix 
consisted of Ix manufacturer's reaction buffer (40mM Tris-HCI, 15mM potassium 
acetate (KOAc)), Ix Advantage Genomic PCR polymerase mix (0.1 units/ýd Ph DNA 
polymerase, 0.01ýLg/ml TthStart antibody, 1% glycerol, 0.2mM Tris-HCI, 4.6mM KCI, 
1.5ýtM EDTA, 15ýtM dithiothreitol, 7.3ýtg/ml bovine serum albumin), 0.2mM each 
deoxynucleotide triphosphate (dNTP), I. ImM magnesium acetate (Mg(OAc), ), IýM 
each primer and 40ng Chlamydia trachomatis serovar A DNA in aI 
00ýtl reaction 
volume. The mixture was overlaid with 30ýtl of mineral oil (Sigma). 
Cycling consisted 
of denaturation at 940C for I minute then 35 cycles of 30 seconds 
denaturation at 940C 
and 3 minutes annealing/extension at 680C, then 3 minutes final extension at 
680C, and 
was perfon-ncd in a DNA thermal cycler (Perkin Elmer Cetus, Norwalk, 
CT, USA). 
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PCR product of the predicted size was visuallsed on an ethidium- stained agarose gel 
agarose (Sigma), 0.004% ethidium bromide (Sigma)) by comparison with a ýJPstl 
marker on exposure to UV light at 254nm 
2.1.2.2 Hi-fidelity Pfu amplification 
Pfu DNA polymerase (Promega) is a high-fidelity DNA polymerase claimed to have an 
error rate of only IX 10-6 per base. 233 Since the PCR products generated ranged from 3- 
5 kb we would thus anticipate 0.003 - 0.005 errors to occur within the PCR product. 
The reaction mixture comprised IX Pfu buffer (Promega), 0.2mM each dNTP 
(Boehringer, Ingelheim, Gen-nany), 1ýtM each primer, 20ng Chlamydia trachomatis 
serovar A DNA and 2.5 units Pfu DNA polymerase (Promega) in a 50ýtl reaction 
volume. The mixture was overlaid with a drop of mineral oil (Sigma). Cycling consisted 
of denaturation at 950C for 2 minutes then 35 cycles of 45 seconds denaturation at 
950C, 30 seconds annealing at 550C and 5 minutes extension at 720C, then 5 minutes 
final extension at 720C, and was perfon-ned in a DNA thermal cycler (Perkin Elmer 
Cetus). In order to add overhanging single adenine nucleotides to each strand of the 
blunt PCR product, following completion of amplification, 2.5 units of Taq DNA 
polymerase was added and a further 10 minutes incubation undertaken at 720C. PCR 
product of the predicted size was visualised on an ethidium bromide-stained agarose gel 
by comparison with a ýJPstl marker by exposure to UV light at 254nm. 
2.1.3 Purification of PCR products 
2.1.3.1 Ethidium bromide gel electrophoresis 
2ýtl I OX agarose gel loading buffer was added to the entire aqueous phase of the PCR 
reaction and mixed thoroughly. The mixture was then electrophoresed in a 0.8-1% low 
melting point agarose (Promega) gel containing 0.5ýtg/ml ethidium bromide using TAE 
buffer (0.04M Tris. acetate, 0.001M EDTA) at 96 volts for 90 minutes with ak IPstl 
marker and the products visualised under 254 nm UV light. Exposure to UV light was 
kept to a minimum to reduce radiation damage to the double-stranded product. 
Amplimers of the appropriate size were excised using a clean scalpel blade and 
transferred to a polyethylene microfuge tube and the DNA extracted using either Qiacx 
11 DNA extraction kito (Qiagen, Dorking, UK) or Invitrogen Snap columnso. 
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2.1.3.2 Crystal violet gel electrophoresis 
In the later stages of the project, crystal violet gels were used for the visualisation of 
PCR products, restriction fragments and vectors and for isolation prior to cloning. 
Crystal violet gels allow direct visualisation of the DNA bands and obviates the 
requirement for ethidiurn. bromide and UV light both of which may damage DNA 234 
5ýtl I OX crystal violet loading buffer (2% Ficoll 400,0.002% xylene cyanol) was added 
to the entire aqueous phase of the PCR reaction mix and this was then loaded into aI% 
low melting point agarose (Promega) gel containing I Oýtg/ml crystal violet (BDH, 
Poole, UK). A ýJPstl marker was used to determine the molecular weights. This was 
then electrophoresed for I hour at 97v in TAE buffer and the bands visualised directly. 
Amplimers of the appropriate size were excised using a clean scalpel blade and 
transferred to a polyethylene microfuge tube and the DNA extracted using either Qiaex 
11 DNA extraction kitg or Invitrogen Snap columnst using the manufacturers 
recommended protocols as below. 
2.1.3.3 Qiaex 11 DNA extraction kit 
300ýtl QXI solubilization buffer (proprietary formulations not available) was added to 
the gel fragment and incubated at 500C until the gel had melted. The Qiaex Ir beads 
were re-suspended by vortexing for 30 seconds then 10ýd of the suspension added to the 
melted agarose solution. The mixture was incubated at 500C for 10 minutes with gentle 
vortexing every 2 minutes to maintain the suspension. The beads were then pelleted by 
centrifugation at 16,000g for 2 minutes and the supernatant removed and discarded. The 
pellet was washed by re-suspending in 500ýd QXI buffer and then centrifugation at 
16,000g; the supernatant was discarded and the pellet washed twice, in the same way, 
with 500ýtl PE wash buffer. The pellet was allowed to air-dry for 15 minutes. The DNA 
was then eluted from the beads by re-suspension in 20ýtl lOmM TE buffer (pH 8.5) 
followed by centrifugation for 2 minutes at 16,000g with collection of the supernatant. 
The process was then repeated with a further I Oýtl I OmM TE buffer (pH 8.5) to increase 
the total yield of DNA. The two supernatants were then combined and stored at -200C. 
2.1.3.4 Invitrogen Snap Columnso 
Two hundred and fifty microlitres of 6.6 molar (M) sodium iodide (Invitrogen, 
Groningen, The Netherlands) was added to the excised gel fragment and mixed by 
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gentle inversion. The mixture was then incubated for two minutes at 500C until the gel 
had melted. Proprietary binding buffer (525ýtl) was then added and mixed thoroughly. 
The solution was then loaded into a Snaps column and centrifuged at 2000g. The flow- 
through was poured back into the top of the column and the process repeated twice. The 
column was then washed twice by the addition of 400ý0 IX proprietary final wash 
buffer and centrifugation at 2000g. After the second wash, the column was dried by 
centrifugation at 16,000g for one minute. The column was placed in a fresh microfuge 
tube and 40ýd TE buffer (pH 8.5) added. The column was spun for I minute at 16,000g 
and the cluted DNA stored at -200C. 
2.1.4 Preparation of vectors and inserts for ligation 
2.1.4.1 pGEM-To 
The cloning vector pGEM-T (Promega) is designed for easy cloning of PCR products 
through the presence of single 3'-thymydine overhangs. The vector contains T7 and SP6 
RNA polymerase promoters flanking a multiple cloning region within the (X- 
complementation peptide coding region of P-galactosidase, which enables blue/white 
colony selection of recombinant clones. As pGEM-T is designed for direct cloning of 
PCR products, no vector preparation was required. 
2.1.4.2 pTrcHisO 
The expression vector pTrcHis (Invitrogen) is designed for the expression of non-toxic 
gene products in E. coli. Expression is under the control of the trc promoter (a hybrid 
promoter derived from the trp and lac promoters). Expressed products have an N- 
terminal polyhistidine (6xHis) tag to facilitate purification and an N-terminal Xpress 
epitope for easy detection with the manufacturer's anti-Xpress antibody. pTrcHis is 
supplied in circular form, it was therefore digested with the appropriate restriction 
enzyme(s) and purified either by ethidium bromide gel electrophoresis and Qlaex IV, 
extraction of vector DNA from the gel or by the phenol/chloro form method. Where a 
single enzyme was used to cut the vector, the 5' termini were de-phosphorylated as 
described in section 2.1.4.8. 
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2.1.4.3 pBluescript 11 phagemid (SKII) 
pBluescript 11 (Stratagene, Amsterdam, The Netherlands) is a high copy number, 
ColE I -based phagemid with a large polylinker, an fl origin available in either (+) or (-) 
orientation and T3 and T7 promoters for in vitro RNA transcription. Recombinant 
selection is facilitated by ampicillin resistance and blue/white colony colour selection. 
Bluescript 11 is supplied in circular form; it was therefore digested with the appropriate 
restriction enzyme(s) and purified by the phenol/chloroform method (section 3.1.1.1). 
Where a single enzyme was used to cut the vector, the 5' termini were de- 
phosphorylated as described below. 
2.1.4.4 pBAD-TOPO TAO 
The expression vector pBAD-TOPO TA (Invitrogen) is designed for direct cloning of 
PCR products through the presence of single 3'-T overhangs. Ligation is achieved 
rapidly using topoisomerase, which is bound to the vector. Expression in E. coli is 
driven by the araBAD promoter. Low levels of transcription occur in the absence of 
arabinose and the level of expression is arabinose dose-dependent allowing accurate 
titration of the level of expression. pBAD is designed for direct cloning of PCR 
products, therefore no vector preparation was required. 
2.1.4.5 pCR-11-TOPO@ 
The cloning vector pCR-11-TOPO (Invitrogen) is designed for direct cloning of PCR 
products through the presence of single 3'-T overhangs. Ligation is achieved rapidly 
using topoisomerase, which is bound to the vector. It incorporates kanamycin and 
ampicillin resistance, blue/white colony selection through disruption of the lacZa gene, 
M13 forward and reverse priming sites for insert sequencing and T7 promoter/primer 
for in vitro RNA transcription/translation. pCR-11 is designed for direct cloning of PCR 
products and therefore no vector preparation was required. 
2.1.4.6 PET-30@ 
The expression vector pPET (Novagen, Nottingham, UK) ensures that target genes are 
cloned under the control of strong bacteriophage T7 transcription/translation signals and 
thus expression is induced by the T7 RNA polymerase of the expression host. Cloning 
in hosts that do not contain T7 RNA polymerase renders the cloned gene 
transcriptionally silent thus eliminating plasmid instability due to the cxpression of 
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proteins potentially toxic to the host cell. During the 
expression phase, T7 RNA polymerase is highly 
selective and active such that almost all of the cell's 
resources are converted to target gene expression; the 
target protein may compose more than 50% of the 
total cell protein after a few hours of induction. pPET- 
30 is supplied in circular form; it was therefore 
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digested with the appropriate restriction enzyme(s) and Figure 2-1: PET-30a 
purified by the pheno I/chloro form method. Where a expression vector 
single enzyme was used to cut the vector, the 5' termini were de-phosphorylated as 
described below. 
2.1.4.7 Isolation of restriction fragments for use as inserts 
1.25ýtg of plasmid, containing the restriction fragment of interest, was digested with 10- 
20 units restriction enzyme, 1.5ýd manufacturer's restriction enzyme buffer and dH20in 
a final volume of 15pl for one hour at 370C. Following digestion the restriction 
fragments were separated using either ethidium bromide or crystal violet gel 
electrophoresis as described above. DNA bands of the appropriate size were excised 
using a clean scalpel blade and transferred to a polyethylene microfuge tube and the 
DNA extracted using the Qiaex 11 DNA extraction kiO). An assumption was made that 
80% of the original DNA would be extracted using this method. 
2.1.4.8 De-phosphorylation of vector or insert termini prior to 
cloning 
De-phosphorylation of the 5'-termini of vectors or inserts was performed to prevent re- 
linking of compatible vector termini or the formation of concaterners by the linkage of 
several inserts together. De-phosphorylated termini can only be joined by the action of 
DNA ligase. 
DNA (1.25ýtg) was added to 100ýtl IX calf intestinal alkaline phosphatase buffer 
(lOmM NaCl, 5mM Tns-HCI, ImM MgCl,, O. ImM dithiothreitol - New England 
Biolabs, Hitchin, Herts, UK. ) and I pl calf intestinal alkaline phosphatase (New England 
Biolabs). The mixture was incubated at 370C for 30 minutes. Iýil shrimp alkaline 
phosphatasc was then added and incubated for a further 30 minutes to ensure that de- 
phosphorylation was complete. The mixture was then heated to 650C for 15 minutes to 
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inactivate the enzymes. 100[d phenol/chloroform (50: 50 v/v) was added and mixed by 
gentle inversion. The solution was centrifuged at 16,000g for 10 minutes at 40C and the 
aqueous phase transferred to a fresh microfuge tube. One hundred microlitres of dH20 
was added to the organic phase and mixed by gentle inversion. The mixture was 
centrifuged at 16,000g for 10 minutes at 40C and the aqueous phase added to that 
obtained with the first extraction. 200ýd isopropanol was added to the combined 
aqueous phase and mixed by gentle inversion. The solution was then centrifuged at 
16,000g for 15 minutes. The supernatant was removed and discarded and the DNA 
pellet washed with 500ýd of 70% ethanol (Sigma) then centrifuged at 16,000g for 5 
minutes. The supernatant was discarded and the pellet spun at 16,000g for a further I 
minute. The remaining supernatant was removed and discarded and the pellet allowed to 
air dry. The DNA pellet was re-suspended in 20ýtl l0rnM TE buffer pH 8.5. An 
arbitrary assumption was made that 80% of the DNA would be recovered. Thus, the 
concentration of the DNA solution was taken to be 50ng/ýLl. 
2.1.4.9 Filling in 5' single stranded extensions with Klenow 
fragment of DNA polymerase 
Klenow fragment of DNA polymerase was used to fill in 5' single stranded extensions 
of double-stranded DNA to provide blunt ends for cloning. 
After restriction enzyme digestion the restriction enzyme was de-activated either by 
heating to 650C for 10 minutes or by phenol/chloroform extraction of the DNA. I ýtl 
dNTPs, 0.2ýtl bovine serum albumin (BSA - Promega) and 2.5 units Klenow fragment 
(Promega) was added and the mixture incubated for 10 minutes at room temperature. If 
further digestion of the DNA was required, the Klenow fragment was heat-inactivated at 
750C for 10 minutes. 
2.1.5 Ligation 
2.1.5.1 Calculation of vector/insert ratio 
For ligation the following formula was used to calculate the amount of insert required 
for a given quantity of vector. In most cases a vector: insert ratio of 1: 3 was used. 
ng qf vectorx sl--c (? f insert (kb) i, nsert : vector rati ,o= ng of insert required 
sizc of vector (kb) 
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2.1.5.2 pGEM -T@ 
One microlitre of PCR product was mixed with Iýtl T4 DNA ligase buffer (30mM Tris- 
HCI (pH 7.8), IOMM MgC12, lOmM DTT, ImM ATP - Promega), Iýtl (10 units) T4 
DNA ligase (Promega), 25ng pGEM-T vector and 6.5ýtl dH20. The mixture was 
incubated overnight at 40C. 
2.1.5.3 pTrcHisO 
The vector: insert ratio was calculated as above. The appropriate quantity of insert was 
added to I Ong appropriately digested pTrcHis vector in a 10ýtl solution containing I ýtl 
T4 ligase buffer and 10 units T4 DNA ligase. The mixture was incubated overnight at 
40C. 
2.1.5.4 pBluescript III 
The vector: insert ratio was calculated as above. The appropriate quantity of insert was 
added to I Ong appropriately digested pTrcHis vector in a 10ýtl solution containing I ýtl 
T4 ligase buffer and 10 units T4 DNA ligase. The mixture was incubated overnight at 
40C. 
2.1.5.5 pBAD-TOPO@ 
Two microlitres of PCR product was mixed with 0.5ýtl (5ng) pBAD-TOPO and 1.5ýtl 
dH20. The mixture was incubated at room temperature for 5 minutes then transferred to 
ice and used for immediate transformation. 
2.1.5.6 pCR-11-TOPO@ 
Four and a half microlitres of PCR product was mixed with 0.5ýfl (5ng) pCR-11-TOPO. 
The mixture was incubated at room temperature for 5 minutes then transferred to ice 
and used for transformation as soon as possible. 
2.1.5.7 pPET@ 
The vector: insert ratio was calculated as above. The appropriate quantity of insert was 
added to I Ong appropriately digested pPET vector in aI Oýtl solution containing I ýLl T4 
figase buffer and 10 units T4 DNA ligase. The mixture was incubated ovcmight at 40C. 
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2.1.5.8 Preparation of competent cells 
Laboratory stocks of the appropriate strain, stored at -700C, were streaked out onto 
Luria-Bertani (LB) agar (1% w/v enzymatic casein digest, 0.5% w/v yeast extract, 0.5% 
sodium chloride (NaCI), 1.5% agar - Difco/BD, Oxford, UK) plates and incubated 
overnight at 370C. A single colony was then selected and used to inoculate 5ml sterile 
SOB medium (2% w/v bacto-tryptone, 0.5% w/v yeast extract, 0.05% w/v NaCl, 
2.5mM potassium chloride (KCI), lOmM magnesium chloride (MgCl-, )) which was 
incubated on a shaking water bath overnight at 370C. One millilitre of this culture was 
then used to inoculate 100ml SOB medium and incubated on a shaking water bath at 
370C with hourly monitoring of the OD550- When the culture reached an OD550 of 0.55 
- 0.65 the solution was transferred to centrifuge bottles and incubated on ice for 30 
minutes before being centrifuged at 6174g. The supernatant was discarded and the 
bacterial pellet re-suspended in 28ml ice-cold simple frozen storage (SFS) buffer 
(100mM KCI, 50mM calcium chloride (CaCIA lOmM KOAc, 10% w/v glycerol). The 
suspension was incubated on ice for 15 minutes then centrifuged at 6174g for 15 
minutes. The supernatant was discarded and the bacterial pellet re-suspended in 6.4ml 
ice-cold SFS buffer. The suspension was then transferred to sterile cryopreservation 
tubes in 200ýLl aliquots and frozen in liquid nitrogen. The aliquots were stored at -700C. 
In order to test the efficiency of transformation of the competent cells, an aliquot was 
transformed with Ing of the super-coiled plasmid pT7-7 according to the standard 
protocol described below. The whole transformation volume was plated onto an LB 
agar plate containing 100ýLg/ml ampicillin (Sigma) and incubated overnight at 370C. 
The number of colonies was counted and the transformation efficiency calculated using 
the formula: 
volume plated 
trans. formation efficiency= total volume 
numberof coloniesxlOOO 
2.1.6 Transformation into competent cells 
2.1.6.1 Competent cells used 
XLI-Blue: A recombination-deficient strain that will support the growth of vectors 
carrying some amber mutations, but not those with the SamlOO mutation. Transfected 
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DNA is modified but not restricted. The F in this strain allows blue/white colony 
screening 235 and the strain is also tetracycline resistant. 
Invitrogen TopI0 One-Shot@: A high-efficiency cloning strain of E. coli capable of 
cloning efficiencies as high as Ix 109 . 
233 
BL21: A strain employed for high-level expression of genes cloned into expression 
vectors containing the bacteriophage T7 promoter. Bacteriophage T7 RNA polymerase 
is carried on the bacteriophage X DE3, which is integrated into the chromosome of 
BL21 236 
. 
2.1-6.2 Transformation into XL1 -Blue 
Aliquots of XLI-Blue competent cells were thawed on ice. lOgI of ligation mix was 
diluted with 200ýd ice-cold SFS buffer in a glass tube. 200ýtl suspension of competent 
cells was added to the diluted ligation mix and incubated on ice for 10 minutes. The 
mixture was then subjected to a heat-shock by immersion in a water bath at 420C for 60 
seconds then transferred immediately to ice and left for 5 minutes. Iml SOC medium 
(2% w/v bacto-tryptone, 0.5% w/v yeast extract, lOmM NaCl, 2.5mM KCI, lOmM 
M902, lOmM magnesium sulphate (MgS04), 20mM glucose) at 37CC was then added 
and the mixture incubated in a rotating incubator at 370C for I hour. After incubation, 
the mixture was transferred to a 1.5ml polyethylene microfuge tube and centrifuged at 
10,000g for 30 seconds. 1200ýtl of the supernatant was removed and discarded and the 
bacteria re-suspended in the remaining 200ýd supernatant. The suspension was then 
plated onto agar plates containing appropriate antibiotics together with the indicator 
sugar derivative 5-bromo-4-chloro-3-indolyl P-D-galactopyranoside (X-gal) (Sigma). 
2.1.6.3 Transformation into ToplO One-Shor competent cells 
A vial of Top 10 One-Shote cells was removed from storage at -700C and thawed on 
ice. 2ýtl 0.5M P-mercaptoethanol (Invitrogen) was gently stirred into the competent 
cells. 2gl ligation mix was added and incubated on ice for 30 minutes. The cells were 
then heated, in a water bath, to 420C for 30 seconds and returned to ice for two minutes. 
250gl SOC medium was added and the cells incubated in a rotating incubator at 370C 
for 30 minutes after which the suspension was mixed by gentle vortexing then plated 
out, in aliquots of 20,40 and 200ýd, onto agar plates containing appropriate antibiotics. 
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2.1.6.4 Transformation into BL21 
Aliquots of BL21 competent cells were thawed on ice. lOng of purified expression 
construct DNA was diluted with 200ýtl ice-cold SFS buffer in a glass tube. 200ýtl 
suspension of competent cells was added to the diluted ligation mix and incubated on 
ice for 10 minutes. The mixture was then subjected to a heat-shock by immersion in a 
water bath at 420C for 60 seconds then transferred immediately to ice and left for 5 
minutes. Iml SOC medium at 370C was then added and the mixture incubated on a 
rotating incubator at 370C for I hour. After incubation, the mixture was transferred to a 
1.5ml polyethylene microfuge tube and centrifuged at 10,000g for 30 seconds. 1200ýtl 
of the supernatant was removed and discarded and the bacteria re-suspended in the 
remaining 200ýLl supernatant. The suspension was then plated onto agar plates 
containing appropriate antibiotics. 
2.1.7 Screening of transformants 
2.1.7.1 Screening by antibiotic selection 
Screening of bacterial colonies containing recombinants was facilitated through the use 
of antibiotic resistance encoded within the vector as detailed in the table. LB agar 
containing the appropriate antibiotic was used for the initial plating of transforinants 
and for subsequent maintenance of the plasmid-bearing strains. 
Vector Antibiotic resistance 
pBAD Ampicillin 
pBluescript Ampicillin 
pCRII Ampicillin + kanamycin 
pGEM-T Ampicillin 
pPET Kanamycin 
pTrcHis Ampicillin 
Table 2-2: Plasmid antibiotic resistance 
2.1.7.2 Blue/white screening for lacZ 
Following transforination of plasmids bearing the IacZ gene the transforination mix was 
plated out onto agar containing the appropriate antibiotic(s) together with 
X-gal and 
incubated overnight at 370C. Bacterial colonies not containing an insert were 
identified 
by their blue colouration due to their ability to metabolise the X-gal, through (X- 
coniplementation to a blue coloured pigment. Conversely, those 
bacteria containing an 
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insert, which disrupts the IacZ gene, were unable to metabolise X-gal and therefore 
remained white. White colonies were transferred to a fresh agar plate, containing the 
appropriate antibiotic(s) together with X-gal, in a gridded pattern to allow identification. 
These plates were then incubated overnight to confirm the colour selection. 
Plasmids allowing blue/white selection were: pGEM-T, pBluescript 11 and pCR-11- 
TOPO. 
2.1.7.3 Quick plasmid preparation 
This method was used as a rapid method of isolating DNA from overnight cultures of 
plasmid-bearing bacteria. The method was used to obtain DNA for restriction enzyme 
analysis but not for cloning or other procedures. 
Individual colonies were selected from the gridded colony plates and inoculated into 
glass tubes containing 2ml of LB broth with the appropriate antibiotic(s) - see Table 
2.2. The cultures were incubated overnight at 370C in a shaking incubator. 1.5ml of the 
culture was transferred to 1.5ml polyethylene microfuge tubes and centrifuged at 
16,000g for 30 seconds. The supernatant was discarded and the bacterial pellet re- 
suspended in II Oýtl STET buffer (0.1 M NaCl, I OmM Tris. Cl (pH 8), 1 mM EDTA (pH 
8), w/v 5% Triton X-100) containing 500ýtg/nil lysozyme (Sigma). The mixture was 
incubated for 10 minutes at room temperature then boiled for 2 minutes in a water bath. 
After boiling the mixture was cooled on ice, then centrifuged at 16,000g for 15 minutes. 
The pellet, containing cell debris and denatured protein, was then removed with a 
toothpick. I 10ýtl 5M lithium chloride (LiCl - Sigma) was then added, mixed by gentle 
inversion and incubated on ice for 15 minutes to precipitate the RNA. The solution was 
then centrifuged at 16,000g for 15 minutes and the supernatant transferred to a clean 
microfuge tube. 550ýtl of absolute ethanol (Sigma) was then added and mixed by gentle 
inversion. The solution was then centriftiged at 16,000g for 15 minutes and the 
supernatant discarded. The DNA pellet was solubilized in 35ýd I OmM TE buffer pH 8.5 
and the solution stored at -200C. 
2.1.7.4 Restriction enzyme analysis of plasmid DNA 
Screening of white colonies for the presence of the insert was performed on plasmid 
DNA extracted by the 'quick plasmid preparation' protocol described above (section 
2.1.7.3). Restriction enzyme analysis was performed on these plasmid preparations by 
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digesting 3ýd DNA with 10 units of appropriate restriction enzyme, 1.5ýtl 
manufacturer's restriction enzyme buffer and dH20m a total volume of 15ýd in a sealed 
96 well micro-titre plate. Digestions were allowed to progress at 370C for 2 hours. 1.5ýtl 
IOX gel loading buffer was then added to each restriction mix and the entire volume 
loaded into the well of a 10 x 10cm 1% w/v agarose (Promega) gel, which was then 
electrophoresed at 97 volts (V) with TAE buffer for I to 1.5 hours until adequate 
separation of the fragments had been achieved. A X/Pstl marker was used to allow 
estimation of the size of fragments which were visualised under 254 nm UV light and 
recorded with a Polaroidý) Gel Documentation camera. 
2.1.8 Purification and archiving of plasmid constructs and 
plasmid-bearing bacterial strains 
2.1.8.1 Plasmid purification - QlAwell 81 kit 
The QlAwell 8'ý' kit (Qlagen) is a proprietary anion-exchange column designed for the 
vacuum-driven isolation of ultra-pure plasmid DNA from minipreps. Five millilitres of 
LB broth was inoculated with a single colony of the plasmid-bearing strain and 
incubated overnight in a shaking incubator at 370C. The broth was transferred to a 
microfuge tube and centrifuged at 16,000g for I minute. The supernatant was discarded 
and the pellet re-suspended in 300ýtl PI re-suspension buffer (proprietary formulations 
not available). 300ýd P2 lysis buffer was then added, mixed by inversion and incubated 
for 5 minutes at room temperature. 300ý0 chilled P3 neutralisation buffer was then 
added and mixed by gentle inversion. The solution was incubated on ice for 10 minutes, 
re-mixed, and then centrifuged at 16,000g for 15 minutes. The supernatant was then 
applied to a QlAwell 8 column in the manufacturer's manifold and suction applied. The 
columns were washed twice by the addition of Iml QW wash buffer under suction. A 
clean 1.2ml collection tube was then placed under the column and the DNA cluted by 
the addition of 500ýd QF elution buffer and the application of suction. The eluate was 
transferred to a fresh 1.5ml microfuge tube and 350ýfl 100% isopropanol added and 
mixed thoroughly. The mixture was then centrifuged at 16,000g for 30 minutes. The 
supernatant was removed and discarded and the DNA pellet washed with Iml 70% 
ethanol (Sigma) then centrifuged at 16,000g for 5 minutes. The supernatant was 
discarded and the pellet spun at 16,000g for a further I minute. The remaining 
supernatant was removed and discarded and the pellet allowed to air dry. The DNA 
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pellet was re-suspended in 50ýd I OmM TE buffer pH 8.5. DNA concentration, yield and 
purity were measured by spectrophotometry as described (section 2.1.1.2) and the DNA 
frozen in 25ýd aliquots at -200C. 
2.1.8.2 Plasmid purification - Plasmid Midi Kir 
The Plasmid Midi Kit" (Qiagen) is a proprietary anion-exchange column designed for 
the gravity-driven isolation of ultra pure plasmid DNA from 25- 1 00ml cultures. Twenty 
five millilitres of LB broth was inoculated from a single colony of the plasmid-bearing 
strain and incubated overnight in a shaking incubator at 370C. The broth was transferred 
to a 40ml centrifuge tube and centrifuged at 3951g for 5 minutes at 40C. The 
supernatant was discarded and the pellet re-suspended in 4ml PI re-suspension buffer 
(proprietary formulations not available). 4ml P2 lysis buffer was then added, mixed by 
inversion and incubated for 5 minutes at room temperature. 4ml chilled P3 
neutralisation buffer was then added and mixed by gentle inversion. The solution was 
incubated on ice for 15 minutes, re-mixed, and then centrifuged at 17,640g for 30 
minutes. Meanwhile a Qiagen-tip 100 was equilibrated with 4ml QBT equilibration 
buffer. The supernatant was then applied to the Qiagen-tip 100 and allowed to drain 
through by gravity. The columns were washed twice by the addition of 10ml QC wash 
buffer. A clean 14ml centrifuge tube was then placed under the column and the DNA 
eluted by the addition of 5ml QF elution buffer. 3.5ml cold isopropanol was added to 
the eluate and mixed thoroughly. The mixture was then centrifuged at 17,640g at 40C 
for 30 minutes. The supernatant was removed and discarded and the DNA pellet washed 
with 5ml 70% ethanol then centrifuged at 11,290g for 10 minutes. The supernatant was 
discarded and the pellet spun at 16,000g for a further I minute. The remaining 
supernatant was removed and discarded and the pellet allowed to air dry. The DNA 
pellet was re-suspended in 100ýtl lOmM TE buffer pH 8.5. DNA concentration, yield 
and purity were measured by spectrophotometry as described (section 2.1.1.2) and the 
DNA frozen in 50ýtl aliquots at -200C. 
2.1.8.3 Freezing of plasmid-bearing bacterial strains 
Two microlitres of LB broth was inoculated from a single colony of the plasmid-bearing 
strain and incubated overnight in a shaking incubator at 370C. The following morning 
800[tl LB broth/glycerol (50: 50 v/w) was added and mixed by gentle ýv-ortexing. The 
mixture was thcn divided into three aliquots and frozen in liquid nitrogen, dry ice or a 
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commercial freezing box (Nalgene, Rochester, NY, USA) at -700C. The frozen strains 
were stored at -700C. 
2.1.9 Individual cloning strategies 
2.1.9.1 Cloning of pTrcHis/pmpG-1410 
pmpG DNA was amplified using the Clontech Advantage8 PCR system as above. 
Restriction enzyme analyses with Sac 1, Bam H I, Hind 111, Bg1 11 were used to confirm 
the correct product had been amplified. The PCR product was ligated into pGEM-Vý as 
described and the ligation mix transformed into XLI-Blue competent cells. DNA was 
extracted from 10 clones by the quick plasmid preparation method and restriction 
enzyme analyses with Sac 11, Bam H I, Hind III, Bg1 11 and Sac I (NEB) was performed 
and used to confirm correct insertion and orientation. A high purity stock of pGEM- 
T/pmpG was generated using the QlAwell 8 method and XLI-Blue bacteria containing 
the plasmid were frozen. A 1410 base pair (bp) Hind III fragment from the pGEM-T 
was isolated by restriction enzyme digestion and electrophoresis followed by 
purification using the Qiaex 110 method. The purified fragment was then ligated into 
pTrcHisCO (previously digested with Hind 111, de-phosphorylated and extracted by the 
phenol/chloroform method), in frame to allow expression, and transformed into XLl- 
Blue. Transformants were screened by purification of plasmid DNA, by the quick 
plasmid preparation method, followed by restriction enzyme analysis with Hind III and 
Bam H 1. A high purity stock of pTrcHis/pmpG- 1410 was purified using the QlAwell 8 
method and XLI-Blue bacteria containing the plasmid were stored as frozen glycerol 
stocks. The high purity DNA preparation was again screened by restriction enzyme 
analysis with Hind III and Bam HI- 
2.1.9.2 Cloning of pl3luescript/pmpD-1218 
pmpD DNA was amplified using the Clontech Advantage'ý' PCR system as above. 
Restriction enzyme analyses with Sac I, Bam HI, Hind III and Bgl 11 was used to 
confirm the correct product had been amplified. A 1218 base pair Bam HI fragment 
from the PCR product was isolated by restriction digestion and electrophoresis followed 
by purification using the Qiaex 11"' method. The purified fragment was then ligated into 
pBluescript SKII+ (previously digested with Bam HI, de-phosphorylated and purified 
by the phenol/chloroform method) and transformed into XL I -Blue. Transformants were 
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initially identified by blue/white selecti II1 10 clones ion and ampicillin resistance and 
screened by purification of plasmid DNA by the quick plasmid preparation method, 
followed by restriction enzyme analysis with Hind 111, Sac I and Bam H 1. A high purity 
stock of pSKIPpmpD-1218 was purified using the QlAwell 8 method and XLI-Blue 
bacteria containing the plasmid were stored as frozen glycerol stocks. The high purity 
DNA preparation was again screened by restriction enzyme analysis with Hind III and 
Bam H 1. 
2.1.9.3 Cloning of pBAD/pmpG 
pmpG DNA was amplified using Pfu high-fidelity DNA polymerase as described. The 
PCR product was incubated with Taq DNA polymerase in order to add overhanging 
adenine nucleotides, visualised by ethidium bromide gel electrophoresis and the correct 
sized band (2924bp) purified by the Qiaex 11' , 'kit. The purified PCR product was ligated 
into pBAD-TOPO"ý' and transformed into One-ShoO' competent cells. Transformants 
were initially identified by ampicillin resistance and 10 clones screened by purification 
of plasmid DNA by the quick plasmid preparation method, followed by restriction 
enzyme analysis with Bam H I, Eco RV and Nco 1. A high purity stock of pBAD/pmpG 
was purified using the QlAwell 8 method and One-ShoOý bacteria containing the 
plasmid were stored as frozen glycerol stocks. 
2.1.9.4 Cloning of pPET/pmpGc 
An aliquot of the high-purity pBAD/pmpG DNA was digested with Xho I and Sac I and 
a 1761 bp fragment of pmpG demonstrated by ethidium bromide gel electrophoresis. 
The remainder of the reaction volume was then electrophoresed on a 1% crystal violet 
agarose gel and the fragment purified using the Qlaex W` kit. pPET-30a vector was 
similarly digested with Xho I and Sac I and purified in the same manner. The fragment 
was ligated into the digested pPET-30a vector and transformed into commercial TOPIO 
competent cells (Invitrogen). Transfon-nants were initially identified by kanamycin 
resistance and 9 clones screened by purification of plasmid DNA by the quick plasmid 
preparation method, followed by restriction enzyme analysis with Bg1 11. A high purity 
stock of pPET/pmpGc was purified using the QlAwell 8 method and TOPIO bacteria 
containing the plasmid were stored as frozen glycerol stocks. In order to increase the 
yield of recombinant protein, pPET/pmpGc was transforined in BL21 for expression. 
BL2 I- pPET/pmpGc strains were frozen for storage as frozen glycerol stocks. 
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2.1.9.5 Cloning of pCR-11/pmpG 
pmpG DNA was amplified using Pfu high-fidelity DNA polymerase as described. The 
PCR product was incubated with Taq DNA polymerase in order to add overhanging 
adenine nucleotides. The crude PCR product was visualised by ethidium bromide gel 
electrophoresis and the correct sized band (2924 bp) purified by the Qiaex 111, kit. The 
purified PCR product was ligated into pCR-11-TOPOO and transforined into commercial 
TOPIO competent cells (Invitrogen). Transformants were initially identified by 
ampicillin resistance and 9 clones screened by purification of plasmid DNA by the 
quick plasmid preparation method, followed by restriction enzyme analysis with Eco 
RV. A high purity stock of pCR-11/pmpG was purified using the QlAwell 8 method and 
TOPIO bacteria containing the plasmid were stored as frozen glycerol stocks. The high 
purity DNA preparation was again screened by restriction enzyme analysis with Eco RI 
+ Eco RV. 
2.1.9.6 Cloning of pPET/pmpGa 
An aliquot of the high-purity pCR-lFpmpG DNA was digested with Eco RI and Eco 
RV and a 1504 bp fragment of pmpG demonstrated by ethidium bromide gel 
electrophoresis. Eco RV was used to cut the vector fragment in order to facilitate 
separation of the fragment by gel electrophoresis for later cloning. The remainder of the 
reaction volume was then electrophoresed on a 1% w/v crystal violet agarose gel and 
the fragment purified using the Qlaex 110 kit. pPET 30a vector was digested with Eco 
RI, de-phosphorylated and purified in the same manner. The fragment was ligated into 
the digested pPET30a vector and transfon-ned into commercial TOP 10 competent cells. 
Transforinants were initially identified by kanamycin resistance and 10 clones screened 
by purification of plasmid DNA by the quick plasmid preparation method, followed by 
restriction enzyme analysis with Bam HI. A high purity stock of pPET/pmpGa was 
purified using the QlAwell 8 method and TOPIO bacteria containing the plasmid were 
stored as frozen glycerol stocks. In order to increase the yield of recombinant protein, 
pPET/pmpGa was transfon-ned in BL21 for expression. BL21- pPET/pmpGa strains 
were stored as frozen glycerol stocks. 
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2.2 Expression 
2.2.1 Basic techniques 
2.2.1.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The BioRad Mini-Protean 11 (BioRad, Hemel Hempstead, UK) was used for SDS- 
PAGE electrophoresiS237,238. The glass plates were assembled according to the 
manufacturer's instructions. 
10ml of 10% separating gel was made up by mixing monomer solution (40% 
acrylamide solution (Sigma), 0.008% N, N'-methylenebisacrylamide) with 4X 
separating gel buffer (375mM Tris-HCI, pH 6.8), 10% v/v SDS, dH20,10% ammonium 
persulphate (Sigma) and N, N, N', N'-tetramethylethylenediamine (TEMED - Sigma) in 
the quantities given in the table as appropriate for the size of proteins to be 
differentiated. The gel mix was then poured between the glass plates and overlaid with 
isopropanol. Once the gel had set, the isopropanol was poured off and the gel surface 
washed with dH20 and dried with blotting paper. The 15-well comb was then inserted 
between the plates. 4ml of stacking gel was then made by mixing 532ýd monomer 
solution with I ml 4X stacking gel buffer (I 25mM Tris-HCI, pH 6.8), 40ýtl 10% SDS, 
2.4ml dH20,20ýtl 10% ammonium persulphate and 2ýtl TEMED. The stacking gel mix 
was then poured between the glass plates and allowed to set. Once the stacking gel had 
set, the comb was removed and the wells washed with dH20. The gels were then 
fastened to the electrode assembly and placed in the buffer tank. Tris-glycine 
electrophoresis buffer (25mM tris(hydroxymethyl)aminomethane, 250mM glycine 
(Sigma), 0.1 % SDS was added to the top and bottom reservoirs. 
Protein 
molecular weight 
Acrylamide 
con Cn (%) 
Monomer 
Soln 
4X separating 
gel buffer 
10% SDS dH 20 
Ammonium 
phosphate 
TEMED 
40-200 7.5 2.5ml 2.5ml 100PI 4.9ml 50PI 3.3pi 
21 - 100 10 3.3ml 2.5ml 100PI 4m] 50PI 3.3pl 
10-40 12.5 4.2ml 2.5ml 100PI 3.2ml 50pi 3.3pl 
Table 2-3: SDS-PAGE gel composition 
The protein sample to be electrophoresed was mixed with an equal volume of 2X SDS- 
PAGE loading buffer (125mM Tris-HCI, 5% P-mercaptoethanol (Sigma), 2% SDS, 
0.6% bromophenol blue (Sigma), 20% glycerol (Sigma)) and heated to IOOOC in a 
boiling water-bath for 3 minutes to denature the proteins. The protein/buffer mix was 
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then loaded into the wells of the stacking gel and 200v applied vertically across the gel 
until the bromophenol blue dye-line reached the bottom of the gel. The gels were then 
removed from the assembly and either stained with Coomassie brilliant blue or used for 
Western blotting. 
SDS-PAGE gels were stained with Coomassie Brilliant Blue R250 to demonstrate 
separated protein bands. The gels were immersed in staining solution (0.25% 
Coomassie Brilliant Blue R-250 (BDH), 45% methanol (BDH), 45% dH20,10% glacial 
acetic acid (BDH)) for I to 2 hours on a rocking platform. The gel was then transferred 
to de-staining solution (45% methanol (BDH), 45% dHA 10% glacial acetic acid 
(BDH)) and left on the rocking platform overnight. After adequate de-staining gels were 
dried between plastic sheets for long-term archiving. 
2.2-1.2 Western blotting & immuno-cletection 
A standard Western blotting protocol was used 239 . Hybond P"ý' nylon membrane 
(Amersham, Chalfont, UK) was used for immunoblotting. A piece of membrane was cut 
to the size of the gel, wetted briefly in methanol (Sigma), then soaked in Towbin buffer 
(39mM glycine, 48mM Tris, 0.037% SDS, 20% methanol) for at least 10 minutes. The 
components of the Western blot were then assembled in the BioRad MiniProtean 11 
blotting cassettes (BioRad), under Towbin buffer, in the order: porous pad, Whatman 
3MM blotting paper, gel, Hybond PO membrane, Whatman 3MM paper, porous pad. 
The cassette was then closed and inserted in the blotting electrode assembly in the 
Towbin buffer filled tank, such that the Hybond PO membrane was closest to the anode. 
Current was applied across the cassettes at 200m-A for one hour with an ice pack to 
prevent heating. 
After I hour, the cassette was removed and opened, and the membrane transferred to 
blocking buffer (Tris-buffered saline (TBS - 150mM NaCl, I OOmM Tris-HCI, pH 7.5), 
0.0005% v/v Tween-20,3% w/v dried skimmed milk powder (Tesco, Cheshunt)) for 
one hour. After blocking, the membrane was transferred to an individual plastic bag, in 
which it was sealed with primary antibody, diluted in rinse buffer (TBS, 0.0005% v/v 
Tween-20,1% w/v dried skimmed milk powder) at the appropriate dilution. The 
membrane was incubated with the antibody solution for I hour on a rotating platform. 
The membranes were then removed from the bags and washed, individually, three times 
in rinse buffer. They were then sealed into plastic bags with the secondary antibody, 
diluted appropriately in rinse buffer and incubated on a rotating platform for one hour. 
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The membranes were then washed twice in rinse buffer and once in TBS, each for 8 
minutes. Finally, the membranes were equilibrated in detection buffer (lOOmM Tris- 
HCI, IOOmM NaCl, 50mMMgCI2, pH 9.5) then incubated with 0.33mg/ml nitro blue 
tetrazolium (NBT - Sigma) and 0.165mg/ml 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP) in detection buffer for 5 minutes to allow the colour to develop, then washed 
and allowed to dry. 
2.2.2 pTrcHis constructs 
A single colony of XLI-Blue containing the expression construct of interest was 
inoculated into 2ml of LB broth containing 50ýLg/ml ampicillin and 15ýtg/ml 
tetracycline and incubated overnight at 370C in a shaking incubator. I ml of this culture 
was then transferred to 40ml pre-warmed LB broth, also containing ampicillin and 
tetracycline, and incubated in a shaking incubator with hourly monitoring of the OD600- 
When the OD600 reached - 0.6, five millilitres of culture were aliquoted into each of six 
tubes labelled A to F. Each tube received either 6.25ýtl, 0.625gl or no 0.8M isopropyl 
P-D-thiogalactopyranoside (IPTG - Sigma) to give final concentrations of I mM, 0.1 mM 
or OmM IPTG, and was then transferred to a shaking incubator at either 250C or 370C 
as detailed in . After 4 hours, 2ml of the culture was removed and centriffiged at 
16,000g for 30 seconds. The pellet was stored at -200C pending analysis. The 
remaining culture was returned to the incubator and a further 2ml aliquot taken and 
centrifuged after 20 hours. 
Table 2-4: IPTG concentrations used to induce expression in pTrcHis constructs 
Tube 
IPTG 
Concentration 
(MM) 
Temperature 
(OC) 
A 0 37 
B 0.1 37 
C 1 37 
D 0 25 
E 0.1 25 
F 1 25 
The bacterial pellets were re-suspended in 200ýfl 
phosphate buffered saline (PBS: 138mM NaCl, 
2.7mM KCI, pH 7.4) and subjected to four 
freeze/thaw cycles alternating between solid 
carbon dioxide (C02) and a 370C water-bath. 
10ýfl of each suspension was then mixed with 
10ýd 2X SDS-PAGE loading buffer and 
electrophoresed in duplicate 10% SDS-PAGE gels; each lane therefore containing the 
equivalent of 50ýtl original culture. One gel was stained with Coomassie blue stain and 
the other was used for Western blotting. Anti-XpressR antibody (Invitrogen), diluted 
1: 5000, was used as the primary antibody and goat anti -mouse-alka I ine phosphatase 
conjugate (Promega), diluted 1: 7500, was used as the secondary antibody. Nitro blue 
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tetrazollum (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) were used as the 
chromogenic substrates. 
2.2.3 pBAD constructs 
A single colony of One-Shot" bacteria containing the expression construct of interest 
was inoculated into 3ml of LB broth containing 20ýLg/rnl ampicillin and incubated 
overnight at 370C in a shaking incubator. 250ýtl of this culture was then used to 
inoculate each of 10 labelled tubes, each containing 10ml LB broth (+ ampicillin) and 
incubated in a shaking incubator with hourly monitoring of the OD600-When the OD600 
reached - 0.5 a Iml aliquot was removed from each tube and centrifuged at 16,000g for 
30 seconds. The pellet was stored at -200C pending analysis. Each tube then received 
90ý0 of the appropriate arabinose stock solution (Invitrogen) to give final concentrations 
as shown in Table 2-5. The tubes were then transferred to a shaking incubator at either 
250C or 370C as detailed in Table 2-5. After 4 hours, Iml of the culture was removed 
and centrifuged at 16,000g for 30 seconds. The pellet was stored at -200C pending 
Tube Arabinose 
stock solution 
Final arabinose 
concentration 
Temperature 
(OC) 
1 2% 0.02% 37 
2 0.2% 0.002% 37 
3 0.02% 0.0002% 37 
4 0.002% 0.00002% 37 
5 0.0002% 0.000002% 37 
6 0% 37 
7 2% 0.02% 25 
8 0.2% 0.002% 25 
9 0.02% 0.0002% 25 
10 0.002% 0.00002% 25 
11 0.0002% 0.000002% 25 
12 
1 
0% 
1 
25 
analysis. The remaining culture was 
returned to the incubators and a 
further IMI aliquot taken and 
centri ge after 20 hours. 
Table 2-5: Arabinose concentrations 
used to induce expression in pBAD 
constructs 
The bacterial pellets were re- 
suspended in I 00ýtl phosphate- 
buffered saline and subjected to four 
freeze/thaw cycles using solid C02 
and a 370C water bath. 10ýd of each 
suspension was then mixed with 10ýd 2X SDS-PAGE loading buffer and 
electrophoresed in duplicate 10% SDS -PAGE gels. One gel was stained with 
Coomassie blue stain and the other was used for Western blotting. Anti I, -V5 , 
monoclonal antibody (Invitrogen), diluted 1: 5000, was used as the primary antibody. 
Anti-V50 monoclonal antibody recognises the paramyxovirus P and V protein sequence 
-G I y-Lys -Pro- II e-Pro-A sn-Pro-Leu- Leu-G ly- Leu-Asp- S er-Thr- which is encoded in the 
V5 epitope of the pBAD vectors. Goat anti -mouse-a Ika I ine phosphatase conjugate 
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(Promega), diluted 1: 7500, was used as the secondary antibody. NBT/BCIP was used as 
the chromogenic substrate. 
2.2.4 pPET constructs 
A single colony of BL21 containing the expression construct of interest was inoculated 
into 2ml of LB broth containing 50ýtg/rnl ampicillin and 15ýtg/rnl tetracycline and 
incubated overnight at 370C in a shaking incubator. Iml of this culture was then 
transferred to 40ml pre-warryied LB broth, also containing ampicillin and tetracycline, 
and incubated in a shaking incubator with hourly monitoring of the OD600. When the 
OD600 reached - 0.6 5ml of culture was aliquoted into each of six tubes labelled A to F. 
Each tube received 6.25ýfl, 0.625ýd or no 0.8M IPTG to give final concentrations of 
I mM, 0.1 mM or Om. M IPTG, and was then transferred to a shaking incubator at either 
250C or 370C as detailed in Table 2-6. After 4 hours, 2ml of the culture was removed 
and centrifuged at 16,000g for 30 seconds. The pellet was stored at -200C pending 
analysis. The remaining culture was returned to the incubators and a further 2ml aliquot 
taken and centrifuged after 20 hours. 
Table 2-6: IPTG concentrations used to induce expression in pPET constructs 
Tube 
IPTG 
Concentration 
(MM) 
Temperature 
(OC) 
A 0 37 
B 0.1 37 
C 1 37 
D 0 25 
E 0.1 25 
F 1 25 
The bacterial pellets were re-suspended in 
200ýtl PBS and subjected to four 
freeze/thaw cycles using solid C02 and a 
370C water-bath. 10ýd of each suspension 
was then mixed with 10ýtl 2X SDS-PAGE 
loading buffer and electrophoresed in 
duplicate 10% SDS-PAGE gels, each lane 
therefore containing the equivalent of 50pl 
original culture. One gel was stained with Coomassie blue stain and the other was used 
for Western blotting. Anti-S protein monoclonal antibody-alkaline phosphatase 
conjugate (Novagen), diluted 1: 5000, was used as the sole antibody. NBT/BCIP was 
used as the chromogenic substrate. 
2.2.5 rMOMP construct 
The construct used to prepare Chlamydia trachomatis serovar A rMOMP was kindly 
provided by Lyn Appleby and Michael Ward (Southampton Medical School, UK). A 
77 
Materials & Methods 
single colony of the expression host containing the expression plasmid was inoculated 
into 40ml LB and incubated overnight at 370C in a shaking incubator. The following 
morning the culture was added to 1000ml pre-warmed LB. The culture was then grown 
in a shaking incubator at 370C to an OD600 of 0.6. IPTG was then added to a final 
concentration of 0.5mM and the cultures induced at 370C in a shaking incubator for 5 
hours. The broth was then divided into four 250ml aliquots and centrifuged at 10,976g 
for 15 minutes at 40C. The pellets were stored for purification. 
2.3 Recombinant Protein Purification 
2.3.1 General methods 
2.3.1.1 Determination of the solubility of recombinant proteins 
in PBS 
Each of the recombinant proteins produced was assessed to deten-nine its solubility in 
PBS. As described above, an aliquot of bacterial culture for each time point and inducer 
concentration was centrifuged, then re-suspended in 1/10 the original volume of PBS 
and subjected to four freeze/thaw cycles using dry ice and a 370C water-bath. 50ýfl of 
this was then taken and centrifuged. The supernatant was transferred to a fresh 
microfuge tube and the pellet re-suspended in 50ýLl PBS. 5ýtl of each was then analysed 
by SDS-PAGE as described above. 
2.3.1.2 Purification of inclusion bodies 
All the recombinant proteins used for the field studies were mostly present in PBS 
insoluble form in the bacterial cells after expression. Purification of inclusion bodies 
was therefore performed first and the inclusion bodies then used for further affinity 
purification. 
A pellet from 500ml of culture was re-suspended in 20ml BugBusterý` Protein 
Extraction Reagent (Novagen - proprietary formulation not available) to which 25ýtl 
protease inhibitor cocktail (Sigma - contains 4-(2-aminoethyl)benzenesulfonyl fluoride 
(AEBSF), bestatin, pepstatin A, trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane 
(E-64), and N-(alpha-rhamnopyranosyloxyhydroxyphosph*myl)-Leu-Trp (phosphoramidon)) 
and 20ýtl Benzonase*ý Nuclease mix (Novagen) had been added. The suspension was 
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mixed on a rocking platform for 20 minutes at room temperature until no longer 
viscous. The suspension was then centrifuged at 20,070g for 20 minutes at 40C. The 
supernatant was removed and stored for SDS-PAGE analysis. 
The pellet was re-suspended in 5ml BugBuster"' reagent and 50ýtl lysozyme 20ml/ml 
added. The mixture was incubated at room temperature for 5 minutes then 30ml 0.1 X 
BugBuster ®R reagent was added and the suspension vortexed for I minute. The 
suspension was then centrifuged at 20,070g for 15 minutes at 40C. The supernatant was 
removed, an aliquot stored for SDS-PAGE analysis, and the pellet re-suspended in 30ml 
0.1 X BugBuster 9 reagent. The suspension was vortexed for I minute then centrifuged at 
20,070g for 15 minutes at 40C. The supernatant was removed and an aliquot stored for 
SDS-PAGE analysis. The wash process was repeated once more. The pellet, containing 
the purified inclusion bodies was frozen. 
2.3.2 Purification of rMOMP 
Two pellets of inclusion bodies, each from 250ml of culture were used. Each pellet was 
re-suspended in 12.5ml 2% sarkosyl (Sigma) + 40m-M dithiothreitol (Sigma) and mixed 
on a rotating platfon-n at room temperature for I hour. The suspension was then 
centrifuged at 15,366g for 20 minutes and the supernatant removed and stored. The 
pellet was again re-suspended in the sarkosyl/dithiothreitol solution and the process 
repeated. The pellet was re-suspended in 5ml TBS and an aliquot stored for SDS-PAGE 
analysis. The two supernatants were combined and placed into a lOkDa exclusion size 
Slide-A-Lyzer"ý' dialysis cassette (Pierce, Tattenhall, Cheshire, UK) and dialysed against 
a saturated solution of (NH4)2SO4 (Fluka, Poole, UK) overnight at 40C. The suspension, 
containing the precipitated rMOMP, was then removed from the cassette, transferred to 
a clean centrifuge tube and centrifuged at 15,366g for 15 minutes at 40C. The pellet was 
then re-suspended in 9ml of 2% octylglucoside (Sigma) + 40mM dithiothreitol and 
mixed overnight at 40C. The rMOMP remains insoluble in the octylglucoside. The 
suspension was centrifuged at 15,366g for 15 minutes at 40C and the rMOMP re- 
suspended in I ml PBS. 
The aliquots collected during the purification process were then analysed by SDS- 
PAGE. 
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2.3.3 Ni-NTA Protein Affinity Purification 
Ni-NTA Spin Colurnns'ý' (Qiagen) were used for the purification of recombinant 
proteins carrying a 6X histidine tag. The Ni-NTA Spin Columns'ý' contain silica beads to 
which nickel-chelating resin is bound. The histidine-tag containing recombinant 
proteins bind strongly to the nickel tetradentate complexes allowing stringent washing. 
As the recombinant proteins were all insoluble in PBS., they were purified under 
denaturing conditions. 
250ml of culture was centrifuged and the resultant pellet re-suspended in 2.5ml PBS. 
100ýtl of this suspension (equivalent to 10ml original culture) was added to 900ýd lysis 
buffer B (8M urea, OAM NaH2PO4, lOmM Tris-HCI pH 8.0) and mixed on a rotary 
shaker for I hour at 40C. Once completely lysed the suspension was centrifuged at 
16,000g for 20 minutes at 40C. 20gl supernatant (equivalent to 20%Ll original culture) 
was stored for SDS-PAGE analysis. Meanwhile a Ni-NTA Spin Columno was 
equilibrated with 600ýtl lysis buffer B then centrifuged for 2 minutes at 920g. 60%Ll of 
the cleared lysate was then added and spun for 2 minutes at 920g. 20ýd flow-through 
(equivalent to 200ýd original culture) was stored for SDS-PAGE analysis. The column 
was then washed with 60%Ll wash buffer C (8M urea, 0.1 M NaH2PO4, I OmM Tris-HCl 
pH 5.9) and centrifuged for 2 minutes at 920g. 20ýtl flow-through (equivalent to 200ýtl 
original culture) was stored for SDS-PAGE analysis. This wash process was then 
repeated. The recombinant protein was then eluted from the column by adding 20%d 
elution buffer E (8M urea, OAM NaH2PO4, lOmM Tris-HCI pH 4.5) and then 
centrifuging for 2 minutes at 920g. The flow-through contained the recombinant 
protein. Five microlitres of the flow-through (equivalent to 250ýtl original culture) was 
set aside for SDS-PAGE analysis. The elution process was then repeated. 
The aliquots collected during the purification process were then analysed by SDS- 
PAGE. 
2.3.4 ProBondo Column Resin Affinity Purification 
ProBondo resin contains divalent nickel cations immobilised onto ProBond resin and is 
used for affinity purification of recombinant proteins with a 6X His tag. As the 
recombinant proteins were all insoluble in PBS, they were purified under denaturing 
conditions. This method was used for the purification of recombinant proteins from the 
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expression of pPET-30a, pPET/pmpGa and pPET/pmpGc used in the field studies i I in 
The Gambia. 
The ProBond"" column (Invitrogen) was prepared by first re-suspending the resin, and 
then centrifuging at 920g for 2 minutes. The supernatant was then aspirated and 
discarded. 7ml sterile dH20was then added and the resin re-suspended. The column 
was then centrifuged at 920g for 2 minutes and the supernatant again removed and 
discarded. This wash process was then repeated with a further 7ml sterile dH20.7ml of 
denaturing binding buffer (8M urea, 20mM sodium dihydrogen orthophosphate 
(NaH2PO4), 500mM NaCl, pH 7.8) was then added and the resin re-suspended. The 
column was then centrifuged at 900g for 2 minutes and the supernatant discarded. This 
process was then repeated a further two times. 
Pelleted bacterial cells or purified inclusion bodies equivalent to 250ml of culture were 
used for each purification. 20ml guanidinium lysis buffer (6M guanidinium 
hydrochloride (GuHCI), 20mM sodium phosphate (NaP04), 5OOmM NaCl, pH 7.8) was 
warmed to 370C. Each pellet of either bacteria or inclusion bodies was re-suspended in 
10ml guanidiniurn lysis buffer and mixed on a rocking platform at room temperature for 
10 minutes. The bacterial suspensions were then sonicated, on ice, at high intensity at 
20 kHz for 3 bursts of 5 seconds each. The suspensions were then centrifuged at 1200g 
for 15 minutes and the supernatant transferred to a clean tube and the pH adjusted to 
7.8. The pellet was then re-suspended in 10ml PBS and an aliquot stored for later SDS- 
PAGE analysis. 
Five millilitres of the cleared lysate was added to the column and the resin re- 
suspended. The suspension was mixed on a rocking platforrn for 10 minutes. The 
column was then centriftiged for 2 minutes at 920g and the supernatant removed and 
stored at -200C. The second 5ml of the cleared lysate was then added to the column and 
the process repeated for all four 5ml aliquots. The column was then washed by adding 
4ml denaturing binding buffer, mixing on the rocking platform for 5 minutes, 
centrifuging for 2 minutes at 920g and aspirating and storing the supernatant. This 
process was repeated one further time. The washing process was then repeated twice 
each with denaturing wash buffer pH 6.0 (8M urea, 20mM NaP04,500mM NaCl, pH 
6.0) and denaturing wash buffer pH 5.3 (8M urea, 20mM NaP04,500mM NaCl, pH 
5.3). 1 ml denaturing clution buffer (8M urea 20mM NaP04,500mM NaCl, pH 4.0) was 
then added and the resin re-suspended. The suspension was mixed on the rocking 
platforrn for 5 minutes, and then centrifuged for 2 minutes at 920g. The supcmatant was 
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aspirated and stored. The elution process was repeated four more times with furthcr I 
ml aliquots of denaturing elution buffer. 
The aliquots collected during the purification process were then analysed by SDS- 
PAGE. 
2.3.5 TALONO Metal Affinity Resin Column 
TALON Metal Affinity Resin (Clontech) is used for the purification of 6XHis tagged 
proteins. The resin contains sepharose beads to which cobalt-chelating resin is bound. 
The histidine-tag containing recombinant proteins bind strongly to the cobalt 
tetradentate complexes. As the recombinant proteins were all insoluble in PBS, they 
were purified under denaturing conditions. This method was used for the purification of 
recombinant proteins from the expression of the pPET/pmpGa and pPET/pmpGc. 
Bacterial cells from 500ml of induced culture were centrifuged in two 250ml aliquots at 
10,976g for 15 minutes and the supernatants discarded. The pellets were each re- 
suspended in 10ml lysis buffer (6M GuHCl, 50mM NaHP04, I OmM Tris-HCI, I OOmM 
NaCl, pH 8.0), and then mixed on a rocking platform at room temperature for 30 
minutes until completely lysed. The suspension was passed through an 18 gauge needle 
several times to shear the DNA and reduce viscosity. The suspension was then 
centrifuged at I 1,290g for 20 minutes at 40C. The supernatant was transferred to a clean 
tube and used for further purification, a small aliquot being stored for SDS-PAGE 
analysis. The pellet was re-suspended in 10ml PBS and an aliquot stored for SDS- 
PAGE analysis. 
Iml of a 50% suspension of TALONO metal affinity resin was transferred to each of 
two 40ml centrifuge tubes and centrifuged at 22,658g for 10 minutes. The supernatant 
was removed and discarded. 2.5ml lysis buffer was added, mixed on a rocking platforrn 
for 5 minutes then the suspension was centrifuged at 22,658g for 10 minutes and the 
supernatant discarded. The 10ml cleared bacterial lysate was then added to each tube, 
the pellet re-suspendcd and the suspension mixed on a rocking platform at room 
temperature for 20 minutes. The tubes were then centrifuged at 22,658g for 10 minutes 
and the supernatants removed and stored. The pellets were then each re-suspended in 
5ml lysis buffer and mixed on a rocking platform for 5 minutes. The tubes were again 
centrifuged at 22,658g for 10 minutes and the supernatant removed, ail aliquot being 
saved for SDS-PAGE analysis. Two further wash processes were carried out. Finally 
500ýtl elution buffer (8M urea, 50mM NaH2PO4, I OOmM NaCl, 20mM piperazine-N, N'- 
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bis(2-ethanesulfonic acid) pH 6.2 - (PIPES, Sigma) was added, the pellet re-suspended 
and the suspension mixed on a rocking platform for 5 minutes. The tubes were then 
centrifuged at 22,658g for 10 minutes and the supernatant removed and stored. This 
elution procedure was then repeated three further times each with 500ýd elution buffer. 
The aliquots collected during the purification process were then analysed by SDS- 
PAGE. 
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2.4 Whole Blood Assay 
2.4.1 Preparation of antigens 
2.4.1.1 Phytohaemagglutinin 
Phytohaernagglutinin (PHA - Sigma) was purchased as a lmg/ml solution. This 
solution was diluted as required to a final concentration of 20ýLg/ml with supplemented 
Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco/Life 
Technologies/Invitrogen, Paisley, Scotland) when making up the antigen plates for the 
whole blood assay. 
2.4.1.2 Purified protein derivative 
Purified protein derivative (PPD - Statens Seruminstitute, Copenhagen, Denmark) was 
purchased as a lmg/ml solution. This solution was diluted as required to a final 
concentration of 2%tg/ml with supplemented RPMI 1640 medium when making up the 
antigen plates for the whole blood assay. 
2.4.1.3 Candida albicans 
Candida albicans was purchased as a freeze-dried powder (Alk Laboratories, 
Wallingford CT, USA). The powder was suspended in PBS/10% glycerol to a final 
concentration of lmg/ml. This solution was diluted as required to a final concentration 
of 20ýtg/ml with supplemented RPMI when making up the antigen plates for the whole 
blood assay. 
2.4.1.4 Induced pPET without insert 
As a control for the specificity of the recombinant proteins in subsequent 
immunological studies, the pPET vector without an insert was induced with IPTG and 
the bacterial cells subjected to the same recombinant protein extraction procedure and 
affinity purification of putative protein in the exactly the same way as the pPET pMPG 
constructs. No recombinant protein bands were visible on SDS-PAGE analysis, and so 
the resultant extract was diluted by the mean of the dilution factors for pPET/pmpGa 
and pPET/pmpGc as required to obtain a lmg/ml suspension. This solution was diluted 
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as required as for the pPET/pmpG recombinants with supplemented RPMI when 
making up the antigen plates for the whole blood assay. 
2.4.1.5 Chlamydia trachomatis elementary bodies 
Chlamydia trachomatis serovar A elementary bodies (EB's), grown from an Isolate 
from an individual with trachoma in Jali, The Gambia, were kindly provided by 
Professor Michael Ward (Southampton Medical School, UK) as a 1.35 mg/ml 
suspension. This was diluted with sterile PBS to give a stock solution of 0.5mg/ml. This 
solution was diluted as required to a final concentration of 10ýtg/ml with supplemented 
RPMI when making up the antigen plates for the whole blood assay. 
2.4.1.6 M0MP 
Recombinant MOMP was prepared as described above. The final concentration after 
purification was 5mg/ml. This was diluted with sterile PBS to give a stock solution of 
lmg/ml. This solution was diluted as required to a final concentration of 20ýtg/ml with 
supplemented RIPMI when making up the antigen plates for the whole blood assay. 
2.4.1.7 omP2 
Recombinant Chlamydia trachomatis serovar AOmP2 was kindly provided by Professor 
Hill Gaston (Cambridge University School of Medicine) as a lmg/ml solution. This 
solution was diluted as required to a final concentration of 20ý1g/ml with supplemented 
RPMI when making up the antigen plates for the whole blood assay. The recombinant 
omP2 was produced by cloning the appropriate PCR product into a pQE60 expression 
vector (Qlagen) which was then transfon-ned into E. coli. The induced proteins could 
then be purified using their C-ten-ninal histidine tag. Bacterial lysates containing the 
antigen were sonicated and centrifuged six times in buffer and solubilized in 6M urea. 
The recombinant was then purified by elution from nickel containing His-Trap columns 
(Pharmacia) using 300 mM imidazole. 
2.4.1.8 HSP60 
Recombinant Chlamydia trachomatis serovar A HsP60 was kindly provided by 
Professor Hill Gaston (Cambridge University School of Medicine) as a 0.7mg/ml 
solution. The recombinant was produced as described above. This solution was diluted 
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as required to a final concentration of 20ýtg/ml with supplemented RPMI when making 
up the antigen plates for the whole blood assay. 
2.4.1.9 PmPGc 
Recombinant PmpGc was prepared as described above. The concentration was estimated 
by comparison against known standards using SDS-PAGE electrophoresis and staining 
with Coomassie Blue. The recombinant protein was then diluted to give a stock solution 
of Img/ml. This solution was diluted as required to a final concentration of 20ýtg/ml 
with supplemented RPMI when making up the antigen plates for the whole blood assay. 
2.4.1.10 PmPGa 
Recombinant PmPGa was prepared as described above. The concentration was estimated 
by comparison against known standards using SDS-PAGE electrophoresis and staining 
with Coomassie Blue. The recombinant protein was then diluted to give a stock solution 
of lmg/ml. This solution was diluted as required to a final concentration of 20ýtg/ml 
with supplemented RPMI when making up the antigen plates for the whole blood assay. 
2.4.2 Preparation of antigen plates 
Assay plates containing antigens and controls were prepared in advance and stored 
frozen at -200C. All preparation was undertaken with full aseptic technique using a 
Class 11 microbiology safety cabinet (British Standard 5726: 1992). The cabinet was 
regularly serviced, and cleaned daily with 70% ethanol before and after use, and sterile 
disposable equipment was used within the hood space. 
Antigen plates were prepared in batches of forty. RPMI (20.5ml), supplemented with 100 
units/ml penicillin, 100ýtg/ml streptomycin and 2mM L-glutamMe (all Gibco/Life 
Technologies/Invitrogen), was placed in each of eleven 50ml sterile plastic, screw-topped, 
labelled tubes. Sufficient stock solution of each antigen was added to the appropriate tube to 
give a final concentration of 20ýtg/ml (except for EB's which were used at I Oýtg/ml). 
Forty 96-well, lidded, round-bottom cell culture plates (Nalge Nunc International) were 
then opened in the cabinet and 200ýd sterile PBS pipetted into the outside wells as 
shown in Figure 2-2.100ýtl of each antigen was then pipetted, in turn, into the 
appropriate wells. Once all the wells had been filled the plates were frozen at -200C 
until required. 
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Figure 2-2: Whole blood assay plate layout 
2.4.3 Setting up whole blood assays 
Whole blood assays were perfon-ned using methods established by Elliot 320 and Dockrell. 319 
Approximately 10ml of blood was taken fi7om each patient into a Vacutainers tube (BD, 
Oxford, UK) containing 143 units/ml sodium heparin for the whole blood assay. These 
samples were used to set up the whole blood assays within I hour of venesection. 
Meanwhile the requisite nw-nber of antigen plates were allowed to thaw in the class H 
microbiology safety cabinet. All manipulations of the blood were conducted within the 
safety cabinet and all contaminated disposables were soaked in 1% Virkono (Antec 
International,. Sudbury, UK) then incinerated. For each patient two plates were used, the 
first to be harvested on day I for the assays of TNF-(x, IL-2 and transforming growth factor 
P (TGF-P) and the second plate to be harvested on day 6 for IFNy, IIL-5 and EL- 10. 
Two volumes of blood/RPMI were used, the larger where TGFP was to be assayed in 
addition to the other five cytokines. For six cytokines 6ml of blood was diluted with 
9ml of supplemented RPMI, for five cytokines 5ml of blood was diluted with 7.5ml 
supplemented RPML The blood/RPMI was mixed thoroughly by pipetting up and 
down. The blood/RPMI mix was then transferred into a sterile reservoir and then 100ýtl 
pipetted into each of the antigen/control wells in the antigen plate. The lid was then 
replaced, fastened with porous dressing tape and the plates incubated at 370C in a 
humidified incubator with 5%CO2- 
After 24 hours incubation the day I plates were removed from the incubator and 
transferred to the safety cabinet. Using a multi-channel pipette, the supernatants were 
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removed from the wells and transferred to labelled 96-well microtitre plates (Life 
Technologies); one such plate being used for each of the supernatants to be assayed, 
with up to three patients' supernatants being stored in each plate. On day 6, the process 
was repeated. 
2.5 Cytokine ELISA 
2.5.1 Standard ELISA protocol 
Measurement of the cytokine levels in the whole blood assay supernatants was 
performed using an enzyme-linked immunosorbent assay (ELISA) technique (OptEIA, 
BD PharMingen, San Diego, USA). Each well from the whole blood assay duplicates 
was assayed individually, rather than being pooled, as it was considered that the whole 
blood assay was a more likely source of variability than the ELISA measurements. The 
supplied, Iyophilised cytokine standards were reconstituted with sterile water to give a 
stock solution of I OOng/ml. This stock solution was then aliquoted and stored at -200C. 
For the assays the cytokine standards were prepared by doubling dilutions prepared in 
tubes to ensure thorough mixing, then pipetted onto the ELISA plate. Details of 
dilutions used are given below. 
The ELISA plates were first coated overnight with capture antibody. The supplied anti- 
human cytokine antibody was diluted 1: 250 with coating buffer (0.1 M NaHM, 33mM 
Na2CO3, pH 9.5) and used, at 100ýtl per well, to coat the wells of the microtitre plate 
(Dynex Technologies, Middlesex, UK). The plates were covered and allowed to 
incubate overnight at 40C. The following morning the plates were washed in an 
automated microtitre plate-washer (ELP-40, Bio-Tek Instruments, Winooski, Vermont, 
USA). The wells were aspirated then washed three times with 300ýLl/well of wash buffer 
(PBS, 0.05% Tween-20). After the last wash, the plates were inverted onto a blotting 
pad to remove any last traces of wash buffer. The plates were then blocked with 
200ýtl/well of assay diluent (PBS, 10% foetal calf serum, Sigma) for I hour at room 
temperature, and then washed three times in the same manner as before. Meanwhile, 
doubling dilutions of the appropriate cytokine standard were prepared to the appropriate 
dilutions (see below). 
I 00[tl of each supernatant from the whole blood assay, the control supernatants and the 
cytokine controls were then transferred to the appropriatc wells of the microtitre plate. 
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Any necessary dilutions (see below) being first carried out in the storage plate. The 
plates were covered and allowed to incubate for 2 hours at room temperature. The wells 
were then aspirated and washed as before, but with a total of 5 washes. Meanwhile the 
detection solution was mixed. The biotinylated anti -human-c ytokine detection antibody 
and avidin-horseradish peroxidase conjugate were diluted together 1: 250 in assay 
diluent. 10%Ll detection solution was then pipetted into each well and allowed to 
incubate at room temperature for I hour. The wells were then washed again as before, 
but with a total of 7 washes. 
ABTS substrate (Kirkegaard & Perry Laboratories, Guildford, UK) was then prepared 
by adding equal volumes of 0.01% H202 and 0.3g/l 2,2'-azino-di(3-ethylbenzthiazoline- 
6-sulphonate) in glycine/citric acid buffer. 100ýtl of the ABTS substrate mix was then 
added to each well and allowed to develop in the dark for -30 minutes. The reaction 
was then stopped by the addition of 100ýtl 1% SDS. The absorbance was then read at 
410nm using an automated ELISA plate reader (MRX ELISA plate reader, Dynex 
Technologies), a standard curve generated from the cytokine standard results and the 
concentration calculated from each sample and control well. Concentrations were 
calculated automatically as the mean of the replicates although the plates and the 
individual results were checked manually for any obvious contamination. 
2.5.2 Variations on the standard method for individual cytokine 
ELISA 
2.5.2.1 TNFcc 
Cytokine standards: 2000,1000,500,250,125,62.5,31.25,15.63,7.81,0 pg/ml 
PIIA, Candida and EB whole blood assay supematants diluted X5 
2.5.2.2 IFNy 
Cytokine standards: 1200,600,300,150,75,37.5,18.75,9.75,4.69,0 pg/ml 
Control supernatant diluted X 500 
PHA wholc blood assay supematants diluted X 40 
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2.5.2.3 TGFP 
Cytokine standards: 4000,2000,1000,500,250,125,62.5,31.25,15.63,0 
pg/mI 
Control supernatant diluted X 10 
2.5.2.4 1 L-2 
Cytokine standards: 1000,500ý 250,125,62.5,31.25,15.63,7.81,3.91,0 pg/ml 
Control supernatant diluted X 10 
2.5.2.5 IL-5 
Cytokine standards: 1000,500,250,125,62.5,31.25,15.63,7.81,3.91,0 pg/ml 
PHA supernatant diluted X 10 
2.5.2.6 IL-10 
Cytokine standards: 1000,500ý 250,125,62.5,31.25ý 15.63,7.81 
ý 3.9 1,0 pg/mI 
Control supernatant diluted X 10 
PHA supematant diluted X 10 
2.5.3 Preparation of whole blood assay control supernatants 
In order to compare plate-to-plate variation, a control supernatant was produced to be 
used on every ELISA plate. 40ml of blood was taken from two members of the UK 
laboratory staff and used to set up 10 whole blood assay plates each. The blood was 
diluted 1: 1.5 with supplemented RPMI and pipetted out into 10 x 96-well microtitre 
plates where each well contained 20ýtg/ml PHA in RPML The plates were incubated for 
either one or six days and the supernatants from each day's harvesting pooled, mixed 
thoroughly then frozen in aliquots at -200C. These control supernatants were then used 
on each ELISA plate, diluted if necessary as above. Due to restricted time and reagents 
undiluted control was used for the first few plates and in some instances this gave 
results outside the most accurate part of the standard curve; hence results for the 
cytokine levels in the control wells for these plates may well have been less accurate 
than in subsequent plates where the control sera were diluted. 
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2.6 Immunoblotting 
SDS-PAGE electrophoresis, Western blotting and immuno-detection of antibodies was 
perfon-ned with the sera of all individuals to demonstrate, in a semi -quantitative manner, 
the presence of antibodies to a number of the chlarnydial antigens (MOMP, omP2, 
HsP60, PmpGa and PMPGc) together with the negative control 'PET-no antigen I. 
A 10% SDS-PAGE gel with 4% stacking buffer was made as described in 2.2.1.1. Each 
gel was loaded with 5ýtl Precision Pre-Stained Protein Marker (Bio-Rad), then 2ýtg each 
of PET-no antigen, MOMP, omP2, HsP60, PmPGa and PmpGc. Using a 14-well comb 
allowed 2 sets of antigens to be electrophoresed on each gel. Two gels were 
electrophoresed in parallel. After electrophoresis, Western blotting was perfori-ned as 
described in 2.2.1.2. After the blocking stage the membranes were cut in half such that a 
ftill set of antigens, markers and control were on each half. These membranes were then 
transferred to individual plastic bags, in which they were sealed with individual patient 
sera, diluted 1: 100 in 5ml rinse buffer (TBS, 0.0005% Tween-20,1% dried milk 
powder). The membranes were incubated with the sera overnight on a rotating platform. 
The membranes were then removed from the bags and washed individually, three times 
in rinse buffer. They were then sealed, in pairs, into plastic bags with affinity-purified, 
goat anti-human IgG (H+L) alkaline phosphatase-conjugated antibody (Invitrogen), 
diluted 1: 3000 in 5ml rinse buffer and incubated on a rotating platform for one hour. 
The membranes were then washed twice in rinse buffer and once in TBS, each for 8 
minutes. Finally, the membranes were equilibrated in detection buffer (I OOmM Tris- 
HCI, I OOmM NaCl, 50mMMgCI2, pH 9.5) then incubated with 0.33mg/ml nitro blue 
tetrazolium (NBT) and 0.165mg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP) in 
detection buffer for 5 minutes to allow the colour to develop, then washed and allowed 
to dry. 
The intensity of each band was assessed by three observers independently and graded 
from 0 to 3, according to the criteria: 0- not visible, I -just visible, 2- clearly visible, 
3- strongly positive. This grading scheme worked well with little variation between the 
observers. The mean of the three values was used for analysis. 
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2.7 Full blood count 
3ml blood was taken into EDTA-containing Vacutainerst. An aliquot was used, on the 
day of venesection, for automated full blood count analysis, including differential, using 
a Medonic Cellanayzer CA530 (Medonic, Bromma, Sweden). The remaining blood was 
stored at -800C until extraction of DNA. 
2.8 Extraction of DNA from whole blood 
DNA extraction was performed using the commercial Genecleant kit (Qbiogene, 
Harefield, UK). The 5ml EDTA blood sample used for the full blood count was 
removed from the freezer and thawed rapidly in a 370C water bath. As soon as the 
blood had thawed it was transferred to ice. For each blood sample, 9ml of RBC Lysis 
solution (proprietary formulations not available) was placed in a labelled 15ml tube. 
3ml of the blood was added and, after mixing, left to incubate for 10 minutes at room 
temperature. The mixture was then centrifuged at 30OOg for 10 minutes and all but 
-100ýLl of the supernatant was removed and discarded. The pellet was re-suspended by 
vortexing, and then 3ml Cell Lysis solution added and mixed. If the presence of any cell 
clumps was noted the mixture was incubated at 370C until they had dispersed. 15ýtl 
RNAse A was then added and the mixture incubated at 370C for 30 minutes. The 
solution was cooled to room temperature, then Iml Protein Precipitation solution added 
and mixed. The sample was centrifuged at 30OOg for 10 minutes. The supernatant was 
then transferred to a separate tube containing 3ml isopropanol and mixed. The solution 
was centrifuged at 30OOg for 5 minutes and the supernatant carefully poured off and 
discarded. The pellet was washed with 3ml 70% ethanol, then centrifuged at 30OOg for 
5 minutes. The pellet was allowed to air dry, then solubilized in 250ýtl DNA Hydration 
solution. The DNA solution was stored in two separate aliquots of 125ýtl at -800C. 
2.9 Chlamydia PCR 
2.9.1 Extraction of DNA from eye swabs 
After collection eye swabs were stored in 500ýtl TE buffer at -20('C. After thawing, a-, 
much solution as possible was expressed from the swabs into the 
TE buffer. The tubes 
were then centrifuged at 9500g for 30 minutes to pcllet ccIlular material. 
After removal 
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of supernatants, the pellets were re-suspended in 20ýtl of protemase solution (0.5% 
Tween 20 (BDH), 0.5% Nonidet P-40 (BDH) and 100ýtg/ml proteinase K (Boehringer 
Mannheim, Lewes, UK)). The suspension was incubated for one hour at 600C after 
which the proteinase K was inactivated by boiling for 10 minutes. The crude DNA 
preparation was stored at -200C until required. 
2.9.2 Amplicor CTO PCR for Chlamydia 
The Amplicor CT'ý' test for Chlamydia trachomatis (Roche Diagnostics, Branchburg, 
NJ, USA) is a commercial test in kit form which a 207 bp target sequence from the 
Chlamydia trachomatis cryptic plasmid is amplified by PCR using biotinylated primers. 
Following amplification, the amplimers are denatured to form single-stranded DNA and 
added to proprietary microtitre plates coated with oligonucleotide probes specific for the 
Chlamydia trachomatis target sequence. After removal of excess amplimers, avidin- 
horseradish peroxidase conjugate is added to the wells and binds to the biotin-labelled 
amplimers. After ftirther washing a 3,3', 5,5'-tetramethylbenzidine (TMB)/hydrogen 
peroxide substrate is added to the wells and the substrate is oxidised to a coloured 
complex in the presence of horseradish peroxidase. The absorbance of the complex is 
measured at 450nm using an automated microtitre plate reader. 
2.9.3 Stool microscopy 
A modified Stoll's method was used for counting helminth eggs in faecal samples. 4ml 
of 10% formalin in water was placed in a 7ml bijou. Ig of stool was added to the formal 
water with an orange stick and mixed thoroughly by vortexing. Samples so prepared 
could be stored for examination at a later date. 
A 50ýtl aliquot of the stool suspension was placed on a microscope slide and covered 
with a coverslip. Any helminth eggs seen were identified using the x40 objective and 
the numbers under the entire coverslip were counted using the xIO objective. The 
number of eggs per gram of faeces was calculated by multiplying the number of eggs 
seen in the 50[tl aliquot by 100. 
2.10 Recruitment 
The study protocol was approved by the ethics committee of the London School of 
Hygiene & Tropical Medicine and by the MRC/Gambian Government Ethical 
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Committee. All individuals gave informed, written consent either by signature or 
fingerprint. For children under the age of 16 consent was obtained from their parent or 
guardian. All cases of active trachoma were treated with tetracycline eye ointment and 
any other illnesses identified were either treated immediately or an appropriate referral 
for assessment and treatment was made. Cases and controls were sex matched in all 
cases. Age matching was to within three years for those under 20 and within 10 years 
for those aged 20 and above though in most cases age matching was exact. Cases and 
controls were matched by ethnic group as much as possible. 
2.10.1 Sample size calculation 
Sample size calculations were carried out for a two-sample test of equality of means 
using the formula derived by Rosner . 
240 For each group the sample size was: 
9 Active trachoma 
o 50 cases and 25 controls - providing 80% power to detect a 35% 
difference in response at a level of p<0.05 
* Scarred trachoma 
o 25 cases and 25 controls - providing 80% power to detect a 40% 
difference in response at a level of p<0.05 
* Infertile women 
o 20 cases and 20 controls - providing 80% power to detect a 50% 
difference in response at a level of p<0.05 
2.10.2 WHO classification of trachoma 
All cases of active and scarred trachoma were classified, using the criteria proposed by 
24 
Thylefors et al , as normal, 
follicular trachoma (TF), intense trachoma (TI), scarred 
(TS) or trichiasis (TT). Examples of each are illustrated below. 
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Normal 
-- 
Figure 2-3: WHO classification of trachoma (from Dawson et alf 
The criteria for classification, as described by Thylefors are: 
Follicular trachoma: "The presence of five or more follicles (at least 0.5mm) in 
the upper tarsal conjunctiva" 
Intense trachoma: "Pronounced inflanimatory thickening of the upper tarsal 
conjunctiva that obscures more than half of the normal deep tarsal vessels" 
Trachomatous scarring: "The presence of scarring in the tarsal conjunctiva" 
Trachomatous trichiasis: "At least one eyelash rubs on the eyeball" 
2.10.3 Active trachoma 
Individuals with active trachoma were identified by a trained field-worker as part of 
ongoing national screening. As trachoma control has been very effective in the study 
villages of Jali and Berending, a number of other villages and schools were visited. 
Individuals with active trachoma were identified and their disease graded according to 
World Health Organisation criteria. One age, sex, ethnicity and locality-matched control 
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was identified for every two children with active trachoma. Since the whole blood 
assays needed to be set up within one hour, and as the villages were located more than 
one hour's drive from the laboratory, the study participants were brought to the MRC 
laboratories where venesection was performed. 
2.10.4 Trachomatous scarring 
Individuals resident in the villages of Jall and Berending in The Gambia have been co- 
operating in a number of studies for over 14 years. Through these studies a large 
number of scarred individuals have been identified together with age, sex, ethnicity and 
locality-matched controls. These individuals were invited to participate in this study. 
Both the cases and the controls were examined by the principal investigator and/or a 
trained field-worker for signs of trachoma and signs were graded as above. Individuals 
agreeing to participate in the study visited the MRC laboratories as above. 
2.10.5 Infertile women 
A cohort of women with secondary infertility have been identified through an ongoing 
study of infertility and sexual health in the villages surrounding Farafenni in Central 
Gambia, and age, ethnicity and locality-matched controls identified. All the cases have 
undergone hysterosalpingography to identify any structural lesions and only women 
with tubal factor infertility were included. Individuals were approached in their villages 
and invited to participate in the study. For this group, venesection was performed in the 
villages and the blood brought to the laboratory for analysis. 
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Materials & Methods 
2.12 Statistical analysis 
2.12.1 General data management 
Data were entered into a Microsoft Access'ý' database, access to which was restricted to 
protect the confidentiality of the study participants. Statistical analysis was undertaken 
using the Stataqo statistical package v. 6 (Stata Corporation, College Station, Texas, 
USA). Most graphs were constructed using Stata although a few were generated using 
GraphPad Prismo v. 3.02 (GraphPad Software Inc, San Diego California USA). 
2.12.2 Statistical analysis 
Frequency distribution plots were generated for cases and controls for each variable in 
each category. The method of scoring the immunoblots resulted in the scores falling 
into 10 discrete values (0,0.3,0.7,1.0,1.3,1.7 .... 3.0) and the 
distribution within these 
scores is shown graphically. The cytokine ELISA results are continuous variables. The 
number of bins for the graphical display of the cytokine results was calculated as double 
the square root of the number of observations. Initial analysis of the data was 
comparison of the population means using a t-test (Stata: ttest) and determination of 
the means and 95% confidence intervals. As much of the data was skewed away from 
the norinal distribution the non-parametric Mann-Whitney U test was also applied 
(Stata: ranksum). To maximise the power afforded by the matched case-control pairs, 
conditional logistic regression was then used (Stata: clogit). This analysis provided 
an odds ratio of the likelihood of being a case for each incremental rise in the 
immunoblot density score (e. g. I to 2,2 to 3). For the cytokine data these initially gave 
an odds ratio for each I pg/ml rise in cytokine concentration, these were therefore 
recoded to give an odds ratio for a 25% rise in cytokine concentration as this provided a 
more meaningful value. Where associations were noted between responses and clinical 
state, a X2 analysis for trend (Stata: tabodds) was performed to stratify the odds at 
each exposure level. For the immunoblots these levels corresponded to the scores of 0- 
3 for the immunoblot density. For cytokine responses the strata corresponded to the 
interquartile ranges. Associations between responses to various antigens and to 
variables other than that of case or control (such as presence of helm nths or prior 
BCG 
vaccination) were determined by a t-test to provide a univariate analysis then 
by 
analysis of covariance (Stata: anova) for multivariate analysis. The variables used 
for 
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this were: age, sex, prior BCG vaccination, presence of intestinal helminths, presence of 
intestinal protozoa and ethnicity. 
Thus, in the results chapter these results are presented in the following format: 
9 Frequency distribution plot broken down into cases and controls 
0 Table showing mean values and 95% confidence intervals for the cases and 
controls for each antigen, together with the results of the t-test and Mann- 
Whitney U-test 
e Graph illustrating the mean and 95% confidence intervals for the cases and 
controls 
* Table showing the results of logistic regression and the F figure and p value for 
the multivariate analysis 
* Tables showing the results of a X2 analysis for trend for any significant 
associations 
A general graphical summary of all results is shown in section 4.6 
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3 Results 1- Generation of plasmid 
constructs and expression of recombinant 
protein 
3.1 Cloning 
3.1.1 Purification of Chlamydia trachomatis serovar A DNA 
Chlamydia trachomatis serovar A DNA was purified as described in 
2.1.1.1. Spectrophotometry of the DNA, solubilized in TE buffer 
demonstrated a concentration of 463ng/ýtl, giving a total yield of 
58.8ýtg. The A26o/A28o ratio however was 1.03, indicating organic 
solvent and/or protein contamination. After ether extraction of the 
phenolic phase the A26o/A28o ratio was 1.17 suggesting continuing 
protein contamination. After re-extraction the final DNA 
concentration had reduced to 200ng/ýtl, and as further purification 
would probably result in the loss of more DNA, it was decided to 
continue with cloning and undertake further purification only if 
required. 
Figure 3-1: Restriction 
The purified DNA was incubated with BamHl, EcoRl 
enzyme analysis of and Pstl and the resulting products electrophoresed as 
Chlamydia trachomatis 
genomic DNA described. The resultant electrophoretic pattern is seen 
in Figure 3-1. 
3.1.2 PCR Amplification 
Chlamydia trachomatis serovar pmp gene A DNA was amplified by PCR using either 
the Clontech Advantageo PCR kit or using Pfu to ensure the fidelity of amplification. 
The resultant product was analysed by agarose gel electrophoresis to ensure amplicons 
of the anticipated size had been generated. The PCR products are shown in Figure 3-2 
and Figure 3-3. (Predicted PCR product sizes are shown in Table 2-1, page 56). 
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Figure 3-2: pmpC, pmpD and pmpG 
PCR products amplified using the 
Clontech Advantageo PCR kit and 
visualised on an ethidium bromide- 
stained agarose gel under 254nm UV 
illumination 
Figure 3-3: pmpC and pmpG PCR 
products amplified using Pfu DNA 
polymerase and visualised on an 
ethidiurn bromide-stained agarose 
gel under 254nm UV illumination 
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3.1.3 Restriction enzyme analysis of PCR products 
PCR products were examined by restriction enzyme analysis to confirm that the correct 
product had been generated. 
3.1.3.1 pmpG 
Restriction sites predicted using serovar D sequence data for pmpG from the Chlamydia 
Sequencing Project are shown in Figure 3-4 and fragment sizes predicted on restriction 
enzyme analysis of pmpG PCR product with Sac 1, BamHl, HindIII and BgIII, 
individually and in combination are shown in Table 3-1 together with the actual 
fragment sizes seen on restriction enzyme analysis of the PCR product obtained by PCR 
(Figure 3-5). 
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Figure 3-4: Predicted pmpG PCR product restriction map 
Purple = primers, other colours = restriction sites 
Figure 3-5: Fragments obtained on restriction enzyme analysis of 
pmpG PCR product and visualised under 254nm UV illumination 
after agarose gel electrophoresis 
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Enzyme Predicted Actual 
Bam 1-11 
Cuts at 
950,1933,2045,2318, 
2354 
950,1933,2045,2318, 
2354 
Fragment sizes 950,983,112,273,36,573 950,983,112,273,36,573 
Cuts at 406,2270 406,2270 
B gi 11 
Fragment sizes 406,1864,657 406,1864,657 
Cuts at 512,1922,2343 512,1922 
Hi d III n 
Fragment sizes 512,1410,421,584 512,1410, ! Cio 
Cuts at 88 ? 88, ý-ither -1-,, O(D P I st 
Fragment sizes 88,2RV- -1ý00 -1200, ? 88 
Cuts at Not cut Not cut 
P I vU 
Fragment sizes 2927 2927 
Cuts at Not cut Not cut 
M I sp 
Fragment sizes 2927 2927 
Cuts at 1140 1140 
S I ac 
Fragment sizes 1140,1787 1140,1787 
Cuts at 
512,950,1922,1933,2045, 
2318,234 3,2354 
512,950,1922,1933, 
2045,2318,2354 
Bam 1-11 + Hind III 
Fragment sizes 
512,438,972,11,112,273, 
21ý 11,573 
512,438,972,11,112,273, 
'1ý7ý, 573 
Cuts at 406,1140,2270 406,1140,2270 
Bg1 11 + Sac I 
I 
Fragment sizes 406,734,1130,657 406,734,1130,657 
Table 3-1: Predicted and observed fragments of the pmpG PCR product after restriction 
enzyme analysis 
As the table shows there is a discrepancy between the predicted and observed digestion 
patterns with HindIll. This is most likely explained by a change in the enzyme 
recognition sequence in the DNA substrate leading to a loss of the HindIII site. Without 
further investigation it is not possible conclude that this represents a difference in 
sequence between our serovar A strain and the reference serovar D strain. Additionally, 
the pmpG PCR product had a Pstl restriction site at position either - 1300 or - 1700, not 
present in the sequenced serovar D strain. For the other enzymes the results were 
entirely as predicted. 
3.1.3.2 pmpD 
Restriction sites predicted using serovar D sequence data from the Chlamydia 
Sequencing Project are shown in fragment sizes predicted on restriction enzyme 
analysis of pmpD PCR product with BamH I, BgIlI, HindIII and Sacl, 
individually and 
in combination are shown in Table 3-2 together with the actual fragment sizes seen on 
restriction enzyme analysis of the PCR product obtained by PCR (Figure 
3-7). 
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Figure 3-6: pmpD PCR product. Predicted restriction map 
Figure 3-7: pmpD pCR product. Results of restriction enzyme 
analysis (BamH1 + Bg1ll digestion not shown) 
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Enzyme Predicted Actual 
Cuts at 2637,3855 2637,3855 Bam HI 
Fragment sizes 2637,1218,596 2637,1218,596 
Cuts at 47,392 47,392 
B i 11 g 
Fragment sizes 47,345,4059 47,345,4059 
Cuts at 
355,1864,2584,3322, 355,1864,2584,3322, 
4228 4228 
Hind III 
Fragment sizes 
355,1509,720,738,906, 355,1509,720,738,906, 
223 223 
Cuts at 
1301,1481,17', 8,1859, 1301,1481,1859, 
4295 - MO, -1,200,4295 S I ac 
Fragment sizes 
1301,180,29,1,81,2436, 1301,180,378, -1 iW 
156 156 
Cuts at 47,392,2637,3855 47,392,2637,3855 
Bam 1-11 + Bg1 11 47,392,2637,3855,2637 
Fragment sizes 47,345,2245,1218,596 - due to incomplete Bg111 
digestion 
Cuts at 
355,1864,2584,2637, 355,1864,2584,2637, 
3322,3855,4228 3322,3855,4228 
Bam H1 +Hind III - 355,1509,720,53,685, 355,1509,720,53,685, 
Fragment sizes 533,373,223 533,373,223 
4 7,392,1301,148 1,1 7 47,392,1301,1481,1859, 
Cuts at 1859,4295 -- iO00,4295 
Bgl 11 + Sac 1 
47,345,909,180,21A7, 47,345,909,180, 
1 
Fragment sizes -, -436,156 11 1 156 
Table 3-2: Predicted and observed fragments of the pmpD PCR product after restriction 
enzyme analysis 
These results demonstrate a discrepancy between the results predicted from the 
sequence of serovar D and those seen with serovar A for restriction with Sacl. It appears 
that that our serovar A DNA has lost the Sacl site at 1778 but gained an additional Sacl 
site at either - 3000 or - 3200. It is not possible to detennine this more accurately with 
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the available data. Results from restriction enzyme analysis with other enzymes was 
entirely as predicted from the serovar D data. 
3.1.4 Preparation of competent cells 
Transformation efficiency of competent cells was estimated as shown below. 
Strain Date Transformation 
efficiency 
XL1 Blue Dec 97 2.0 x 106 
XL1 Blue May 98 1.4 x 101 
TOP 10 July 98 2.1 x 101 
BL21 July 99 5.1 x 10-1 
Table 3-3: Transformation efficiencies of competent cells 
3.1.5 Individual cloning strategies 
3.1.5.1 Cloning of pTrcHis/pmpG-1410 
PmpG DNA obtained by PCR was first ligated into pGEM-V' and the vector 
transformed in XL-I Blue as described in section 2.1.9.1. The quick plasmid 
Hpall - 30 PvtA - 5788 DpmpG-N - 76 Hpall - 5618 Psil - 139 
BgAl - 457 
Hirtdill - 563 
Hpall-4856 
PvtA - 4692 
Hpall - 4614 
Hpall-4504 
Hpall-4437 
Hpall-4403 
Baffdil - 1984 Hpall - 3809 BaMHI - 2096 Hpall-3783 Bg4l -2321 Hpall - 3636 R.,,, Hl . 7-, IRQ 
pGEM-T pmpG 
5927 bp 
BamHl - 1001 1 
Sad - 1191 1 
Hpall - 3999 HindIll - 1973 
Hpall - 3809 
Baffdil - 1984 
BamHl - 2096 Hpall-3783 BgAl - 2321 Hpall - 3636 BamHl - 2369 
Hindill - 2394 Hpall - 3147 BarnHI - 2405 Sad - 3021 DpmpG-C - 2954 Pstl - 3000 
Figure 3-8: Predicted restriction map of pGEM-T/pmpG 
Note: In this and subsequent figures the numbering of restriction 
sites begins at position 1 on the host vector, hence numbering 
on the insert will be different from that seen in the PCR maps. 
preparation method was 
used to extract plasmid 
DNA from the 
success fully-trans formed 
cells and this was 
subjected to restriction 
enzyme analysis with 
Sad, BamH 1, HindIII, 
Dg1I1 Pstl and Hpall 
(Mspl), both individually 
and in combination. The 
predicted structure of this 
recombinant plasmid is 
shown in Figure 3-8. 
The results of 
electrophoretic analysis of the restriction products is shown in Figure 3-9, and the 
results of predicted and observed fragment sizes shown in Table 3-4. 
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Figure 3-9: Restriction enzyme analysis of pGEM-T/pmpG 
Enzyme Predicted Observed 
Cuts at 
1001,1984,2096,2369, 1001,1984,2096,2369, 
Bam HI 2405 2405 
Fragment sizes 983,112,273,36,4523 983,112,273,36,4523 
Cuts at 457,2321 457,2321 
B l 11 g 
Fragment sizes 1864,4063 1864,4063 
Cuts at 563,1973,2394 563,1973,2394 
Hi d III n 
Fragment sizes 1410,421,4096 1410,421,4096 
Cuts at 1191,3021 1191,3021 
Sac I 
Fragment sizes 1830,4097 1830,4097 
563,1001,1973,1984, 563,1001,1973,1984, 
Cuts at 2096,2369,1'3,1 2405 2096,2369,2405 
Bam HI+ Hind III 
438,972,11,112,273,21 438,972,11,112,273,36 
Fragment sizes 11,4085 4085 
Cuts at 457,1191,2321,3021 457,1191,2321,3021 
Bgl 11 + Sac I 
Fragment sizes 734,1130,700,3363 734,1130,700,3363 
30,139,3000,3147,3636, 30,139, ', 3000,3147, 
3783,3809,3999,4403, 3636,3783,3809,3999, 
Cuts at 4437,4504,4614,4856, 4403,4437,4504,4614, 
Pst I+ Hpa 11 (Msp 1) 5618 4856,5618 
109,1861,147,489,147, 109, -1 6(-)o 147, 
Fragment sizes 26,190,404,34,67,110, 489,147,26,190,404,34, 
1 
242,762,339 67,110,242,762,339 
Table 3-4: Predicted and observed fragments of pGEM-T/pmpG after restriction enzyme 
analysis 
These results are in agreement with those seen on restriction enzyme analysis of the 
pmpG PCR product and appear to indicate a loss of the HindIll site at position 2394. 
The results also confirm the presence of an additional Pstl site within the pmpG PCR 
fragment. In all other respects the results are as predicted, confirming the expected 
insert. 
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The 1410 bp HindlIl fragment was then isolated from high-purity plasmid DNA and 
ligated into pTrcHis as described in section 2.1.9.1. The resultant construct was 
transformed into XLI-Blue and plasmid DNA, extracted by the quick plasmid 
preparation method from transformants, was screened by restriction enzyme analysis 
with HindIll and BamHl. The predicted restriction map is shown in Figure 3-10, the 
restriction enzyme analysis in Figure 3-11 and the predicted and observed restriction 
fragments in Table 3-5. These confirm the correct fragment in the correct orientation for 
expression. 
BamHl - 513 
Hindill - 557 
pTrcHisC-pmpG Hind 1410 
5822 bp 
BamHl - 995 
HindIll - 19671 
Figure 3-10: Predicted restriction map of pTrcHis/pmpG-1410 
Figure 3-11: Restriction enzyme analysis of pTrcHis/pmpG-1410 
Enzyme Predicted Observed 
Cuts at 513,995 513,995 
Bam HI 
Fragment sizes 482,5340 5340,482 
Cuts at 557,1967 557,1967 
Hind III 
Fragment sizes 1410,4412 1410,4412 
Table 3-5: Predicted and observed restriction fragments of pTrcHis/pmpG-1410 
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3.1.5.2 Cloning of pBluescript/pmpD-1218 
PmpD DNA was obtained by PCR as shown (Section 3.1.2). A 1218bp BamHl 
restriction fragment (Figure 3-7) was purified and ligated into pBluescript SK11+ 
(Figure 3-12) as described in section 2.1.9.2. 
Kpni - 657 
Hindill - 689 
- BamHl - 720 
pBluecript SKII+ pmr 
4180 bp 
Hindill - 1405 
- BamHl - 1938 
Eagl - 1957 
Sad - 1978 
Figure 3-12: Predicted restriction map of pBluescript/pmpD-Bam- 
1218 
Figure 3-13: Restriction enzyme analysis of pBluecript/ 
pmpD-Bam-1218 (Kpni + Eagl digestion not shown) 
Enzyme Predicted Observed 
Cuts at 720,1938 720,1938 
Bam Hl 
Fragment sizes 1218,2962 1218,2962 
Cuts at 689,1405 689,1405 
Hind III 
Fragment sizes 716,3464 716,3464 
Cuts at 19 78 
Sac I 
Fragment sizes 4180 ý230 950 
Cuts at 657,1957 657,1957 
Kpn I+ Eag I 
Fragment sizes 1300,2880 1300,2880 
cu 
E SKII pmpD 
Bam-1218 
E --Z: 
kb E Z 
E 
m 0Z co 
115 -. 
5.0 
75 
1.7 
1.2 
0.8 
0.5 
Table 3-6: Predicted and observed fragments of pBluescript/pmpD-Bam-1218 after 
restriction enzyme analysis 
Confirmation of the correct fragment was obtained by restriction enzyme analysis with 
BamHI, HindIII, KpnI and EagI as shown in Figure 3-13 and Table 3-6. 
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The additional Sacl site within the cloned pmpD DNA was again detected and can now 
be placed more accurately at around position 2950. On examining the sequence there 
are two sites at which single point mutations from adenine to cytosine might lead to the 
formation of a novel Sacl site (GAGCTC) at positions 2931 and 2955 (Figure 3-14), 
with no other sites close by where another point mutation, insertion or deletion would 
generate a Sacl site. However, more rigorous sequencing would be necessary to confirrn 
this change. These positions equate to 3097 and 3121 in the original serovar D pmpD 
sequence. 
2651 CTATTTTGCA GGTAAAGAAT CGCATATTAC AGCCCTGAAT GCTACGGAAG 
2701 GACATGCTAT TGTTTTCCAC GACGCATTAG TTTTTGAAAA TCTAGAAGAA 
2751 AGGAAATCTG CTGAAGTATT GTTAATCAAT AGTCGAGAAA ATCCAGGTTA 
2801 CACTGGATCT ATTCGATTTT TAGAAGCAGA AAGTAAAGTT CCTCAATGTA 
2851 TTCATGTACA ACAAGGAAGC CTTGAGTTGC TAAATGGAGC CACATTATGT 
2901 AGTTATGGTT TTAAACAAGA TGCTGGAGCT lAGTTGGTAT TGGCTGCTGG 
2951 AGCTIAACTG AAGATTTTAG ATTCAGGAAC TCCTGTACAA CAAGGGCATG 
3001 CTATCAGTAA ACCTGAAGCA GAAATCGAGT CATCTTCTGA ACCAGAGGGT 
3051 GCACATTCTC TTTGGATTGC GAAGAATGCT CAAACAACAG TTCCTATGGT 
3101 TGATATCCAT ACTATTTCTG TAGATTTAGC CTCCTTCTCT TCTAGTCAAC 
Figure 3-14: Potential point mutations leading to a novel Sacl site in pmpD 
3.1.5.3 Cloning of pBAD/pmpG 
PmpG DNA was obtained by high-fidelity PCR as described above (section 2.1.2.2). 
The purified PCR product was ligated into pBAD-TOPOO and transformed into One- 
Shoto competent cells. DNA, extracted from the clones by the quick plasmid 
preparation method was subjected to restriction enzyme analysis with EcoRV and Ncol, 
individually and in combination. The predicted map of this recombinant plasmid is 
shown in Figure 3-15. The results of electrophoretic analysis of the restriction products 
is shown in Figure 3-16, and the results of predicted and observed fragment sizes shown 
in Table 3-7. 
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Ncol - 344 
I ECORV - 6438 
BgAl - 792 
Sad - 15261 
pBAD-TOPO pmpG 
7052 bp 
- Ncol-3258 
Xhol-3287 
EcoRV - 2566 
Bgnl - 2656 
Figure 3-15: Predicted restriction map of pBAD/pmpG 
Figure 3-16: Restriction enzyme 
analysis of pBAD/pmpG 
a) 
co cu EE 
cc m 'a pBAD pmpG 
. 10 
2 
kb EE TO Eco RV Nco I 
11.5 
50 
2,5 
17 
08 
0,5 
pBAD 
pmpG 
E 
U (o 
+ 
E zo kb T >< 
11 5 
50 
25 
20 
17 
12 
0b 
Enzyme Predicted Observed 
E 
Cuts at 2566,6438 2566,6438 
co RV 
Fragment sizes 3180,3872 3180,3872 
Cuts at 344,3258 344,3258 
Nco I 
Fragment sizes 2914,4138 2914,4138 
Xh +S I 
Cuts at 1526,3287 1526 3287 
oI ac 
I 
Fragment sizes 1761,5291 1761,5291 
Table 3-7: Predicted and observed fragments of pBAD/pmpG after restriction enzyme 
analysis 
The restriction enzyme analysis demonstrates that the vector contains the expected 
insert in the correct orientation for expression. 
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3.1.5.4 Cloning of pPET/pmpGc 
pBAD 
A 176 1 bp XhollSacl fragment (Figure 3 -17) was ligated into pPET3 Oa'ý' as pmpG EZ 
0M CL (n described. The resultant clone is shown in Figure 3-18. Restriction enzyme + 
E 
analysis with BgIII was used to confirm the correct fragment in the correct 
kb 
-2 X 
115 
orientation for expression. 50 
25 
Figure 3-17: XholSac fragment of pmpG 2C 17 
used for cloning pPET/pmpGc 
81 
12 
Xhol - 158 
pPET30 pmpGc 
7159 bp Sad . 1927 
EcoRV - 1943 
Bgnl - 1978 
B9nl - 789 
EcoRV - 883 
r) 
E 
pPET 
pmpGc 
E -a 75 kb co cn 
11.5 
ýý 
Figure 3-19: Restriction enzyme 
analysis of pPET/pmpGc 50 
2.5 
1.7 
1.2 
1.1 
0.8 
Enzyme Predicted Observed 
Cuts at 789,1978 789,1978 
Bgl 11 I Fragment sizes 
Tl 
189,5970 1189,5970 
Table 3-8: Predicted and observed fragments of pPET/pmpGc after restriction enzyme 
analysis 
The restriction enzyme analysis confluns that the vector contains the fragment in the 
Figure 3-18: Predicted 
restriction map of 
pPET/pmpGc 
correct orientation. 
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3.1.5.5 Cloning of pCR-11/pmpG 
pmpG DNA obtained through Pfu PCR amplification was ligated into pCR-11-TOP08 
as described (section 2.1.9.5). The possible orientations of this insert are shown in 
Figure 3-20. Restriction enzyme analysis with EcoRI and EcoRV (Figure 3-21) 
indicated that the pmpG DNA had been inserted in reverse orientation. 
EcoRI-325 EcoRI-325 
EcoRV - 1082 
pCRilpmpG pCRII-TOPO 
6898 bp EcoRI-1834 66898 bp EcoRI-1760 
ECORV 2516 
EcoRI-3268 EcoRI-3269 
EcoRV . 3280 EcoRV - 3280 
Figure 3-20: Predicted restriction maps of pCRII/pmpG showing both forward and reverse 
orientations of insert 
cu E pCRII 
to, 
a- pmpG 
mo 
>> 
kb E 00 0u ww 
11.5 
5.0 
2.5 
2.1 
1.7 
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11.5 
5.0 
2.5 
17 
1.1 
&8 
0.5 
pCRII 
pmpG 
ui w 
Figure 3-21: Restriction enzyme analysis of pCRII/pmpG 
Predicted Enzyme Predicted Observed (reversed) 
Cuts at 2516,3280 1082,3280 1082,3280 
V Eco R 
Fragment sizes 764,6134 2198,4700 4700,2198 
325,1834, 325,1082, 325,1082, 
Cuts at 2516,3268, 1760,3268, 1760,3268, 
Eco RV + 3280 3280 3280 
Eco Rl 757 678 757,682, 
Fragment sizes 
1508,682, 
752,12,3943 
, , 1508,12, 1503,12, 
3943 3943 
Table 3-9: Predicted and 
observed fragments of 
pCRII/pmpG after 
restriction enzyme 
analysis 
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3.1.5.6 Cloning of pPET/pmpGa 
A 1509bp EcoRI fragment was released from pCR-11/pmpG and ligated into EcoRI 
digested pPET302-' described. The predicted clone is shown in Figure 3-22. Restriction 
enzyme analysis with BamH I confirmed all recombinants contained the fragment in the 
correct orientation for expression (Figure 3-23 and Table 3-10) 
EcoRl - 192 
BamHl - 740 
pPETpmpGa 
6930 bp 
EcoRI-1700 
BamHl - 1706 
EcoRV - 1714 
Figure 3-22: Predicted restriction map of pPET/pmpGa 
kb 
Figure 3-23: Restriction enzyme analysis 111.5 
of pPET/pmpGa 15.0 
Enzyme Predicted Observed 
Cuts at 740,1706 740,1706 
Bam HI 
I Fragment sizes , 
966,5964 966,5964 
m ý pPET 
In pmpGa Q-. 
EE EMm 
ýT Co m 
2.5 
1.7 
1.1 
0.8 
0.5 
Table 3-10: Predicted and observed fragments of pPET/pmpGa after restriction enzyme 
analysis 
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3.2 Expression and purification of recombinant 
proteins 
3.2.1 pTrcHis/pmpG 
3.2.1.1 Expression of pTrcHis/pmpG 
Determination of expression conditions at both 250 and 370C under varying 
concentrations of the inducer IPTG was undertaken as described. An aliquot of pelleted 
cells, equivalent to 100gl original culture, was lysed and analysed by SDS-PAGE 
electrophoresis and by Western blotting as described in section 2.2.1. A band of 
recombinant protein is just visible at the predicted size (54kDa) on the SDS-PAGE gel 
(Figure 3-24) and appears to show maximal expression after incubation at 370C with 
I mM IPTG for 20 hours. 
4 hours 20 hours 
370C 25'C 37oC 250C 
IPTG 0 0.1 1.0 0 0.1 1.0 0 0.1 1.0 0 0.1 1.0 
kDa 
97.4 
66.2 
54 logo 
31 4 
40M 
21.5 401M 
Figure 3-24: Expression of recombinant protein from pTrcHis/pmpG - SDS-PAGE 
Inspection of the Western blot detected with anti-Xpress(g) antibody (Figure 3-24) 
revealed that observable quantities of recombinant proteins were produced at 0-Irnm at 
250C after 4 hours, with fewer degradation products than were apparent at 370C or after 
20 hours. These incubation conditions were therefore chosen as the optimal expression 
conditions for larger-scale production of recombinant protein. 
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E 
4 hours 
370C 250C 
IPTG 0 0.1 1.0 0 0.1 1.0 CL. 
kDa 
102 
81 
11 
47 
33 
31 
Western blot probed with Anti- 
Xpresse antibody (Invitrogen) 
Figure 3-25: Expression of recombinant protein from pTrcHis/pmpG - Western blot 
3.2.1.2 Determination of solubility of recombinant proteins from 
pTrcHis/pmpG 
The solubility of the recombinant proteins in PBS was determined as described in 
section 2.3.1.1. Five microlitre aliquots, equivalent to 100[tl original culture were 
examined by Western blotting. The majority of the recombinant product was insoluble 
in PBS as demonstrated in Figure 3-26. 
4 hours 20 hours 
IPTG 0.1 1.0 0.1 1.0 
- -a - -5 - -a -z 0 U) 0 V) 000 U) 
kDa 
102 
81 
47 
1400 - 
V- 
33 
alp 
31 
Western blot probed with Anti- 
Xpresslo antibody (Invitrogen) 
Figure 3-26: Solubility of recombinant protein from pTrcHis/pmpG - Western blot 
3.2.1.3 Purification of recombinant proteins from pTrcHis/pmpG 
Purification of an induced bulk culture of pTrcHis/pmpG was undertaken using Ni- 
NTP columns under denaturing conditions as described in section 2.3.3. The 
recombinant protein was eluted first with 200ýtl of elution buffer and then again with 
I 00gl. The recombinant protein band was not visible on SDS-PAGE analysis (Figure 
20 hours 
_370C 
0 0.1 100 
%W, 
3-27) but was clearly seen on Western blotting (Figure 3-28). The presence of 
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recombinant protein in the flow-through showed that the column was not able bind all 
of the product. None of the recombinant protein was removed during the washing phase. 
Purified product, without degradation contaminants, was successfully eluted from the 
columns. 
pTrcHis pmpG 9 
-FU 0 m0 (Z 
kDa 
0- E Lu w 
kDa 
102 ob 
97 81 40 
66 
47 
45 
33 «o 
die 
31 
22 
Figure 3-27: Ni-NTP column purification of recombinant protein from pTrcHis/pmpG - SDS-PAGE 
pTrcHis pmpG _0 
z 
.2 0 
Cc - 4) 
r- Q) 0) (D 1 9 - - , ia :30 
75 U) 
T -12 
E 
. - cu 3: U) m (o 0 co :3 :3 
C: , kDa -i ! ý Lu ui 
102 
81 
47 
GWAý 
33 
30 
Western blot probed with Anti- 
Xpresso antibody (Invitrogen) 
Figure 3-28: Ni-NTP column purification of recombinant protein from pTrcHis/pmpG - 
Western blot 
Purification was also undertaken using a Pro-Bond resin column as described in section 
2.3.4. Using this method the recombinant protein band was observed on SDS-PAGE 
(Figure 3-29) and is clearly visible on the Western blot (Figure 3-30). The column was 
clearly saturated with the first aliquot of lysate with excess recombinant protein then 
appearing in the flow-through. No recombinant protein was lost in the wash and the 
majority eluted in the first two eluate volumes. 
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Figure 3-29: ProBond resin column purification of recombinant protein from 
pTrcHis/pmpG - SDS-PAGE 
- (14 Cl) 
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Western blot probed with Anti- 
Xpresso antibody (Invitrogen) 
Figure 3-30: ProBond resin column purification of recombinant proteins from 
pTrcHis/pmpG -Western blot 
3.2.2 pBAD/pmpG 
3.2.2.1 Expression of pBAD/pmpG 
Determination of expression conditions at both 250 and 370C under varying 
concentrations of the arabinose inducer was undertaken as described in section 2.2.3. 
An aliquot of pelleted cells, equivalent to 50ýtl original culture, was lysed and analysed 
by SDS-PAGE electrophoresis and by Western blotting as described in section 2.2.1. 
No bands of recombinant protein were visible on SDS-PAGE analysis (Figure 3-3 1) .A 
recombinant band was observed after Western blotting using anti-V5 antibody (Figure 
3-32), although only small quantities were evident together with numerous degradation 
products. Optimal expression conditions were determined to be 4 hours incubation at 
250C in the presence of 0.002% arabinose. 
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pBAD pmpG 
4 hours 20 hours 
d) 
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Figure 3-31: Expression of recombinant protein from pBAD/pmpG- SDS-PAGE 
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Western blot probed with Anti- 
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(Invitrogen) 
. Predicted size of 
recombinant protein marked by 
arrow. 
Figure 3-32: Expression of recombinant protein from pBAD/pmpG- Western blot 
3.2.2.2 Purification of recombinant proteins from pBAD/pmpG 
Recombinant PmPG was purified from bulk culture using both the Ni-NTA columns and 
the TALON spin-columns for comparison using the methods described in section 2.3. 
Samples equivalent to 250ýtl original culture were analysed by SDS-PAGE and Western 
blotting. For the stained SDS-PAGE gel, eluates equivalent to 1000ýtl original culture 
were used to improve visualisation. Despite this adjustment, no recombinant protein 
bands could be seen on the Coomassie-stained SDS-PAGE gels (Figure 3-33), however 
recombinant PmPG was successfully observed by Western blotting and demonstrated 
that the TALON spin-columns were more efficient at binding the recombinant protein 
and also had higher concentrations of recombinant protein in the eluates (Figure 3-34). 
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Figure 3-33: Purification of recombinant protein from pBAD/pmpG using Clontech 
TALON and Qiagen Ni-NTA methods - SDS-PAGE 
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Figure 3-34: Purification of recombinant protein from pBAD/pmpG using Clontech 
TALON and Qiagen Ni-NTA methods - Western blot 
With such poor yields it was apparent that the pBAD construct would not generate 
adequate amounts of recombinant protein for development of assays for the fieldwork 
and a decision was made to generate a further construct in pPET. 
3.2.3 pPET/pmpGc 
3.2.3.1 Expression of pPET/pmpGc 
Detennination of expression conditions at both 250 and 370C under varying 
concentrations of the inducer EPTG was undertaken as described in section 2.2.4. An 
aliquot of pelleted cells, equivalent to 50ýd original culture, was lysed and analysed by 
SDS-PAGE electrophoresis and by Western blotting as described. A band of 
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recombinant protein at the predicted size (74kDa) is clearly visible on the SDS-PAGE 
gel (Figure 3-35) and this is confirmed on Western blotting (Figure 3-36). 
pPET pmpGc 
4 hours 20 hours 
25 oC 370C 250 C 37cC 
IPTG 0 0.1 1.0 0 0.1 to 0 0.1 1.0 0 0.1 1.0 
kDa 
107 
74 
fts 
49 
Figure 3-35: Expression of recombinant protein from pPET/pmpGc - SDS-PAGE 
pPET pmpGc 
4 hours 20 hours 
250C 37oC 250 C 370C 
IPTG 0011.0 0 0.1 to 0 01 10 0 01 1.0 
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no 
e 
Western blot probed with Anti- 
S-protein monoclonal antibody 
(Novagen) . Predicted size of 
recombinant protein marked by 
arrow. 
Figure 3-36: Expression of recombinant protein from pPET/pmpGc - Western blot 
Optimal expression appeared to occur at 370C for 4 hours in the presence of O. IMM 
IPTG. These conditions were used for further larger-scale inductions. 
3.2.3.2 Purification of recombinant proteins from pPET/pmpGc 
Recombinant PMPGc was purified from bulk culture using TALON spin-columns as 
described in section 2.3.5. Samples equivalent to 75ýtl original culture were analysed by 
SDS-PAGE and Western blotting. The columns were fully saturated with recombinant 
protein as demonstrated by the excess appearing in the flow-through. Very little 
recombinant protein was lost in the washing stage and relatively moderate amounts 
recovered on elution (Figure 3-37) and (Figure 3-38) 
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Figure 3-37: TALON spin-column purification of 
recombinant protein from pPET/pmpGc - SDS- 
PAGE 
Figure 3-38: TALON spin-column 
purification of recombinant protein 
from pPET/pmpGc - Western blot 
Western blot probed with Anti- 
S-protein monoclonal antibody 
(Novagen) . Predicted size of 
recombinant protein marked by 
arrow. 
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As larger quantities of recombinant protein were required for development of assays for 
the field work, larger-scale purification was undertaken using Pro-Bondo resin as 
described in section 2.3.4. Results were very similar to those seen with the TALON 
spin-columns method (Figure 3-39) and (Figure 3-40) in that once again excess 
recombinant protein was seen in the flow-through, very little protein was lost in the 
washing stage, and the majority of the protein was recovered in the first two eluates. 
-0 
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Figure 3-39: Pro-Bond purification of recombinant protein from pPET/pmpGc - SDS- 
PAGE 
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Figure 3-40: Pro-Bond purification of recombinant protein from pPET/pmpGc - Western 
blot 
3.2.4 pPET/pmpGa 
3.2.4.1 Expression of pPET/pmpGa 
Determination of expression conditions at both 250 and 370C under varying 
concentrations of the inducer IPTG was undertaken as described in section 2.2.4. An 
aliquot of pelleted cells, equivalent to 50ýLl original culture, was lysed and analysed by 
SDS-PAGE electrophoresis and by Western blotting as described in section 2.2.1. A 
band of recombinant protein of the predicted size (61kDa) was clearly visible on the 
SDS-PAGE gel (Figure 3-41) and this was confirmed on Western blotting (Figure 
3-42). 
pPET pmpGa 
4 hours 20 hours 
250C 370C 250C_ 370C 
IPTG 0 0.1 1.0 0 0.1 1.0 0 01 1.0 0 0.1 1.0 
kDa 
103 
abaft 
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It 
49 
,A 
Figure 3-41: Expression of recombinant protein from pPET/pmpGa - SDS-PAGE 
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Figure 3-42: Expression of recombinant protein from pPET/pmpGa - Western blot 
It is evident that production of recombinant protein occurred even in the absence of 
IPTG. Further larger-scale cultures were undertaken for 4 hours at 370C in the presence 
of 0.1 mM IPTG. 
3.2.4.2 Purification of recombinant proteins from pPET/pmpGa 
Recombinant PmPGa was purified from large-scale culture using TALON spin-columns 
as described in section 2.3.5. Samples equivalent to 75ýtl original culture were analysed 
by SDS-PAGE and Western blotting. The columns were again fully saturated as 
demonstrated by recombinant protein appearing in the flow-through. Relatively little 
recombinant protein was lost in the washing stage and acceptable amounts recovered on 
elution (Figure 3-43) and (Figure 3-44) 
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Figure 3-43: TALON spin-column purification of 
recombinant protein from pPET/pmpGa - SDS- 
PAGE 
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Figure 3-44: TALON spin-column 
purification of recombinant protein from 
pPET/pmpGa - Western blot 
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As larger quantities of recombinant protein were required for the field work, large-scale 
purification was undertaken using Pro-Bondo resin as described in section 2.3.4. Results 
were very similar to those seen with the TALON spin-columns method (Figure 3-45) 
and (Figure 3-46) in that excess recombinant protein was seen in the flow-through, 
relatively small amounts were lost in the washing stage and the majority of the 
recombinant protein was recovered in the first two eluates. 
m LO 
pPET pmpGa (3) 0) cm 
22 P tn CN m tn 
mmmm 
kDa LE U- LL LL ui Lu ui ww 
1030 
76 
490 
34 
29 
Figure 3-45: Pro-Bond purification of recombinant protein from pPET/pmpGa - SDS- 
PAGE 
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Figure 3-46: Pro-Bond purification of recombinant protein from pPET/pmpGa - Western 
blot 
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3.2.5 pPET without insert 
3.2.5.1 Expression of pPET without insert and purification of 
induced products 
Bacterial cells containing pPET without an insert were induced with IPTG as described 
in section 2.2.4. Pelleted cells were then subjected to an identical Pro-Bond'ý' 
purification protocol as used for PMPGc and PmPGa. As expected no recombinant 
protein bands were seen on the SDS-PAGE (Figure 3-47) or on the Western blot (Figure 
3-48). These eluates were then used in assay development as material to control for 
potential cross-reacting immunological responses to contaminating E. coli proteins. 
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Figure 3-47: Pro-Bond purification of products of induction of pPET vector without an 
insert - SDS-PAGE 
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Figure 3-48: Pro-Bond purification of products of induction of pPET vector without an 
insert - Western blot 
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3.2.6 MOMP 
3.2.6.1 Expression and purification of rMOMP 
The MOMP expressing host was induced as described in section 2.2.5, inclusion bodies 
isolated and MOMP purified from those inclusion bodies as described in section 2.3.2. 
Aliquots equivalent to 150ýtl original culture (purified MOMP 300ýtl equivalent) were 
then analysed by SDS-PAGE (Figure 3-49). The recombinant protein band of MOMP 
was clearly visible. 
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Figure 3-49: Purification of recombinant MOMP - SDS-PAGE 
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4 Results 2- Results of field work in 
The Gambia 
4.1 Quality control issues 
4.1.1 Quality control issues for immunoblots 
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Figure 4-1: Two typical immunoblots 
Antigen -specific IgG from 
patient sera, bound to 
chlamydial proteins on a 
Western blot and detected 
using goat anti-human 
Two typical immunoblots are shown (Figure 4-1). The intensity of each individual 
result was scored by three independent observers as described in section 2.6. 
Correlation between the observers was good. Correlation coefficients for immunoblot 
scores between the three observers are given in Table 4-1 and the full dataset is 
provided in the appendix. No individuals demonstrated antibody responses to the sham 
Correlation between: 
1&21&32&3 
MOMP 0.76 0.68 0.77 
omp2 0.84 0.83 0.85 
hsp60 0.76 0.75 0.78 
pmpGa 0.83 0.88 0.87 
pmpGc 0.86 0.90 0.92 
antigen 'pPET without insert', this 
antigen is therefore excluded from the 
immunoblot result analyses which follow. 
Table 4-1: Correlation coeff icients 
between observers for immunoblot 
scores 
4.1.2 Quality control issues for cytokine ELISAs 
The cytokine assay used was proven to be robust and reliable in this setting. Standard 
curves were highly accurate as seen by the R2 values in Table 4-2 where a value of I 
indicated a perfect correlation. Optical density values for the cytokine concentrations 
used for the standard curves were highly reproducible. The median values and inter- 
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quartile ranges for the positive control wells demonstrate that the variation was quite 
small, however there were a few outliers, a few of which lay well outside the 
interquartile ranges (Figure 4-2). There was insufficient supernatant to repeat the study 
ELISAs from these plates, however it was felt that results should not therefore be 
adjusted to control for the positive control well values. Any patient samples which gave 
results outside the standard curve were repeated at a higher dilution to give an accurate 
result. 
C tokine 
NO of 
R-squared for standard 
curve 
Control wells 
y 
plates 
Mean Coeff of 
variation 
Min Max Median 25th 
centile 
75th 
centile 
TNF 58 0.996 0.5% 0.979 1.000 1826 1716 1899 
IFN 57 0.990 1.9% 0.876 1.000 14500 10800 18800 
11-2 58 0.988 2.0% 0.899 1.000 1060 696 1140 
11-5 56 0.994 0.6% 0.973 1.000 534 483 595 
11-10 53 0.992 1.4% 0.929 1.000 1922 1794 2033 
TGF 37 0.976 2.1% 0.929 1.000 1756 1280 2146 
Table 4-2: Quality control statistics for cytokine ELISAs 
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L- 
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TNF 1L2 1L5 1L10 TGF IFN 
Figure 4-2: Distribution of values for cytokine positive control wells 
Figure 4-2 shows median value and interquartile ranges for each cytokine in positive 
control supernatants. The error bars indicate the range of the outlying values. 
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There was some concern that this variation in the positive control wells might also 
reflect similar variation in the patient samples. Correlation coefficients were therefore 
calculated between the control well values and those of the patient samples on the same 
plate. The correlation coefficients range from 0.00 1 to 0.361 with a mean of 0.11 if 
TGFP excluded and 0.23 for TGFP. (The higher correlations between TGFP results is 
due to a number of individuals with non-specific activation affecting all wells including 
the negative controls, see below. ) These levels of correlation are not considered 
significant242 and their effects are very small, for example the mean correlation 
coefficient of 0.11 indicates that only 1.2% of the variance is due to this correlation. 
TNF IFN IL-2 IL-5 IL-1 0 TGF 
PHA 0.175 0.155 0.015 0.088 0.328 0.243 
No antigen 0.044 0.006 -0.082 0.035 0.243 -0.001 
Candida 0.122 0.179 -0.046 0.066 0.172 0.237 
PPD 0.065 0.120 -0.061 0.213 0.080 0.178 
PET - no antigen 0.008 0.037 -0.123 0.117 -0.101 0.176 
EBs 0.076 0.181 0.063 0.044 0.182 0.140 
MOMP 0.067 0.310 0.050 0.084 -0.138 0.222 
omp2 0.123 0.297 0.150 0.055 0.114 0.285 
hsp60 0.043 0.254 -0.026 -0.004 0.076 0.327 
pmpGa 0.090 0.143 0.055 0.099 0.121 0.361 
pmpGc 0.159 0.078 0.055 0.081 0.169 0.359 
Table 4-3: Correlation coefficients between values for the positive control wells and 
those for patient samples on the same plate 
TGFP was the only cytokine to provide results which were difficult to interpret. This 
was because in many cases there was non-specific TGFP secretion, unrelated to the 
specific antigen, producing high results for all wells including the negative controls. 
Those samples showing non-specific high-level secretion were unrelated to any of the 
clinical groups by X2 analysis (active trachoma p=1.00, scarred trachoma p=0.91, 
infertile women p=0.66) and also unrelated to age, gender or BCG status. On 
reviewing the data it was apparent that cases with non-specific TGFP production had 
negative control values of greater than 130 pg/ml and thus all individuals generating 
more than 130 pg/ml of TGFP with the negative control were removed from the 
analysis. In this way 41 of 106 samples were excluded. Figure 4-3 illustrates the 
variation in values in the total sample set (upper) and those used for analysis (lower). 
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Figure 4-3: Spread of values for TGFP by ELISA, for each antigen or control (upper 
distribution of each pair is the entire sample set, lower of each pair is after removal of 
results for all individuals who generated >130 pg/ml TGFP in the negative control well) 
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4.2 Dernography 
175 individuals were recruited into the immunological studies conducted in The 
Gambia, made up of 59 (33.7%) males and 116 (66.3%) females. These comprised 52 
children with active trachoma and 26 controls, 27 cases of trachomatous scarring and 27 
controls and 22 infertile women with 21 controls. Study participants were recruited 
from 6 ethnic groups (Table 4-4) in 21 villages (Table 4-5) . The ages ranged 
from 4 to 
57 with a mean age of 20 (Figure 4-4). In keeping with the epidemiology of trachoma 
the study participants in the trachoma groups formed two clusters, those with active 
trachoma who were aged from 4 to 15 years and those with trachomatous scarring who 
where in the 20+ age group. Additionally the infertile women and their controls fell into 
this latter age group. 
10 5005 10 15 20 25 
Controls Cases 
Figure 4-4: Age distribution graph of all cases and controls 
Cases Controls 
Ethnic group Number Percentage Number Percentage 
Fula 9 8.8% 8 11 % 
Jola 15 14.7 % 15 20.6 % 
Mandinka 57 55.9% 46 63% 
Manjago 8 7.8 % 0 0% 
Serere 1 1% 0 0% 
Wolof 8 7.8% 2 2.7 % 
Not known 4 3.9 2 2.7 % 
Table 4-4: Distribution of study participants by ethnicity 
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Figure 4-5: Distribution of study participants by ethnicity 
The ethnic breakdown of study participants approximates to that of the country as a 
whole (Mandinka 42%, Fula 18%, Wolof 16%, Jola 10%, Serere, 9%, other 4% - ref 
http: //www. cia. gov/cia/publications/factbook 2001) though with some variation due to 
the sampling of individual villages which often have a somewhat homogenous 
population in terms of ethnicity. 
Village Number Percentage Village Number Percentage 
Barnbali 7 4.1 % Konte Kunda Niji 0.6% 
Bassik 1 0.6% Konteh Kunda Sukoto 4 2.3% 
Berending 30 17.4% Kurnbija 2 1.2% 
Dai Mandinka 3 1.7% Medina Kiaf 6 3.5% 
Dibba Kunda Wollof 1 0.6% Nyoro Angeleh 8 4.7% 
India Badibu 2 1.2% Palen Fula 4 2.3% 
Jajari 6 3.5% Sandaly 5 2.9% 
Jali 63 36.6% Sare Sajo 5 2.9% 
Jasobo 8 4.7% Sinchu Sanjal 1 0.6% 
Kani Kunda Suba 5 2.9% Yallal 3 1.7% 
Kanton Kunda 
1 
4 2.3% 1 1 Not known 6 3.4% 
Table 4-5: Distribution of study participants by village of residence 
The locations of the study villages are indicated on 1.7.3. 
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Active Scarred Infertile 
Case Control Case Control Case Control 
TIVI 0 0 0 0 0 0 
TF 51 0 1 0 0 0 
TI 1 0 1 0 0 0 
TS 0 0 27 0 0 1 
TT 0 0 5 0 0 0 
Table 4-6: Clinical classification of trachoma in study participants 
All individuals were examined for the presence of trachoma. The results are shown in 
Table 4-6. Two individuals with scarring also had active trachoma and one control for 
the infertile women had trachomatous scarring. Only one individual with active 
trachoma was classified as intense active trachoma (TI) making comparison of the 
different classifications of trachoma impossible. 
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4.3 Results of studies on individuals with trachoma 
4.3.1 Immunoblot results 
4.3.1.1 Active trachoma 
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Figure 4-6: Frequency-distribution graphs of 
immunoblot density scores for children with 
active trachoma and their controls 
The frequency distribution graphs clearly 
show that the children with active trachoma 
have higher immunoblot density scores than 
their controls. The graphs also demonstrate 
that many of the children have antibodies to 
the recombinant PMP proteins. 12/18 (67%) of 
controls and 22/44 (50%) of cases have 
detectable antibodics to PmPGa whilst 7/18 
(39%) of controls and 12/44 (27%) of cases 
have antibodies to PmpGc. 
Additionally 5/18 controls (28%) had no 
detectable antibodies to MOMP suggesting 
they may never have been exposed to 
Chlamydia compared to only 1/50 (2%) of 
cases (p < 0.002). However three of these individuals did have antibodies to other 
chlamydial antigens. Two individuals, a six year old boy and an eight year old girl, both 
from Jall, had no antibodies to any chlarnydial antigens and presumably had either 
never been exposed or there were technical problems with the Western blots. 
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MOMP omP2 HSP60 PmPGA PmpGc 
12,42,66 92 11 
11112,13,42,48, 
, , , 93,100,101,102 
66,92,93,100,101, 
13 48,115 103 103,104,105,10ý6, 102.103,104,105, 
Active case 112,114,115,120 
106 
' 
112,114,115, 
120 
+1 other +1 other 
+5 others negative negative for negative for 
omp2 Ab only hsp60 Ab only 
for pmpGc Ab only 
9,70,72,79, 79,80,129, 79,80, 17,20,79,80,111, 9,17,20,72,79,80, 
80 129, ill 
Activecontrol +lo#xrnegaffve 
forMOMPAb +4 others negative 
Ordy 
for pmp Gc Ab only 
Table 4-7: Individuals with negative immunoblot responses to chlarnydial antigens 
(numbers are unique identifiers for individual study participants) 
A ti G 
Mean 
i bl t 
Nest Mann-Whitney 
n gen roup n mmuno o 
score 95% C. I. p< p< 
MO 
Active 44 2.08 1.88-2.28 
MP 
Control 19 1.33 0.93-1.73 
0.0003 0.0018 
2 
Active 34 1.95 1.63-2.26 
omP Control 19 2.01 1.52-2.49 
0.83 0.76 
60 
Active 44 2.22 2.03-2.42 
HsP Control 19 2.14 1.80-2.49 
0.66 0.89 
Active 44 0.92 0.66-1.19 
PmPGa Control 19 1.41 0.90-1.91 
0.06 0.04 
Active 44 0.60 0.33-0.87 
PmPGc Control 19 0.79 0.30-1.28 
0.46 0.73 
Table 4-8: Mean immunoblot density scores for children with active trachoma and their 
controls 
Using a t-test to compare the means of the two populations as a whole, cases vs. 
controls, reveals a clear difference in antibody responses to MOMP and to PmPGa. 
Individuals with active trachoma demonstrate a mean immunoblot response of 2.08 vs. 
1.33 for the control population (p < 0.0003) to MOMP and 0.92 vs. 1.41 (p < 0.06) to 
PmPGa. The frequency plots of antibody responses (Figure 4-6) show that these data are 
generally not normally distributed, they were therefore also investigated using the non- 
parametric Mann-Whitney U test. This test confirmed the significance of the differing 
responses to MOMP and to PmPGa. 
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Figure 4-7: Mean immunoblot density scores and 95% confidence intervals for children 
with active trachoma and their controls 
Figure 4-7, showing the mean and 95% confidence intervals, clearly illustrates the 
differing responses of children with active trachoma and matched controls towards 
MOMP and suggests that there may be a trend towards a lower response to PmPGa in 
those with trachoma. 
logistic regression 
Antigen O. R. 
95% C. I. p< 
MOMP 5.79 1.68-20.02 0.006 
omP2 0.96 0.43-2.16 0.92 
HsP60 1.24 0.52-2.91 0.63 
PmpGa 0.65 0.36-1.14 0.13 
PmpGc 0.75 0.41 -1.34 0.33 
Table 4-9: Conditional logistic regression of immunoblot scores from children with active 
trachoma and their controls 
Conditional logistic regression was used to maximise the power given by the case- 
control matched data. This again confirms the strong association between higher 
immunoblot density scores to MOMP and the presence of active trachoma. Each 
incremental rise in the arbitrary immunoblot density score is associated with an odds 
ratio of 5.79 of being a case (95% C. I. 1.68-20.02, p<0.006). X2 analysis for trend 
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enables a further estimation of the odds ratio of being a case for each level of MOMP 
immunoblot density. 
Immunoblot Group n Odds ratio 95% C. I. p< 
score 
MOMP Active 1 1.00 - <1 Control 5 
MOMP Active 17 12.1 0.9-169 0.01 1 -1-99 Control 7 
MOMP Active 35 
>=2 
13.5 1.2-154 
I Control 1 13 1 1 1 
2 Table 4-10: x analysis for trend for immunoblot scores to MOMP in children with active 
trachoma and their controls 
X2 test for trend was also used to look again at the relationship between antibody 
responses to PmPGa having active trachoma. This again picks up a trend towards a 
lower likelihood of being a case with increasing responses to PmPGa significant at the 
6% level. 
Immunoblot Group n Odds Ratio 95% C. I. p< 
score 
PmPGa Active 19 00 1 
< 0.4 Control 6 . - 
PmPGa Active 8 26 1 87 20-7 0 
0.4-0.99 Control 2 . . . 0 06 . 
PmPGa Active 18 59 0 16-2 13 0 
1.0-1-99 Control 8 . . . 
PmPGa Active 10 32 0 20 08-1 0 
2.0-3.0 Control 10 . . . 
2 
Table 4-11: x analysis for trend for immunoblot scores to PmPGa in children with active 
trachoma and their controls 
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Figure 4-8: Frequency distribution of 
immunoblot scores for individuals with 
scarring and their controls 
In contrast to the situation seen in children 
with active trachoma and their controls, in the 
case of scarred trachoma 0/25 controls and 
2/22 (9%) of cases have no detectable 
antibodies to MOMP suggesting that in this 
group almost all individuals have been exposed 
to chlarnydial infection. 
In contrast to previous studies, no association 
is demonstrated between detectable antibodies 
to HSP60 and the presence of scarring; 24/25 
(96%) of controls and 22/22 of scarred 
individuals have antibodies to HSP60. There is 
perhaps some evidence of a trend at higher 
levels of response; 17/25 (68%) of controls vs. 
19/22 (86%) of scarred individuals have immunoblot density scores of 2 or higher (p < 
0.14). 
Again these graphs demonstrate that the majority of individuals have detectable 
antibodies to the PmPG recombinant proteins. 17/25 (68%) of the controls and 19/22 
(86%) of those with scarring have antibodies to PmPGa whilst 9/25 (36%) of controls 
and 14/22 (64%) of those with scarring have antibodies to PmpGc, a 'significantly' 
higher proportion in those with scarring for PmpGc (p < 0.06). 
139 
Results 2 
Mean t-test Mann-Whitney 
Antigen Group n immunoblot 
score 95% C. I. p p 
Scarred 22 1.91 1.59-2.23 
MOMP 
Control 25 2.01 1.82-2.33 
0.40 0.37 
Scarred 22 2.42 2.15-2.70 
omP2 Control 25 2.32 2.07-2.58 
0.59 0.60 
60 
Scarred 22 2.46 2.24-2.67 
HsP Control 25 2.36 2.03-2.68 
0.60 0.96 
G 
Scarred 22 1.65 1.27-2.04 
PmP a Control 25 1.35 0.96-1.74 
0.25 0.27 
G 
Scarred 22 1.24 0.75-1.72 
PmP c Control 
r2 
5 0.64 0.26-1.03 
0.05 0.06 
Table 4-12: Mean immunoblot density scores for scarred individuals and their controls 
Comparison of the mean responses of the scarred case and control populations using a t- 
test demonstrates an association between antibody responses to PmpGc and the presence 
of trachomatous scarring with cases responding at twice the intensity of controls (1.24 
vs. 0.64, p<0.05) though there is overlap in the 95% confidence intervals (Figure 4-9). 
Again the data are skewed away from the normal distribution and so were also analysed 
using the Mann-Whitney U test, this confirmed the association but at a slightly reduced 
level of significance (p < 0.06). 
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Figure 4-9: Mean immunoblot density scores for scarred individuals and their controls 
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A ti O R 
logistic regression 
n gen . . 95% C. I. p< 
MOMP 0.70 0.28-1.73 0.44 
omP2 1.26 0.47-3.36 0.65 
HSP60 1.22 0.50-2.95 0.66 
PmpGa 1.65 0.79-3.45 0.18 
PmpGc 2.03 
mmmmmý 
0* 99-4.19 
- 
0.05 
Table 4-13: Conditional logistic regression of immunoblot scores for scarred individuals 
and their controls 
Conditional logistic regression analysis, using pair-wise analysis, again highlights the 
association between response to PMPGc and scarring with each incremental rise in 
response to PmPGc being associated with an odds ratio of 2.03 for being scarred (p < 
0.05) though the odds ratio does just include 1. Using a X2 analysis for trend to calculate 
the relationship for each level of response again shows a rise in the odds ratio of being a 
case with rising responses to PmpGc with individuals demonstrating immunoblot density 
scores in the highest quartile being 4.5 times more likely to be scarred than those 
without demonstrable anti-pmpGc IgG (p <0.02 - Table 4-14). 
Immunoblot Group n Odds Ratio 95% C. I. p< score 
PmPGc Scarred 8 
< 0.4 Control 16 
1.00 - 
PmPGc Scarred 1 
0.4-0.99 Control 2 
1.00 0.07-13.39 
0.02 
PmPGc Scarred 9 3.60 0.83-15.66 1.0-1-99 Control 5 
PmPGc Scarred 9 7 4.50 0.94-21.5 2.0-3.0 Control 4 
2 Table 4-14: x analysis for trend for immunoblot scores to PmpGc in scarred individuals 
and their controls 
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4.3.2 Cytokine ELISAs from whole blood assays 
4.3.2.1 Active trachoma 
4.3.2.1.1 TNF-cc 
The frequency-distribution plots of TNF(x concentrations (Figure 4-10) demonstrate 
some responses for which the spread of concentrations is approximately normally 
distributed, such as PHA, and EB's and others for which the distribution was Much 
more strongly skewed, such as PPD. Accordingly both the t-test and Mann-Whitney U 
test were used to compare the population means for cases and controls. 
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Figure 4-10: Frequency distribution of TNF(x responses in children with active trachoma 
and their controls 
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Analysis of the mean TNF(x concentrations for cases of active trachoma and controls 
using a t-test reveals a higher TNF(x response in children with active trachoma to 
Candida (1467 pg/ml vs. 823, p<0.01), to chlamyclial elementary bodies (1273 vs. 868, 
p>0.06), to omP2 (2726 vs. 1455, p>0.002). to HsP60 (1188 vs. 73 1, p<0.0 1) and to 
PmpGa (463 vs. 235, p<0.04). Use of the Mann-Whitney U test reduces the level of 
significance for the difference in response to EBs and PMPGa and certainly there is some 
overlapping of the 95% confidence intervals for these antigens. Conditional logistic 
regression was therefore used to exploit the additi i ing ional power provided by examin' 
each case-control pair in turn. 
Antigen Grou n 
Mean TNF t-test Mann-Whitney 
p level (pg/ml) 95% C. I. P< p< 
PHA 
Active 50 953 794-1112 
Control 25 767 - 600-934 
0.14 0.29 
N ti 
Active 50 7 4-11 
o an gen 
Control 25 10 -6-26 
0.65 0.13 
C did 
Active 50 1467 1127-1807 
an a 
Control 25 823 598-1048 
0.01 0.03 
PPD 
Active 50 130 89-170 
Control 25 94 27-162 
0.33 0.19 
PET - no Active 50 9 5-14 
antigen Control 25 19 -15-54 
0.40 0.02 
E 
Active 50 1273 1000-1547 
Bs 
Control 25 868 622-1114 
0.06 0.11 
MOMP 
Active 50 70 44-96 
Control 25 52 5-98 
0.45 
1 
0.06 
2 
Active 50 2726 2192-3260 
omP 
Control 25 1455 1126-1784 
0.002 0.003 
Active 50 1188 960-1415 
HsP60 Control 25 731 520-942 
0.01 0.02 
Active 50 463 321 -606 
PmPGa Control 25 235 116-354 
0.04 0.11 
Active 50 23 11 -34 6 0 00 PmpGc 
Control 25 30 -9-69 
0. 4 . 7 
Table 4-15: Mean TNF concentrations in children with active trachoma and their controls 
143 
Results 2 
Active trachoma 
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Figure 4-11: Mean TNF(x concentrations in children with active trachoma and their 
controls 
logistic regression 
Antigen O. R. for 25% 
rise in TNF 
95% C. I. p< 
PHA 1.26 0.97-1.62 0.08 
No antigen 1.00 0.95-1.04 0.86 
Candida 1.31 1.05-1.65 0.02 
PPD 1.12 0.95-1.31 0.17 
PET - No 
antigen 
0.99 0.96-1.03 0.65 
EB's 1.31 1.01 -1.70 0.04 
MOMP 1.05 0.96-1.15 0.29 
omp2 1.45 1.08- 1.96 0.01 
HsP60 1.29 1.04-1.61 0.02 
PmpGa 1.18 1.00- 1.39 0.06 
PmpGc 1.00 0.95-1.04 0.85 
Table 4-16: Conditional logistic regression of TNFcc concentrations in children with active 
trachoma and their controls 
Conditional logistic regression confinns the higher responses in those with active 
disease to Candida (p < 0.02), EBs (p < 0.04), OmP2 (p < 0.004), HsP60 (p < 0.02) and 
pmpGa (p < 0.06) and also demonstrates an association for PHA (p < 0.08) (Table 4-16). 
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Quartille Group n Odds ratio 95% C. I. p< 
TINIF Active 9 1 00 * 25th cent Control 9 . - 
TNF Active 12 1 71 0 45 6 56 25-50% Control 7 . . . - 
TNF Active 13 
0.03 
50-75% Control 6 
2.17 0.54-8.62 
TNF Active 16 
* 75th cent Control 3 
5.33 1.00-28.56 
2 Table 4-17: x test for trend for TNF(x responses to Candida in children with active 
trachoma and their controls 
Here the X2 test clearly demonstrates an increasing likelihood of being a case with 
increasing TNF(x responses to the common recall antigen Candida. 
Quartille Group n Odds ratio 95% C. I. p< 
TNF Active 11 
* 25th cent Control 7 
1.00 - 
TNF Active 12 
25-50% Control 7 
1.09 0.28-4.20 
0 19 
TNF Active 11 8 0 23 3 32 
. 
50-75% Control 8 
0.8 . - . 
TNF Active 16 39 17 37 0 66 
* 75th cent Control 3 
3. - . . 
2 Table 4-18: x test for trend for TNF(x responses to chlamydial EBs in children with active 
trachoma and their controls 
The X2 test for trend does not demonstrate a consistent trend although those 
demonstrating the highest quartile of TNFu. response to chlarnydial EBs are 3.39 times 
more likely to be cases than controls. 
Quartile Group n Odds ratio 95% C. I. p< 
TNF Active 10 1 00 - * 25th cent Control 8 . 
TNF Active 9 72 0 19-2 69 0 
25-50% Control 10 . . . 0 004 
TNF Active 13 73 1 84 44-6 0 
. 
50 -75% Control 6 . 
. . 
TINIF Active 18 14 4 15 - 180 25 1 * 75th cent Control 1 . 1 
. . 
1 1 
Table 4-19: test for trend for TNF(x responses to omP2 in children with active trachoma 
and their controls 
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A clear relationship between the odds ratio for having active trachoma and the 
concentration of TNFoc generated in response to omP2 is demonstrated by the X2 test for 
trend . 
Quartile Group n Odds ratio 95% C. I. p< 
TINIF Active 9 
* 25th cent Control 9 
1.00 - 
TINIF Active 11 
25-50% Control 8 
1.38 0.37-5.14 
TINIF Active 14 
0.03 
50 -75% Control 4 
3.50 0.76-16.18 
TNF Active 15 
* 75th cent Control 4 
3.75 0.81 -17.33 
2 Table 4-20: x test for trend for TNF(x responses to HSP60 in children with active trachoma 
and their controls 
Quartile Group n Odds ratio 95% C. I. p< 
TNF Active 10 
* 25th cent Control 8 
1.00 - 
TNF Active 11 12 2 4 25-50% Control 8 
1.10 . 0. 9- 
0 05 
TNF Active 84 44 
. 
50-75% Control 6 
1.73 -5. 0. 
TNF Active 16 19 82 22 0 
* 75th cent Control 3 
4.27 - . . 
2 
Table 4-21: x test for trend for TNF(x responses to PMPGa in children with active 
trachoma and their controls 
The association between the odds ratio of being a case and the concentration of TNFOC 
generated in response to HsP60 and PmPGa are similar as shown in the two tables. 
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4.3.2.1.2 1F Ny 
The frequency distribution plots for IFNy again demonstrate marked skewing in the 
distribution of the data, such that, in general, the Mann-Whitney U test is more 
appropriate for assessing the differences between cases and controls. 
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Figure 4-12: Frequency-distribution graphs of IFNy responses in children with active 
trachoma and their controls 
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Results 2 
Mean IFN t-test Mann-Whitney Antigen Group n level (pg/mI) 95% C. I. p< p< 
Active 47 2894 2085-3703 
PHA 
Control 25 6032 3344-8719 
0.005 0.03 
N 
Active 47 8 6-11 
o antigen 
Control 25 10 4-16 
0.47 0.92 
C 
Active 47 73 41 -105 andida 
Control 25 159 48-269 
0.06 0.21 
PPD 
Active 47 590 275-906 
Control 25 653 398-909 - 
0.79 0.14 
PET - no Active 47 5 3-7 
antigen Control 25 16 3-29 
0.02 0.43 
EB 
Active 47 13 9-17 
s 
Control 25 33 16-50 
0.004 0.05 
MOMP 
Active 47 22 13-31 
Control 25 39 13-65 
0.12 0.49 
2 
Active 47 107 60-154 
omP 
Control 25 85 51 -120 
0.53 0.47 
60 
Active 47 48 30-66 
HsP Control 25 85 24-144 
0.14 0.68 
G 
Active 47 15 11 -20 PmP a Control 25 18 7-29 
0.59 0.77 
G 
Active 47 7 5-9 
Pmp c 
Control 25 11 5-17 
0.11 0.56 
Table 4-22: Mean IFNy concentrations in children with active trachoma and their controls 
Comparison of the means of the two population groups demonstrates significantly lower 
IFN7 concentrations in the cases in response to PHA (2894 vs. 6032, p<0.005) and to 
chlarnydial elementary bodies (13 vs. 39, p<0.004). These differences are still 
significant when the Mann-Whitney U test is used. Although no other significant 
differences were noted, responses in the children with active trachoma were generally 
lower than in controls. 
148 
Results 2 
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Figure 4-13: Mean IFNy concentrations in children with active trachoma and their controls 
logistic regression 
Antigen O. R. for 25% 
rise in IFN 
95% C. I. p< 
PHA 0.83 0.69-0.99 0.04 
No antigen 0.98 0.90-1.07 0.65 
Candida 0.94 0.86- 1.02 0.14 
PPD 0.99 0.91 -1.07 0.74 
PET - No 
antigen 
0.94 0.86- 1.02 0.14 
EB's 0.89 0.80-1.00 0.06 
MOMP 0.95 0.88-1.03 0.20 
omp2 1.03 0.93-1.14 0.52 
HsP60 0.95 0.88-1.04 0.27 
PmpGa 0.99 0.89-1.09 0.77 
PmpGc 0.94 0.84-1.05 0.27 
Table 4-23: Conditional logistic regression of IFNy concentrations for children with active 
trachoma and their controls 
Using a conditional logistic regression method it can be seen that there is indeed a 
significantly lower response in children with active trachoma to PHA and to chlanlydial 
EBs. A X2 test for trend shows that individuals with IFN7 responses in the highest 
quartile have an odds ratio for disease of 0.2 against those in the 
lowest quartilc for 
PHA and an odds ratio of 0.1 for EBs. 
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Results 2 
Quartile Group n Odds ratio 95% C. I. p< 
IFN Active 15 00 1 
* 25th cent Control 3 . - 
IFN Active 11 31 0 08 61 0 1 25-50% Control 7 . - . . 
IFN Active 12 
0.06 
50-75% Control 6 
0.40 0.08-2.05 
IFN Active 9 
* 75th cent I Control 9 
0.2 0-04-1.07 
2 Table 4-24: x test for trend for IFNy responses to PHA in children with active trachoma 
and their controls 
Quartile Group n Odds ratio 95% C. I. p< 
IFN Active 18 
* 25th cent Control 7 
1.00 - 
IFN Active 19 
25-50% Control 6 
1.23 0.34-4.43 
IFN Active 9 6 1 
0.03 
50 -75% Control 8 
0.44 0.12- .6 
IFN Active 1 1 1 34 
* 75th cent IControl 14 
0.10 
1 
0.0 - . 
1 1 
2 Table 4-25: x test for trend for lFNy responses to chlarnydial EBs in children with active 
trachoma and their controls 
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Figure 4-14: Frequency-distribution graphs of IL-2 responses in children with active 
trachoma and their controls 
These frequency-distribution plots demonstrate that a higher proportion of the cases 
produce detectable IL-2 in response to antigen than controls. This is also noticeable 
where the blood was incubated without antigen when 11/25 (56%) of controls produced 
IL-2 vs. 43/50 (86%) of children with active trachoma (p < 0.0005). This would be in 
keeping with a higher level of general T-cell activation associated with an active 
infection. Similar effects are seen with chlarnydial antigens, for example 10/25 (40%) of 
controls vs. 3 1150 (62%) of cases produced IL-2 in response to chlarnydial EBs (p < 
0.07), similarly 10/25 (40%) of controls vs. 32/50 (64%%) of cases prodLICed IL-2 in 
response to chlamydial HSP60 (p < 0.05). 
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Results 2 
Mean 11-2 t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. P< p< 
Active 50 490 398-582 
0 39 0 47 PHA 
Control 25 564 403-725 . . 
Active 50 8 6-11 
No antigen 
Control 25 4 0-8 
0.08 0.0005 
Active 50 12 8-17 
Candida 
Control 25 11 3-20 
0.83 0.49 
P 
Active 50 68 41 -94 PD 
Control 25 89 34-144 
0.42 0.62 
PET - no Active 50 7 3-11 
antigen Control 25 8 0-22 
0.89 0.007 
Active 50 5 2-7 
EBs 
Control 25 5 0-11 
0.96 0.06 
Active 50 8 4-11 
MOMP 
Control 25 5 0-11 
0.31 0.02 
Active 50 5 2-7 
omP2 
Control 25 4 0-10 
I 
0.82 0.05 
Active 50 3 2-4 
0 29 0 13 HsP60 Control 25 2 1 -4 
. . 
Active 50 6 4-7 
96 0 98 PmPGa Control 25 6 4-8 
0. . 
Active 50 3 2-4 
0 07 0 02 PmpGc Control 25 
mmm 
2 
imý 
0-3 
ilý 
. . 
Table 4-26: Mean IL-2 concentrations in children with active trachoma and their controls 
The frequency-distribution plots show that the results are markedly skewed with the 
exception of responses to PHA which are more normally distributed. Thus the Mann- 
Whitney U-test results are more appropriate. These demonstrate significantly higher IL- 
2 responses in the children with active trachoma in the absence of antigen and also in 
response to the sham PET antigen (effectively also a negative control), MOMP, OmP2 
and PMPGc. However, with the exception of the true negative control, the confidence 
intervals overlap to a high degree as can be seen from Figure 4-15, making these 
differences unconvincing. More importantly, most of these results lie below the lower 
limit of accurate detection (8 pg/ml). Conditional logistic regression fails to confirm any 
of these associations. 
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Results 2 
Active trachoma 
1000- 
100- 
0 
U 10- t Cý4 t t 
-6 -6 U) U) 2 U) U) 
C: Cu 
(f) Co I= CO Co I= CU Cu CO C) C) C) C) 00 00U00 
No PET PHA Antigen Can da PPD No EBs MOMP ornp2 hsp6o prnpGa pmpGc Antige n 
Figure 4-15: Mean IL-2 concentrations in children with active trachoma and their controls 
logistic regression 
Antigen O. R. for 25% 
rise in IL-2 
95% C. I. p< 
PHA 0.95 0.76-1.18 0.63 
No antigen 1.11 0.97-1.27 0.14 
Candida 1.01 0.94-1.10 0.76 
PPD 0.96 0.88-1.04 0.31 
PET - No 
antigen 
0.99 0.96-1.03 0.73 
EB's 1.00 0.95-1.06 0.91 
MOMP 1.04 0.96-1.12 0.38 
omp2 1.01 0.96-1.05 0.79 
HsP60 1.06 0.94-1.20 0.33 
PmpGa 1.00 0.86-1.16 0.98 
PmpGc 1.13 0.97-1.31 0.11 
Table 4-27: Conditional logistic regression of IL-2 concentrations for children with active 
trachoma and their controls 
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Figure 4-16: Frequency-distribution graphs of IL-5 responses in children with active 
trachoma and their controls 
The frequency-distribution graphs for IL-5 indicate that only the responses to PHA 
approximate to a normal distribution, thus the Mann-Whitney U-test provides the most 
accurate comparison of the means. 
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Results 2 
Mean IL-5 t-test Mann-Whitney 
Antigen Group n level (pg/mI) 95% C. I. p< p< 
Active 47 1094 792-1396 0 74 0 46 PHA 
Control 25 1176 762- 1591 . . 
Active 47 11 8-15 
No antigen 
Control 25 11 5- 16 
0.90 0.41 
Active 47 10 7-13 
Candida 
Control 25 9 5- 12 
0.47 0.44 
PP 
Active 47 12 8-16 
D 
Control 25 14 6-22 
0.68 0.90 
PET - no Active 47 5 3-8 
antigen Control 25 6 2-10 
0.77 0.92 
EB 
Active 47 6 4-9 
s 
Control 25 3 1 -5 
0.09 0.05 
Active 47 6 4-9 
MOMP 
Control 25 4 1 -6 
0.13 0.15 
Active 47 8 5-11 
omP2 
Control 25 4 2-6 
0.05 0.07 
Active 47 8 5-10 
0 41 0 53 HsP60 Control 25 11 0-23 . . 
Active 47 11 8-13 
PmPGa Control 25 20 6-34 
0.08 0.43 
Active 47 7 4-9 
0 40 0 35 PmpGc Control 25 5 3-8 . . 
Table 4-28: Mean IL-5 concentrations in children with active trachoma and their controls 
The Mann-Whitney U-test shows that children with active trachoma generate higher IL- 
5 responses to EBs (6 vs. 3 pg/ml, p<0.05) and to OmP2 (8 vs. 4 pg/ml, p<0.07) than 
controls. 
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Figure 4-17: Mean IL-5 concentrations in children with active trachoma and their controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in IL-5 
95% C. I. p< 
PHA 1.01 0.87-1.17 0.89 
No antigen 1.01 0.91 -1.13 0.81 
Candida 1.08 0.93-1.24 0.31 
PPD 0.98 0.88-1.10 0.73 
PET - No 
antigen 
1.00 0.93-1.07 0.93 
EB's 1.13 0.99-1.29 0.07 
MOMP 1.12 0.97-1.28 0.11 
omp2 1.17 1.00-1.37 0.04 
HsP60 0.97 0.90- 1.04 0.42 
PmpGa 0.93 0.84-1.03 0.17 
PmpGc 1.07 0.95-2.21 0.27 
Table 4-29: Conditional logistic regression of IL-5 concentrations for children with active 
trachoma and their controls 
Conditional logistic regression confirms the association between having active trachoma 
and higher responses to EBs and chlamydial omP2. However, there is no significant 
difference between the IL-5 responses to any of the chlamydial or common recall 
antigens and those seen in the negative control wells, and the IL-5 concentrations 
produced are less than the minimum level of reliable detection (8pg/ml), thus little if 
any confidence can be placed upon these associations. 
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Figure 4-18: Frequency-distribution graphs of IL-10 responses in children with active 
trachoma and their controls 
The frequency-distribution plots for IL-10 show approximately normally distributed 
data with the exception of responses to PmpGc, thus the t-tests provide the most reliable 
comparisons of the means. Quite marked differences in the distributions between cases 
and controls are apparent in the responses to Candida, PPD, EBS, HSP60 and PmPGa. 
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Results 2 
Mean IL-10 t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. p< p< 
Active 46 1717 1381 -2052 0 85 86 0 PHA 
Control 24 1663 1236-2090 . . 
Active 46 19 16-23 
No antigen 
Control 24 16 7-25 
0.42 0.02 
Active 46 153 132-174 
Candida 
Control 24 98 71 -125 
0.002 0.001 
Active 46 133 115-151 
PPD 
Control 24 101 78-125 
0.03 0.03 
PET - no Active 46 23 18-27 
antigen Control 24 23 10-37 
0.89 0.02 
EB 
Active 46 321 280-362 
s 
Control 24 251 205-297 
0.03 0.03 
MOMP 
Active 46 62 49-75 
Control 24 50 30-70 
0.30 0.08 
Active 46 588 500-675 
omP2 
Control 24 124 320-528 
0.02 0.006 
Active 46 469 412-525 
HsP60 Control 24 295 229-361 
0.0003 0.0001 
Active 46 161 130-192 
PmPGa Control 24 92 56-127 
0.006 0.001 
Active 46 58 36-81 
02 0 PmpGc Control 24 30 19-42 
0.08 . 1 
Table 4-30: Mean IL-10 concentrations in children with active trachoma and their controls 
The t-test confirms the higher levels of IL-10 produced by children with active 
trachoma in response to Candida, PPD, EBS, HsP60 and PmPGa and also demonstrates 
significantly higher responses to omP2 which was less obvious from the frequency- 
distribution graphs. The Mann-Whitney U-test also shows significantly higher levels of 
IL- 10 produced in response to PMPGc. 
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Figure 4-19: Mean IL-10 concentrations in children with active trachorna and their 
controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in IL-10 
95% C. I. p< 
PHA 1.06 0.87-1.29 0.59 
No antigen 1.08 0.92-1.28 0.33 
Candida 1.76 1.17-2.64 0.007 
PPD 1.46 1.03-2.07 0.04 
PET - No 
antigen 
0.99 0.88-1.12 0.91 
EB's 1.44 1.01 -2.07 0.05 
MOMP 1.10 0.92-1.33 0.30 
omp2 1.69 1.08-2.66 0.02 
Hsp60 1.95 1.27-2.98 0.002 
PmpGa 1.35 1.05-1.74 0.02 
PmpGc 1.22 0.97-1.55 0.09 
Table 4-31: Conditional logistic regression of IL-10 concentrations for children with 
active trachoma and their controls 
Conditional logistic regression analysis confirins the associations discussed above. The 
association for PmpGc is less strong with this analysis. 
Quartile Group n Odds ratio 95% C. I. p< 
IL-10 Active 7 
* 25th cent Control 10 
1.00 - 
IL-1 0 Active 11 
25-50% Control 7 
2.24 0.55-9.11 
IL-1 0 Active 12 7 1 
0.003 
50 -75% Control 5 
3.43 0. 6- 5.53 
IL-10 Active 16 02 
* 75th cent Control 2 
11.43 1.45-90. 
2 Table 4-32: X test for trend for IL-10 responses to Candida in children with active 
trachoma and their controls 
Quartile Group n Odds ratio 95% C. I. P< 
IL-10 Active 8 0 
* 25th cent Control 9 
1. 0 - 
IL-10 Active 13 77 12 
25-50% Control 5 
2.93 . 0.67- 
0 10 
IL-I 0 Active 11 2 0 4 
. 
50-75% Control 6 . 
6 0.50-8.5 
IL-1 0 Active 14 3 4 
* 75th cent Control 4 .9 
0.82-18.85 
2 
Table 4-33: x test for trend for IL-10 responses to PPD in children with active trachoma 
and their controls 
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Results 2 
Quartile Group n Odds ratio 95% C. I. p< 
IL-10 Active 10 1 00 
* 25th cent Control 7 . - 
IL-11 0 Active 10 0 88 41 0 22 3 25-50% Control 8 . . . - 
IL-10 Active 9 
0.04 
50-75% Control 8 
0.79 0.20-3.13 
IL-1 0 Active 17 
* 75th cent I Control 
11.90 0.97 - 145.71 
2 Table 4-34: x test for trend for IL-10 responses to chlarnydial EBs in children with active 
trachoma and their controls 
Quartille Group n Odds ratio 95% C. I. p< 
IL-1 0 Active 6 
* 25th cent Control 10 
1.00 - 
IL-10 Active 11 
25-50% Control 5 
3.67 0.77-6.33 
IL-1 0 Active 9 
0.003 
50-75% Control 7 
2.14 0.50-9.25 
IL-1 0 Active 16 4 85 
* 75th cent Control 11 
26.67 
1 
1.51 - 69. 
1 1 
2 Table 4-35: x test for trend for IL-10 responses to omP2 in children with active trachoma 
and their controls 
Quartile Group n Odds ratio 95% C. I. P< 
IL-1 0 Active 6 00 1 
* 25th cent Control 11 . - 
IL-I 0 Active 11 2 88 68-12 19 0 
25-50% Control 7 . . . 0006 0 
IL-I 0 Active 13 96 5 70 12-31 1 
. 
50-75% Control 4 . . . 
IL-1 0 Active 16 67 14 65 69 - 127 1 * 75th cent Control 2 . . . 
2 
Table 4-36: x test for trend for IL-10 responses to HSP60 in children with active trachoma 
and their controls 
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Results 2 
Quartile Group n Odds ratio 95% C. I. p< 
IL-10 Active 6 00 1 
* 25th cent Control 10 . - 
IL-10 Active 11 
25-50% Control 8 
2.29 0.56-9.39 
IL-10 Active 14 
0.002 
50-75% Control 3 
7.78 1.24-48.75 
IL-I 0 Active 15 
* 75th cent I Control 3 
8.33 1.32-52.53 
2 Table 4-37: x test for trend for IL-10 responses to PMPGa in children with active trachoma 
and their controls 
Quartille Group n Odds ratio 95% C. I. p< 
IL-1 0 Active 10 
* 25th cent Control 7 
1.00 - 
IL-11 0 Active 8 
25-50% Control 9 
0.62 0.16-2.49 
IL-10 Active 13 
0.05 
50 -75% Control 5 
1.82 0.43-7.74 
IL-1 0 Active 15 
* 75th cent I Control 3 
3.50 0.67-18.34 
2 Table 4-38: x test for trend for IL-10 responses to PmpGc in children with active trachoma 
and their controls 
x2 analysis for trend for each of the associations confirms the increasing likelihood of 
having active trachoma with increasing IL- 10 levels generated in response to the 
antigens. This effect is most strikingly seen for omP2 where those generating IL-10 in 
the highest quartile of concentrations are almost 27 times more likely to be cases than 
those in the lowest quartile. Corresponding figures for the other antigens are 11.4 for 
Candida, 3.9 for MOMP, 11.9 for EBs, 14.7 for HsP60,8.3 for PMPGa and 3.5 for 
PmpGc. 
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Figure 4-20: Frequency-distribution graphs of TGFP responses in children with active 
trachoma and their controls 
As explained in section 5.1.2, a significant number of TGFP assays were discarded due 
to non-specific high levels of TGFP production. Despite this a number of suspicious 
values remain which appear well outside the standard deviation and may represent 
spurious results. Two such examples from the graphs above are those at -6-1 pg/ml for 
PPD and -400 pg/ml for PNipGc. 
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Results 2 
Mean TGF t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. p< p< 
Active 7 219 67-372 
26 0 0 41 PHA 
Control 7 403 49-757 . . 
Active 7 21 0-42 
No antigen 
Control 7 39 0-82 
0.37 0.59 
Active 7 20 0-54 
Candida 
Control 7 59 0-128 
0.24 0.31 
P 
Active 7 9 0-31 
PD 
Control 7 0 0-0 
0.33 0.14 
PET - no Active 7 1 0-4 
antigen Control 7 3 0-9 
0.60 0.92 
EB 
Active 7 4 0-11 
s 
Control 7 28 0-74 
0.24 0.75 
Active 7 9 0-23 
MOMP 
Control 7 9 0-26 
0.94 1.00 
Active 7 14 0-38 
omP2 
Control 7 38 2-74 
0.18 0.20 
Active 7 22 0-64 
HsP60 Control 7 31 0-88 
0.76 0.60 
Active 7 102 33-172 
PmPGa Control 7 88 31 -144 
0.70 0.90 
Active 7 61 0-195 
PmpGc Control 7 34 0-8 U, 
5 0.71 
Table 4-39: Mean TGFP concentrations in children with active trachoma and their 
controls 
The pattern of distribution of TGFP responses is somewhat difficult to determine from 
the frequency-distribution graphs above, however neither the t-test nor the Mann- 
Whitney U-test find any significant differences between cases and controls. 
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Figure 4-21: Mean TGFP concentrations in children with active trachoma and their 
controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in TGF 
95% C. I. p< 
PHA 0.78 0.49-1.23 0.28 
No antigen 0.91 0.73-1.14 0.43 
Candida 0.63 0.29-1.38 0.25 
PPD - - 
PET - No 
antigen 
0.97 0.87-1.08 0.61 
EB's 0.91 0.75-1.11 0.35 
MOMP 0.98 0.78-1.24 0.90 
omp2 0.90 0.74- 1.09 0.30 
HsP60 0.98 0.85-1.12 0.76 
PmpGa 1.11 0.70-1.76 0.65 
PmpGc 1.03 0.91 -1.17 0.65 
Table 4-40: Conditional logistic regression of TGFP concentrations for children with 
active trachoma and their controls 
The conditional logistic regression confirins the earlier analyses and shows no 
association between TGFP responses and active trachoma. 
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Results 2 
4.3.2.2 Scarred trachoma 
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Figure 4-22: Frequency-distribution graphs of TNFcc responses in individuals with 
trachomatous scarring and their controls 
Examination of the frequency distribution plots for TNF(x in response to the II antigens 
and controls reveals very similar responses in those individuals with trachornatous 
scarring and tlicir controls. 
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Results 2 
Mean TNF t-test Mann-Whitney 
Antigen Group n level (pg/ml) - 95% C. I. p< p< 
Scarred 27 908 677-1138 
PHA 
Control 27 851 635-1067 
0.71 0.82 
Scarred 27 5 1.2-9 
No antigen 
Control 27 2 0.6-4 
0.18 0.16 
Scarred 27 617 451 -782 Candida 
Control 27 758 529-967 
0.28 0.44 
PPD 
Scarred 27 94 55-133 
Control 27 99 59-138 
0.85 0.69 
PET - no Scarred 27 7 1.5- 13 
antigen Control 27 3 0.5-6 
0.22 0.44 
EB 
Scarred 27 1068 798-1339 
s 
Control 27 1276 932-1620 
0.33 0.44 
O 
Scarred 27 29 17-40 
M MP 
Control 27 30 14-46 
0.89 0.83 
2 
Scarred 27 1524 1220-1828 
omP 
Control 27 1833 1461 -2206 
0.19 0.27 
60 
Scarred 27 771 557-986 
HsP Control 27 681 500-862 
0.51 0.64 
Scar-red 27 322 172-473 
PmPGa Control 27 254 94-414 
0.52 0.52 
Scarred 27 10 4-17 
9 0 83 PmpGc - Control 27 10 4-15 
0. 5 . 
Table 4-41: Mean TNFcc concentrations in individuals with trachomatous scarring and 
their controls 
Fon-nal statistical analysis confirms the impression gained from the frequency- 
distribution graphs that no significant differences are noted between the groups by t-test 
or Mann-Whitney U test. 
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Results 2 
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Figure 4-23: Mean TNF(x concentrations in individuals with trachornatous scarring and 
their controls 
logistic regression 
Antigen O. R. for 25% 
rise in TNF 
95% C. I. p< 
PA 1.05 0.86-1.30 0.62 
No antigen 1.05 0.96-1.15 0.26 
Candida 0.91 0.74-1.11 0.33 
PPD 1.00 0.86-1.15 0.95 
PET - No 
antigen 
1.04 0.97-1.11 0.27 
EB's 0.91 0.73-1.13 0.40 
MOMP 0.99 0.90-1.10 0.92 
omp2 0.85 0.64-1.12 0.25 
Hsp60 1.08 0.88- 1.34 0.46 
PmpGa 1.04 0.94-1.15 0.50 
PmpGc 1.01 0.93-1.09 0.88 
Table 4-42: Conditional logistic regression of TNF(x concentrations for individuals with 
trachornatous scarring and their controls 
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Conditional logistic regression also fails to pick up any associations thus there appear to 
be no difference in the responses of cases and controls in respect of TNFa generation as 
measured by these assays. 
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Figure 4-24: Frequency-distribution graphs of IFNy responses in individuals with 
trachornatous scarring and their controls 
The trcqucncy distribution plots for IFN-y rcsponscs dcnionstratc niarkcdly skewcd 
results for scarred individuals as for children with active trachoma again making the 
Mann-Whitney U-test probably more accurate for comparing the cases and controls. 
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Results 2 
Mean IFN t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. p< p< 
Scarred 27 15165 9195-21136 
PHA 
Control 27 13361 5347-21375 
0.71 0.32 
N 
Scarred 27 12 0.1 -24 o antigen 
Control 27 15 4-26 
0.68 0.04 
C 
Scarred 27 71 27-116 
andida 
Control 27 62 41 -84 
0.70 0.19 
PPD 
Scarred 27 916 303-1529 
Control 27 739 251 -1227 
0.64 0.93 
PET - no Scarred 27 11 -2-24 
antigen Control 27 11 1 -20 
0.96 0.38 
EB 
Scarred 27 38 11 -64 s 
Control 27 52 5-99 
0.58 0.70 
MOMP 
Scarred 27 21 5-38 
Control 27 28 8-49 
0.59 0.90 
2 
Scarred 27 151 56-246 
omP 
Control 27 134 70-198 
0.76 0.73 
Scarred 27 74 29-120 
HsP60 Control 27 94 27-161 
0.63 0.86 
Scarred 27 24 7-42 
PmPGa Control 27 33 16-51 
0.45 0.07 
Scarred 27 17 2-31 
0 PmpGc Control 27 20 6-33 
0.74 . 75 
Table 4-43: Mean IFNy concentrations in individuals with trachomatous scarring and their 
controls 
Comparison of the means of those with trachomatous scarring and their controls failed 
to demonstrate and significant differences using the T-test. The Mann-Whitney U test 
suggests differences in response to the negative control and to PmPGa, however the 95% 
confidence intervals overlap widely (Figure 4-25). 
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Figure 4-25: Mean IFNy concentrations in individuals with trachornatous scarring and 
their controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in IFN 
95% C. I. p< 
PHA 1.07 0.88-1.30 0.47 
No antigen 0.98 0.92-1.04 0.55 
Candida 1.02 0.92-1.13 0.75 
PPD 1.04 0.93-1.17 0.51 
PET - No 
antigen 
1.00 0.95- 1.05 0.86 
EB's 0.98 0.92- 1.05 0.56 
MOMP 0.98 0.91 -1.05 0.54 
omp2 1.02 0.93-1.12 0.72 
HsP60 0.98 0.90-1.06 0.62 
PmpGa 0.97 0,89-1.05 0.44 
PmpGc 0.98 0.92-1.05 0.63 
Table 4-44: Conditional logistic regression of IFNy concentrations for individuals with 
trachornatous scarring and their controls 
Conditional logistic regression fails to demonstrate any statistically significant 
differences between those with trachornatous scarring and their controls with respect to 
IFN7 production. 
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Figure 4-26: Frequency-distribution graphs of IL-2 responses in individuals with 
trachomatous scarring and their controls 
Once again the frequency-distribution graphs show data which are all non-normally 
distributed except, perhaps, for the responses to PHA. 
171 
Results 2 
Mean 11-2 t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. P< p< 
Scarred 27 644 495-793 
0 67 0 67 PHA 
Control 27 599 450-748 . . 
Scarred 27 4 0-7 
No antigen 
Control 27 5 2-9 
0.47 0.85 
Scarred 27 13 8-19 
Candida 
Control 27 17 9-25 
0.45 0.53 
Scarred 27 102 68-136 
PPD 
Control 27 94 54-134 
0.75 0.28 
PET - no Scarred 27 4 0-8 
antigen Control 27 15 4-26 
0.07 0.15 
Scarred 27 7 2-11 
EBs 
Control 27 19 5-33 
0.10 0.28 
Scarred 27 5 2-9 
MOMP 
Control 27 16 5-28 
0.07 0.29 
Scarred 27 6 0-12 
omP2 
Control 27 13 3-23 
0.23 0.28 
Scarred 27 5 1 -9 0 45 HsP60 Control 27 11 4-18 
0.14 . 
Scarred 27 7 4-11 
0 99 PmpGa Control 27 9 5-14 
0.48 . 
Scarred 27 3 0-6 
12 0 05 PmpGc Control 27 7 3-12 . . 1 
Table 4-45: Mean IL-2 concentrations in individuals with trachomatous scarring and their 
controls 
The Mest appears to show lower responses in the negative control and in response to 
MOMP and chlarnydial EBs. However, as we have seen, these data are not non-nally 
distributed and the more appropriate Mann-Whitney U-test shows no significant 
differences between the two groups. 
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Figure 4-27: Mean IL-2 concentrations in individuals with trachornatous scarring and 
their controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in IL-2 
95% C. I. p< 
PHA 1.04 0.84-1.29 0.70 
No antigen 0.98 0.92-1.04 0.58 
Candida 0.94 0.81 -1.08 0.35 
PPD 1.02 0.89-1.16 0.81 
PET - No 
antigen 
0.91 0.82-1.02 0.11 
EB's 0.94 0.86-1.03 0.17 
MOMP 0.92 0.83-1.03 0.16 
omp2 0.96 0.90-1.03 0.29 
Hsp60 0.94 0.85-1.03 0.19 
PmpGa 0.96 0.87- 1.07 0.50 
PmpGc 0.95 0.87-1.03 0.20 
Table 4-46: Conditional logistic regression of IL-2 concentrations for individuals with 
trachornatous scarring and their controls 
In keeping with the results of the Mann-Whitney U-test, conditional logistic regression 
shows no differences in the IL-2 responses between those with trachornatous scarring 
and their controls. 
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Results 2 
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Figure 4-28: Frequency-distribution graphs of IL-5 responses in individuals with 
trachornatous scarring and their controls 
Once again the IL-5 data are not non-nally distributed. 
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Results 2 
Mean IL-5 t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. p< p< 
Scarred 27 1676 1110-2242 
93 0 0 88 PHA 
Control 27 1645 1179-2112 . . 
Scarred 27 11 7-15 
No antigen 
Control 27 26 15-37 
0.01 0.03 
C 
Scarred 27 10 6-13 
andida 
Control 27 16 7-25 
0.18 0.53 
PP 
Scarred 27 15 10-19 
D 
Control 27 23 10-36 
0.23 0.99 
PET - no Scarred 27 4 1 -7 
antigen Control 27 7 2-13 
0.35 0.26 
EB 
Scarred 27 8 3-12 
s 
Control 27 10 2- 18 
0.67 0.47 
O 
Scarred 27 7 3-11 
MP M 
Control 27 15 0-31 
0.31 0.46 
Scarred 27 7 3-11 
omP2 
Control 27 12 1 -23 
0.40 0.81 
Scarred 27 8 4-13 
84 0 HsP60 Control 27 18 3-33 
0.23 . 
Scarred 27 12 8-16 
0 PmPGa 
, 
Control 27 14 1 -27 
0.78 0. 5 
Scarred 27 7 4-11 
34 0 40 PmpGc Control 27 14 0-27 
1 0. . 1 
Table 4-47: Mean IL-5 concentrations in individuals with trachomatous scarring and their 
controls 
The Mann-Whitney U-test indicates that the control individuals generate less than half 
the amount of IL-5 when incubated without antigen compared to scarred adults (I I vs. 
26 pg/ml, p<0.03). However, no differences are seen in response to any of the 
antigens. 
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Results 2 
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Figure 4-29: Mean IL-5 concentrations in individuals with trachornatous scarring and 
their controls 
logistic regression 
Antigen O. R. for 25% 
rise in IL-5 
95% C. I. p< 
PHA 1.01 0.82-1.23 0.95 
No antigen 0.82 0.66-1.01 0.06 
Candida 0.91 0.77-1.07 0.24 
PPD 0.92 0.79-1.06 0.24 
PET - No 
antigen 
0.96 0.89-1.05 0.38 
EB's 0.98 0.91 -1.06 0.67 
MOMP 0.97 0.91 -1.04 0.36 
omp2 0.97 0.91 -1.04 0.42 
HsP60 0.95 0.88- 1.04 0.28 
PmpGa 0.99 0.92- 1.06 0.75 
PmpGc 0.97 0.91 -1.04 0.37 
Table 4-48: Conditional logistic regression of IL-5 concentrations for individuals with 
trachornatous scarring and their controls 
Conditional logistic regression analysis confirms no association between trachomatous 
scarring and IL-5 responses apart from that in the negative control wells. 
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Figure 4-30: Frequency-distribution graphs of IL-10 responses in individuals with 
trachornatous scarring and their controls 
As was seen with the active trachoma group, the IL-10 responses are much more 
normally distributed than those for the other cytokines. The graphs appear to show 
lower IL-10 responses to chlamydial EBs and to PmpGc in scarred individuals vs. 
controls. 
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Results 2 
Mean IL-10 t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. p< p< 
Scarred 27 2048 1559-2538 
PHA 
Control 19 2230 1705-2755 
0.61 0.70 
Scarred 27 11 7-15 
No antigen 
Control 19 15 8-22 
0.27 0.35 
Scarred 27 59 46-72 
Candida 
Control 19 90 49-131 
0.09 0.43 
Scarred 27 57 43-71 
PPD 
Control 19 67 48-87 
0.35 0.47 
PET - no Scarred 27 16 7-26 
antigen Control 19 15 7-24 
0.88 0.88 
EB 
Scarred 27 149 119-179 
s 
Control 19 238 164-312 
0.01 0.04 
Scarred 27 32 18-46 
MOMP 
Control 19 29 13-46 
0.81 0.60 
Scarred 27 271 194-349 
omP2 Control 19 341 206-475 
0.33 0.40 
Scarred 27 214 159-270 
HsP60 Control 19 237 128-345 
0.68 0.80 
Scarred 27 51 37-66 
PmPGa Control 19 79 46-112 
0.08 0.33 
Scarred 27 14 9-19 
0 13 PmpGc Control 19 31 16-45 
0.02 . 
Table 4-49: Mean IL-10 concentrations in individuals with trachomatous scarring and 
their controls 
The t-test shows that scarred individuals do indeed generate less IL- 10 than controls in 
response to EBs (149 vs. 238 pg/ml, p<0.01) and PmPGc (14 vs. 31pg/ml, p<0.02). It 
also shows lower responses to Candida (59 vs. 90 pg/ml, p<0.09) and PmPGa (51 vs. 
70 pg/ml, p<0.08). 
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Figure 4-31: Mean IL-10 concentrations in individuals with trachomatous scarring and 
their controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in IL-1 0 
95% C. I. p< 
PHA 0.95 0.74-1.22 0.67 
No antigen 0.93 0.79-1.11 0.42 
Candida 0.88 0.72-1.08 0.22 
PPD 0.86 0.64-1.16 0.32 
PET - No 
antigen 
1.02 0.91 -1.15 0.74 
EB's 0.80 0.62-1.03 0.08 
MOMP 1.03 0.90-1.18 0.71 
omp2 0.94 0.79-1.11 0.46 
HsP60 0.97 0.81 -1.17 0.73 
PmpGa 0.88 0.73-1.07 0.21 
PmpGc 0.85 0.72-1.02 0.08 
Table 4-50: Conditional logistic regression of IL-10 concentrations for individuals with 
trachornatous scarring and their controls 
Conditional logistic regression provides further confin-nation of lower IL-10 responses 
to EBs and PmpGc in scarred individuals but fails to confirm the association for 
Candida or PmpGa. 
Quartile Group n Odds ratio 95% C. I. p< 
IL-1 0 Scarred 8 
* 25th cent Control 3 
1.00 - 
IL-1 0 Scarred 8 2 4 25-50% Control 4 
0.75 0.1 - . 69 
0 06 
IL-1 0 Scarred 7 0 66 10 4 21 0 
. 
50-75% Control 4 . . - . 
IL-1 0 Scarred 4 37 03 1 
* 75th cent I Control 8 
0.19 0. - . 
2 
Table 4-51: x test for trend for IL-1 0 responses to chlarnydial EBs in individuals with 
trachornatous scarring and their controls 
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Results 2 
Quartile Group n Odds ratio 95% C. I. p< 
IL-11 0 Scarred 8 00 1 
* 25th cent Control 3 . - 
IL-1 0 Scarred 7 0 53 22 09 3 0 
25-50% Control 5 . . . - 
IL-10 Scarred 8 
0.11 
50 - 75% Control 3 
1.00 0.15-6.83 
IL-11 0 Scarred 4 
* 75th cent Control 8 
0.19 0.03-1.37 
2 Table 4-52: x test for trend for IL-10 responses to pmpGc in individuals with 
trachomatous scarring and their controls 
The X2 test for trend shows individuals generating IL-10 responses in the highest 
quartile in response to EBs and to PmpGc are five times less likely to have scarring than 
those with responses in the lowest quartile. 
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Results 2 
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Figure 4-32: Frequency-distribution graphs of TGFP responses in individuals with 
trachornatous scarring and their controls 
As discussed earlier the numbers of TGFP assays analysed is less than that for the other 
cytokincs. Due to the presence of non-specific activation a small number of results 
included may still be spurious such as the values seen here at -2000 pg/ml in response I 
to PPD, PET and EBs amongst the cases. 
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Results 2 
Mean TGF t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. p< p< 
Scarred 11 190 31 -349 1 00 0 40 PHA 
Control 10 190 65-315 . . 
Scarred 11 37 5-68 
No antigen 
Control 10 12 0-27 
0.15 0.30 
Scarred 11 116 0-281 
Candida 
Control 10 21 0-54 
0.24 0.13 
Scarred 11 175 0-538 
PPD 
Control 10 12 0-38 
0.35 0.36 
PET - no Scarred 11 186 0-569 
antigen Control 10 3 0-11 
0.32 0.16 
EB 
Scarred 11 189 0-538 
s 
Control 10 12 0-38 
0.30 0.09 
Scarred 11 225 0-605 
MOMP 
Control 10 3 0-8 
0.23 0.01 
Scarred 11 333 0-735 
omP2 
Control 10 7 0-24 
0.10 0.03 
Scarred 11 349 0-739 
0 08 0 008 HsP60 Control 10 3 0-9 . . 
Scarred 11 144 5-283 
9 PmPGa Control 10 9 0-19 
0.05 0.0 
Scarred 11 330 0-761 
0 12 0 008 PmpGc Control 10 0 0-0 . . 
Table 4-53: Mean TGFO concentrations in individuals with trachornatous scarring and 
their controls 
TGFp - Scarred trachoma 
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Figure 4-33: Mean TGFP concentrations in individuals with trachomatous scarring and 
their controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in TGF 
95% C. I. p< 
PHA 1.02 0.84-1.24 0.86 
No antigen 1.34 0.93-1.38 0.21 
Candida 1.13 0.84-1.53 0.41 
PPD 1.06 0.80-1.40 0.69 
PET - No 
antigen 
2.00 0.53- 7.57 0.31 
EB's 1.29 0.76-2.19 0.35 
MOMP 6.77 0.11 -434 0.37 
omp2 2.83 0.47-17.00 0.26 
HsP60 (3.45 x 101) 
PmpGa 1.41 0.81 -2.44 0.23 
PmpGc (5.03 X 106) 1- I- 
Table 4-54: Conditional logistic regression of TGFP concentrations for individuals with 
trachornatous scarring and their controls 
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Results 2 
4.4 Results of studies in infertile women 
4.4.1 Immunoblot results 
Controls Infertile 
MOMP 
Controls Infertile 
0 
omp2 
Conlrols 
0 
Inferlile 
Controls Infertile 
a 
if ý, - 0 a 
0 
L 
IN 
F-1 7 &1 m 301? 
pmpGa 
Controls 
p mpGc 
I nfe. rtiie 
Figure 4-34: Frequency-distribution graphs of 
immunoblot density scores from infertile 
women and their controls 
2/15 (13%) of controls and 0/22 infertile 
women had no detectable antibodies to MOMP 
(p<0.09). It is clear from the frequency 
distribution graphs that infertile women had 
higher immunoblot density scores for MOMP 
than controls. 
in contrast to previous stud' Again iI ies, no 
association is seen with antibodies to HSP60 
and infertility. 13/15 (87%) controls and 18/20 
(90%) of infertile women have detectable 
antibodies to HsP60. Even at higher levels of 
response there is no difference between the 
cases and controls; 12/15 (80%) of controls 
and 17/20 (85%) of infertile women have 
immunoblot scores of 2 or greater. 
As was seen in the two trachoma groups, a large number of individuals demonstrate 
detectable antibodies to the recombinant PmPG proteins. 4/15 (27%) of controls vs. 
12/20 (60%) of the infertile women have antibodies to PmPGa -a significantly higher 
proportion in the infertile women (p<0.05). 5/15 (33%) of the controls and 10/20 
(50%) of the infertile women demonstrate antibodies to PmpGc (p < 0.32) 
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Results 2 
A ti 
Mean 
bl t 
t-test Mann-Whitney 
n gen Group n immuno o 
score 95% C. I. p p 
MOMP 
Inferfile 20 2.50 2.24-2.75 
Control 15 1.75 1.27-2.23 
0.004 0.005 
2 
Infertile 6 1.65 0.85-2.45 
omP 
Control 8 1.29 0.45-2.12 
0.47 0.43 
60 
Infertile 20 2.40 1.98-2.08 
HsP Control 15 2.03 1.58-2.48 
0.22 0.07 
PmPGa 
Infertile 20 1.1 0.65-1.55 
Control 15 0.69 0.17-1.22 
0.22 0.27 
PmPGc 
Infertile 20 0.93 0.47-1.38 
Control 15 0.57 0.14-1.01 
0.26 0.32 
Table 4-55: Mean immunoblot density scores from infertile women and their controls 
For infertile women, comparison of the population means between cases and controls 
using the t-test demonstrates a clear difference in the responses to MOMP with infertile 
women producing a mean immunoblot density score of 2.50 vs. 1.75 for matched 
controls (p < 0.004). Again this data is somewhat skewed to the right and so the non- 
parametric Mann-Whitney U test was also applied. This confirmed the association with 
a very similar level of significance (p < 0.005). The Mann-Whitney U test appears to 
point to a trend towards higher responses to HsP60 in infertile women however the 
means are very close and the 95% confidence intervals are overlapping. 
Infeftile women 
ep e, 0\ e, &p 0\ eý 1Q, 0 C; CP -C, 60 Cý 
de 1 646", 
Figure 4-35: Mean immunoblot density scores from infertile women and their controls 
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Results 2 
A 
logistic regression 
ntigen O. R. 
95% C. I. p< 
MOMP 3.57 0.92-13.90 0.07 
omP2 1.31 0.41 -4.20 0.65 
HSP60 1.54 0.67-3.52 0.31 
PmpGa 2.18 0.66-7.21 0.20 
PmpGc 1.83 0.59-5.63 0.29 
Table 4-56: Conditional logistic regression of immunoblot density scores for infertile 
women and their controls 
Pair-wise conditional logistic analysis again suggests the association of antibody 
response to MOMP with the presence of infertility, each incremental increase of 
response to MOMP being associated with an odds ratio of 3.57 for being infertile, but 
the level of significance is reduced compared to that obtained using the t-test and Mann- 
Whitney U test (95% C. I. 0.92 - 13.90, p<0.07). The response to HsP60 shows no 
association with infertility in this response. This conflict between the results of the 
Mann-Whitney U-test and conditional logistic regression may be explained by the fact 
that these tests use two different models and two different outcomes. The Mann- 
Whitney U-test tests if the immunoblot score is dependent on whether the individual is a 
case or control whilst the conditional logistic regression analysis estimates the 
likelihood of being a case for a given immunoblot score. 
Immunoblot Group n Odds 95% C. I. p< 
score 
MOMP Infe rti le 0 0 
< 0.4 Control 2 
MOMP Infertile 1 5 51 0 05 0.50 - . . 0.4-0.99 Control 2 
0 03 . MOMP Infertile 3 0 50 00 0 13 2 
1-0-1-99 Control 61 . . - . 1 
MOMP Infe rti le 
L 
8 18 
1 4 46 77 3 0 .6 - . . 2.0-3.0 Control 11 11 11 
2 
Table 4-57: x test for trend for immunoblot density scores in response to MOMP in 
infertile women and their controls 
X2 analysis for trend (Table 4-57) demonstrates an increase in the odds of being Infertile 
with an increasing rise in antibody response as measured by the Immunoblot density 
scorc for MOMP (p < 0-03). The confidence intervals however do include 1. 
186 
4.4.2 Cytokine ELISAs from whole blood assays 
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Figure 4-36: Frequency-distribution graphs of TNF(x responses in infertile women and 
their controls 
The whole blood assays and cytokine ELISAs failed to detect any difference between 
the infertile women and their controls in terms of the amount of TNFo( generated in 
response to the II antigens and controls. This can be seen in the frequcncy-distribution 
plots (Figure 4-36) and in the subsequent formal statistical analysis by t-test and Mann- 
Whitney U test. 
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Results 2 
Mean TNF t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. p< p< 
Infertile 22 1182 887-1477 
70 0 0 66 PHA 
Control 21 1098 746-1449 . . 
Infertile 22 3 0.8-5 
No antigen 
Control 21 5 3-8 
0.13 0.11 
Infertile 22 954 662-1245 
Candida 
Control 21 1078 686-1470 
0.60 0.81 
Infe rti le 22 243 143-343 PPD 
Control 21 260 153-366 
0.81 0.46 
PET - no Infertile 22 7 2-13 
antigen Control 21 8 1 -14 
0.90 0.26 
Infertile 22 1550 1223-1877 
ElBs 
Control 21 1441 1007-1875 
0.68 0.37 
Infertile 22 41 17-65 
MOMP 
Control 21 46 26-66 
0.74 0.47 
Infertile 22 2421 1712-3129 
omP2 
Control 21 2577 1723-3431 
0.77 0.92 
Infertile 22 944 621 -1266 0 76 HsP60 Control 21 1013 682-1344 
0.75 . 
Infertile 22 296 152-440 
0 64 PmPGa Control 21 323 188-458 
0.78 . 
Infertile 22 62 1 -123 39 0 0 64 PmpGc Control 21 35 19-50 . . 
Table 4-58: Mean TNF(x concentrations in infertile women and their controls 
Infertile women 
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Figure 4-37: Mean TNFcc concentrations in infertile women and their controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in TNF 
95% C. I. p< 
PHA 1.08 0.83-1.41 0.55 
No antigen 0.92 0.83-1.03 0.16 
Candida 0.94 0.72-1.21 0.63 
PPD 0.99 0.82-1.18 0.87 
PET - No 
antigen 
1.00 0.92-1.08 0.94 
EB's 1.10 0.81 -1.50 0.53 
MOMP 0.98 0.86-1.12 0.78 
omp2 0.98 0.78- 1.23 0.88 
HsP60 0.98 0.78-1.23 0.86 
PmpGa 0.98 0.83-1.16 0.85 
PmpGc 1.05 0.93-1.20 0.41 
Table 4-59: Conditional logistic regression of TNF(x concentrations for infertile women 
and their controls 
As expected from the frequency-distribution graphs and the t-test and Mann-Whitney 
U-test results, conditional logistic regression confirms that no detectable differences 
exist between the infertile women and their controls in respect of the levels of TNF(x 
generated. 
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Figure 4-38: Frequency-distribution graphs of IFNy responses in infertile women and 
their controls 
Comparison of the IFNy responses of infertile women and their controls using the t-test 
demonstrates significantly higher responses by the infertile women towards chlarnydial 
elementary bodies (156 vs. 71, p<0.008) and this difference is also confirmed by the 
Mann-Whitney U test. The latter test also suggests differences between the two groups 
in response to MOMP and PMPGa although the 95% confidence intervals show a wide 
overlap. 
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Results 2 
A ti Mean 
IFN t-test Mann-Whitney 
n gen Group n level (pg/ml) 95% C. I. p< p< 
PH 
Infe rti le 22 19194 12431 - 25957 A 
Control 21 18725 12508 - 24943 
0.92 0.86 
N ti 
Infertile 22 8 4-12 
o an gen 
Control 21 10 7-12 
0.52 0.11 
C did 
Infertile 22 165 89-242 
an a 
Control 21 122 52-193 
0.40 0.36 
PPD 
Infertile 22 1370 738-2002 
Control 21 1197 631 -1762 
0.67 0.47 
PET - no Infertile 22 7 4-10 
antigen Control 21 7 3-11 
0.97 0.85 
EB 
Infertile 22 156 102-211 
s 
Control 21 71 40-101 
0.008 0.001 
MOMP 
Infertile 22 104 38-170 
Control 21 44 0-93 
0.14 0.006 
2 
Infertile 22 396 227-564 
omP 
Control 21 238 136-339 
0.11 0.13 
60 
Infertile 
- 
22 200 76-325 
HsP 
Control 21 136 66-206 
0.36 0.55 
G 
Infertile 22 37 25-50 
PmP a 
Control 21 26 12-40 
0.21 0.09 
G 
Inferti le 22 10 5-14 
Pmp c 
Control 21 11 5-16 
0.79 0.88 
Table 4-60: Mean IFNy concentrations in infertile women and their controls 
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Figure 4-39: Mean IFNy concentrations in infertile women and their controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in IFN 
95% C. I. p< 
PHA 1.03 0,82-1.31 0.80 
No antigen 0.93 0.76-1.13 0.45 
Candida 1.07 0.91 -1.27 0.40 
PPD 1.05 0.88-1.24 0.60 
PET - No 
antigen 
1.00 0.87-1.15 1.00 
EB's 1.56 1.04-2.33 0.03 
MOMP 1.08 0.95-1.23 0.23 
omp2 1.13 0.95-1.35 0.16 
HsP60 1.08 0.93-1.26 0.31 
PmpGa 1.16 0.92-1.46 0.20 
PmpGc 0.95 0.77-1.18 0.66 
Table 4-61: Conditional logistic regression of IFNy concentrations for infertile women and 
their controls 
Conditional logistic regression confirms the difference in responses to chlamydial 
elementary bodies with a 1.56 increase on odds ratio for each 25% rise in IFNy but falls 
to confirrn a difference for MOMP or PmpGa. 
Quartille Group n Odds 95% C. I. p< 
IFN Infertile 0 
* 25th cent Control 10 
0 
IFN Infertile 7 75 6 00 0 50 
25-50% Control 4 1. - . . 
0 001 
IFN Infertile 6 1 2 37 3 90 0 
. 
50-75% Control 5 . - . . 
IFN Infertile 8 4 0 84 18 85 0 
* 75th cent I Control 21 . . - . 1 
2 
Table 4-62: x test for trend for lFNy responses to PHA in infertile women and their 
controls 
The X2 test for trend (Table 4-62) demonstrates a much higher ratio for being a scarred 
for those generating IFNy responses in the highest quartile than those in the lowest 
quartile (4.0 vs 0p<0.001). As the odds for the lowest quartile are 0 an odds ratio 
compared to this cannot be calculated. 
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Figure 4-40: Frequency-distribution graphs of IL-2 responses in infertile women and their 
controls 
The t-tcst demonstrates higher levels of IL-2 being produced by the infertile women in 
response to PHA compared to controls (724 vs. 535 pg/ml, p<0.05). These data appear 
normally distributed thus the t-test is more appropriate than the Mann-Whitney U-test. 
There is a wide discrepancy between the significance levels ascribed to the IL-2 
response to PmPGa and it is difficult to be certain if the data are normally distributed or 
not from tile frequency-distribUtion graphs. However the 95% confidence intervals 
overlap considerably suggesting that the difference is probably not significant. 
193 
Results 2 
Mean 11-2 t-test Mann-Whitney Antigen Group n level (pg/mI) 95% C. I. p< p< 
Infertile 22 724 573-874 
PHA 
Control 21 535 407-663 
0.05 0.13 
N 
Infertile 22 9 5-13 
o antigen 
Control 21 10 5-15 
0.75 0.88 
C 
Infertile 22 12 8- 15 
andida 
Control 21 14 9-19 
0.37 0.68 
PIRD 
Infe rti le 22 104 69-139 
Control 21 80 43-117 
0.35 0.27 
PET - no Inferti le 22 4 2-6 
antigen Control 21 6 3-9 
0.33 0.56 
EB 
Infertile 22 6 4-9 
s 
Control 21 7 3-11 
0.77 0.53 
Infertile 22 9 4-14 
MOMP 
Control 21 6 3-10 
0.30 0.17 
2 
Infertile 22 3 1 -5 omP 
Control 21 5 2-8 
0.41 0.66 
60 
Infertile 22 7 4-9 
HsP Control 21 5 2-9 
0.58 0.26 
Infertile 22 9 5-12 
PmPGa Control 21 6 3-10 
0.28 0.07 
Infertile 22 5 2-7 
PmpGc 
Control 21 4 1 -7 
0.47 0.18 
Table 4-63: Mean IL-2 concentrations in infertile women and their controls 
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Figure 4-41: Mean IL-2 concentrations in infertile women and their controls 
Figure: IL2 infertile logistic. tbl 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in IL-2 
95% C. I. p< 
PHA 1.59 1.02-2.48 0.04 
No antigen 0.98 0.84-1.13 0.80 
Candida 0.91 0.73-1.13 0.34 
PPD 1.10 0.91 -1.33 0.32 
PET - No 
antigen 
0.93 0.82-1.07 0.31 
EB's 0.97 0.83-1.13 0.69 
MOMP 1.08 0.92-1.26 0.35 
omp2 0.95 0.86- 1.06 0.40 
HsP60 1.04 0.89-1.22 0.61 
PmpGa 1.07 0.92-1.23 0.39 
PmpGc 1.03 0.93-1.14 0.57 
Table 4-64: Conditional logistic regression of IL-2 concentrations for infertile women and 
their controls 
Conditional logistic regression confirins the association of higher levels of IL-2 in 
response to PHA for infertile women. The association with PmPGa is, as expected, not 
confirmed. 
Quartile Group n Odds ratio 95% C. I. p< 
IL-2 Infertile 2 
* 25th cent Control 4 
1.00 - 
IL-2 Infertile 6 32 3 10 
25-50% Control 6 
2.00 - . 0. 
0 13 
IL-2 Infertile 5 15 10 11 0 
. 
50-75% Control 8 
1.25 . - . 
IL-2 Infertile 9 4 66 69 
* 75th cent I Control 31 
6.00 - . 0.5 
2 
Table 4-65: x test for trend for IL-2 responses to PHA in infertile women and their 
controls 
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Figure 4-42: Frequency-distribution graphs of IL-5 responses in infertile women and their 
controls 
No clear differences in IL-5 responses are apparent from the frequency-distribution 
graphs and this is confirmed by the lack of any statistically significant associations by t- 
test or Mann-Whitncy U-test. 
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A Mean IL-5 
t-test Mann-Whitney 
ntigen Group n level (pg/ml) 95% C. I. p< p< 
PH 
Infertile 20 748 473-1024 
A 
Control 20 933 368-1497 
0.54 0.64 
N i 
Inferd le 20 8 4-11 
o ant gen 
Control 20 4 2-7 
0.16 0.51 
C did 
Infertile 20 7 4-11 
an a 
Control 20 4 2-7 
0.18 0.32 
PPID 
Infertile 20 14 7-21 
Control 20 21 0-50 
0.64 0.10 
PET - no Infertile 20 6 2-10 
antigen Control 20 2 0-4 
0.08 0.23 
EB 
Infertile 20 11 0-23 
s 
Control 20 5 1 -8 
0.32 0.56 
MOMP 
Infertile 20 6 2-11 
Control 20 3 1 -5 
0.15 0.42 
2 
Inferti le 20 4 1 -7 omP 
Control 20 3 1 -5 
0.34 0.41 
60 
Inferti le 20 4 1 -6 HsP 
Control 20 4 1 -6 
0.85 0.78 
G 
Inferti le 20 8 5-10 
PmP a 
Control 20 5 3-7 
0.16 0.21 
G 
Infertile 20 4 2-7 
Pmp c 
Control 20 3 1 -5 
0.26 0.31 
Table 4-66: Mean 11-5 concentrations in infertile women and their controls 
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Figure 4-43: Mean IL-5 concentrations in infertile women and their controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in IL-5 
95% C. I. p< 
PHA 0.96 0.83-1.11 0.54 
No antigen 1.11 0.95-1.30 0.18 
Candida 1.10 0.94-1.29 0.22 
PPD 0.97 0.89-1.07 0.58 
PET - No 
antigen 
1.11 0.97- 1.28 0.14 
EB's 1.05 0.94-1.17 0.42 
MOMP 1.11 0.94-1.30 0.21 
omp2 1.06 0.94- 1.20 0.34 
HsP60 0.99 0.88- 1.12 0.85 
PmpGa 1.14 0.93-1.40 0.20 
PmpGc 1.11 0.93-1.33 0-2 5_ 
Table 4-67: Conditional logistic regression of IL-5 concentrations for infertile women and 
their controls 
Conditional logistic regression provides further confirmation that there are no 
differences between infertile women and their controls with respect to IL-5 responses to 
these antigens. 
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Figure 4-44: Frequency-distribution graphs of IL-1 0 responses in infertile women and 
their controls 
The only association shown by the t-test and Mann-Whitney U-test is a lower IL-10 
response in the negative control wells (5 vs. 9 pg/ml), of uncertain significance. No 
differences were noted with antigens. 
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Results 2 
Mean IL-10 t-test Mann-Whitney Antigen Group n level (pg/ml) 95% C. I. p< p< 
Infe r1i le 22 1565 1201 -1929 PHA 
Control 21 1308 807 -1808 
0.39 0.10 
N 
Infertile 22 5 3-8 
o antigen 
Control 21 9 6-13 
0.06 0.05 
C 
Infertile 22 56 41 -71 andida 
Control 21 68 36-99 
0.48 0.91 
PPD 
Infe rti le 22 87 63-111 
Control 21 95 - 67-122 
0.67 0.74 
PET - no Infertile 22 10 3-17 
antigen Control 21 12 6-18 
0.60 0.45 
EB 
Infertile 22 167 115-219 
s 
Control 21 178 126-231 
0.75 0.76 
MOMP 
Infertile 22 26 14-39 
Control 21 34 21 -47 
0.38 0.22 
2 
Infertile 22 207 155 -258 omP 
Control 21 230 155-306 
0.59 0.99 
60 
Infertile 22 180 133-226 
HsP 
Control 21 202 130-273 
0.59 0.79 
Infertile 22 57 41 -74 PmpGa Control 21 67 44-90 
0.48 0.78 
Infertile 22 22 10-33 
PmpGc lControl 21 30 15-45 
0.35 0.61 
Table 4-68: Mean IL-10 concentrations in infertile women and their controls 
IL-10 infertile women 
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Figure 4-45: Mean IL-10 concentrations in infertile women and their controls 
200 
Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in IL-10 
95% C. I. p< 
PHA 1.16 0.88-1.52 0.29 
No antigen 0.86 0.71 -1.03 0.11 
Candida 0.95 0.79-1.13 0.55 
PPD 0.97 0.78-1.21 0.77 
PET - No 
antigen 
0.97 0.87-1.09 0.64 
EB's 0.97 0.76- 1.23 0.79 
MOMP 0.94 0.81 -1.10 0.46 
omp2 0.94 0.71 - 1.23 0.65 
HsP60 0.95 0.75-1.20 0.66 
PmpGa 0.95 0.78-1.15 0.60 
PmpGc 0.94 1 0.83-1.07 1 037 1-- 
Table 4-69: Conditional logistic regression of IL-10 concentrations for infertile women 
and their controls 
Conditional logistic regression also shows a trend towards a reduced odds ratio of being 
infertile with increasing IL-10 responses in the negative control wells though this no 
longer reaches significance. 
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Figure 4-46: Frequency-distribution graphs of TGFP responses in infertile women and 
their controls 
As for the two trachoma groups, there are a reduced number of data for the infertile 
women and their controls and again perhaps a few spuriously high results due to non- 
spccl c activation. 
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Results 2 
Mean TGF t-test Mann-Whitney 
Antigen Group n level (pg/ml) 95% C. I. ID < P< 
Infe rti le 16 99 54-144 0 13 0 13 PHA 
Control 14 153 92-214 . . 
Infertile 16 13 0-28 
No antigen 
Control 14 35 8-62 
0.13 0.09 
Infertile 16 7 0-20 
Candida 
Control 14 18 1 -36 
0.27 0.28 
PPID 
Infertile 16 26 0-63 
Control 14 13 0-28 
0.50 0.74 
PET - no Infertile 16 123 0-289 
antigen Control 14 3 0-8 
0.16 0.61 
Infertile 16 117 0-273 
ElBs 
Control 14 25 0-53 
0.26 0.57 
P 
Infertile 16 104 0-295 
MOM 
Control 14 15 0-33 
0.36 0.74 
Infertile 16 109 0-291 
omP2 
Control 14 27 0-54 
0.38 0.66 
Infertile 16 61 0-157 
2 HsP60 Control 14 22 1 -42 
0.43 0.9 
Infertile 16 36 9-63 
0 42 PmPGa Control 14 73 24-123 
0.15 . 
Infertile 16 32 0-71 
0 70 0 72 PmpGc Control 14 44 0-98 . . 
Table 4-70: Mean TGFO concentrations in infertile women and their controls 
The T-test and Mann-Whitney U-test fail to demonstrate any associations between IL- 
10 responses to these antigens and being infertile. 
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Figure 4-47: Mean TGFP concentrations in infertile women and their controls 
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Results 2 
logistic regression 
Antigen O. R. for 25% 
rise in TGF 
95% C. I. p< 
PHA 0.81 0.61 -1.07 0.14 
No antigen 0.86 0.71 -1.04 0.12 
Candida 0.91 0.80-1.05 0.19 
PPD 1.03 0.95-1.11 0.53 
PET - No 
antigen 
1.19 0.74-1.92 0.47 
EB's 1.09 0.86-1.37 0.48 
MOMP 1.04 0.92-1.18 0.55 
omp2 1.04 0.93-1.15 0.49 
HsP60 1.03 0.94-1.13 0.48 
PmpGa 0.87 0.73-1.04 0.14 
PmpGc 0.99 0.91 -1.07 0.76 
Table 4-71: Conditional logistic regression of TGFP concentrations for infertile women 
and their controls 
Conditional logistic regression also shows no differences between infertile women and 
their controls with respect to TGFP production in response to these antigens. 
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4.5 Miscellaneous results 
As described in section 3.12.2, the following tables show the results for a number of 
other variables; gender, ethnicity, Chlamydia PCR results from conjunctival swabs, 
effects of prior BCG vaccination, and the presence of faecal helminth ova and protozoan 
cysts. As the numbers are small in some instances, cases and controls have been pooled. 
Only the statistically significant results are presented. 
The results are presented first for univariate analysis using a t-test and Mann-Whitney 
U-test, and then for multivariate analysis controlling for age, sex, ethnicity, prior BCG 
vaccination, presence of faecal helminth ova and protozoan cysts and whether the 
individual is a case or control. 
4.5.1 Effect of gender 
Mean t-test 
Mann - Multivariate 
T 
Assay Group n res onse 
Whitn ey analysis p 
95% C. I. p< p< FI p< 
Active tracnoma 
Immunoblot Male 28 1.65 1.32-1.97 
MOMP Female 34 2.05 1.80-2.30 
0.05 0.08 3.09 0.09 
TNF Male 36 1037 853-1221 
PHA Female 39 756 607-905 
0.02 0.02 6.23 0.02 
TNF Male 36 1396 1074-1718 
EB Female 39 900 663-1137 
0.01 0.003 5.80 0.02 
IL-2 Male 36 621 485-757 
PHA Female 39 417 334-499 
0.01 0.02 5.42 0.02 
IL-2 Male 36 5 2-8 
No antigen Female 39 9 5-12 
0.09 0.07 3.52 0.07 
IL-5 Male 37 1464 1100-1827 
PHA Female 35 762 490-1034 
0.003 0.002 8.04 0.006 
IL-11 0 Male 35 327 277-378 
EB I Fernale 351 267 1 229-304 
0.06 0.09 1 3.20 0.08 
Scarred trachoma 
TNF Male 21 128 78- 178 
PPD Female 33 76 46-107 
0.06 0.05 2.78 0.10 
TNIF Male 21 957 755-1159 
HSP60 Female 33 579 408-750 
0.006 0.002 3.21 0.08 
TGF Male 10 18 10-25 
No antigen Female 9 4 1 -6 
0.002 
1 
0.004 28.40 0.0005 
1 
TGF Male 10 68 46-90 
p PD Female 9 34 24-43 
0.006 0.004 3.87 0.08 
TGIF Male 10 243 192-294 
HsP60 Female 9 127 33-222 
0.02 0.009 3.44 0.10 
TGIF Male 10 20 10-29 
PmpGc Female 9 6 1- 11 
0.02 1 0.006 1 25.5 1 0.0007 
Table 4-72: Effects of gender 
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Where a difference was noted between males and females, males had a higher response 
with the exceptions of antibody responses to MOMP and the IL-2 response in the 
negative controls for children with active trachoma and their controls. 
4.5.2 Effect of ethnicity 
Mean t-test 
Mann - 
l Multivariate 
Assay Group n res 
Whitney analysis 
ponse 
95% C. I. p< p< 
I FI p< 
Active trachoma 
Immunoblot Mandinka 24 1.57 1.21 -1.92 
MOMP Not Mandinka 38 2.06 1.82-2.29 
0.02 0.03 11.93 0.001 
Immunoblot Mandinka 23 1.66 1.29-2.02 
omP2 Not Mandinka 29 2.22 1.86-2.59 
0.03 0.02 7.70 0.008 
Immunoblot Mandinka 24 1.93 1.62-2.23 
HsP60 Not Mandinka 38 2.38 2.19-2.56 
0,008 0.01 9.05 0.004 
IFN Mandinka 30 155 59-251 
Candida Not Mandinka 42 65 37-93 
0.04 0.04 3.75 0.06 
IFN Mandinka 30 834 358-1310 
PPD Not Mandinka 42 454 280-627 
0.09 0.06 4.15 0.06 
IL-2 Mandinka 33 21 12-29 
Candida Not Mandinka 42 5 4-7 
0.00011 0.00001 14.3 0.0004 
IL-2 Mandinka 33 119 69-170 
PPD Not Mandinka 42 40 25-55 
0.001 0.00001 9.62 0.003 
IL-1 0 Mandinka 28 47 31 -62 
MOMP Not Mandinka 42 65 50-80 
0.09 0.06 2.46 0.12 
TGF Mandinka 3 13 0-42 
MOMP I Not Mandinka 10 1 56 34-79 
0.05 1 0.01 1 12.64 1 0.02 
Scarred trachoma 
IFN Mandinka 44 544 327-761 
PPD Not Mandinka 10 2076 208-3945 
0.001 0.04 5.26 0.03 
IL-5 Mandinka 44 21 14-29 
No antigen Not Mandinka 10 7 2-11 
0.06 0.02 6.09 0.02 
Infertile women 
TNF Mandinka 25 3063 2375-3751 
omP2 Not Mandinka 18 1710 964-2458 
0.009 0.006 3.46 0.07 
TNF Mandinka 25 1259 971 -1547 
HSP60 Not Mandinka 18 587 310-864 
0.002 0.002 8.21 0.008 
Table 4-73: Effects of ethnicity - Mandinka 
In the active trachoma and infertile women groups, where there was a difference 
between Mandinka and other individuals, the Mandinka showed what might be 
described as a more pro-inflammatory or THI -type response, i. e. higher IFN'y, higher IL- 
2 lower IL-5 and lower IL- 10. In the scarred trachoma group the lower IFNy and higher 
IL-5 responses are more TH2 type responses however it would be wrong to reach any 
conclusions from only two such results. 
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Mann - Multivariate 
Assay Group n 
Mean t-test Whitney analysis 
response 95% C. I. p< p< F P< 
Active trachoma 
Immunoblot Fula 7 0.19 0-0.53 98 0 007 
PmpGa Not Fula 55 1.16 0.91 -1.41 
0.008 0.009 7. . 
Immunoblot Fula 7 0.04 0-0.15 
PmpGc Not Fula 55 0.71 0.45-0.96 
M7 0.05 4.60 0.04 
IL-2 Fula 9 194 130 - 258 
PHA Not Fula 66 558 473-643 
0.003 
1 
0.0005 6.47 
1 
0.01 
IL-2 Fula 9 14 2-26 
EB Not Fula 66 3 1 -6 
0.006 0.0003 7.94 0.007 
IL-2 Fula 9 19 2-35 
MOMP Not Fula 66 5 2-8 
0.003 0.002 9.89 0.003 
IL-2 Fula 9 14 1 -26 
omP2 Not Fula 66 3 1 -5 
0.003 0.0001 10.04 0.002 
IL-2 Fula 9 5 3-8 4 38 0 04 
HSP60 Not Fula 66 3 2-3 
0.003 0.01 . . 
IL-5 Fula 9 270 145-395 0 03 
PHA Not Fula 63 1244 986-1503 
0.006 0.0007 4.83 . 
IL-1 0 Fula 9 190 138-243 6 20 0 02 Candida Not Fula 61 126 107-144 
0.01 0.01 . . 
IL-1 0 Fula 9 154 116-193 62 0 04 
PPD Not Fula 61 118 102-133 
0.09 0.05 4. . 
IL-1 0 Fula 9 85 1 26-144 0 05 0 36 4 13 0 05 
MOMP [ýýla 1 61 54 1 44-63 . . . . 
Table 4-74: Effects of ethnicity - Fula 
Mann - Multivariate 
Assay Group n 
Mean t-test Whitney analysis 
response 95% C. I. P< P< F P< 
Artiva trqrhnmn 
Immunoblot Wolof 6 2.67 2.22-3.12 0 008 0 006 4 47 0 04 
MOMP Not Wolof 56 1.78 1.57-1.99 . . . . 
Immunoblot Wolof 6 2.68 2.30-3.07 0 06 0 06 4 78 0 03 
HSP60 Not Wolof 56 2.15 1.97-2.32 . . . . 
TNF Wolof 6 2249 949-3550 0 02 0 02 3 21 0 08 
Candida Not Wolof 69 1165 922- 1409 . . . . 
IL-2 Wolof 6 19 0-39 0 002 0 02 13 69 0 0005 
No antigen Not Wolof 69 6 4-8 . . . . 
IL-5 Wolof 6 305 0-686 0 04 0 004 3 63 0 06 
PHA Not Wolof 66 1197 946-1448 . . . . 
IL-10 Wolof 6 226 136-315 0 001 0 006 9 70 0 003 
Candida Not Wolof 64 125 109-142 . . . . 
IL-10 Wolof 6 423 277-568 0 01 0 02 5 15 0 03 
EB Not Wolof 64 285 254-317 . . . . 
IL-1 0 Wolof 6 107 89-124 0 005 0 001 20 7 0 01 
MOMP Not Wolof 64 53 42-64 . . . 
. 
IL-1 0 Wolof 5 802 413-1191 0 02 0 04 3 45 0 07 
omP2 Not Wolof 60 507 439-575 . . 
. . 
IL-1 0 Wolof 6 656 381 -931 0 0009 0 007 8 12 U06 
HSP60 Not Wolof 64 386 342-430 , . . 
IL-1 0 Wolof 6 278 170-386 0 0002 0 002 64 12 0 0008 
PmpGa Not Wolof 64 124 101 -147 
. . . . 
Table 4-75: Effects of ethnicity - Wolof 
The most marked difference between the Wolof and those of other ethnic groups is the 
higher levels of IL-10 generated in response to all the chlarnydial antigens except 
PmPGc. Higher antibody responses were also noted which, like high IL-10 responses are 
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usually taken to be TH2 type responses, however the Wolof also demonstrated some 
higher TNF(x and IL-2 results more typical of an TH I type response. 
Mann - Mufti ariate 
Assay Group n 
Mean t-test Whitney analysis 
response 
95% C. I. p< p< F F P< 
Active trachoma 
Immunoblot Jola 18 2.54 2.15-2.92 
omP2 Not Jola 34 1.67 1.36-1.99 
0.001 0.0009 10.61 0.002 
Immunoblot Jola 18 1.66 1.28-2.03 
PmpGa Not Jola 44 0.80 0.53 - 1.07 
d 
0.0007 0.001 9.77 0.003 
IL-2 Jola 19 680 470-890 
PHA Not Jola 56 458 380-537 
0.01 0.05 4.96 0.03 
IL-2 Jola 19 3 1 -5 
Candida Not Jola 56 15 10-20 
0.009 0.00001 
1 
4.05 0.05 
IL-2 Jola 19 42 20-64 
PPD Not Jola 56 86 54-118 
0.12 0.09 3.63 0.06 
IL-5 Jola 19 1660 1182-2138 
PHA Not Jola 53 930 666-1194 
0.006 0.002 8.69 0.005 
IL-5 Jola 19 15 8-23 
No antigen Not Jola 53 9 6-13 
0.08 0.05 2.74 0.10 
IL-5 Jola 19 15 9-22 
Candida Not Jola 53 8 6-10 
0.003 0.01 11.00 0.002 
IL-1 0 Jola 19 2450 1760-3139 
PHA Not Jola 51 1418 1202-1634 
0.0002 0.007 9.97 0.003 
IL-1 0 Jola 19 101 81 -121 
Candida Not Jola 51 146 124-168 
0.02 0.03 4.26 0.04 
IL-1 0 Jola 19 91 64-118 
PmpGa Not Jola 51 155 124-186 
0.02 0.05 4.52 0.04 
IL-1 0 Jola 19 25 12-38 
PmpGc Not Jola 51 58 38-78 
0.06 0.0005 3.25 0.08 
Scarred trachoma 
IFN Jola 10 2076 208-3945 1 0 04 26 0 03 PPD Not Jola 44 544 327-761 
0.00 . 5. . 
IL-5 Jola 10 7 2-11 0 06 0 02 6 09 0 02 
No antigen Not Jola 44 21 14-29 . . . . 
Table 4-76: Effects of ethnicity - Jola 
Where differences were noted between Jola and other ethnic groups, they tend to show 
more of a TH2-like response, e. g. higher antibody responses, higher IL-5 and lower 
IFN7 results. However they also tend to have lower IL-10 responses so no clear pattern 
emerges. 
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4.5.3 Chlamyclial PCR results 
Active Scarred 
Case TControl Case I Control 
PCR negative 
No 18 1 20 21 24 
% 
1 
36% 
1 80% 78% 92% 
PCR positive 
No 32 5 6 2 
%1 64% 20% 22% 8% 
Table 4-77: Chlamyclial PCR results 
As expected, the prevalence of chlarnydial organisms being detected in the eye was 
highest from those with active trachoma where 32/50 cases had positive PCRs vs. 5/25 
controls (p < 0.0005). The prevalence was also higher in those with trachornatous 
scarring vs. controls but this did not reach significance (p<0.14). 
Mann - Multivariate 
Assay Group n 
Mean t-test Whitne yj analysis 
response 
95% C. I. p< p< I FI p< 
Active trachoma 
TNF PCR positive 37 1606 1179-2034 
Candida PCR negative 37 928 712-1145 
0.005 o. 02 2.74 0.10 
IL-2 PCR positive 37 50 33-67 
PPD PCR negative 37 98 51 -146 
0.06 0.21 3.19 0.08 
Scarred trachoma 
Immunoblot PC R positive 7 2.81 2.57-3.06 0 06 0 05 7 29 0 01 
HSP60 PCR negative 39 2.32 2.10-2.53 . . . . 
Immunoblot PCR positive 7 2.31 1.56-3.07 0 01 0 007 18 6 0 02 
PmpGa PCR negative 39 1.38 1.11 -1.65 . . 
. . 
IFN PC R positive 8 61 12-109 0 12 0 06 71 6 0 01 
Candida PCR negative 45 75 47 - 102 . 
. . . 
IFN PCR positive 8 61 12-109 0 21 0 24 67 3 0 06 
omP2 PCR negative 45 160 94-225 . . . . 
IFN PCR positive 8 27 0-56 0 22 0 14 3 18 0 08 
hsp60 PCR negative 45 96 49-142 . . . . 
TGF PCR positive 3 0 0-0 0 37 0 13 6 86 0 03 
PmPGa PCR negative 18 93 7-178 . . . . 
TGF PC R positive 3 380 0-2015 0 44 0 91 57 10 0 01 
PmpGc PC R negative 
T-18 138 0-369 . . 1 . . 
Table 4-78: Effects of positive chlamydial PCR 
Where a difference in response was noted between those with positive and negative 
chlarnydial PCR results amongst the scarred individuals and their controls, those with a 
positive chlarnydial PCR tended to show more TH2-type responses, e. g. lower IFN'y and 
higher antibody levels. There was no such pattern amongst children with active 
trachoma and their controls. 
209 
Results 2 
4.5.4 Effect of BCG vaccination 
Of all study participants 58.3% had a BCG scar. Females were more likely to have been 
vaccinated than males, 66.7% vs. 41.4% (p < 0.001). Rates of BCG vaccination 
appeared to be declining as the younger children were far less likely to have been 
vaccinated than the adults and the proportion vaccinated increased with age. 
Age Group n Odds ratio 95% C. I. p< 
0 9 
BCG 31 
- No BCG 35 
1.0 - 
10 19 
BCG 15 
- No BCG 14 
1.21 0.50-2.92 
20 29 
BCG 8 
- No BCG 5 
1.81 0.53-6.20 0.003 
39 0 
BCG 24 
- 3 No BCG in 10 
2.71 1.09-6.73 
BCG 24 
> 40 
No BCG 9 
3.01 1 1.18-7.70 
1 1 
Table 4-79: Likelihood of having received BCG vaccination by age group 
All individuals 
V 
C-) 
12 
4 
Figure 4-48: Likelihood of having received BCG vaccination by age group 
The presence of a BCG scar was not associated with the presence or absence of active 
trachoma, trachomatous scarring or infertility (p < 0.75, p<0.10 and p<0.17 
2 
respectively by X analysis). 
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Mann - Multivariate 
Assay Group n 
Mean t4est Whi analysis 
response 95% C. I. p< p< F p< 
Active trachoma 
Immunoblot BCG 27 2.32 2.02-2.62 
omP2 No BCG 25 1.60 1.18-2.01 
0.005 0.009 9.47 0.004 
1 
IL-5 BCG 36 9 5-12 
No antigen No BCG 36 14 9-19 
0.10 0.19 3.06 0.09 
IL-5 BCG 36 8 4-11 
Candida No BCG 36 12 8-15 
0.12 0.01 4.94 0.03 
IL-5 BCG 36 9 5-13 
PPD No BCG 36 16 10-22 
0.04 0.03 3.34 0.07 
IL-5 BCG 36 9 6-11 
PmpGa No BCG 36 19 9-30 
0.04 0.15 3.80 0.06 
IL-1 0 BCG 36 143 120-165 
Candida No BCG 34 125 97- 153 
0.31 0.16 3.51 0.07 
IL-1 0 BCG 36 135 112-157 
PPD I No BCG 1 36 1 109 92-127 
0.08 0.12 4.04 0.05 
Scarred trachoma 
Immunoblot BCG 26 2.31 2.01 -2.62 
HsP60 No BCG 21 2.52 2.29-2.74 -- 
0.28 0.56 3.56 0.07 
TNF BCG 28 119 78-160 
PPD No BCG 26 72 38-106 
0.07 0.08 8.06 0.007 
IFN BCG 28 206 105-306 
omP2 No BCG 26 75 45-105 
0.02 0.09 5.85 0.02 
IFN BCG 28 99 37-160 
HsP60 No BCG 26 69 17-120 
0.45 0.20 3.19 0.08 
IL-2 BCG 28 699 530-867 
PHA No BCG 26 538 425-651 
0.12 0.21 5.12 0.03 
IL-1 0 BCG 25-1 -ýý 1928-3019 
PHA No BCG 21 1 1706 1340-2073 
0.03 0.07 3.51 0.01 
Infertile women 
TNF JBCG 27 322 171 -473 0.52 0.52 6.83 0.01 
PmpGa 
No 
BCG 27 254 94 - 414 
ýIII 
Table 4-80: Effects of prior BCG vaccination 
Amongst the scarred individuals, where there was a difference in response between 
those with prior BCG vaccination and those without, those with BCG vaccination 
tended to have a more THI-type response as might be expected, e. g. lower antibody 
levels and higher TNF(x, IFN7 and IL-2 levels. The pattern was however much more 
mixed for the children with active trachoma and their controls. Interestingly there was 
much less difference than might have been expected between responses to PPD with 
only a lower IL-5 response in the active trachoma group though this is only significant 
to the 7% level. 
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4.5.5 Effects of helminth and parasitic infestation 
No % Knight 1981 
Bundy 
1995 
Helminths 24 16.0 
Hookvýorm 14 9.3 80-94% 30% 
Hymenolepis nana 5 3.3 0.7% 0 
Ascaris 5 3.3 0.7% 25% 
Enterobius 1 0.7 0 0 
Strongyloides 1 0.7 0 0 
Trichuris 0 0 3.7% 2.4% 
Schistosoma mansom . 0 0 0.3% 1.5% 
Taenia saginata 0 0 0.3% 0 
Wucheraria bancrofti not tested - 8-21% not tested 
Mansonella perstans not tested - 25-30% not tested 
Protozoa 35 23.3 
Entamoeba coli 33 21.6 not tested not tested 
Entamoeba histolyticaldispar 1 0.7 not tested not tested 
Giardia lamblia 1 0.7 not tested , not tested 
Table 4-81: Prevalence of helminth and protozoan infection, and comparison with 
previous studies in The Gambia 
24 (16%) individuals had helminth ova in their stools. Of these, 2 had dual infections. 
35 (23.3%) had protozoan cysts detected in their stool. Three individuals had both 
helminth ova and protozoan cysts. The species involved are detailed in the table above. 
As expected helminths were found more commonly in children; the mean age of those 
with helminths was 12.3 years vs. 23.7 years for those without helminths (p < 0.001). 
Corresponding figures are given from the two most recently published surveys of 
243,244 
helminth infection in rural Gambia. The prevalence of hookworm infection is very 
much lower than in previous studies although the prevalence had fallen from 94% in 
1981 to 30% in 1995 and so may well have continued to fall. All samples were checked 
by a very experienced parasitologist. It has been noted previously that there are 
large 
244 
variations in the prevalence of intestinal helminths both between and within villages . 
The presence of helminth ova was unrelated to gender or previous 
BCG vaccination and 
there was no relationship to having active trachoma or to being 
infertile. There was 
however an association with scarring; 4/24 of those with trachomatous scarring (16.7%) 
had helminth ova whilst 0/23 controls had ova detected (p < 0.04). 
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There was no relationship between the presence of protozoan cysts and gender, age, 
previous BCG vaccination or to having active trachoma, trachomatous scarring or to 
being infertile. 
Mann - Multivariate 
Assay Group n 
Mean t-test Whitneyl analysis 
response 95% C. I. P< P< I FI p< 
Active trachoma 
IFN Worms 16 110 13-207 
omP2 No worms 52 47 33-62 
0.03 0.48 3.17 0.08 
IFN Worms 16 26 8-44 
PmpGa No worms 52 14 10-17 
0.03 0.31 4.88 0.03 
IL-1 0 Worms 16 74 12-136 
PmpGc No worms 50 42 31 -53 
0.05 
TGF Worms 2 0-673 
EB No worms 10 277 204-349 
0.06 0.05 14.64 0.03 
Scarred trachoma 
IFN Worms 4 5 0-11 
Candida No worms 43 75 47-104 
0.14 0.003 3.19 0.08 
IL-2 Worms 4 400 106-693 9 0 02 PHA No worms 43 664 543-786 
0.19 0.14 5.5 . 
IL-1 0 Worms 4 1295 0-2651 7 0 01 
PHA No worms 37 2287 1881 -2693 
0.12 1 0.14 1 6.8 1 . 
Table 4-82: Effects of intestinal helminth infection 
The presence of gut helminths did not induce a particularly TH2 bias in immune 
responses, where differences were noted they presented a mixed picture. 
Mann - Multivariate 
Assay Group n 
1 
Mean t-test Whitneyl anatysis 
response - 95% C. I. P< p< IFI p< 
Aýfiua tr-qrhn n 
IL-5 Protozoa 14 16 6-26 0 10 0 13 4 53 
1 
0 04 
No antigen No protozoa 54 10 7-13 . . . 
. 
TGF Protozoa 2 1703 0-7827 0 12 0 09 47 5 
1 
0 10 
PHA No protozoa 10 2947 2255-3639 . . 
. . 
TGF P rotozoa 2 178 0-1118 - 0 35 0 39 9 43 0 05 EB No protozoa 10 264 183-345 . 1 
. 
- 
. . 
TGF P rotozoa 2 240 0-1384 0 43 0 39 
1 
77 5 0 10 
HSP60 No protozoa 10 1 314 232-396 
. . . 1 
. 
ca---. 4 *-, k- 
TNF Protozoa 12 953 600-1307 0 06 0 10 3 34 0 08 
Candida No protozoa 35 658 512-805 
. . . . 
IL-5 Protozoa 12 25 0-55 04 0 11 0 87 2 0 10 
PmpGa No protozoa 35 8 5-11 
. . . . 
IL-5 Protozoa 7 3170 2046-4294 02 0 0 03 82 6 0.01 
PHA No protozoa 34 1989 1595-2383 
. 1 . 11 . 1 
TNF Protozoa 9 55 6-104 0 11 0 46 6 70 0 02 
PmpGc No protozoa 23 27 14-41 
. . . . 
IFN Protozoa 9 34 10-58 0 27 67 0 8 50 0.008 
PmpGa No protozoa 23 25 17-32 
. . . 
IL-5 Protozoa 9 47 0-116 0 05 0 57 58 8 0.008 
PPD No protozoa 21 8 5-10 . 
. . 1 
TGF Protozoa 5 2540 567-4515 0 03 0 07 
1 
79 6 02 
10 
PHA No protozoa 18 1311 903-1720 . 
. 
1 
. . 
Table 4-83: Effects of intestinal protozoan infection 
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4.6 Summary of results 
II 
PHA 
INog 
Ctrýandidý PPD 
I 
PET 
I 
EBs 
I 
MOMP 
I 
omp2 
I 
hspW 
I 
pmpGa 
I 
pmpGc 
I 
Active trachoma 
Immunoblots 
TNF 
IFN 
IL2 
ILS 
IL10 
TGF 
Scarred trachoma 
Immunoblots 
TNF 
IFN 
IL2 
IL6 
IL10 
TGF 
Infertile women 
Figure 4-49: Summary of results - cases vs. controls for all groups 
This key is used for the figures in this and the 
KEY 
Not investigated 
following pages. For example in Figure 4-49, the red 
No difference arrow in the box corresponding to immunoblot 
Increase p<0.05 responses to MOMP indicates that children with active 
Increase p<0.1 trachoma generated stronger responses to MOMP than 
Decrease p<0.05 
their controls (p < 0.05), whilst the arrow in the box Decrease p<0.1 
corresponding to immunoblot responses to PMPGa 
indicates that children with active trachoma showed a trend towards weaker responses 
to PmPGa (p < 0.0. 
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5 Discussion 
This discussion first presents the principal findings of the study and discusses these 
findings in relation to the current literature. Potential weaknesses of the study are then 
presented together with possible solutions. Finally unanswered questions and potential 
future research directions are discussed. 
5.1 Principal findings 
5.1.1 Pmp-G IgG antibodies are commonly detected in individuals from a 
trachoma-endemic population. Higher levels of antibody to the 
amino-terminus half are associated with a reduced risk of trachoma 
but higher levels of antibody to the carboxyl-terminus half are 
associated with scarring 
The immunoblot analysis demonstrated that 22/44 (50%) of children with active 
trachoma and 12/18 (67%) of controls had detectable IgG antibodies to the amino- 
tenninal half of PmPG, PmPGa. In this group it was also noted that higher levels of 
antibody to PmPGa were associated with a reduced likelihood of having acute trachoma 
(O. R 0.32, p<0.06 for an immunoblot density score of > 2) which raises the possibility 
that these antibodies might give some protection against re-infection. This contrasts 
sharply with the situation for MOMP where children with the highest immunoblot 
density scores were 13.5 times more likely to have active trachoma than those without 
detectable antibody. 
In the trachomatous scarring group 19/22 (86%) of those with scarring and 17/25 (68%) 
of controls had antibodies to PMPGa. A similar pattern was seen with the infertile 
women where 12/20 (60%) of the infertile women but only 4/15 (27%) of the controls 
had anti-PmPGa antibodies, a significant difference between the infertile women and the 
controls (p < 0.05). 
Antibodies to the recombinant half of PMPG which includes the carboxyl terminus, 
PmpGc, were also found in natural infection though at a lower prevalence and a lower 
levcl than PmPGa. In the active trachoma group 12/44 (27%) of children with active 
trachoma and 7/18 (39%) of controls had antibodies to PmpGc (p = N. S. ). Again the 
prevalence of antibodics is higher in those without active disease but there was no direct 
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relationship between the immunoblot density and likelihood of acute trachoma as was 
seen for PmPGa. Antibodies to PMPGc were more prevalent in individuals with 
trachomatous scarring than in controls, 14/22 (64%) vs. 9/25 (36%) (p < 0.06) and 
individuals with trachomatous scarring demonstrated higher immunoblot density scores 
to PmpGc than the controls,, 1.24 vs. 0.64 (p < 0.05). Increasing immunoblot density 
scores were associated with a corresponding increase in the likelihood of being scarred. 
Those with responses in the highest quartile were 4.5 times more likely to be scarred 
than those with undetectable antibody (p < 0.02) 
Working with a PMP protein from Chlamydia psittaci, Longbottom et al demonstrated 
that although the carboxyl fragment was capable of generating antibody responses, such 
antibodies were not generated during natural infection in sheep. 159 Immuno-staining 
also suggests that the carboxyl ten-ninus is not surface exposed. 163 The carboxyl- 
ten-ninal recombinant PmPG fragment used for this study also included a significant 
portion of the central region of the PmPG protein which, on examination of predicted 
trans-membrane regions, is likely to be surface exposed and hence in contact with the 
immune system effectors, and this may be responsible for its recognition by immune 
responses in this study. Additionally both the prevalence and the immunoblot density 
scores were lower for PmpGc than for PmPGa. 
5.1.2 PmPG stimulates cell-mediated responses and PmPGa stimulates 
higher levels of TNFa and IL-10 in children with active trachoma 
than controls, and lower levels of IL-10 in scarred individuals. 
Both PmPGa and PmpGc are potent stimulators of TNF(x and IL-10 production in the 
whole blood assay. PmPGa, but not PmpGc, also stimulates the production of IFNy and 
TGFP but to a lesser degree (Table 5-1). 
PmPGa is a particularly potent stimulator of TNFa production. Wells stimulated with 
PmPGa generated between 24 and 127 times more TNF(x than the negative control wells. 
Children with active trachoma also appear to generate higher TNFa levels in response 
to PmPGa than their controls (463 vs. 235 pg/ml, p<0.06). PmPGc also stimulates 
TNFoc production but at a very much lower level, approximately two to seven times that 
of the negative control wells. 
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No 
pmpGa p< pmpGc p 
antigen 
IIII 
TNF 
A ti 
Case 7 463 0.00005 23 0.005 
c ve 
Control 10 235 0.0002 - - 
S 
Case 5 322 0.0002 10 0.02 
carred 
Control 2 254 0.003 10 0.003 
I f til 
Case 3 296 0.0004 62 0.06 
n er e 
-- 
Control 
L- I 
5 
- 
323 
I 
0.0001 
I 
35 
I 
0.0004 
I 
IL-1 0 
A ti 
Case 19 161 0.00005 58 0.0007 
c ve 
Control 16 92 0.0001 30 0.001 
S d 
Case 11 51 0.00005 14 0.02 
carre 
Control 15 79 0.0001 31 0.004 
I f til 
Case 5 57 0.00005 22 0.003 
n er e 
Control 9 
1 
67 0.00005 30 
1 
0.004 
1 
IFN 
A i 
Case 8 15 0.0002 
ct ve 
Control 10 18 0.01 
d 
Case 12 24 0.006 17 0.01 
Scarre 
Control 15 33 0.01 - - 
Case 8 37 0.00005 
Infertile 
Control 
II 
10 26 0.02 
TGF 
Case 21 102 0.04 
Active 
Control 39 88 0.07 
Case 37 144 0.11 
Scarred 
Control - - - 
Case 13 36 0.04 
Infertile 
Control 35 73 0.03 
Table 5-1: Stimulation of TNFcý IL-10, IFNy and TGFP by PmPG recombinant proteins 
The generation of IL- 10 is also stimulated by both PmpGa and PmpGc and here again IL- 
10 levels are significantly higher after stimulation with PmpGa (5 -II times higher than 
the negative controls) than they are with PmpGc (1.4 - 4.4 times higher). Blood from 
children with active trachoma is again more responsive to stimulation with PMPGa than 
their controls (161 vs. 92 pg/ml, p<0.02) and a similar trend is seen for PMPGc (58 vs. 
30 pg/ml, p<0.09). In scarred individuals there was a trend towards less IL-10 
production in response to PmPGc (14 vs. 31 pg/ml, p<0.08), and a similar pattern was 
seen for PmpGa though this was not significant (51 vs. 79 pg/ml, p<0.21). 
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PMPGa also stimulated the generation of IFNy at levels between 1.8 and 4.6 times that of 
the negative control wells. Scarred individuals produced slightly elevated levels of IFN'Y 
in response to PmpGc but this was not seen in their controls or in any other groups. 
PMPGa also stimulated TGFP production in all groups at levels approximately two to 
five times that of the negative controls and stimulated IL-2 production at low levels in 
the scarred individuals and their controls. 
Confidence that these results are due to the recombinant proteins themselves and not 
due to contaminants is provided by the differences between the responses to PmPGa and 
PmpGc and also by the fact that for all the assays there was no significant difference 
between the responses to the recombinant protein preparation using the PET vector 
without an insert and the negative control. 
The only published work in relation to cell-mediated responses to the PMP proteins 
demonstrated that CD4 T-cells, from individuals with Chlamydia-associated reactive 
arthritis, proliferated in response to recombinant PmPD. The results of this current study 
clearly indicate that both the amino and carboxyl-tenninal halves of PmPG provoke cell- 
mediated responses, particularly TNFoc and IL-10 production, that children with active 
trachoma produce more IL-10 in response to PmPGa than controls and that scarred 
individuals appear to produce less IL-10 than controls in response to PmpGc and 
possibly PmPGa. The IL- 10 responses are discussed further in section 6.1.10 
As discussed in section 1.3.4 TNF(x is known to be produced in the conjunctivae and the 
reproductive tract during chlarnydial infection. 100,103 Blocking TNFOC can lead to an 
increase in organism load in murine pneumonia, 104 but has little or no effect in 
reproductive tract infection of mice or guinea pigs. ' 
07 This study demonstrates that 
PmPG stimulates TNFoc production and moreover, that children with active trachoma 
produce more TNFoc than their controls in response to the amino-terminal half of the 
protein. Although certain TNF(x polymorphisms have been shown to be associated with 
scarring in trachoma, 102 this study did not demonstrate any differences between those 
with scarring and their controls with respect to the levels of TNF(x produced in response 
to PmPG or any other antigen. 
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5.1.3 Anti-MOMP IgG antibodies are associated with active trachoma and 
with tubal infertility 
The children with active trachoma demonstrated a higher prevalence of detectable antl- 
MOMP IgG than their controls, 43/44 (98%) vs. 14/19 (74%) (p < 0.003). The mean 
immunoblot score was higher for children with active trachoma than for controls 2.08 
vs. 1.33 (p < 0.0003), and there was a clear relationship between the immunoblot 
density score and the likelihood of having active disease; children with the immunoblot 
density scores in the highest quartile were 13.5 times more likely to have active disease 
than those without detectable antibody (p < 0.0 1). 
A similar pattern was seen in women with tubal infertility where 20/20 infertile women 
and 13/15 (87%) of controls had detectable antibodies to MOMP (p < 0.09). The 
infertile women also demonstrated stronger antibody responses than their controls, 2.5 
vs. 1.75 (p < 0.005). 
In a study of Nepalese children with trachoma, 22/40 (55%) of children with active 
disease had anti-MOMP IgG, a figure not significantly different from that seen in 
controls. 141 Similar figures were seen in patients with either urethral or cervical 
Chlamydia trachomatis infection where 26/45 (58%) of the cases and 10/31 (32%) of 
the controls had antibody to MOMP. 245 In the current study the prevalence of antibodies 
to MOMP is higher in both cases and controls and this may reflect the higher levels of 
trachoma transmission in this community. 
Although neutralising antibodies to MOMP can be clearly demonstrated in vitro 
117-119 
serum antibodies very often do not provide protection in vivo 
127 as appears to be the 
case here. 
5.1.4 MOMP stimulates cell-mediated production of IFNyand TNFa but 
this is not associated with pathology 
MOMP was shown to act as a stimulant to IFNy production in the whole blood assay 
with approximately four-fold increases in IFNy concentration (39 vs. 10 pg/ml overall, p 
< 0.00005). Significant production of IFNy in response to MOMP was seen for all the 
children with active infection and their controls and for the scarred adults and infertile 
women but not for the controls in either group. 
T-cclis isolated from cord-blood are known to prollferate and produce IFN7 in response 
to MOMP '46 and IFNy is produced by PBMCs from women 'at risk of chlarnydial PID' 
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on incubation with MoMp. 
247 Working with patients with trachomatous scarring, 
Holland et al demonstrated higher IFN-y production by PBMCs of controls on Incubation 
248 with MOMP than those from cases . In the present study MOMP is shown to be 
capable of stimulating 1FN'y production but there are no significant differences in 
response between those with long-term sequelae of chlarnydial infection and controls. 
TNF(x production in response to MOMP was higher than that seen in the negative 
control wells in all groups with mean concentrations of 48 vs. 6 pg/ml (p < 0.00005). 
No published work has addressed the question of whether MOMP stimulates the 
production of TNF(x, this study demonstrates that it does but the level of response does 
not correlate with the presence of acute infection or long-terrn sequelae. 
5.1.5 Anti-omP2 IgG antibodies are detectable in the majority of 
individuals but are not associated with pathology 
IgG antibodies to OmP2 were highly prevalent in all groups. Ninety-one percent (31/34) 
of children with active trachoma had detectable anti-omP2 antibodies vs. 16/19 (84%) of 
controls. A slightly higher prevalence of anti-omP2 antibodies was also noted amongst 
the infertile women, 5/6 (83%) vs. 6/8 (75%), but in neither case was the difference 
significant, perhaps due to the low numbers. All of the individuals with trachomatous 
scarring and their controls had anti-omP2 antibodies. 
These findings are in keeping with other studies which have demonstrated that anti- 
omP2 antibodies are almost always present after chlarnydial infection. All of 17 patients 
with Chlamydia trachomatis urethritis, 133 89% of individuals with urethritis or 
cervicitis 116 and almost all women with either PID or ectopic pregnancy 132 have been 
demonstrated to have anti-omP2 antibodies, as have 43% of 'healthy' Swiss blood 
donors. 11 6 It has even been suggested as a marker for Chlamydia pneumoniae infection 
in patients with coronary heart disease. 249 
Despite the high prevalence, there have been no suggestions that immune responses to 
OMP2 are associated with pathology other than the observation of a higher intensity of 
binding to omP2 of IgG from the synovial fluid of patients with ChlamYcha trachomatis- 
associated reactive arthritis. 250 This study confirms the high prevalence of antibodies to 
omP2 and shows no association with pathology. 
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5.1.6 omP2 stimulates the production of TNFq, IFNyand IL-10. TA/Fa 
responses are higher in those with active trachoma than controls 
This study demonstrates that omP2 is a potent stimulant of TNF(X production. This was 
true for each group and for all individuals the mean TNF(x concentration after 
incubation with omP2 was 2152 pg/ml compared to 6 pg/ml in the negative control 
wells. Children with active trachoma generated higher levels of TNFOC in response to 
oMP2 than their controls (2726 vs. 1455, p<0.01). There was no difference in response 
in those with long-term sequelae. 
IFN7 was also produced in response to OmP2. For the study population as a whole the 
mean IFNy concentration was 169 pg/ml after incubation with OmP2 compared to 10 
pg/ml for the negative controls (p < 0.00005). This was true of all study groups but 
there were no significant differences between cases and controls in any group. It should 
be remembered that most if not all individuals, both cases and controls, will have been 
exposed to Chlamydia though ocular infection. The only exceptions to this are likely to 
be a few of the younger controls in the active infection study ann. 
omP2 also stimulated the production of IL-10 in all groups, with a mean concentration 
of 374 pg/ml compared to 13 pg/ml for the negative controls (p < 0.00005). Again there 
were no differences between cases and controls. 
T-cells responsive to omP2 have been isolated from individuals with Chlamydia- 
associated reactive arthritis and with chlarnydial urethritis 137 and also from 
atheromatous plaques '25 
1 but results of cellular cytokine responses to OmP2 have not 
been published. 
Both OmP2 and HsP60 were generously donated by another laboratory and therefore 
control antigens, similar to the 'PET-no antigen' control used in this study, were not 
available. The possibility of contaminants, notably lipopolysaccharide (LPS), affecting 
the results must therefore be considered. The supplier of these recombinant proteins has 
addressed this issue and estimates the LPS contamination to be at very low levels (< 0.2 
251 endotoxin unjts/ýtg protein) . 
Correlations between responses to OmP2 and HsP60 are 
quite high in several cases; 0.38 for IFNy, 0.89 for IL-10 and 0.69 for IL-2 and this 
raises concerns that the responses may be due to contaminants common to both 
recombinant proteins. However, these levels of correlation are not significantly different 
from the correlation between responses to these antigens and to EBs. For the examples 
quoted above corresponding correlation coefficients between responses to HsP60 and 
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EB's are 0.41 for IFNy, 0.81 for IL-10 and 0.74 for IL-2 and for responses to OmP2 and 
EB's the corresponding coefficients are 0.59 for IFNy, 0.82 for IL-10 and 0.89 for IL-2. 
Similar figures are seen in correlations with responses to MOMP. It seems likely 
therefore that the responses seen to OmP2 and HsP60 are made to the recombinant 
proteins themselves and not to any contaminants. 
5.1.7 Antibodies to HSP60 are detectable in most individuals but are not 
associated with pathology 
Almost all individuals studied had detectable IgG antibodies to chlarnydial HsP60. Of 
the children with active trachoma 43/44 (98%) had anti-HSP60 antibodies as did 17/19 
(89%) of controls. Similarly high levels were seen in adults with scarring (22/22) and 
their controls (24/25 [96%]), and in the infertile women (18/20 [90%]) and their 
controls (13/15 [87%]). 
The mean immunoblot density scores for the infertile women are slightly higher than for 
their controls, 2.40 vs. 2.03 (p < 0.07) and this trend is supported by the multivariate 
analysis (p < 0.06) although a straight case-control conditional logistic regression 
analysis finds the difference not to be significant. 
These findings are at odds with other studies which show a clear relationship between 
antibodies to HsP60 and pathology. Previous work by Peeling et al in The Gambia 
showed that 47/148 (32%) individuals with trachomatous scarring had antibodies to 
HsP60 compared to 24/148 (16%) of controls (p < 0.001). Similar associations have 
been shown for infertility; two separate studies demonstrated anti-chlarnydial HsP60 
antibodies in 79% and 59% of women with tubal infertility compared to 23% and 16% 
of controls respectively. 209,2 10 The levels of anti-Hsp60 antibodies in controls in this 
study are higher than in most other published work and such a high background level 
would make the detection of a difference between cases and control difficult. The 
Peeling study used an ELISA method to determine anti-Hsp60 antibodies and thus the 
sensitivity may have been less than this current study depending on how the cut-offs 
were determined. Another important difference between the current study and the early 
study by Peeling et al is in the number of individuals investigated. The current study 
only investigated 25 patients with scarring and an equal number of controls compared to 
148 in each group in the Peeling study. Sample size calculations, taking into account the 
mean values for cases and controls reveals that 83 individuals in each group would have 
been enough to demonstrate a statistically significant difference in the current study. 
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Thus, if more individuals had been investigated this study may have confin-ned the 
association between HsP60 and scarring and/or infertility. 
5.1.8 HSP60 stimulates the production of TNFq, IFNyand IL-10. TNFa and 
IL-10 responses are higher in children with active trachoma than in 
controls 
Production of TNFoc, IFNy and IL- 10 were all seen to be increased after incubation with 
HSP60. TNF(x production was the most marked with mean levels in HsP60-stimulated 
wells being 912 pg/ml compared to 6 pg/ml in the negative control wells (p < 0.00005). 
Children with active trachoma also produced higher levels of TNF(x in response to 
HsP60 than did their controls (1188 vs. 731 pg/ml, p<0.02). 
IFN'y production was also increased after incubation with HsP60. Mean IFN'Y 
concentration after incubation with HsP60 was 96 pg/ml compared to 10 pg/ml in the 
negative control wells (p < 0.00005). There were no differences between cases and 
controls in any of the groups. 
IL- 10 concentrations in response to HSP60 were also increased, 296 vs. 14 (p < 0.00005) 
and were also higher in children with active trachoma than in controls (469 vs. 295, p< 
0.002). 
A variety of bacterial heat shock proteins have been shown to induce the production of 
TNFoc, IFNy, IL-1 and IL-10.145,252,253 Debattista has previously demonstrated reduced 
IFN7 responses to chlamydial HsP60 in women with PID or multiple previous 
chlamydial infections . 
254 In their study there was no difference in IL-10 responses to 
HsP60 in any of the groups. In another study however, T-cells isolated from salpingeal 
tissues of women with tubal factor infertility responded to chlarnydial HsP60 by 
producing predominantly IL- 10.255 Taken together these might suggest a switch from a 
THI -type to a TH2-type response to chlamydial HsP60 in women with chronic 
chlamydial infection of the reproductive tract. However, in mice T-cells isolated from 
animals immunized with chlarnydial HsP60 produce less IL-10 and more IFN7 than 
256 those immunized with mouse HsP60 . 
In a study of a small number of patients with 
Chlamydia-associated reactive arthritis, T-cells isolated from the synovium secreted 
257 
primarily IL- 10 in response to MOMP and chlamydial HsP60 . 
In the present study no differences were noted in IFNy or IL- 10 responscs in the infertile 
women although the IFNy: IL-10 ratio was higher (i. e. more THI-fike) In infertile 
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women than in their controls (1.34 vs. 0.75, p<0.07). Higher IL-10 as well as TNFoc 
responses were seen in children with active trachoma. This has not been documented 
previously. 
5.1.9 Secretion of TNFa in response to both common recall and 
Chlamydia-specific antigens is increased during active trachoma 
Children with active trachoma demonstrated higher TNFV production in the whole 
blood assay in response to PHA, Candida, EBs, OMP2, HsP60 and PmPGa with cases 
generating between 1.5 and 2 times the amount of TNF(x as controls. Higher TNF(x 
concentrations in the assay were much more strongly associated with the presence of 
trachoma; children generating TNF(x levels in the top quartile in response to oMP2 were 
14.4 times more likely to have active trachoma than those in the lowest quartile (p < 
0.004). Similar associations were seen for HSP60 (3.75, p<0.03), PMPGa (5.33, p< 
0.05) and for the common recall antigen Candida (5.33, p<0.03). 
TNFoc has been clearly demonstrated to be important in the successful response to 
chlarnydial infections in general (reviewed in 1.3.4). In trachoma, increased levels of 
TNF(x have been found in the tears' 02 and conjunctivae' 03 of individuals with acute 
trachoma and certain polymorphisms of the TNF(x-promoter are also associated with 
scarring. 1 02 In this study no significant differences were noted between those with 
trachomatous scarring or infertile women and their controls. This study does however 
demonstrate an increase in either the number, or the TNF(x producing ability or both, of 
circulating immune cells in response to Chlamydia-specific and common recall antigens 
and mitogen in children with active trachoma. 
5.1.10 Secretion of IL-10 in response to both common recall and 
Chlamydia-specific antigens is increased in active trachoma 
Children with active trachoma produced higher levels of IL-10 in the whole blood assay 
than their controls for a variety of common recall as well as Chlamy(fia-specific 
antigens: Candida 153 vs. 98 pg/ml (p < 0.007); PPD 133 vs. 10 1 pg/ml (p < 0.04)-, EBs 
321 vs. 251 pg/ml (p < 0.05); omP2 588 vs. 124 pg/ml (0.02); HsP60 469 vs. 295 pg/ml 
(p < 0.002), PmPGa 161 vs. 92 pg/ml (0.02) and PmpGc 58 vs. 30 pg/ml (p < 0.09). 
IL-10 is known to be secreted in response to chlarnydial infection. IL-10 mRNA was 
detected in primary 258 and secondary 57 reproductive tract infection in macaqucs and is 
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more common in endocervical samples from women with chlarnydial PID than in 
controlS. 259High levels of IL-10 are also produced by synovial fluid mononuclear cells 
from patients with Chlamydia-associated reactive arthritis in response to chlarnydial 
antigens, 257 and peripheral blood mononuclear cells from anonymous blood donors also 
260 produce high levels of IL-10 in response to Chlamydia pneumoniae EBs . 
Interestingly in this latter study low doses of EBs generated predominantly IL-12 
responses whilst high levels of EB's produced predominantly IL- 10 responses. 
261 IL-10 is a TH2-type cytokine which down-regulates TH I -type responses . 
In contrast to 
the situation in mice, where it is produced only by TH2 cells, in humans it is produced 
by both THI and TH2 cells and appears to down-regulate both types of response. 262 In 
keeping with this, an immunohistochernical study of genital chlarnydial infection in 
mice showed that maximal IL-10 expression was seen at three weeks post-infection 
when the infection was nearing resolution, whilst pro-inflammatory cytokines such as 
IL- 12 and TNFoc were seen in the earlier stages. 87 
Experimental evidence suggests that strong IL-10 responses to chlamydial infection 
benefit the organism but not the host. BALB/c mice demonstrate higher IL-10 and 
lower IFNy responses to chlamydial infection and this is associated with reduced 
clearance of Chlamydia and a worse prognosis. Treatment of the animals with anti-IL- 
10 monoclonal antibodies results in increased bacterial clearance and improved 
survival . 
89 IL-10 knockout mice clear chlarnydial infection much more rapidly, have 
higher IFNy responses and are more resistant to re-infection, 263 but these improvements 
can be abrogated by the administration of exogenous IL- 10.264 In humans, PBMCs from 
women with tubal factor infertility demonstrated higher levels of IL- 10 secretion in 
response to chlarnydial EBs and chlarnydial HsP60 than did controls, and increased 
responsiveness to chlamydial HsP60 was associated with the IL- 10- 1082 gene promoter 
polymorphi SM265 which is associated with increased IL- 10 production. 266 Associations 
between this polymorphism and scarring trachoma were looked for in The Gambia and 
homozygosity for IL-10-1082G was found more commonly in cases than controls 
223 
amongst the Mandinka but not amongst other ethnic groups . In the current study IL- 
10 responses to chlamydial antigens amongst Mandinkas were only significantly 
different between scarred cases and controls with respect to PmPGa (15 pg/ml for cases 
vs. 31 pg/ml for controls, p<0.04). 
it may be that the ability to stimulate IL- 10 production is an evolutionary adaptation by 
Chlainytha to enable them to sur-vivc within the host. Human mononuclear cells infected 
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with Chlamydia pneumoniae showed high levels of IL- 10 secretion and an associated 
reduction in MHC Class I expression. 77 Since chlarnydial antigens are presented to CD8 
cytotoxic T-cells through MHC Class 1, this down-regulation would render the infected 
cells less likely to be killed. In addition to protecting against CTL-mediated killing, 
stimulation of IL-10 production may also prevent apoptosis. Host cells frequently 
respond to intracellular bacteria with apoptosis. This has been clearly demonstrated for 
a number of organisms including Shigella, 267 Listeria, 268 Mycobacterium 
tuberculosis, 269 and Salmonella. 270 Infection with Chlamydia trachomatis and with 
Chlamydia psittaci has also been shown to induce apoptosis in macrophages, epithelial 
cells and activated T-cells. 271-273 Human PBMCs, when infected by Chlamydia 
pneumoniae, respond by secreting IL- 10 and become resistant to apoptosi S. 274 Inhibition 
of apoptosis through IL-10 has also been seen in Mycobacterium tuberculosis 
infection. 275 Chlamydia trachomatis infection has also been shown to render HeLa cells 
resistant to apoptosis although the mechanism was not defined. 276 At least in some cases 
this inhibition appears to be mediated through NF-KB and caspase-3 dependent 
mechanisms, 277 however the picture remains unclear as IL-10 can also promote 
apoptosis through a CD95 receptor/ligand pathway. 278 The importance of apoptosis in 
chlarnydial infections remains unclear but it is an area receiving much more attention 
recently. One recent study suggested that acute infection of alveolar carcinoma cells 
with Chlamydia pneumoniae provoked apoptosis whilst chronic infection rendered the 
cells resistant to apoptotic stimul 1 . 
279 It may be that Chlamydia facilitate the release of 
EBs from cells early in the course of infection by provoking apoptosis but then maintain 
chronic infection later by inhibiting the same process. Stimulating the production of 
high levels of IL-10 would be an effective way to prevent apoptosis and maybe also to 
provoke it. 
5.1.11 Intestinal helminth infection is associated with trachomatous 
scarring 
Examination of faecal samples revealed an association between intestinal helminth 
infection and conjunctival scarring; 4/24 of those with trachomatous scarring (16.7%) 
had helminth ova whilst 0/23 controls had ova detected (p < 0.04). 
The effects of helminth infection on down-regulating THI-type responses and up- 
regulating TI-12-type responses have been clearly demonstrated. Sabin et al demonstrated 
that individuals previously vaccinated with tetanus toxoid produced relatively large 
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amounts of IFN-y in response to re-stimulation with tetanus toxoid but that individuals 
infected with Schistosoma mansoni produced low or immeasurable levels of IFN7 on re- 
stimulation. 280 Schistosoma mansoni infection has also been shown to markedly reduce 
IL-2 and IFNy responses to sperm whale myoglobin in naYve animals whilst, at the same 
time, increasing IL-4 responseS281 and in a similar study PPD was shown to induce IFNy 
responses in healthy mice but IL-4 and IL-5 responses in mice infected with BrIlgia 
malayi. 282 In a clinical study in Ethiopia individuals with intestinal helminths were 
randomised to receive either albendazole (an anti -helm inthic) or placebo and were 
subsequently vaccinated with BCG. Those who had received placebo subsequently had 
283 significantly lower levels of T-cell proliferation and IFNY responses to PPD. One 
implication of these experiments is that a helminth-infected individual may have 
impaired cell-mediated responses to other microbial agents. 
Since THI-type responses are much more effective in clearing chlarnydial infection and 
TH2-type responses have been shown to be associated with scarring in trachoma, it is 
plausible that ongoing helminth infection might give rise to a TH2-type environment and 
hence predispose to scarring. In this study only the presence of intestinal helminths was 
investigated. The serous cavity-inhabiting filarial nematode Mansonella perstans is 
present at high prevalence in The Gambia (25-30% in 1981 )243 and there is also focal 
infection with Wucheraria bancrofti (8-21% in 1981 but probably less prevalent 
nOW)243 . These would 
be expected to provide a higher level of immune stimulation than 
intestinal helminths as they migrate through soft tissue and their microfilaria live in the 
bloodstream. Serum is stored on all patients and can be tested for filarial antigens. 
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5.2 Limitations of this study 
5.2.1 'Intense' trachoma is under-represented in this study 
In this study 51/52 (98%) of the children with active trachoma or were classified as 
having follicular trachoma (TF). Only a single case of intense trachoma (TI) was 
identified. These figures are somewhat lower than for other studies. In Tanzania 
100/137 (73%) of children with active trachoma had TF vs. 37/137 (27%) with TI 
284 
285 
whilst in Nepal 195/210 (93%) had TF vs. 15/210 (7%) with TI. 
Grading of trachoma in this study was confinned by a very experienced field-worker 
who has been working on trachoma for many years. There is an excellent national eye 
care programme in The Gambia and most of the villages have taken part in studies of 
trachoma for many years. Research staff and workers from the eye care programme are 
frequent visitors to the villages. It is likely therefore that individuals with more severe 
trachoma would seek treatment thus resulting in a reduction in the prevalence of intense 
trachoma. A reduction in the proportion of cases with TI is commonly seen as trachoma 
prevalence falls. 
It is thought that children with TI are more likely to go on to develop scarring than 
children with TF and thus it would have been interesting to compare immune responses 
between these two groups. Clearly this was not possible with only one child having TI. 
5.2.2 Controls for the children with active trachoma may themselves be 
recovering from or about to develop active trachoma 
The natural history of trachoma in an endemic area such as The Gambia is that children 
will have many episodes of acute trachoma in the first decade or so of their lives then, 
as they develop immunity, the frequency and duration of acute episodes declines and 
acute trachoma is uncommon in adulthood. One implication of this is that the children 
without active trachoma at the time of the study may well have had active trachoma in 
recent weeks or may be incubating infection, indeed 5/26 (19%) of the controls had 
Chlamytha trachomatis DNA detected in conjunctival swabs by PCR compared to 
32/50 (64%) of cases. In recent comparable studies, 110/378 (29%) of Egyptian 
children with clinically non-nal eyes had Chlamy(ha trachomatis detected in 
conjuiictival swabs vs. 245/353 (69%) of those with clinically apparent active 
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286 
1 trachoma , whilst in Tanzania 
31/696 (4%) of children with 'normal' eyes had PCR 
evidence of Chlamydia trachomatis infection vs. 17/63 (27%) of children with TF on 
287 
examination. 
As a result of this somewhat blurred distinction between 'cases' and 'controls' it is 
necessary to be cautious when drawing conclusions about differences between the two 
groups. It is reasonable however to assume that those with clinical signs of activc 
trachoma are at the peak of their inflammatory response to infection and this study has 
demonstrated clear differences in responses to both chlarnydial and common recall 
antigens between the two groups. Perhaps of more significance is the relationship 
between the responses during acute infection and the subsequent development of 
scarring as discussed below. 
5.2.3 The women with tubal infertility form a heterogenous group and not 
all infertility will be due to Chlamydia trachomatis infection 
The infertile women selected for inclusion in this study had all been investigated for 
secondary infertility and found to have tubal occlusion on hysterosalpingography. At 
the current time the aetiology of their infertility is not known. In many instances their 
tubal infertility is likely to be due to Chlamydia trachomatis infection, however other 
infections and pathologies will be the cause in some. In one group of women with tubal 
infertility in Egypt, 51.8% had active Chlamydia trachomatis infection of the cervix at 
the time of investigation for their infertility, 288 whilst in a similar group in South Africa 
14/40 (35%) had active cervical chlarnydial infection . 
289 The incidence of previous 
infection is likely to be very much higher. Brunham et al found that 13/18 (72%) of 
American women with tubal infertility had serological evidence of previous chlamydial 
infection 21 1, a similar study in Turkey found evidence of prior chlamydial infection in 
103/185 (56%) 
'290 and 
65% of Australian women with tubal infertility had Positive 
serological tests for Chlamydia. 29 1 Elsewhere in Africa 104/135 (77%) of women with 
tubal infertility in Zimbabwe had antibodies to Chlamydia trachomatis, 52/135 (39%) at 
high level292 and even higher levels were found in South Africa where 87% of women 
with tubal pathology and 38% of pregnant women had antibodies to Chlamydia 
293 trachomatis . 
It seems reasonable therefore to speculate that at least 50% of the 
infertile women in our study would have had previous reproductive tract chlamydial 
infection, indeed a previous serological study of women with secondary tubal infertility 
iii The Gambia demonstrated that 17/24 (71%) had antibodies to Chlall7j'(110 
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trachomatis. 294 . The 
infertile women in this study have been part of a larger study of 
sexual health in The Gambia. 295 In this study the women as a whole (not just the 
infertile women), were shown to have Chlanýydia trachomatis prevalence of 1.2% by 
PCR of DNA extracted from cervical swabs. However the sensitivity of the PCR 
technique used was subsequently questioned (West, B. Personal communication) and 
therefore it is difficult to know how much reliance can be placed upon this figure. 
Additionally, these women are all living in an area endemic for trachoma. It is likely 
therefore that most of the women will have been exposed to trachoma during their lives 
and some of the responses may be due to this exposure to Chlamydia rather than to 
urogenital exposure. However, both the infertile women and their controls were selected 
from the same villages and it is therefore likely that they will have had the same 
exposure to non-urogenital Chlamydia. 
5.2.4 Are antibodies in the serum representative of antibodies in the 
mucosae? 
The lacrimal glands, conjunctivae and accessory glands secrete immunoglobulins which 
are predominantly of the s-IgA type but also include IgG and IgM. 296 The pattern of 
locally produced antibodies found in tears might be expected to differ from that of 
serum immunoglobulins. This certainly appears to be the case for s-IgA; Chlamydia- 
specific s-IgA was detected in the tears of 8/8 patients with chlarnydial conjunctivitis 
but not in the serum of any. 297 Interestingly anti-chlarnydial tear IgA was also found in 
20/50 patients with chlarnydial urethritis and no exposure to ocular trachoma, 298 though 
tear IgG is found only in patients with ocular chlarnydial infection . 
299 Serum IgG does 
however appear to be more representative of the local mucosal situation. In the non- 
human primate IgG directed against specific chlarnydial antibodies was found in both 
tears and serum, and serum IgG antibodies were directed at the same antigens as tear 
IgA . 
300 In men with chlamydial urethritis Chlamydia-specific IgG and IgA were 
detected in urethral swabs 39 and Chlamydia-specific IgG is also found in the sera of 
men with urethritis. 116 The detection antibody used for immunoblotting in this study 
detected all IgG subtypes but not IgM or IgA. 
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5.2.5 Is cytokine production in blood a reliable indicator of cytokine 
production in mucosal surfaces? 
One of the important questions in studies of immunity to mucosal pathogens is whether 
antigen-specific T-cells found in the peripheral blood are reliable indicators of the 
presence of such T-cells at infected mucosal sites and vice versa. Most of the work 
undertaken using the whole blood assay method has been with more systemic infections 
such as tuberculosis and HIV and the validity of the method is well established under 
these conditions. A review of the literature did not reveal any studies using this 
methodology to investigate more localized or mucosal infections and this study is the 
first to apply the technique to chlarnydial infection. 
Studies of lymphocyte proliferation and the production of cytokines by separated 
peripheral blood mononuclear cells (PBMCs) have been undertaken previously in the 
context of chlarnydial infection. These have demonstrated: reduced lymphocyte 
proliferation in response to chlarnydial antigens in individuals with trachomatous 
scarring; 301 proliferation in response to chlarnydial HsP60 in women with chlarnydial 
cervicitis; 302 and proliferation in response to MOMP in patients with various chlarnydial 
infections. 303 Chlamydia-reactive T-cells have been isolated from atheromatous 
plaques 251 and the synovium of patients with Chlamydia-associated arthritIS304 and in 
animal studies genital tract T-cells have been shown to produce high levels of TNF(x'OO 
and IFNy, 90 but the responses of both PBMCs and local mononuclear cells have never 
been directly compared. It would be expected that investigation of the infected mucosa 
would provide the most accurate information however this may not always be the case, 
one immuno-histological study of conjunctival biopsies in individuals with trachoma 
demonstrated the expression of IL-1, TNF(x and platelet-derived growth factor by 
conjunctival mononuclear cells but no expression of IFNJ 05 despite the fact that IFNy 
has been shown to be of major importance in the immune response to Chlamydia 
(reviewed in 2.3.4). 
In the absence of any definitive study comparing responses in mucosal sites with those 
of PBMCs or in the whole blood assay it is necessary to compare the results of such 
assays with experimental data from all available studies in order to determine the likely 
validity of the new data. 
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5.2.6 The TGFP assay is unsuited to a whole blood assay method 
The TGFP ELISA results showed high levels of non-specific activation unrelated to the 
antigen being used for stimulation and including the negative control wells. These high 
levels of TGFP production were unrelated to clinical status and independent of all the 
other variables measured. As a consequence the results of 41/106 individuals had to be 
excluded from analysis, and of those that were used for analysis quite a number of 
suspiciously high values remained rendering any conclusions unreliable. TGFP is 
produced by many cells including activated T-cells and macrophages, platelets, tumour 
cells, ostcoblasts and osteoclaStS306,307 and high levels of non-specific activation have 
been seen by other workers using the whole blood assay, leading them to conclude that 
these high levels probably result from platelet activation and that the whole blood assay 
is an inappropriate methodology for investigating TGFP responses (Omer, F. M. 
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personal communication) . 
5.2.7 The cytokine ELISA used may not have been sensitive enough for 
the IL-2 and IL-5 concentrations generated 
Statistical comparison of the IL-5 responses to the common recall and Chlamydia- 
specific antigens with those of the negative control wells demonstrates that none of 
these antigens stimulated an IL-5 response significantly higher than that seen in the 
negative control. The results were better for IL-2, for example mean IL-2 concentration 
after incubation with PPD was 87 pg/ml vs. 7 pgýtl for the negative control (p < 
0.00005), corresponding figures for Candida were 13 vs. 7 pg/ml (p < 0.00005). 
Inspection of the raw results shows that for the IL-5 assay a very significant proportion 
of the results were below the lowest reliably accurate optical standard (8 pg/ml). This 
proportion varied from 71/166 (43%) for PPD to 127/166 (77%) for MOMP. In all 
734/1162 (63%) were below the minimum reliable level of accurate measurement. All 
of the responses to the mitogen PHA were well above this level. 
The IL-2 results were better. Results below the minimum level for accurate 
measurement (also 8 pg/ml) varied from 3/172 (2%) for PPD to 115/172 (67%) for 
omP2. Overall 530/1204 (44%) were below this lowest accurate standard. 
Whilst it is perfectly plausible that many of the samples may generate low levels of 
cytokine in response to stimulation, or even not respond at all, it is slightly worrying 
that only PHA stimulated a detectable response in the IL-5 assays and it may be that this 
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assay simply was not sensitive enough. Clearly no differences detected with this assay 
can be relied upon. The IL-2 ELISA is clearly also lacking in sensitivity for the levels of 
IL-2 generated in many of the assays, however the significant levels of IL-2 measured 
in response to the common recall antigens Candida and PPD suggest that the results 
generated are likely to be reliable. 
5.2.8 The number of individuals studied did not always provide adequate 
power to detect differences between cases and controls? 
At the initial planning stage a number of decisions were made in order to decide the 
number of individuals to be investigated in each group. The numbers chosen provided 
80% power to detect a 50% difference in measurement between cases and controls for 
the infertile women, a 40% increase for the scarred individuals and a 35% increase for 
children with active trachoma. The studies subsequently demonstrated a variety of 
differences between the children with active trachoma and their controls and rather less 
for the scarred individuals and the infertile women. Some of that may be explained by 
the higher power provided by the larger numbers in the active trachoma group. Using 
sample size calculations, the figures (Table 5-2) show the number of cases required to 
demonstrate a significant difference between cases and controls using the means and 
standard deviations from this study. An equal number of controls would also be 
required. Boxes highlighted in red are those for which significant differences between 
cases and controls (p <0.05) were demonstrated in this study and those highlighted in 
yellow are those for which a trend (p < 0.1) was demonstrated. 
In most instances for the scarred individuals and infertile women, the number of cases 
and controls required to demonstrate differences are too large to make such a study 
feasible, for example in a resource-poor country such as The Gambia it would be 
difficult to recruit a hundred or more women with secondary infertility and tubal 
blockage confirmed by hysterosalpingography. Such a study may be feasible in a 
developed country setting however. 
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b lot 
O 
lot 
TTNF 
IFN IL-2 IL-10 
Active trachoma 
EB - 62 38 122,827 50 
MOMP 16 494 130 276 236 
omp2 4030 21 547 5820 40 
hsp60 1123 38 147 233 16 
pmpGa 81 51 1142 105,343 30 
pmpGc 398 1563 124 46 65 
Scarred trachoma 
EB 223 673 75 29 
MOMP 273 11,517 716 63 2139 
omp2 604 146 2313 143 186 
hsp60 666 489 880 93 1042 
pmpGa 144 524 375 418 60 
pmpGc 46 52,895 1920 85 32 
Infertile women 
EB 959 22 1925 1676 
MOMP 16 1490 74 150 215 
omp2 96 1958 62 248 576 
hsp60 83 1741 195 560 569 
pmpGa 86 2080 106 141 342 
pmpGc 96 219 2319 321 191 
Table 5-2: Number of cases required to give adequate power to determine significant 
differences between cases and controls 
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5.3 Conclusions and implications 
The molecular biology methods and tools used in this work enabled the production of 
two recombinant fragments of PmPG enabling separate study of immune responses to 
the amino and carboxyl halves. The recombinant proteins were produced in ample 
quantity and high purity and there was no evidence of unwanted effects from 
contaminants in the assays used for the field work. Restriction fragment length 
polymorphism analysis of the pmp genes demonstrated only minor differences between 
the pmp genes from a clinical isolate of Chlamydia trachomatis serovar A from the 
Gambia used to generate the recombinant PmPG, and the reference strain (Serovar D 
(D/UW-3/Cx), trachoma biovar) used for sequencing in the Chlamydia Genome Project. 
Field studies in The Gambia confirmed that antibodies to PMPG are generated during 
natural trachoma infection and that these are more commonly directed towards the 
amino-terminal fragment (PmpGa) than to the carboxyl-terminal half (PmpGc) 
supporting animal studies and in vitro work which suggests that the amino-tenninal is 
exposed on the surface of the organism whilst the carboxyl -terminal is located within 
the membrane or cytosol. Antibodies to PmPGa were found more commonly, and at a 
higher titre, in children without active trachoma suggesting that they may confer some 
protection. This clearly requires further investigation as, if confirmed, this may be a 
useftil component of a future vaccine. Conversely antibodies to PmpGc were more 
prevalent and found at a higher titre in those with trachomatous scarring. 
PmPG was also able to stimulate the production of TNFcc, IFNy, IL- 10 and TGFP in the 
whole blood assay and again the amino-ten-ninal fragment was much more active than 
the carboxyl-terminal fragment. Children with active trachoma produced significantly 
higher levels of TNF(x and IL- 10 than their controls in response to PmPGa whilst scarred 
individuals produced less IL-10 than controls. 
Antibodies to MOMP were seen at a higher prevalence and titre in children with active 
trachoma suggesting that serum anti-MOMP antibodies do not provide good protection, 
perhaps due to strain variation in MOMP. A higher prevalence and titre of antibodies to 
MOMP was also seen in infertile women and may reflect recurrent or prolonged 
infection. In the whole blood assay MOMP stimulated the production of both IFN7 and 
TNFOc but there was no association with pathology. 
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OmP2 was shown to be highly immunogenic, confinning the findings of other published 
studies. Antibodies to omP2 where highly prevalent in all groups but were not 
associated with pathology. omP2 also stimulated the production of TNF(x, IFNy and IL- 
10 in the whole blood assay and TNF(x responses were higher in children with active 
trachoma than in their controls, but no differences were seen in those with long-term 
sequelae. 
Similarly antibodies to HSP60 were highly prevalent in all groups but this study failed to 
demonstrate any association with pathology, a finding contrary to much previously 
published work. This is probably due to the sample size being inadequate to detect a 
significant difference and the higher sensitivity of this assay compared to the previously 
used ELISA methods causing a high background level rather than due to a lack of real 
difference. HsP60 was also shown to be capable of stimulating TNF(X, IFN7 and IL- 10 in 
the whole blood assay. Both TNF(x and IL-10 concentrations were higher in children 
with active trachoma than in their controls but no differences were found in the groups 
with long-term sequelae of infection. 
High levels of IL-10 were noted in response to both common recall antigens and all 
chlamydial antigens except MOMP, in children with active trachoma. Though non-nally 
associated with resolving inflammation, high levels of IL-10 secretion are also 
promoted by a variety of intracellular pathogens in order to subvert host responses by 
down-regulating MHC expression and inhibiting apoptosis. Increased production of IL- 
10 on infection with Chlamydia has been noted previously, as has the ability of 
Chlamydia to inhibit apoptosis. Clearly ftirther work is required to tease out the details 
of this relationship. 
One further fascinating, and previously undescribed, finding was that of an association 
between intestinal helminth infection and scarring trachoma. Ongoing helminth 
infection is known to predispose to a TH2-type response to other microbial pathogens 
and trachomatous scarring is itself known to be associated with TH2-type responses to 
chlarnydial antigens. Only intestinal helminth infection was investigated in this study 
and it is likely that many of the individuals would have also been infected with 
Mansonella perstans which may also have an effect. One implication of this observation 
is that regular de-worming of children in a trachoma-endemic area might reduce the 
incidence of scarring as well as that of anaernia and malnutrition. As cvldcnce increases 
of the detrimental effects of ongoing helminth infection on other diseases such as HIV, 
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TB and leishmaniasis it is important that these associations are determined and anti- 
helminthic medication given where appropriate. 
Fewer statistically significant differences were noted in cytokine responses between 
cases and controls in the trachomatous scarring and infertile women groups than in the 
active trachoma group. This may reflect an expansion of circulating, Chlamydia- 
reactive, mononuclear cells in children with acute infection whilst those with 
trachomatous scarring or tubal damage have much lower numbers of circulating 
memory cells. As a consequence of this the differences between cases and controls are 
not sufficiently large to be detected using the whole blood assay unless unfeasibly large 
numbers of individuals are studied. The implication of this finding is that whilst the 
whole blood assay has been shown to be an effective tool to detect differences in the 
responses of children with active trachoma, even though the infection is mucosally 
located and affects only a relatively small amount of tissue, it may not be an appropriate 
methodology for studying individuals after the acute phase when few Chlamydia- 
specific cells are likely to be in circulation. 
One of the most important fundamental questions regarding chlarnydial infections is 
why some individuals develop long-term sequelae whilst others resolve the infection 
with no long-term consequences. Due to limitations in the sensitivity of the assays and 
the number of individuals studied, this study has not shed a great deal of light on this 
question. It has however provided new information on the acute responses to trachoma. 
Given the blurred distinctions between cases and controls in this population as 
described above, it is difficult to draw any important conclusions from these findings. 
However, a review of these individuals in five to ten years time may allow conclusions 
to be drawn as to the association between acute responses to trachoma and the 
subsequent development of scarring. 
This work has perhaps raised more questions than it has answered and certainly further 
work is indicated. Potential avenues for future research are described below. 
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5.4 Unanswered questions and future research 
5.4.1 Do antibody or cytokine responses during an episode of active 
trachoma predict subsequent development of scarring? 
Children with active trachoma were shown to demonstrate differences in a variety of 
humoral and cytokine responses compared to controls. The importance of these is 
difficult to determine due to the blurring of the division between cases and controls in 
this population as discussed earlier. The fundamentally important question in 
chlamydial infection is why some individuals develop scarring of the conjunctivae or 
fallopian tubes whilst others resolve infection without any long-term sequelae. Most 
studies attempt to answer that question by looking at the differing responses between 
those who have developed scarring and those who have not, long after the acute illness 
has resolved. This study provides an opportunity to revisit these children in five to ten 
years time to determine which children have developed scarring. It may then be possible 
to relate their responses during active infection with the subsequent development of 
long-term sequelae. 
5.4.2 Do in vivo cytokine responses correlate with those predicted from 
cytokine gene and gene-promoter polymorphism analysis? 
Previous studies in The Gambia have looked at associations between scarred trachoma 
and polymorphisms of the TNF(x and IL-10 gene promoters. 
102,223 Some of the 
individuals investigated during the course of those studies were also included in this 
current study. It would be interesting therefore to compare the results of cytokine 
production in response to common recall and chlamydial antigens with the results of 
those polyrnorphism analyses to detennine if the phenotypic responses are in keeping 
with the genotype. As DNA has been isolated and stored from all individuals in this 
study it will be possible to genotype for other cytokine genes and gene-promoters and 
correlate these with responses seen in the whole blood assay. 
5.4.3 Do antibodies to the amino-terminal fragment of PmPG protect 
against re-infection? 
Antibodies to the amino-tenninal fragment of PmPG were found at higher prevalence 
and higher titre in controls than in children with active trachoma. Those with the highest 
io for having active trachoma of 0.32 when compared to those with titres had an odds rati III 
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undetectable antibody. These differences were found to be significant at a level of p< 
0.04 using non-parametric tests and p<0.06 using a t-test and X2 for trend, but the 
significance was reduced to p<0.13 using conditional logistic regression. Hence this 
finding needs to be confirmed using larger numbers of individuals. Sample size 
calculations suggest that 81 cases and 81 controls would provide 80% power to detect a 
significant difference using the means determined from this pilot study. If this finding is 
confirmed then ftirther studies using in vitro neutralisation of infectivity and passive 
immunisation in animal models would be indicated. 
5.4.4 Are antibodies to the carboxyl-terminal of PmPG associated with 
scarring? 
Antibodies to the carboxyl-tenninal fragment of PmPG were shown to be associated 
with the presence of scarring. Those with conjunctival scarring had a higher prevalence 
of antibodies and these were present at higher titres. Those with the highest antibody 
titres were 4.5 times more likely to be scarred than those with undetectable antibodies (p 
< 0.02). In general, evidence from the current study supports the conclusions of 
previous work which suggest that the carboxyl-terminal of the molecule is not surface 
exposed and thus less antigenic. The recombinant protein used in this study however 
includes a significant portion of the protein's central region which is predicted to be 
surface exposed and this may account for it having some antigenicity. Clearly this 
association with scarring needs further investigation and in the first instance this should 
be by the production of further, smaller recombinant fragments of PmPG to allow the 
region responsible for this association to be determined. It would also be interesting to 
determine if the PmPG protein includes predicted HLA-binding motifs and indeed if 
PmPG epitopes are presented through MHC. 
5.4.5 Does TGFP have a role in the development of scarring? 
TGFP is produced by a wide variety of cells and has widespread effects as most cells 
have TGFP receptors. It plays an important role in the control of immune responses and 
wound healing. At low levels it stimulates fibroblast proliferation and the deposition of 
extracellular matrix whilst inhibiting proliferation at higher levels. 
306 TGFP suppresses 
macrophage function and this is utilised by Leishmania, Trypanosoma cruzi and 
A111-cobactcrium auum to suppress macrophage killing and allow intracellular 
prolifcration of the organisms. 
309,310 In the context of chlarnydial infection, pulmonary 
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infection of mice is associated with increases in the local expression of TGF p3l 1 and 
human synovial cells infected with Chlamydia trachomatis also produce TGF p'3 12 thus 
Chlamydiae may also make use of the immunosuppressive effects of TGFP. In addition 
high levels of TGFP are though to be associated with the development of keloid 
scarring 313 and therefore TGFP, produced in response to chlarnydial infection, may be 
important in the development of scarring in trachoma. 
As a result of the difficulties associated with the TGFP assays used in this study it was 
not possible to make any meaningful comments on the TGFP responses in relation to 
active trachoma, trachomatous scarring or infertility but these remain an important area 
for investigation using alternative methods, perhaps by measuring local mRNA 
transcripts. 
5.4.6 How much does helminth infection contribute to scarring in 
trachoma? 
Intestinal helminth infection was shown to be associated with trachomatous scarring and 
this may be due to the induction of TH2-type responses to chlamydial antigens. 
Although the higher prevalence of intestinal helminth infection was statistically 
significant, the numbers were small and it would be important to confirm this finding 
with a larger study. Additionally the effects of Mansonella perstans and Wucheraria 
bancrofti were not assessed in this study and may also be important. Sera from all 
patients are in storage and filarial serology could easily be undertaken on these samples. 
Any larger scale studies of this association should also include filarial serology. When 
these children are reviewed in 5 to 10 years time it will be interesting to see if helminth 
infection detected during this study is associated with subsequent scarring although 
clearly all individuals found to have helminth infection were given appropriate 
treatment. The intestinal helminths isolated in this study are all easily treated and may 
themselves be associated with anaemia and reduced nutrition. It would be useful to 
know if treatment may also reduce the incidence of the long term sequelae of trachoma. 
5.4.7 What role does IL-10 play in chlamydial infection? 
High levels of IL-10 production were seen in children with active trachoma. As 
discussed earlier IL-10 tends to be produced in the later stages of an immune response 
to infection and is an effective mechanism through which the host terminates the 
inflammatory response. However IL-10 production seems to occur earlier in the course 
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of chlamydial infection and may be induced by Chlamydia itself in order to evade host 
responses, perhaps through the inhibition of apoptosis. Further studies of this 
phenomenon are indicated, initially perhaps by studying temporal changes in mRNA 
transcripts during infection of cell cultures or through in vivo work in animal models. 
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Appendix - Immunoblot scores by observer 
ID No 
Observer 
MOMP 
123 
omp2 
123 
hsp60 
123 
pmpG 
123 
pmpG 
123 
1 2 2 3 3 3 3 2 2 2 3 3 3 3 2 3 
2 1 0 0 3 2 2 3 3 3 0 0 0 0 0 0 
3 1 0 0 3 3 3 3 3 3 3 2 3 3 2 3 
4 2 1 2 2 1 2 3 2 3 2 1 1 2 1 2 
5 3 3 3 3 3 3 3 2 2 1 1 2 3 3 3 
6 3 3 3 3 3 3 3 3 3 1 1 1 3 3 3 
7 3 2 2 3 3 3 2 1 1 2 0 1 2 1 0 
8 2 1 2 3 2 3 3 2 3 1 0 0 2 1 2 
9 1 0 0 3 3 3 3 3 3 0 0 0 2 1 2 
11 2 1 2 3 2 2 3 3 3 0 0 0 0 0 0 
12 3 3 2 3 3 3 3 3 3 2 0 0 2 0 0 
13 2 0 0 3 2 2 2 1 2 0 0 0 2 1 2 
14 3 2 2 3 3 3 3 2 2 0 0 0 2 1 1 
15 3 2 2 3 3 3 2 1 2 0 0 0 2 1 2 
16 3 3 2 3 3 3 3 3 3 0 0 0 2 1 2 
17 3 2 2 2 1 2 3 1 2 0 0 0 1 0 0 
18 3 2 2 3 3 3 3 3 3 1 1 1 2 2 2 
19 2 1 2 3 3 3 2 2 2 1 1 1 2 2 2 
20 2 1 0 3 2 2 3 2 2 0 0 0 1 0 1 
21 1 1 1 3 3 3 3 3 3 0 0 0 2 2 2 
22 3 1 1 3 2 3 3 2 3 2 2 2 3 2 3 
23 2 1 3 2 1 2 3 3 3 2 2 2 2 2 2 
24 1 1 2 3 3 3 2 2 2 0 0 0 2 2 2 
25 2 2 3 3 3 3 2 2 3 0 0 0 2 2 2 
26 1 1 1 3 3 3 1 1 1 0 0 0 1 1 1 
28 1 1 1 0 0 0 3 2 2 3 2 2 2 1 2 
29 3 3 3 2 2 2 2 1 2 3 3 3 1 1 1 
30 3 2 2 3 3 2 2 2 2 2 1 2 3 2 2 
33 2 1 2 3 2 2 2 1 2 2 1 2 2 1 2 
34 3 2 2 3 3 3 3 2 2 1 1 1 1 1 1 
36 2 2 2 3 3 2 3 3 3 0 0 0 3 2 2 
37 2 1 2 3 3 3 3 2 2 0 0 0 2 1 2 
38 2 1 2 2 2 2 3 3 3 0 0 0 3 3 2 
39 2 1 2 3 3 3 3 3 3 0 0 0 1 1 1 
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inNn 
Observer 
MC)MP 
123 
nmn2 
123 
h-qnF; n 
123 
nmnr-. r 
123 
nmnr-iq 
123 
41 2 2 1 3 3 2 3 3 2 3 3 3 0 0 0 
42 2 1 1 1 1 1 2 1 2 1 0 0 0 0 0 
43 3 2 3 2 1 2 2 1 2 3 3 3 0 0 0 
44 2 2 3 2 2 2 2 2 2 2 2 2 0 0 0 
45 3 3 3 3 2 2 3 3 3 2 1 2 1 0 1 
47 3 2 2 2 2 2 2 1 2 3 2 3 1 0 0 
48 1 1 2 1 1 0 2 2 2 1 0 0 3 2 2 
49 2 2 3 1 1 1 3 2 3 0 0 0 3 2 2 
50 2 2 3 2 2 2 2 3 3 0 0 0 3 3 3 
51 3 1 2 3 1 2 3 2 3 0 0 0 3 2 2 
53 2 1 1 3 2 2 0 0 0 0 0 0 0 0 0 
54 3 2 2 3 3 3 2 1 2 1 1 1 2 1 2 
55 1 1 1 3 2 2 3 2 2 0 0 0 2 1 2 
56 2 2 2 3 2 2 2 1 1 0 0 0 0 0 0 
57 2 1 2 3 3 3 3 3 3 0 0 0 2 1 2 
58 2 1 1 2 1 2 2 1 2 0 0 0 2 2 2 
59 2 1 2 3 3 3 3 3 3 1 1 2 3 2 2 
61 2 2 3 3 3 3 3 3 3 0 0 0 2 1 2 
64 3 2 2 2 1 1 2 1 2 0 0 0 0 1 1 
65 2 1 2 2 1 2 3 2 2 0 0 0 2 1 2 
66 2 1 2 1 1 1 3 3 3 0 0 0 1 0 1 
67 3 2 2 3 3 3 3 3 3 0 0 0 0 0 0 
68 1 1 1 3 3 3 3 3 2 0 0 0 1 1 1 
69 2 2 2 3 3 3 2 2 2 2 1 2 2 2 2 
70 0 0 1 2 1 2 2 1 2 2 1 2 3 2 2 
71 1 1 1 2 1 2 2 2 2 3 3 3 3 3 3 
72 0 0 0 1 1 1 2 1 2 0 0 0 1 1 1 
73 1 1 1 2 1 2 2 2 2 2 2 3 0 0 0 
74 2 2 2 3 3 3 3 2 2 2 1 2 2 2 2 
75 2 1 2 3 2 2 3 2 2 2 1 2 2 1 2 
76 2 2 2 3 3 3 2 2 2 2 1 2 1 1 1 
77 1 1 1 1 1 1 2 1 2 0 0 0 1 1 1 
79 0 1 1 1 0 0 0 0 1 0 0 0 0 0 0 
80 0 0 0 o o 0 0 1 1 0 0 0 0 0 0 
81 2 1 2 2 1 2 2 1 2 0 0 0 2 1 2 
82 3 2 2 3 2 2 3 3 3 0 0 0 0 0 0 
83 3 2 2 3 2 2 3 3 3 2 1 2 2 1 2 
84 3 2 2 3 2 2 3 3 3 0 1 0 0 0 0 
85 3 2 2 3 2 2 3 3 2 0 0 0 0 0 0 
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ID Nn 
Observer 
MC)MP 
123 
nrnn9 
123 
h--cnf; n 
123 
nrnnrr- 
123 
nmnr,. q 
123 
86 3 3 3 3 3 2 3 3 3 3 3 2 3 3 2 
87 3 2 3 3 2 2 3 2 3 2 1 2 2 1 2 
88 3 3 3 3 2 2 3 2 2 1 1 1 2 1 2 
89 3 1 2 1 1 2 2 1 2 1 0 0 2 1 2 
91 2 1 1 9 9 9 3 2 2 0 0 0 2 1 2 
92 3 3 3 9 9 9 2 2 2 0 0 0 0 0 0 
93 2 1 2 9 9 9 2 1 1 0 0 0 0 0 0 
94 3 3 3 1 1 1 2 1 2 2 1 2 1 1 1 
95 3 2 2 1 1 1 3 3 3 0 0 0 0 1 1 
96 3 2 2 3 2 2 3 2 2 3 2 3 3 3 2 
97 2 1 2 3 3 3 3 3 3 2 1 2 2 1 2 
98 3 2 2 2 2 2 3 3 2 2 2 2 2 2 2 
99 3 3 3 3 3 3 3 3 3 0 0 0 2 2 2 
100 1 1 1 3 2 2 3 2 2 0 0 0 2 0 0 
101 1 1 1 1 1 1 3 2 2 2 0 0 1 0 0 
102 3 1 2 2 1 1 3 2 2 0 0 0 0 0 0 
103 3 2 2 3 2 3 1 0 1 0 0 0 0 0 0 
104 3 3 3 3 3 3 2 0 2 0 0 0 0 0 0 
105 3 3 2 2 2 2 2 1 2 0 0 0 0 0 0 
106 3 2 2 3 2 2 2 0 2 0 0 0 0 0 0 
ill 3 3 2 3 2 2 3 2 2 0 0 0 0 0 0 
112 3 1 2 3 2 2 3 2 2 1 0 0 0 0 0 
113 2 1 2 2 1 1 2 1 1 0 0 0 2 1 1 
114 3 2 2 1 1 1 3 3 3 0 0 0 0 0 0 
115 3 3 2 0 1 0 3 3 2 0 0 0 0 1 0 
116 3 3 3 1 1 1 3 3 2 0 0 0 1 1 1 
117 3 3 2 9 9 9 3 2 3 2 1 1 0 0 0 
118 3 3 3 9 9 9 3 3 3 1 1 1 0 0 0 
119 3 3 3 9 9 9 3 3 2 2 2 2 2 0 1 
120 2 2 2 9 9 9 2 2 2 0 0 0 0 0 0 
121 3 2 2 9 9 9 3 3 3 2 2 2 2 1 2 
122 1 1 2 9 9 9 3 3 3 3 2 2 2 2 2 
123 2 1 2 9 9 9 3 3 3 3 2 2 2 1 2 
125 2 1 2 3 3 3 2 2 2 1 0 0 3 1 1 
126 2 1 2 1 0 2 2 1 2 1 0 0 2 2 2 
128 2 2 2 2 1 2 2 1 2 1 0 0 2 2 2 
129 1 1 1 1 0 0 3 3 2 0 0 0 0 0 0 
130 3 3 2 2 1 2 3 2 2 0 0 0 0 0 0 
131 2 2 2 2 1 1 3 3 3 0 0 0 1 0 0 
282 
1r) Nn 
Observer 
MOMP 
123 
nmn9 
123 
h-c, -nRn 
123 
nmnrr 
123 
m 
nmnr,; i 
123 
132 3 2 2 2 2 2 3 2 2 0 0 0 2 0 0 
133 3 3 3 9 9 9 3 3 3 1 1 1 2 1 2 
134 1 1 1 9 9 9 2 2 2 2 1 2 2 1 1 
135 3 3 2 9 9 9 3 3 3 0 0 0 0 0 0 
136 3 3 3 9 9 9 3 2 2 2 1 2 2 1 2 
137 2 1 2 9 9 9 2 1 2 0 0 0 1 0 0 
138 2 2 2 9 9 9 3 3 3 0 0 0 0 0 0 
141 2 1 2 9 9 9 2 2 2 1 1 1 2 1 2 
142 3 2 2 9 9 9 3 3 3 1 1 1 2 2 2 
143 3 2 2 3 2 2 1 0 0 0 0 0 0 0 0 
144 2 1 2 3 3 2 3 2 2 0 0 0 0 0 0 
145 2 1 2 0 0 1 0 0 0 0 0 0 0 0 0 
146 2 2 2 9 9 9 3 3 2 0 0 0 0 0 0 
147 3 3 3 9 9 9 3 3 3 2 0 0 2 1 1 
148 3 2 2 9 9 9 3 2 2 2 1 2 2 1 2 
149 3 3 3 9 9 9 3 3 3 2 2 2 3 3 3 
150 3 3 3 9 9 9 3 3 3 0 0 0 0 0 0 
151 3 3 3 9 9 9 3 3 3 3 3 3 3 3 3 
152 3 2 2 9 9 9 2 1 2 1 1 1 2 2 2 
154 3 3 3 9 9 9 3 3 3 0 0 0 0 0 0 
155 3 3 3 9 9 9 2 2 2 0 0 0 2 2 2 
156 2 2 2 9 9 9 3 3 3 0 1 1 2 1 2 
157 2 2 2 9 9 9 2 2 2 0 1 0 2 2 2 
159 3 3 3 1 1 1 3 2 2 2 1 1 0 1 1 
160 3 2 2 2 1 1 3 3 3 3 2 3 2 2 2 
161 3 2 2 3 2 2 3 2 2 1 1 1 1 0 0 
162 3 3 3 2 2 2 3 3 3 3 2 2 2 1 1 
171 3 2 2 9 9 9 3 2 2 3 2 2 2 1 2 
172 1 1 1 1 1 1 2 2 2 1 1 1 0 0 0 
173 1 1 1 3 2 2 2 2 2 1 0 1 0 0 0 
175 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 
176 1 0 0 0 0 0 1 o 0 0 0 0 0 0 0 
180 3 2 2 9 9 9 2 2 2 0 0 0 0 0 0 
283 
77 
BLANK IN ORIGINAL 
284 
